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Abstract 
Three decades ago, the discovery of the Human Immunodeficiency Virus (HIV) was 
announced. The subsequent HIV pandemic has continued to devastate the global 
community, and many countries have set ambitious HIV reduction targets over the years. 
Reliable methods for measuring incidence, the rate of new infections, are essential for 
monitoring the virus, allocating resources, and assessing interventions. The estimation of 
incidence from single cross-sectional surveys using tests that distinguish between ‘recent’ 
and ‘non-recent’ infection has therefore attracted much interest. The approach provides a 
promising alternative to traditional estimation methods which often require more complex 
survey designs, rely on poorly known inputs, and are prone to bias. More specifically, the 
prevalence of HIV and ‘recent’ HIV infection, as measured in a survey, are used together 
with relevant test properties to infer incidence. However, there has been a lack of 
methodological consensus in the field, caused by limited applicability of proposed 
estimators, inconsistent test characterisation (or estimation of test properties) and 
uncertain test performance. This work aims to address these key obstacles. A general 
theoretical framework for incidence estimation is developed, relaxing unrealistic 
assumptions used in earlier estimators. Completely general definitions of the required test 
properties emerge from the analysis. The characterisation of tests is then explored: a new 
approach, that utilises specimens from subjects observed only once after infection, is 
demonstrated; and currently-used approaches, that require that subjects are followed-up 
over time after infection, are systematically benchmarked. The first independent and 
consistent characterisation of multiple candidate tests is presented, and was performed on 
behalf of the Consortium for the Evaluation and Performance of HIV Incidence Assays 
(CEPHIA), which was established to provide guidance and foster consensus in the field. 
Finally, the precision of the incidence estimator is presented as an appropriate metric for 
evaluating, optimising and comparing tests, and the framework serves to counter existing 
misconceptions about test performance. The contributions together provide sound 
theoretical and methodological foundations for the application, characterisation and 
optimisation of recent infection tests for HIV incidence surveillance, allowing the focus 
to now shift towards practical application. 
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Chapter	1
 
Introduction	and	Overview	
This body of work focuses on how to appropriately use tests designed to distinguish 
between ‘recently’ and ‘non-recently’ acquired HIV infections to estimate HIV incidence 
from cross-sectional surveys. This topic and the contributions made within this thesis are 
introduced in three parts below. Firstly, the significance of this research is broadly 
summarised, providing a context for why this work is of interest in epidemiology. 
Secondly, a brief, critical review of past developments in this surveillance approach is 
presented. The review aims to both provide pertinent background information to the 
reader, as well as highlight key shortcomings in the field that this research aims to 
address. Lastly, the contributions made, and the organisation of these in this thesis, are 
outlined.  
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1.1 Significance	
The early 1980s proved to be a period of rapid medical advance as research groups aimed 
to identify the retrovirus that was causing Acquired Immunodeficiency Syndrome 
(AIDS), an illness which was then beginning to sweep across nations [1-3]. Now called 
the Human Immunodeficiency Virus (HIV), the reach of the virus, particularly in the 
developing world, is alarming [4]. In South Africa, an estimated 29.5% of pregnant 
women attending public antenatal care clinics are HIV-positive [5] and 17.9% of the 
general adult population, aged 15 to 49 years old, is living with HIV [4].  
These frightening statistics highlight the need for an effective response to the epidemic. 
There is thus an urgent need for reliable epidemiological measures, which are essential to 
monitor viral spread, optimally allocate limited resources, and plan and assess 
interventions. Incidence, the rate of new infections in a population, although more 
difficult to measure, provides a more direct and current measure of the state of the 
epidemic than prevalence, the proportion of the population infected at a point in time. 
Incidence has therefore become the focus of ‘second-generation HIV surveillance’ [6] in 
South Africa and around the world. 
Time-honoured methods of estimating incidence typically require either longitudinal 
studies or surveys at multiple points in time. These methods have a number of drawbacks, 
such as being prone to capture unrepresentative samples, requiring prolonged study 
periods and relying on highly uncertain external model inputs (such as mortality rates). 
Therefore, the prospect of measuring incidence from a single cross-sectional survey, 
using a test that distinguishes ‘recent’ from ‘non-recent’ infection, has attracted much 
interest [7-14]. However, the widespread use of this approach has been hindered by a lack 
of methodological consensus [7, 15-27] and the poor or uncertain performance of 
candidate tests for recent infection [8-10, 12-14, 28].  
This work has therefore aimed to address these obstacles to the application of cross-
sectional incidence surveillance. A number of closely related original contributions have 
been made; and these have been shared through international journal articles [29-32], 
conference presentations [33-44], local newsletters [45, 46], project websites and online 
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tools [47, 48], training courses [49, 50], and various collaborations1. These contributions 
can be broadly categorised as: 
 The development of a general theoretical framework for incidence estimation,
relaxing the unrealistic assumptions made in earlier work – assumptions that led
to confusion about the validity of this surveillance approach
 Methodological advancement in the measurement of test properties required for
incidence estimation, both by formalising new ideas for the characterisation of
tests, and by building consensus through the rigorous benchmarking of widely
used approaches
 The first independent, large-scale and consistent characterisation of multiple
candidate tests for recent infection, aimed at promoting standardisation in the
field and guiding ongoing ‘recent’ infection ‘biomarker discovery’ projects
 The provision of guidance on the appropriate metric for the evaluation,
optimisation and comparison of tests for recent infection, serving to counter
existing misconceptions that could lead to spurious test assessments
1.2 Review	of	Incidence	Estimation	
Using	Tests	for	Recent	Infection	
The history and state of HIV incidence estimation, from cross-sectional surveys using 
tests for recent infection, excluding the contributions made in this work, are briefly 
reviewed below. 
Traditionally, disease incidence is measured by directly counting the number new 
infections that occur while following a cohort of initially uninfected subjects. However, 
the required longitudinal surveillance is costly and difficult to administer, both practically 
and ethically, while limiting bias in results [12, 54, 55]. Another familiar approach is the 
calculation of historic incidence values that are consistent with prevalence data for 
multiple time points and age groups [56-60]. For example, in South Africa, prevalence 
___________________________ 
1  For example, with the Centers for Disease Control and Prevention (CDC) [51], with the World 
Health Organization (WHO) Technical Working Group on HIV Incidence Assays [52], as a 
member of the Consortium for the Evaluation and Performance of HIV Incidence Assays 
(CEPHIA) [47], and as a member of the HIV Modelling Consortium Task Team for Incidence 
Assay Characterization [53]. 
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data from both general household surveys [61] and the sentinel surveillance of pregnant 
women attending antenatal clinics [5] are used to estimate incidence. This approach also 
underlies the widely-used UNAIDS Estimation and Projection Package (EPP) [62-64]. 
However, post-infection survival, a requisite external input, is typically poorly known and 
evolving (for example, as the effectiveness of treatment, and its coverage, grows). In 
countries such as the USA, case reporting data are used instead to ‘back-calculate’ 
incidence from reported HIV and AIDS cases [65-68]. However, often only incidence far 
into the past can be estimated, and assumptions about HIV progression and testing 
behaviour are required. Alternatively, microscopically descriptive models, such as the 
UNAIDS Modes of Transmission Model [69, 70], could be used. While these models 
attempt to capture the mechanisms of transmission in detail (for example, by estimating 
counts of sexual transmissions in various risk groups), the sophistication is often at odds 
with realistically available data to inform input parameters. 
Consequently, the estimation of incidence using prevalence measurements obtained in a 
single cross-sectional survey, and involving only a few well-estimable parameters, holds 
much appeal [7-27]. This is straightforward for conditions with short and well-
characterised durations, such as influenza: the prevalence of having the condition, relative 
to that of being susceptible to it, is equal to the product of incidence and the average 
duration of the condition (assuming equilibrium of constant incidence and susceptible 
population size over the maximum duration of the condition) [71]. Heuristically, the 
number of persons currently infected is the number of persons infected in, for example, 
the preceding week – and so incidence and prevalence closely track each other. 
However, for an enduring condition, such as HIV, time in the infected state is long, 
difficult to characterise and ever-evolving, and so prevalence becomes uninformative of 
incidence. In 1995, Brookmeyer and Quinn [7] demonstrated that a cross-sectional 
approach to incidence estimation could nevertheless be used, by considering instead an 
early phase of HIV infection, termed ‘recent’ infection, that could be better characterised.  
In the pioneering work of Brookmeyer and Quinn [7], the detection of p24 antigens in 
subjects with undetectable HIV antibodies identified putatively ‘recently’ infected 
subjects. However, this produced a state of ‘recent’ infection that lasted for only a few 
weeks, and therefore unrealistically large samples would be required to obtain precise 
incidence estimates [7, 8, 10, 11]. This triggered the development of further tests for 
recent infection, seeking more enduring post-infection ‘recent’ states [8-10, 12]. 
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However, it quickly became evident that there is substantial inter-subject variability, with 
the result that some subjects who have been infected for many years nevertheless return 
‘recent’ results [8-10, 12-14, 72-81] – typically referred to as ‘false-recent’ results. 
Accounting for this phenomenon has led to the emergence of two schools of thought 
[18-22].  
In the first school of thought, additional parameters are used to discount the observed 
‘recent’ results in the survey by the ‘false-recent’ results. This was introduced in 2006 by 
McDougal et al [16], who proposed an incidence estimator containing a test ‘sensitivity’, 
‘short-term specificity’ and ‘long-term specificity’, which was further studied by 
Hargrove et al [17]. However, in 2009, McWalter and Welte demonstrated redundancy in 
these parameters [23, 82]. Furthermore, relaxing the assumption of uniform infection 
times made in these earlier incidence estimators [23], McWalter and Welte showed that 
one can instead obtain a particular weighted average of recent, and potentially changing, 
incidence. Two parameters naturally occur in their incidence estimator: a ‘false-recent 
rate’ (FRR) and ‘mean duration of recent infection’ (MDRI) [25]. A comparison of 
incidence estimators revealed that even under steady state conditions, only this last 
estimator produced unbiased results [23]. Wang and Lagakos derived the same estimator, 
however using additional assumptions [24].  
Despite these advances, problematic assumptions remained: namely that (i) ‘false-recent’ 
results are caused (solely) by test ‘non-progressors’, defined as individuals who never 
transition out of the ‘recent’ state, while all remaining individuals transition (once) out of 
this state within some relatively short period after infection (for example, a year); and 
(ii) post-infection survival and test classifications are independent [23-25]. Under these 
assumptions, the above-mentioned FRR is the proportion of (infected) individuals who 
are ‘non-progressors’, and MDRI is the average time spent alive and in the ‘recent’ state 
for all other individuals [23-25]. However, it is known that subjects may transition 
(multiple times) between the ‘recent’ and ‘non-recent’ states over many years post 
infection (for example, patients who have AIDS or who are on antiretroviral treatment 
may return to the ‘recent’ state) [72-80] and that survival and test results are dependent 
(for example, survival is related to viral load and treatment [83-85], which are in turn 
related to biomarker results [72-81, 86]).  
In the second school of thought, the original one-parameter incidence estimator (that is, 
the estimator containing a single test property) of Brookmeyer and Quinn [7] has been 
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retained [15, 27, 87-90]. All inter-subject variability (including that elsewhere called 
‘false-recent’ results) is captured in a consistently-defined MDRI, which, in this 
paradigm, is defined as the average time spent alive and in the ‘recent’ state, considering 
all subjects over their full post-infection lifetimes [7, 15]. 
However, as the maximum post-infection time at which a person can return a ‘true-
recent’ result can now be decades, this approach has a number of limitations. For one, the 
assumption of a constant susceptible population size over this duration preceding the 
survey, implicit in all estimators [7, 23, 25], becomes more likely to be substantially 
violated. Also, the larger this maximum post-infection time, the less informative is the 
measured incidence of recent incidence, as the implied weighting of historic incidence 
extends further into the past – thus limiting the ability to detect changes in incidence. 
Researchers have summarised this complexity into a ‘shadow’ or lag of the incidence 
estimator: by assuming a demographic and epidemiological history for the population, 
and particular dynamics of the test for recent infection, the cross-sectional study result 
can be interpreted as an estimate of incidence some time into the past [15, 27].  
Furthermore, the MDRI is more difficult to estimate practically, as it requires a detailed 
understanding of survival and test dynamics even at very large times post infection. The 
MDRI would also be prone to varying by time and place – for example, by treatment 
coverage and as post-infection survival evolves. The estimation of the MDRI is 
burdensome, requiring the extensive longitudinal studies [16, 17, 91-103] that this cross-
sectional surveillance approach aims to avoid. It is therefore key that a single MDRI 
estimate can be used in a number of cross-sectional incidence studies (across study 
populations and time).  
Given these limitations of operating in a one-parameter world, and the current non-ideal 
performance of tests (occurrence of ‘recent’ results at large times after infection), this 
approach is not pursued in this work. 
Alongside the refinement of the theoretical framework for incidence estimation, there has 
been substantial development of Tests for Recent Infection (TRIs), or Recent Infection 
Testing Algorithms (RITAs), over the years [8-10, 12]. These tests are typically based on 
measuring some viral process or host response, with classification rules used to map 
quantitative biomarker measurements onto dichotomous ‘recent’ and ‘non-recent’ 
classifications.  
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A couple of years after the initial work of Brookmeyer and Quinn [7], Janssen et al [91] 
coined the term Serological Testing Algorithm for Recent HIV Seroconversion 
(STARHS) when he introduced a test for recent infection based on a modification of an 
existing diagnostic test. By tailoring laboratory procedures so that antibody measurements 
grew more slowly over time after infection than they did in the original diagnostic test, 
readings below a chosen threshold were interpreted as being indicative of ‘recent’ 
infection. This concept has since been used to develop ‘less-sensitive’ or ‘detuned’ 
versions of other existing diagnostic tests [100, 104-106]. 
In 2002, the CDC attempted to overcome the HIV subtype-dependence of earlier tests 
with the creation of the BED assay, specifically for this surveillance application [92, 96, 
107]. Low BED measurements of HIV-specific Immunoglobulin G (IgG) in total IgG 
indicate ‘recent’ infection. However, subtype differences remain [8, 9, 12, 108-110] and a 
significant proportion of subjects return ‘recent’ results years after infection  [9, 10, 12, 
16, 17, 26, 28, 73, 75-78, 111, 112]. For this surveillance application, an FRR of even a 
few percent critically undermines the potential of a test. In an attempt to address the high 
FRR, the CDC consequently developed the Limiting Antigen (LAg) assay, described in 
2010 [98, 113]. Antibody avidity, the strength of binding between virus antigens and host 
antibodies, is expected to increase over time since infection as the host’s immune 
response matures [9, 107]. LAg seeks to quantify this avidity, with measurements below a 
chosen threshold producing ‘recent’ classifications [98, 113]. The assay has since become 
widely used, despite remaining uncertainty about its performance [79, 81, 114]. 
A number of other candidate tests for recent infection have been developed, founded on 
concepts similar to those introduced above [8-10, 12, 107, 115-121]. Over the last few 
years, further innovative tests have been proposed: some based on measuring genetic 
diversity [122-125]; some using platforms that produce a number of related serological 
markers (such as measures of titre and avidity of antibodies to various HIV proteins), 
which are then together used to produce a classification [39, 40, 44, 86, 102]; some 
combining multiple independently-developed biomarkers, including clinical indicators 
such as viral load and CD4 cell counts [13, 61, 88, 89, 95, 101, 126] (sometimes termed 
Multi Assay Algorithms); and some even of the form of rapid tests [39, 40, 44, 127-129]. 
However, all of this development of new tests for recent infection has continued to be 
undermined by a number of obstacles, discussed below. 
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For application to incidence surveillance, tests must first be characterised – a term used 
in this work to describe the estimation of test properties appearing in the incidence 
estimator, namely the FRR and MDRI. This process of test characterisation has presented 
a bottleneck to test development, as developers and researchers have grappled with the 
questions of which test properties to estimate, how best to estimate them, and where to 
get the relevant data. 
Estimation of the MDRI has typically relied on longitudinal data that describes the 
trajectories of biomarkers as a function of time since infection [16, 17, 91-103]. 
Capturing such data requires the regular follow-up and testing of (initially HIV-negative) 
subjects, and is therefore costly and logistically burdensome. Even given suitable data, 
confusion about the applicability of the theoretical framework for incidence inference has 
led to inconsistencies in, or unclear definitions of, test properties estimated in the 
literature. Furthermore, various analytical methods for characterising tests have been 
applied, and understanding methodological differences and identifying best practices has 
been an ongoing topic among experts in the field over recent years [130]. 
In principle, given a general incidence inference framework, any test can be consistently 
characterised and applied in a cross-sectional study to obtain valid incidence estimates. 
However, this mathematical process alone reveals little about the practical utility of a test 
for this surveillance application. Further challenges in test development therefore arise 
from the lack of standard measures to assess test performance, which are required to 
optimise tests and understand the relative performances of proposed tests. Within the 
research community, a ‘Target Product Profile’ [14] has been circulated and provides 
criteria candidate tests must meet. These criteria include a minimum MDRI (of 4 months) 
and maximum FRR (of 2%), and various conditions that support the viable transferability 
of technology. However, there remain no standards to further discriminate among tests, 
and various analyses have been published on candidate tests. These analyses often present 
estimates of test ‘sensitivity’ and ‘specificity’ (to detect infection within some specified 
period post infection)  [92, 109, 111, 112, 115, 116, 118, 120, 124, 125] – metrics 
familiar in diagnostics settings, rather than performance characteristics which can be 
directly interpreted as indicating a test’s utility for this unique population-level 
surveillance application. Alternatively, analyses compare incidence estimates obtained 
using various tests for recent infection to one another or to incidence measured 
longitudinally, studying the same population or even using the same sample of subjects 
(often termed ‘field validation’) [16, 90, 95, 103, 131-133]. However, this comparison is 
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uninformative as any consistent characterisation and application of tests will lead to 
incidence estimators with similar expected values (although potentially different 
variances).  
In the light of the challenges noted above, there has been a call, in meetings convened by 
the World Health Organisation (WHO) Technical Working Group on HIV Incidence 
Assays, for a statistically sound and consistent comparative analysis of existing tests for 
recent infection as a logical next step to move the field forward [10, 14]. In response to 
such calls, in 2010, the Bill and Melinda Gates Foundation (BMGF) awarded a grant to 
establish the Consortium for the Evaluation and Performance of HIV Incidence Assays 
(CEPHIA) [47] – a collaboration between Public Health England (PHE) in the UK; 
Blood Systems Research Institute (BSRI) in the USA; University of California, San 
Francisco (UCSF) in the USA; and the South African Centre for Epidemiological 
Modelling and Analysis (SACEMA) in South Africa.  
The broad mandate of CEPHIA is to foster consensus in the scientific community. More 
specifically, CEPHIA was tasked with developing a specimen repository, and rigorously 
evaluating existing and new tests for recent infection. Given the successes of CEPHIA, in 
2013, the BMGF awarded funding for a second phase of CEPHIA: the repository is being 
expanded to include non-plasma specimens (such as dried blood spots, oral fluids, stool 
samples, and urine), and the consortium is providing specimens and analytical support to 
a number of ‘biomarker discovery’ groups currently developing novel biomarkers to 
identify ‘recent’ infection. It is as a member of the core CEPHIA team that much of the 
work presented in this thesis has been performed. 
Interest in tests for recent infection extends beyond cross-sectional incidence surveillance, 
but the framework for each application is unique and nuanced. In particular, in countries 
such as France and the USA, HIV incidence is estimated by testing patients newly 
diagnosed with HIV in health care settings for ‘recent’ infection [134-138]. By applying 
tests for recent infection to only patients who actively seek HIV testing, rather than those 
identified as HIV-positive in a cross-sectional survey of the population, testing behaviour 
needs to be accounted for when estimating incidence for the general population. Another 
application that has attracted considerable interest is the estimation of the durations of 
infections in (newly diagnosed) individuals and the reporting of these results to clinicians 
and patients, for example, for purposes of contact tracing and tailoring treatment plans. 
Tests for recent infection have been routinely utilised in clinical settings in areas of the 
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UK since 2009 [139-141], and this application has been piloted elsewhere [142]. Inter-
subject variability in test dynamics should ideally be very small for such individual-level 
diagnostic applications. 
Furthermore, the discourse on incidence estimation is moving rapidly towards 
methodologies that utilise multiple datasets to estimate incidence – combining 
measurements of the prevalence of ‘recent’ HIV infection with, for example, sentinel 
HIV prevalence surveillance data, national household survey data, life tables and 
treatment coverage statistics. Given the substantial subtleties around each application of 
tests for recent infection, the scope of this work is restricted to incidence estimation from 
cross-sectional surveys.  
1.3 Contributions	and	Structure	
	of	Thesis	
This work has focused on addressing key shortcomings in the field, which are highlighted 
in the review provided in Section 1.2. The contributions made, and the presentation of 
these in this thesis, are described below. 
A key aspect of this research has been the dissemination of the work undertaken: in 
international journals [29-32] and local newsletters [45, 46], through presentations and 
posters at local and international conferences [33-44], through collaborations with various 
working groups and organisations, 2 as a member of the Consortium for the Evaluation 
and Performance of HIV Incidence Assays (CEPHIA) [47], by providing training [49, 50] 
and by developing an online resource for guidance and analysis tools [48]. A selection of 
these referenced items is presented in this thesis. 
Within each chapter, the core (published or prepared) journal article is presented as the 
first section, and remaining sections provide ancillary analysis details, related ideas, and 
applications of the concepts described. All articles are reproduced with permission of the 
publishers – with only minor modifications to text and notation, and so there is some 
___________________________ 
2  For example, the Centers for Disease Control and Prevention (CDC) [50], World Health 
Organization (WHO) Technical Working Group on HIV Incidence Assays [51], and HIV 
Modelling Consortium Task Team for Incidence Assay Characterization [52]. 
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repetition of background information. Because accepted terms evolved over the years 
during which this research was conducted, terminology varies slightly across sections. 
Before trying to answer specific questions about its application, a sound theoretical 
foundation for incidence inference is required. A general framework for incidence 
inference was therefore derived, relaxing assumptions, made in previously proposed 
incidence estimators, of demographic and epidemiological equilibrium and about test 
dynamics. This derivation is presented as the opening work of this thesis in Chapter 2 
[29]. The general framework was constructed by introducing a post-infection time cut-off, 
ܶ, separating ‘true-recent’ and ‘false-recent’ results, with an appropriately defined ‘false-
recent rate’ (FRR) and ‘mean duration of recent infection’ (MDRI) emerging from the 
analysis as the required test properties. Any unavoidable residual bias, such as from a 
varying susceptible population size, is systematically defined. Bias terms are considered 
in detail as part of ancillary explorations of the incidence estimator, which also include 
discussions on test characterisation, the moments of the incidence estimator, and the 
prospects of estimators containing additional test property parameters. An online resource 
and set of analysis tools [48], produced to support the application of the framework 
presented, are also described. 
Having developed a general theoretical framework for incidence inference, focus shifts to 
the estimation of the required test properties – namely the FRR and MDRI. These 
properties are typically estimated in separate studies, prior to the incidence survey. The 
estimated test properties would ideally be recycled across multiple incidence surveys. 
A bottleneck to the estimation of the MDRI has been the scarcity of specimen sets needed 
to generate relevant data – traditionally understood to contain multiple specimens per 
subject, drawn over time from soon after some (well-estimable) infection date. 
Furthermore, any access to such precious specimens usually requires that preliminary 
estimates of test properties suggest suitable promise of the test. A novel idea for obtaining 
preliminary estimates of the MDRI, using more widely available specimens, is therefore 
formalised, and its utility demonstrated, in Chapter 3 [31].   
Under the proposed methodology, only a single specimen for each subject in the sample 
is required, drawn at the time of the first HIV-positive test, as well as knowledge of the 
time of the last HIV-negative test [143]. Moreover, if the period between HIV tests is 
approximately equal to the post-infection time cut-off  ܶ (defined above), the proposed 
method of analysis becomes non-parametric, safeguarding against bias from poor 
Introduction and Overview  12 
parametric assumptions (at the expense of reduced precision). The framework in which 
these concepts are presented assumes that infection times are uniformly distributed 
between HIV-negative and HIV-positive tests, and this is reasonable in settings where 
testing schedules can be considered to be independent of subject behaviour. The 
methodology is explored by characterising two tests for recent infection (Less-sensitive 
Vitros [100] and Less-sensitive Vironostika [104]), using data from blood donors in 
South Africa and the USA. Ancillary analysis details are provided, and two further 
applications are summarised – a first characterisation of a new candidate test (based on 
SMARTubeTM technology) [35], and a local characterisation of an already widely used 
test (the BED assay) [33]. At the time of performing the work, the framework of 
McWalter and Welte [25] was in use, and therefore all analyses for estimating the MDRI 
were founded on the definitions of test characteristics presented in their work. A 
discussion of the application of the approach, under the general inference framework 
provided in Chapter 2, shows how the ideas presented remain just as relevant and 
valuable. 
Even when the more precious panels of specimens are available, obtained by following 
subjects over time, various methods of estimating the MDRI have been used. There had 
been little exploration of the methodological differences, and of any artefacts in test 
characterisation which would in turn bias incidence estimates. An extensive, 
benchmarking exercise was therefore performed, and is presented in Chapter 4 [53]. 
Prominent researchers in the field were invited to participate in this project, which was 
commissioned by the HIV Modelling Consortium [144]. A platform for stochastically 
simulating data panels was developed. A large number of characterisation methods were 
implemented, and each used to estimate the MDRI. By simulating data, the experiment 
could be replicated many times, and the true MDRI calculated. This allowed the 
performance of the methods to be rigorously evaluated for the first time, in scenarios 
which systematically varied the extent of challenges encountered in reality. 
A key obstacle to accurate MDRI estimation, as highlighted by the results of the 
benchmarking exercise, is the unknown infection times of subjects (which are only 
known to lie between last HIV-negative and first HIV-positive tests). An innovative idea 
is presented for limiting the bias that this could cause: subjects only enter the ‘HIV-
positive’ (and ‘recent’) state some short time after detectable infection, where the time of 
entry into this deferred state could be more accurately estimated (than the time of entry 
into the otherwise-defined ‘HIV-positive’ state) given typically available data [34]. The 
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procedure for incidence estimation would remain unchanged, with the understanding that 
a short time lag for incidence estimation is introduced. Also, a framework is outlined for 
the estimation of infection times from subjects’ diagnostic testing histories. Published 
analyses have paid little attention to this aspect of MDRI estimation, and any consequent 
artefacts in the estimation (or inconsistent definitions) of infection times would bias 
MDRI estimates.  
Results from the characterisation of five prominent tests for recent infection are presented 
in Chapter 5 [32], and demonstrate the application of the methodologies developed in 
preceding chapters. This is the first of a series of planned publications by CEPHIA, and is 
the culmination of over three years of intense specimen collection and testing, and data 
gathering and analysis – all applying stringent quality control measures which it is hoped 
will guide standards in the field. Potential users of cross-sectional incidence surveillance 
have looked to CEPHIA for independent and careful guidance on its application, and 
therefore this work represents a particularly important milestone. Results indicate that 
each assay, used according to developers’ guidelines, performs inadequately in isolation, 
and therefore further optimisation of these assays is required. Since viral suppression 
appears to drive FRRs, optimal use of assays is likely to include supplemental viral load 
tests. CEPHIA, having produced an invaluable data resource, and other groups are 
currently exploring this and more.  
By consistently applying the concepts presented above, any test can in principle be 
characterised and used to produce valid incidence estimates. With the current surge in the 
development of tests for recent infection, the need for standard measures of a test’s 
performance for this surveillance application has become increasingly urgent. A guidance 
article, targeted at test developers and analysts, is therefore presented in Chapter 6, and 
argues against the widespread use of sensitivity and specificity measures, which can 
produce spurious assessments of a test’s utility. Since bias in incidence estimation is 
demonstrably small in the relevant contexts, the precision of the incidence estimator 
provides the only remaining important metric of performance. Although precision is 
context-specific, it provides a standard measure to assess, optimise and compare tests for 
recent infection. 
As general and standard frameworks for incidence estimation and test evaluation are 
adopted, discourse in the field is inevitably moving towards application. Practical aspects 
of test optimisation are therefore briefly discussed, and include the scope of the 
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optimisation, the context-dependence of test performance, and the consideration of other 
test design criteria. The intention of this final section of the work is to touch on some of 
the topics that are likely to move towards the forefront of future discussions, given recent 
developments in the field, including those provided in this work. 
In closing, the contributions presented in this thesis are summarised in Chapter 7, and 
some perspectives on future directions are provided. 
Appendix A provides a detailed account of the calculation of outputs in each of the online 
analysis tools. All programming was performed in Matlab (The MathWorks, Inc., 
R2013b, 8.2.0.701), and selected code is provided in Appendix B.  
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Chapter	2
 
A	General	Theoretical	
Framework	for	Incidence	
Inference	
A general theoretical framework for the estimation of incidence, from cross-sectional 
surveys using tests for recent infection, is presented. 
In Section 2.1, a general incidence estimator is derived, relaxing assumptions contained in 
earlier proposed estimators. This work is a reproduction of a published journal article 
[29]. 3  The framework is further explored, and ancillary analysis details provided, in 
Section 2.2, which was published as an appendix to the article. An online resource was 
developed over the course of this work, providing theoretical background information and 
practical analysis tools to users of this surveillance approach [48], and is described in 
Section 2.3. 
___________________________ 
3  The contents of Section 2.1 have been published as: ‘Kassanjee R, McWalter TA, 
Bärnighausen T, Welte A. A new general biomarker-based incidence estimator. Epidemiology. 
2012; 23(5):721-728’. The article was reproduced with permission from Wolters Kluwer Health, 
Lippincott Williams & Wilkins. The manuscript was primarily written by RK, who performed the 
analysis, both formal, and of simulated data. TAM generated the simulated data. AW and TAM 
helped conceive the analysis and assisted in writing the manuscript. TB supported the project by 
reviewing results and text. 
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2.1 A	New	General	Biomarker‐Based	
Incidence	Estimator	
2.1.1 Introduction	
The measurement of disease incidence — the rate of new cases in a population — is 
essential for effectively monitoring the spread of disease, and for targeting and assessing 
interventions. Longitudinal studies which directly count new infections are costly, time-
consuming, and prone to capturing unrepresentative behaviour. Estimating incidence by 
modelling multiple prevalence values requires knowledge of the survival of those affected 
and unaffected by the condition. For incurable conditions such as HIV, prevalence 
emerges as a slow convolution (averaging) of historic incidence with survival and the 
variation in the size of the susceptible population. Thus, changes in prevalence over time 
are poor proxies for recent incidence. On the other hand, it has long been noted that 
prevalence of recent infection can be a very good proxy for recent incidence. Deriving an 
incidence estimate from a single cross-sectional survey has enormous practical 
advantages. There has consequently been considerable interest in developing recent 
infection tests based on host or viral biomarkers. This approach has been explored 
particularly in the context of HIV incidence [8-11]. A number of methodologies have 
been proposed [7, 15-17, 24, 25, 87, 91, 107, 143, 145, 146], and these have been 
reviewed and critiqued elsewhere [8-11, 18-21, 23, 26].  
The limitations of current methodologies (using biomarkers for recent infection to 
estimate incidence) are hindering consensus, the development of test technology, and 
field implementation. There is no simple solution to the problem of estimating incidence, 
a rate, from a single cross-sectional survey, because there is an unavoidable loss of 
information when a population history is summarised into an instantaneous population 
state. Previously proposed estimators have been derived under very specific assumptions 
(known to be substantially violated) concerning both the epidemiological and 
demographic context, as well as the behaviour of the recent infection tests (as will be 
described below) [7, 15-17, 23-25, 87, 91, 107, 143, 145, 146]. 
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Methodological	background	
Most tests for recent HIV infection classify persons as ‘recently’ infected based on a 
‘below-threshold’ immune response such as antibody titre, avidity, or HIV-specific IgG 
proportion [8-10]. There is some evidence, for all tests proposed to date, that a small 
minority of persons remain classified as ‘recently’ infected long after infection [16, 17]. 
Additionally, late-stage HIV disease or treatment leading to viral suppression may 
diminish the host immune response, returning long-infected persons to the ‘recent’ 
infection state [8-11, 73-76]. This is the physiological basis for the introduction of the 
notion of ‘false-recent’ results, the effects of which are encoded into a population-level 
parameter widely called the ‘false-recent rate’ [16, 17, 24, 25]. This is not a ‘rate’ in the 
conventional sense, but the proportion of persons not ‘truly’ recently infected, who 
nevertheless produce a ‘recent’ result with the biomarker. In earlier analyses, dynamics 
were summarised into only one parameter – a mean duration of recent infection [7, 15].  
Much of the analytical complexity and methodological contention arises from the 
difficulty of formally defining ‘true-recent’ and ‘false-recent’ results. Initially, attempts to 
account for ‘false-recent’ results were inspired not just by the biological variability noted 
above, but by a pattern of cross-sectional incidence estimates that were higher than 
prospectively obtained estimates in the same populations. However, as pointed out by 
Brookmeyer [18], subtracting ‘false-recent’ results is not the only way to obtain 
consistency – one can simply account for all times spent in the ‘recent’ state when 
defining the mean duration of recent infection. In practice, however, this creates other 
problems, one being that the development of a new test, a process that includes the 
estimation of a mean duration of recent infection, cannot feasibly wait for a decade or two 
of follow-up of a seroconverter cohort. Also, a long duration of recent infection (as 
defined by existing tests) can cause problematic temporal bias or blurring of incidence 
estimates – the extreme case being the use of prevalence as a proxy for incidence. Indeed, 
the notion of recent infection does not provide a totally unbiased estimate of the 
instantaneous incidence, but, at best, a weighted average of recent incidence, which in 
principle can be very close to a uniformly-weighted average over recent times. This 
statistical weighting may be understood by noting that, as people can persist in the 
‘recent’ state for some time, a range of past values of incidence contributes to the current 
population count of ‘recently’ infected individuals.  
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Kaplan and Brookmeyer [15] and, more recently, Brookmeyer [27] explored this in the 
special case of incidence varying linearly with time, in which case the temporal statistical 
weighting can be summarised as a time lag of the incidence estimator, which they refer to 
as the ‘shadow’. The longer this ‘shadow’, the less informative the estimate, with less 
power to detect changes in incidence over short periods of time. A key benefit of a 
rigorous notion of ‘false-recent’ results (in addition to a complementary notion of the 
mean duration of recent infection that is more practical to measure) is the reduction of 
this temporal bias. 
In order to implement a formally consistent definition of both a ‘false-recent rate’ and 
mean duration of recent infection, an explicit time cut-off, ܶ, is introduced to separate 
‘true-recent’ and ‘false-recent’ results. To lead to an informative estimator, this cut-off, 
though theoretically arbitrary, must be chosen to reflect the temporal dynamic range of 
the test for recent infection; that is, at a time ܶ post infection, the overwhelming majority 
of infected people should no longer be testing ‘recent’, and furthermore, ܶ should not be 
larger than necessary to achieve this criterion. Although this time cut-off is reminiscent of 
a cut-off in previous analyses [16, 17], the present work dispenses with problematic 
assumptions of past analyses that have prevented the widespread use of cross-sectional 
incidences estimation from data on recent infection.  
2.1.2 Analysis	
The exposition proceeds in four key steps:  
1. The derivation of a simple, general expression for a weighted mean recent
incidence, which can be constructed without any particular assumptions about the
demographic or epidemiological history or the dynamics of the biomarker used to
classify persons with a disease (such as HIV infection) as ‘recently’ or ‘non-
recently’ infected.
2. The derivation of an incidence estimator by expressing the general weighted
incidence in terms of (i) quantities that can be known by an experimenter, and
(ii) a bias term, the size of which can be approximately estimated in terms of a
number of dimensionless parameters that characterise the failure of the test and
context to conform to certain idealisations.
3. The estimation of the test characteristics.
4. The application of the methodology to estimate incidence in simulated scenarios,
to confirm the consistency of confidence intervals.
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A	general	expression	for	weighted	incidence	
A test for recent infection may employ an arbitrarily complex combination of criteria to 
classify infected persons as ‘recently’ or ‘non-recently’ infected [10]. It is understood that 
there will be natural inter-subject variability in progression through these categories after 
becoming infected. This range of responses may be captured in a function ோܲሺ߬ሻ, which is 
the probability of still being alive and ‘recently’ infected at time ߬ post infection. Let 
஺ܲሺ߬ሻ denote the probability of being alive at time ߬ post infection. 
Throughout this work, ‘infection’ refers to the detectable infection of HIV, which 
depends on the diagnostic test being used. Practically, the delay between actual infection 
and detectable infection merely implies an epidemiologically inconsequential delay in 
entering the operationally HIV-positive state. This point is explored in more detail in 
Section 2.2.1. 
Assuming a continuous population dynamic, and using the reference time ݐ ൌ 0 as the 
time at which a survey is conducted, consider the following explicit weighted averaging 
of incidence over a period of duration ܶ: 
ܫ் ൌ
׬ ܫሺݐሻ ௌܰሺݐሻ ோܲሺെݐሻ dݐ଴ି்
׬ ௌܰሺݐሻ ோܲሺെݐሻ dݐ଴ି்
, (2.1)
where the (possibly time-dependent) incidence is denoted by ܫሺݐሻ and the susceptible 
population by ௌܰሺݐሻ. The incidence at time ݐ contributes to ܫ் with weight ௌܰሺݐሻ ோܲሺെݐሻ, 
that is, with a weight proportional to (i) the susceptible population vulnerable to being 
infected at time ݐ, ௌܰሺݐሻ, and (ii) the probability of a person infected at time ݐ still being 
alive and ‘recent’ at the time of the survey, ோܲሺെݐሻ. It will emerge that, for practical 
purposes, this is very close to a uniformly-weighted average of incidence over a period 
preceding the survey. There is no exact way to extract either a uniformly-weighted 
average or an estimate of incidence at one point in time, given the substantial 
compression of information from a population history into a cross-sectional survey. 
If there is a critical value, ௖ܶ௥௜௧, with the property that ௌܰሺെݐሻ ோܲሺݐሻ ൌ 0 for all ݐ ൐ 	 ௖ܶ௥௜௧, 
then all choices of ܶ ൐ ௖ܶ௥௜௧ yield the same result – the one obtained by Brookmeyer and 
Quinn [7]. For any finite value of ܶ, the ‘shadow’, or temporal bias, is strictly less than ܶ, 
and it is less than ܶ/2 if ௌܰሺെݐሻ ோܲሺݐሻ is a strictly decreasing function of time in the 
interval ሾ0, ܶሿ. 
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Figure 2.1: Epidemiological, demographic, and recent infection test dynamics 
The figure portrays the functions (and areas under functions) of relevance for interpreting 
the weighted average of incidence that is measured in the cross-sectional survey, 
performed at time ݐ ൌ 0. The functions ܫሺݐሻ and ௌܰሺݐሻ are the incidence and susceptible 
population size at time ݐ, respectively; ஺ܲሺ߬ሻ is the probability that a subject is alive at 
time ߬ after infection; and ோܲሺ߬ሻ is the probability that a subject is alive and ‘recently’ 
infected at time ߬ after infection. 
In the interpretation of Equation (2.1), it is useful to consider the labelled areas in 
Figure 2.1:  
 Areas ܣ  and ܦ  (the areas under the curve ܫሺݐሻ ௌܰሺݐሻ ோܲሺെݐሻሻ  represent the
‘recently’ infected population at ݐ ൌ 0, infected for times less than and greater
than ܶ, respectively. ܣ is the numerator of Equation (2.1).
 Areas ܤ  and ܥ  (the areas between the curves ܫሺݐሻ ௌܰሺݐሻ ஺ܲሺെݐሻ  and
ܫሺݐሻ ௌܰሺݐሻ ோܲሺെݐሻ,  that is, the infected population excluding the ‘recently’
infected population) represent the ‘non-recently’ infected population at ݐ ൌ 0,
infected for times less than and greater than ܶ, respectively.
 Area ܧ  (the area under the curve ௌܰሺݐሻ ோܲሺെݐሻ ) is the denominator of
Equation (2.1).
Hence, Equation (2.1) can be rewritten as 
ܫ் ൌ ܣܧ . (2.2)
T
A
B
C
D
I(t)NS(t)PR(−t)
I(t)NS(t)PA(−t) I(0)NS(0)
t 0
T
E
NS(t)PR(−t)
NS(0)
t 0
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Previous derivations of incidence estimators have relied on assumptions of (at least 
recent) epidemiological and demographic equilibrium, some simplifications of the post-
infection dynamics of tests for recent infection, or both. To elucidate the impact of 
general non-equilibrium conditions, it is useful to express the crucial time-dependent 
quantities in terms of time-dependent relative deviations from conveniently chosen 
constants: 
ܫሺݐሻ ൌ ܫ் ∙ ൫1 ൅ ூ݂ሺݐሻ൯ (2.3)
ௌܰሺݐሻ ൌ ௌܰሺ0ሻ ∙ ቀ1 ൅ ே݂ೄሺݐሻቁ (2.4)
஺ܲሺ߬ሻ ൌ 1 ൅ ௉݂ಲሺ߬ሻ. (2.5)
These equations do not represent any approximations or truncated power series, but are 
general, exact decompositions of ܫሺݐሻ,  ௌܰሺݐሻ  and ஺ܲሺ߬ሻ , the point of which is to 
characterise, rather than assume away, the non-ideal aspects of the population and test 
dynamics. More specifically: ூ݂ሺݐሻ  is defined to capture the time dependence of the 
fractional deviation of incidence relative to the weighted incidence as defined in the 
period preceding ݐ ൌ 0; ே݂ೄሺݐሻ is defined to capture the time dependence of the fractional 
deviation  of  the  susceptible  population  from  its  instantaneous  value  at  ݐ ൌ 0; 
and െ ௉݂ಲሺ߬ሻ is defined as the probability of not surviving for at least a time ߬  after 
infection. The averages, over the period of duration ܶ preceding the survey, of products 
of ூ݂ሺ. ሻ, ே݂ೄሺ. ሻ and ௉݂ಲሺ. ሻ, will be shown to summarise the effect of these deviations on 
incidence estimates. 
Particular	forms	for	an	incidence	estimator	
Incidence estimation involves expressing Equation (2.2) as a function of test 
characteristic parameters, and population states. The key link between the numerator and 
the population states is 
ܣ ൌ ோܰ െ ܦ, (2.6)
where ோܰ is the size of the ‘recently’ infected population at ݐ ൌ 0 (Figure 2.1). Various 
authors have used different terms for the situation that ܦ ് 0 (Figure 2.1). These terms 
have included ‘misclassification’, ‘false-positivity’, ‘false-recency’, ‘imperfect long-term 
specificity’, the ‘long tail’ or ‘non-progression’ of the test for recent infection [16-21, 23, 
25, 146]. Formally, the increasingly used term false-recent rate, ߚ், given a cut-off ܶ, is 
defined in this work as the probability that a randomly chosen person infected for longer 
than time ܶ will be classified as ‘recently’ infected by the recent infection test. 
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A variety of approaches may be used for estimating the area ܦ. For example, 
ܦ ൌ ܦܥ ൅ ܦ ∙ ሺܥ ൅ ܦሻ
ൌ ߚ் ∙ ൫ ାܰ െ ሺܣ ൅ ܤሻ൯, (2.7) 
where 
ߚ் ൌ ܦܥ ൅ ܦ , (2.8)
and the areas ܣ ൅ ܤ and ܥ ൅ ܦ represent the current population infected for times less 
than and greater than ܶ, respectively, so that ܣ ൅ ܤ ൅ ܥ ൅ ܦ ൌ ାܰ is the size of the HIV-
positive population.  
By inspection of Figure 2.1,  
ܣ ൅ ܤ ൌ න ܫሺݐሻ ௌܰሺݐሻ ஺ܲሺെݐሻ dݐ
଴
ି்
. (2.9)
Using the parameterisation in terms of the dimensionless ூ݂ሺ. ሻ,  ே݂ೄሺ. ሻ,  and ௉݂ಲሺ. ሻ 
introduced earlier, this gives: 
ܣ ൅ ܤ ൌ න ܫ் ௌܰሺ0ሻ൫1 ൅ ூ݂ሺݐሻ൯ ቀ1 ൅ ே݂ೄሺݐሻቁ ቀ1 ൅ ௉݂ಲሺെݐሻቁ dݐ
଴
ି்
 
ൌ	 ܫ் ௌܰሺ0ሻܶ ∙ ሺ1 ൅ ߛଵ ൅ ߛଶ ൅ ߛଷ ൅ ߛସ ൅ ߛହ ൅ ߛ଺ ൅ ߛ଻ሻ, (2.10)
where the (also dimensionless) ߛ terms capture the consequences of the time-dependence 
of ܫሺݐሻ, ௌܰሺݐሻ and ஺ܲሺെݐሻ: 
ߛଵ ൌ 1ܶන ூ݂ሺݐሻ dݐ
଴
ି்
(2.11)
ߛଶ ൌ 1ܶන ே݂ೄሺݐሻ dݐ
଴
ି்
(2.12)
ߛଷ ൌ 1ܶන ௉݂ಲሺെݐሻ dݐ
଴
ି்
(2.13)
ߛସ ൌ 1ܶන ூ݂ሺݐሻ ே݂ೄሺݐሻ dݐ
଴
ି்
(2.14)
ߛହ ൌ 1ܶන ூ݂ሺݐሻ ௉݂ಲሺെݐሻ dݐ
଴
ି்
(2.15)
ߛ଺ ൌ 1ܶන ே݂ೄሺݐሻ ௉݂ಲሺെݐሻ dݐ
଴
ି்
(2.16)
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ߛ଻ ൌ 1ܶන ூ݂ሺݐሻ ே݂ೄሺݐሻ ௉݂ಲሺെݐሻ dݐ
଴
ି்
. (2.17)
These ߛ corrections may be positive or negative, but ߛଷ is always non-positive. 
Substituting into Equation (2.6) the expression for area ܦ given by Equation (2.7), and 
then the expression for area ܣ ൅ ܤ given by Equation (2.10), the numerator becomes: 
ܣ ൌ ோܰ െ ߚ் ାܰ ൅ ߚ்ܫ் ௌܰሺ0ሻܶ ∙ ൭1 ൅෍ߛ௞
଻
௞ୀଵ
൱. (2.18)
In the denominator of Equation (2.2), 
ܧ ൌ න ௌܰሺݐሻ ோܲሺെݐሻ dݐ
଴
ି்
 
ൌ	න ௌܰሺ0ሻ ቀ1 ൅ ே݂ೄሺݐሻቁ ோܲሺെݐሻ dݐ
଴
ି்
 
ൌ ௌܰሺ0ሻΩ் ∙ ሺ1 ൅ ߛ଼ሻ, (2.19)
where  
Ω் ൌ න ோܲሺെݐሻ dݐ
଴
ି்
 
ൌ න ோܲሺݐሻ dݐ
்
଴
, (2.20)
and 
ߛ଼ ൌ 1Ω் න ே݂ೄሺݐሻ ோܲሺെݐሻ dݐ
଴
ି்
. (2.21)
The mean duration of recent infection, Ω் , thus defined, given a cut-off ܶ , is the 
average time spent both alive and ‘recently’ infected, within a time ܶ post infection.  
Substituting into Equation (2.2) the expressions for the numerator, given by 
Equation (2.18), and the denominator, given by Equation (2.19), gives: 
ܫ் ൌ ோܰ െ ߚ் ାܰ ൅ ߚ்ܫ் ௌܰܶ ∙
ሺ1 ൅ ∑ ߛ௞଻௞ୀଵ ሻ
ௌܰΩ் ∙ ሺ1 ൅ ߛ଼ሻ . (2.22)
The right-hand side of this expression contains not only the mean duration of recent 
infection, Ω்; the false-recent rate, ߚ்; and the uninfected, ‘recently’ infected and ‘non-
recently’ infected populations at ݐ ൌ 0, ௌܰ ൌ ௌܰሺ0ሻ, ோܰ  and ܰேோ , respectively, where 
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ାܰ ൌ ோܰ ൅ ܰேோ; but also the weighted incidence, ܫ், itself. Rearranging and solving for 
ܫ் yields 
ܫ் ൌ ோܰ െ ߚ் ାܰௌܰ ∙ ሺΩ் െ ߚ்ܶሻ ∙ ሺ1 ൅ ݁ሻ
ିଵ, (2.23)
where the equation 
݁ ൌ ൬ Ω்Ω் െ ߚ்ܶ൰ ߛ଼ െ ߚ் ∙ ൬
ܶ
Ω் െ ߚ்ܶ൰෍ߛ௞
଻
௞ୀଵ
 (2.24)
contains all the details that cannot be directly evaluated from an experimenter’s point of 
view. 
Using the sample counts of uninfected, ‘recently’ infected and ‘non-recently’ infected 
subjects at ݐ ൌ 0 , ݊ௌ , ݊ோ  and ݊ேோ , respectively, where ݊ା ൌ ݊ோ ൅ ݊ேோ , a simple 
estimator of weighted incidence, with relative (fractional) error ݁, is obtained: 
ܫመ் ൌ ݊ோ െ ߚ்݊ା݊ௌ ∙ ሺΩ்െߚ்ܶሻ . (2.25)
By using definitions of the test characteristics (Ω்  and ߚ்), which are subtly different 
from those used previously [11, 16, 17, 24, 25, 146], an incidence estimator is thus 
obtained in which multiple transitions between ‘recently’ and ‘non-recently’ infected 
states are allowed, and no assumption is required about the independence of progression 
through the ‘recent’/‘non-recent’ states and post-infection survival (see [23] for a 
comparison of previously proposed incidence estimators). This estimator caters to 
completely general recent infection test dynamics. Bias arising from a non-constant 
incidence or susceptible population (in the period ܶ  before the incidence study) or 
imperfect survival (for ܶ after infection) is fully described by ݁, and further discussed 
below. 
The functional form for the estimator in Equation (2.25) can be obtained directly by 
assuming the system is in demographic and epidemiological equilibrium [146]. The 
present analysis shows that, when the system is away from equilibrium, in particular 
when incidence is not close to constant, this functional form provides an estimate of a 
particular weighted average of recent incidence, with a fractional bias ݁. In Section 2.2.1, 
the structure and meaning of the terms in Equation (2.24) for ݁ are discussed, and the bias 
is computed in model scenarios. 
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The ߛ଼ term, closely related to a bias implicit in all previously proposed estimators [23, 
25], is zero when the susceptible population is constant for ܶ preceding the survey, but a 
time-dependent susceptible population imposes a fundamental limitation to cross-
sectional incidence estimation. This highlights a key motivation for introducing ܶ  – 
namely to decouple the short-term dynamics of the test for recent infection from any 
long-term dynamics (which become convolved with the epidemiology and demography).  
The remaining ߛ terms appear only in conjunction with two further multiplicative factors: 
(i) the fraction, dominated by ܶ and Ω் , which would perhaps typically have a value 
close to two, and (ii) a factor of ߚ் . Therefore the estimator can yield a weighted 
incidence as accurate as desired if ߚ்  is sufficiently small, even when incidence and 
survival are varying substantially over the timescale set by ܶ. It is already well known 
that informative incidence estimation requires that ߚ்  be small [10, 11, 25, 147], and 
developers of tests for recent infection are seeking new technologies and algorithms to 
achieve this [86, 95]. 
Ultimately, the utility of a test for recent infection lies in its ability to produce accurate 
and precise incidence estimates. The expectation value and variance of the incidence 
estimator are approximated in Section 2.2.2. The uncertainty in the estimator, and its 
dependence on the test characteristics, is context-specific, depending on the history of 
HIV incidence and prevalence in the study population. The precision of the estimator 
improves with increasing mean duration of recent infection and with decreasing false-
recent rate. This trade-off has been previously noted [11], with the additional subtlety in 
the present analysis that the choice of ܶ  and the test characteristics are intrinsically 
related.4  
As noted in the introduction, the choice of ܶ  is theoretically arbitrary, but given the 
dynamics of available and foreseeable tests for recent infection, it will need to be around 
a year (or more). This implies a ‘shadow’ [15, 27] of about (but probably comfortably 
less than) half a year. This is considerably smaller than ‘shadows’ substantially exceeding 
one year, as obtained for a number of realistic scenarios considered by Brookmeyer [27] 
___________________________ 
4 The use of the precision of the incidence estimator, as a standard metric for assessing the trade-
off between the false-recent rate and mean duration of recent infection, was formally outlined in 
later work, and is discussed in Chapter 6. 
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when using the original one-parameter incidence estimator [7], and indeed implies less 
temporal bias or blurring than incurred in a cohort followed up for one year. 
Estimation	of	test	characteristics	
As with any method aiming to infer incidence from the cross-sectional application of a 
recent infection test, use of the newly derived estimator requires measuring some 
characteristics of the test ahead of its application in the surveillance context. This test 
characterisation should be performed as locally as feasible, because test performance may 
be context-specific [131]. The false-recent rate, ߚ் , and the mean duration of recent 
infection, Ω், are intuitively close to previously proposed definitions [11, 16, 17, 24, 25, 
146]. However, the definitions of the test characteristics emerging from this work allow, 
for the first time, arbitrary and complex test dynamics to be exactly captured. The 
estimation of each of the characteristics is briefly discussed below, with a slightly more 
technical discussion provided in Section 2.2.3.  
The false-recent rate, ߚ் , would ideally be estimated by the proportion of ‘recently’ 
infected subjects in a representative sample of individuals infected for longer than ܶ. It is 
also conceivable that ߚ் could be estimated from a combination of convenience samples, 
knowledge of the dynamics of anomalous subpopulations (who persist in, or return to, the 
‘recent’ state despite being infected for a time greater than ܶ) and knowledge of the 
embedding demography and epidemiology. 
The mean duration of recent infection emerges as naturally in longitudinal surveillance 
settings (where well-pedigreed biological specimens may be obtained repeatedly over 
time) as it does in the context of cross-sectional incidence estimation analysed above. An 
idealised experiment, which revisits initially HIV-negative persons after a time equal to 
the post-infection time cut-off  ܶ, and counts the frequency of ‘recent’ results in those 
who have become HIV-positive, provides a direct estimate for Ω், assuming a uniform 
distribution of infection times over the inter-test interval (and negligible mortality within 
ܶ post infection).5 Specifically, the ratio Ω்/ܶ	is the probability that a seroconverter is 
‘recently’ infected. This idea can be expanded to account for varying inter-test intervals, 
___________________________ 
5  The methodology for estimating the mean duration of recent infection using only specimens 
drawn at subjects’ first HIV-positive visits, and when inter-test intervals may be large, was 
formalised and demonstrated in earlier work, which is presented in Chapter 3. 
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depending on available data and knowledge of the dynamics of the test for recent 
infection, with an example of such an extension provided in Section 2.2.3.  
More traditionally, measurement of the mean duration of recent infection has been based 
on the frequent follow-up and recent infection testing of seroconverters. A form of 
survival analysis or regression can then be used to characterise the time taken to exit the 
‘recent’ state or the evolution of the biomarker over time after infection, respectively, 
thereby estimating the mean duration of recent infection.6  
Demonstration	of	methodology	using	simulated	data	
Having derived this new, general incidence estimator, and having outlined potential 
approaches for estimating the required test characteristics, implementation of the full set 
of analyses to infer incidence is demonstrated using simulated data.  
Assuming a particular epidemiological and demographic history, post-infection survival 
function, and dynamic for the test for recent infection, one thousand simulations were 
performed, each producing (independent) datasets to (i) estimate the false-recent rate, ߚ்; 
(ii) estimate the mean duration of recent infection, Ω்; and (iii) provide sample counts to 
infer incidence, ܫ், using the incidence estimator in Equation (2.25). 
The generation of the datasets and the maximum likelihood estimation of the test 
characteristics are described in Section 2.2.4. Asymptotic normality of maximum 
likelihood estimators (using estimated characteristics as proxies for true values) was used 
to approximate distributions for the estimated parameters and to obtain confidence 
intervals. Confidence intervals for incidence were then based on these results, the 
approximate normality of the trinomial sample counts (with sample statistics 
approximating population parameters), and the approximate normality of the incidence 
estimator and its estimated variance as provided in Section 2.2.2. As summarised in 
Table 2.1, almost exactly 95% of the one thousand thus generated 95% confidence 
intervals (one for each of the datasets) contained the relevant population parameter used 
in the simulation, demonstrating the numerical consistency of the full set of analyses.  
___________________________ 
6  Methods for estimating the mean duration of recent infection from longitudinal data obtained by  
following (initially HIV-negative) subjects over time were systematically explored in later work, 
and results are presented in Chapter 4. 
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Parameter Input valuei Average point 
estimate 
Average CI 
widthii 
CI coverageiii 
ࢼࢀ 2.5% 2.52% 1.93% 95.5%
ષࢀ  160 days 160.56 days 17.96 days 93.6% 
ࡵࢀ 2% 1.98% 1.38% 94.6%
i The true parameter value, as input into the data simulator 
ii Average width of realised 95% confidence intervals 
iii Percentage of realised 95% confidence intervals containing the true parameter value 
Table 2.1: Observed 95% confidence interval (CI) coverage of parameters using 
simulated data 
Simulated datasets were used to validate the methodologies presented for estimating test 
characteristics and incidence. For each parameter, namely the false-recent rate ߚ்  (%), 
mean duration of recent infection Ω் (days) and incidence ܫ் (% per annum), 1 000 point 
estimates and confidence intervals were obtained (the chosen modelled scenario and 
estimation methods are described in the main text above and Section 2.2.4), for ܶ ൌ 450 
days. The true parameter value, average point estimate, average 95% confidence interval 
(CI) width and CI coverage (%) are tabulated. 
2.1.3 Discussion	
The use of tests for recent infection to infer incidence is of considerable and increasing 
interest, especially for HIV surveillance. It is a fundamental limitation that all currently 
available (and perhaps all conceivable) tests with a mean duration of recent infection that 
is long enough for statistical robustness also classify some individuals as ‘recently’ 
infected at arbitrarily large times after infection. If there were no such ‘false-recent’ 
results, the use of recent infection tests for incidence estimation would be straightforward, 
as shown, for example, by Brookmeyer and Quinn [7]. Various methodological advances 
to accommodate a non-zero ‘false-recent rate’ have attracted attention, but consensus has 
not emerged on the best approach. Previous derivations of incidence estimators have 
relied on strong assumptions: perhaps most crucially that the ‘false-recent rate’ is an 
innate property of the test, rather than a convolution of test properties with the 
demographic and epidemiological context. This assumption is known to be substantially 
violated. 
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A formal approach is presented above for summarising an arbitrarily complicated recent 
infection test dynamic into two parameters, namely a mean duration of recent infection 
and a false-recent rate. A crucial construct is the introduction of a timescale ܶ, describing 
the dynamic range of ‘recent’ infection. The consequence of relaxing the assumptions 
made by the incidence estimators developed previously is that demography and 
epidemiology are no longer perfectly separated from test characteristics, reflecting 
fundamental limitations to the inference of rates from instantaneous population states. If 
the false-recent rate is very close to zero, the limitations imposed by a non-zero false-
recent rate become minor and its variation over time and place is restricted.  
The present analysis offers the opportunity to consistently account for imperfect accuracy 
and precision of the incidence estimator. The utility of the estimator may be assessed in 
terms of changes in incidence and the susceptible population over the preceding period of 
duration ܶ, the probability of survival over ܶ post infection, and the characteristics of the 
recent infection test. The cross-sectional incidence estimator will be informative at 
feasible sample sizes, in a given context, for a suitably well-behaved test, that is, a test 
with a suitably long mean duration of recent infection and low false-recent rate. 
The approach presented here is broad enough to recover previously-proposed estimators, 
with minor modification. It also clarifies the use of estimators that do not account for 
‘false-recent’ results at all. Setting ܶ to a very large value forces the false-recent rate 
arbitrarily close to zero, and the one-parameter estimator of Brookmeyer and Quinn [7] is 
obtained. The properties of the test are then summarised by the mean duration of recent 
infection. However, this mean duration, which is now the average time spent alive and 
‘recently’ infected, is considerably more difficult to measure and more likely to change 
over time than one based on individual durations that are each explicitly limited to ܶ. 
Also, a large ܶ (effectively infinite, if ܶ is not explicitly introduced) leads to a weighting 
scheme for averaging incidence that extends far back into the past. For heuristic purposes, 
the weighted incidence that emerges from the use of a realistically available test and a 
judicious choice of ܶ can be viewed as a good proxy for the uniformly-weighted mean 
incidence in the period of duration Ω் preceding the survey. One may consider whether 
there is any benefit in using additional parameters to characterise the dynamics of the test 
for recent infection [97]. Incidence inference would then be based on a more complex 
distribution of test results than counts of ‘recent’ and ‘non-recent’ cases. Section 2.2.4 
presents a brief argument that suggests this approach has limited prospects. 
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Relaxing all formal assumptions about the dynamics of a putative test for recent infection 
and the demographic and epidemiological context leads to an estimator that substantially 
increases the robustness of incidence estimation based on cross-sectional surveys using 
tests for recent infection. The general analysis leads to a clearer characterisation of the 
utility of the estimator than previously possible. While the analysis is fundamentally 
novel, the resulting estimator has similarities to some previously published estimators 
[24, 25]. These similarities imply that, intuitively, the crucial concepts of a false-recent 
rate and mean duration of recent infection are substantially retained. Numerically, the 
improvement in incidence estimates implied by the new estimator will vary with context.  
While the motivation for this work has been to improve our capacity to estimate HIV 
incidence, the methodology is general, and the approach could be applied to estimate 
incidence of other incurable conditions, such as herpes simplex virus. Future studies 
should examine the application of the methodology to a wider range of diseases, with the 
practical challenge being the development of suitable tests for recent infection.  
2.1.4 Conclusion	
For incurable conditions such as HIV, where prevalence emerges as a slow convolution 
of historic incidence with survival and the dynamics of the susceptible population, 
changes in prevalence are a poor proxy for recent incidence. Estimating incidence from 
cross-sectional surveys has many potential advantages over using longitudinal studies, 
and has attracted much interest in recent years, particular in the HIV context. However, 
previously proposed HIV incidence estimators have been derived under conditions of 
epidemiological and demographic equilibrium, or specific assumptions about the recent 
infection test dynamics, or both. These assumptions are known to be violated in many 
settings, and this has diminished the practical utility of previous methodologies.  
In this article, biomarker-based incidence estimation, which uses data obtained in cross-
sectional surveys, is consistently adapted to a general context. The generalisation implies 
that the strong assumptions about epidemiological and demographic history and 
biomarker dynamics required by previous estimators are no longer necessary for valid 
incidence estimation. Our new estimator thus substantially improves and clarifies the 
utility of tests for recent infection for estimating disease incidence. The familiar practical 
challenge remains – to make available ever better, and better characterised, tests for 
recent infection.  
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2.2 Ancillary	Explorations	of	the	
Incidence	Estimator	
2.2.1 Bias	of	the	Incidence	Estimator	
Bias	arising	from	epidemiological	and	demographic	properties	of	
the	population	
In Section 2.1, the following explicit weighted average of incidence over the preceding 
period ܶ was defined: 
ܫ் ൌ
׬ ܫሺݐሻ ௌܰሺݐሻ ோܲሺെݐሻ dݐ଴ି்
׬ ௌܰሺݐሻ ோܲሺെݐሻ dݐ଴ି்
, (2.26)
where the, possibly time-dependent, incidence is given by ܫሺݐሻ, the susceptible population 
by ௌܰሺݐሻ, and ோܲሺ߬ሻ is the probability of being alive and ‘recent’ at time ߬ post infection. 
This weighted incidence was shown to be: 
ܫ் ൌ ோܰ െ ߚ் ାܰௌܰ ∙ ሺΩ் െ ߚ்ܶሻ ∙ ൭1 ൅ ൬
Ω்
Ω் െ ߚ்ܶ൰ ߛ଼ െ ߚ் ∙ ൬
ܶ
Ω் െ ߚ்ܶ൰෍ߛ௞
଻
௞ୀଵ
൱
ିଵ
, (2.27)
where the population at ݐ ൌ 0 is decomposed into 
 ோܰ = ‘recently’ infected population,
 ܰேோ = ‘non-recently’ infected population, and
 ௌܰ = uninfected or susceptible population;
the characteristics of the test for recent infection is captured by 
 the false-recent rate, ߚ், which is the proportion of ‘recently’ infected individuals
among individuals infected for times greater than ܶ, and
 the mean duration of recent infection, Ω் ൌ ׬ ோܲሺݐሻ	dݐ்଴ , which is the average 
time alive and returning a ‘recent’ result, while infected for times less than ܶ; 
the subscripted ߛ terms capture non-equilibrium epidemiological/demographic conditions 
for a period of duration ܶ preceding the cross-sectional survey (performed at ݐ ൌ 0) and 
imperfect survival until ܶ post infection, 
 ߛଵ ൌ ଵ் ׬ ூ݂ሺݐሻ	dݐ
଴
ି் , 
 ߛଶ ൌ ଵ் ׬ ே݂ೄሺݐሻ	dݐ
଴
ି் , 
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 ߛଷ ൌ ଵ் ׬ ௉݂ಲሺെݐሻ	dݐ
଴
ି் , 
 ߛସ ൌ ଵ் ׬ ூ݂ሺݐሻ ே݂ೄሺݐሻ	dݐ
଴
ି் , 
 ߛହ ൌ ଵ் ׬ ூ݂ሺݐሻ ௉݂ಲሺെݐሻ	dݐ
଴
ି் , 
 ߛ଺ ൌ ଵ் ׬ ே݂ೄሺݐሻ ௉݂ಲሺെݐሻ	dݐ
଴
ି் , 
 ߛ଻ ൌ ଵ் ׬ ூ݂ሺݐሻ ே݂ೄሺݐሻ ௉݂ಲሺെݐሻ	dݐ
଴
ି் , and 
 ߛ଼ ൌ ଵஐ೅ ׬ ே݂ೄሺݐሻ ோܲሺെݐሻ	݀ݐ
଴
ି் , 
where ஺ܲሺ߬ሻ  is the probability of being alive at time ߬  post infection; and the time-
dependencies of ܫሺݐሻ, ௌܰሺݐሻ and ஺ܲሺ߬ሻ are captured by the deviations ூ݂ሺݐሻ, ே݂ೄሺݐሻ and 
௉݂ಲሺ߬ሻ, respectively, 
 ܫሺݐሻ ൌ ܫ் ∙ ൫1 ൅ ூ݂ሺݐሻ൯
 ௌܰሺݐሻ ൌ ௌܰሺ0ሻ ∙ ቀ1 ൅ ே݂ೄሺݐሻቁ, and
 ஺ܲሺ߬ሻ ൌ 1 ൅ ௉݂ಲሺ߬ሻ.
The relative bias of the estimator from the exact weighted incidence is therefore 
݁ ൌ ൬ Ω்Ω் െ ߚ்ܶ൰ ߛ଼ െ ߚ் ∙ ൬
ܶ
Ω் െ ߚ்ܶ൰෍ߛ௞
଻
௞ୀଵ
. (2.28)
A general discussion of the structure and the meaning of the terms that make up the 
relative bias, ݁, is now provided (elaborating on the discussion in the previous section), 
and the bias is quantified and explored in some model scenarios.  
The ߛ଼	term is zero when the susceptible population is constant for a period of duration ܶ 
preceding the survey. If the susceptible population is varying considerably, the incidence 
estimator would be substantially biased by the ߛ଼ term. For example, if the susceptible 
population is increasing (decreasing) over the preceding period ܶ, the weighted incidence 
is expected to be underestimated (overestimated) by this demographic dynamic, although 
the overall net bias will also depend on changes in incidence, post-infection survival and 
the characteristics of the test for recent infection. 
This potential for bias highlights a key motivation for introducing ܶ, rather than defining 
recent duration simply through the function ோܲሺݐሻ – namely to decouple the short-term 
dynamics of the test for recent infection from any long-term dynamics which become 
convolved with the epidemiology/demography. Reducing ܶ, and therefore averaging over 
a much shorter period, would tend to reduce the magnitude of the ߛ correction terms, but 
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ultimately erode the statistical power of incidence estimation by making the test-defined 
‘recent’ state more transient and difficult to measure with confidence at realistic sample 
sizes. 
The ߛ଼ and ߛଶ terms are closely related, both representing (variously weighted) average 
deviations of the susceptible population over the preceding period of duration ܶ from its 
current size, with ߛ଼ typically expected to be smaller in magnitude than ߛଶ. 
The ߛ௞ terms, ݇	 ൌ 	1, 2, … ,7, appear only in conjunction with two further multiplicative 
factors: (i) the fraction, dominated by ܶ  and Ω் , which perhaps typically has a value 
close to two, and (ii) a factor of ߚ் . Therefore, the estimator can yield a weighted 
incidence as accurate as desired if ߚ் is sufficiently small. For an ideal test for recent 
infection – that is, a test for which ோܲሺݐሻ reaches and remains at zero for ݐ larger than the 
time over which incidence is to be averaged (a time much shorter than post-infection 
survival) – there is no need to explicitly introduce ܶ into the analysis. In that case, the 
false-recent rate is effectively zero and a one-parameter incidence estimator is obtained. 
Since the ߛ௞ terms (݇ ൌ 1,2, … ,7) are then multiplied by the factor ߚ் ൌ 0, a consistent 
estimate (unbiased in the limit of large sample size) of the weighted incidence is obtained 
in the case of a constant susceptible population. 
Therefore, bias introduced by a varying incidence (for example, in a population with an 
outbreak of HIV cases, or experiencing a successful prevention intervention) or imperfect 
survival until ܶ post infection (although likely to be negligible) may be suppressed by 
forcing the false-recent rate close to zero.  
Under typical epidemiological conditions and in the applicable regimes of utility, the 
deviations ூ݂ሺ. ሻ, ே݂ೄሺ. ሻ and ௉݂ಲሺ. ሻ are expected to be much less than 1. Therefore, ߛସ 
to ߛ଻ are expected to be smaller in magnitude than ߛଵ to ߛଷ.  
It is worth noting that the deviations, ூ݂ሺ. ሻ, ே݂ೄሺ. ሻ and ௉݂ಲሺ. ሻ, and resulting ߛ correction 
terms, playoff against one another in a complex way, and could together compound the 
bias or bring it cumulatively closer to zero (compared to the bias arising from any one 
deviation or ߛ term considered in isolation). 
In the model scenarios described below, the susceptible population and incidence vary 
over the preceding period of duration ܶ, and the exact relative bias was calculated. The 
estimation of the approximate magnitude of the bias, from the point of view of the 
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experimenter, is also briefly considered. The Matlab code that was produced for the 
investigation below is provided in Appendix B.1. 
Two model scenarios (termed Scenarios 1 and 2) were considered, corresponding to 
increasing and decreasing incidence, respectively, during the period preceding the cross-
sectional incidence estimation at ݐ ൌ 0 (with t measured in years): 
1. Incidence increased linearly over the preceding year, from 1% to ܫሺ0ሻ, where
ܫሺ0ሻ  was varied from 1% to 5% (corresponding to a percentage increase in
incidence of 0% to 400% over the year).
2. Incidence decreased linearly over the preceding year, from ܫሺെ1ሻ to 1%, where
ܫሺെ1ሻ was varied from 1% to 5% (corresponding to a percentage decrease in
incidence of 0% to 80% over the year).
Incidence was constant prior to the specific changes noted. 
In each scenario, the susceptible population changed exponentially over time, with the 
annual growth rate ranging from -10% to 10%, and a susceptible population of 
one million individuals at ݐ ൌ 0.  
The timescale ܶ was set to 1 year, and the following survival and test dynamics were 
assumed: 
 Post-infection survival times followed a Weibull distribution, with a coefficient
of variation of 50% and mean post-infection survival of 8 years.
 The probability of being ‘recently’ infected, conditional on being alive, linearly
decreased from 100% to some constant, between 0.25 years and 0.75 years post
infection, and remained at that constant.
The probability of being both alive and ‘recently’ infected, at time ߬  post infection, 
ோܲሺ߬ሻ , equals the product of the probabilities of being (i) alive; and (ii) ‘recently’ 
infected, conditional on being alive; at time ߬  post infection. By construct, the false-
recent rate, ߚ், equals the constant probability of being ‘recently’ infected, conditional on 
being alive, for times post infection greater than ܶ ൌ 1 year. Scenarios 1 and 2 were each 
further split into two sub-scenarios, namely corresponding to a low false-recent rate of 
ߚ் ൌ 1% (Scenarios 1A and 2A) and high false-recent rate of ߚ் ൌ 5% (Scenarios 1B 
and 2B) respectively. Under the assumptions above, the mean duration of recent 
infection, Ω் , is 184 days for Scenarios 1A and 2A, and 192 days for Scenarios 1B 
and 2B. 
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The population states at ݐ ൌ 0  (sizes of the uninfected, ‘recently’ infected and ‘non-
recently’ infected populations, 	 ௌܰ , ோܰ  and ܰேோ , respectively, where ାܰ ൌ ோܰ ൅ ܰேோ ) 
were calculated based on the described epidemiological/demographic history, survival, 
and test dynamics.  
The relative bias, ݁, of the estimator from the true weighted incidence, is shown as a 
percentage in the contour plots in Figure 2.2, for each of the Scenarios 1A, 1B, 2A 
and 2B: 
 Even in the extreme cases, of atypically large changes in the susceptible
population and/or incidence, the expected value of the incidence estimator
remains within about 5% of the weighted incidence (for example, the expected
value lies within 1.9% and 2.1% per annum when the true weighted incidence is
2% per annum).
 The probability of dying within ܶ post infection is less than 1%, and so imperfect
survival contributes negligible bias, and, when the percentage annual growth in
the susceptible population is 0% and the change in incidence is 0%, the bias is
undetectable.
 When the susceptible population and/or incidence experience non-zero change,
the ߛ corrections become non-zero and bias is introduced. For example, with a
false-recent rate of 5% and increasing incidence (Scenario 1B), for a 200%
growth in incidence (from 1% to 3%) and 2% annual growth in the susceptible
population, the fractional error is 1.25%. While the exact weighted incidence is
2.42%, the expected estimated incidence is 2.45%.
 Since ߚ் is a factor that suppresses the bias from the non-zero ߛ terms, the biases
in Scenarios 1A and 2A (the low false-recent rate scenarios) are expected to be
generally smaller than those in Scenarios 1B and 2B (the high false-recent rate
scenarios), respectively.
 The ߛ corrections playoff against one another to either build-up or reduce the
cumulative bias, just as the deviations ூ݂ሺ. ሻ, ே݂ೄሺ. ሻ and ௉݂ಲሺ. ሻ or their products
average out in different ways to increase or decrease the magnitude of each
ߛ term. Also, perhaps more subtly, ூ݂ሺ. ሻ describes the time-dependent deviation
of incidence from the exact weighted incidence, which itself depends on how
incidence, the susceptible population, and the probability of being ‘recently’
infected and alive over time post infection all vary. This complicated interaction
between all the crucial functions to produce the overall bias is evident in
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Figure 2.2, where, even though the susceptible population and incidence are 
varying, there are contours of zero error. 
Figure 2.2: Relative bias of estimator from weighted incidence in modelled scenarios 
The exact relative bias (%) of the incidence estimator is calculated for each of four model 
scenarios, as a function of susceptible population growth rate and change in incidence. In 
Scenarios 1A and 1B, incidence increases linearly over the preceding ܶ ൌ 1  year, 
beginning at 1% per annum, while in Scenarios 2A and 2B, incidence decreases linearly 
over that time to 1%. Post-infection survival follows a Weibull distribution (mean of 
8 years, coefficient of variation of 50%), and the probability of testing ‘recently’ infected, 
conditional on being alive, decreases linearly from 100% to either 1 % (Scenarios 1A 
and 2A) or 5% (Scenarios 1B and 2B) between 0.25 years and 0.75 years post infection. 
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The experimenter may use more limited knowledge of the study population and its history 
to estimate the magnitude of bias of the incidence estimator, and to understand whether a 
study is in a regime of utility. There should be some data on whether there is potentially 
considerable time-dependence in the susceptible population or incidence, or notable post-
infection mortality, in the study population, for the relevant timescale set by ܶ: 
 Should the experimenter believe that the susceptible population is varying
substantially over the preceding period of duration ܶ, the magnitude of ߛ଼ could
be estimated, and this correction would likely dominate the bias (due to the
remaining correction terms carrying a factor of ߚ்). The ߛଶ term, also describing
the average deviation of the susceptible population from its current size, would
typically be larger in magnitude than ߛ଼, and therefore provides an indication of
the size of the ߛ଼  term. For example, for ܶ ൌ 1 year, estimating a 2% annual
growth rate in the population, the experimenter may consider 0.01 to be a
conservative estimate of the magnitude of ߛଶ  (ߛଶ ൌ െ0.0098 for a population
growing exponentially at 2% per annum).
 The ߛଵ	correction would typically be small as it measures the uniformly averaged
deviation of incidence, over the preceding ܶ, from an alternatively weighted (by
ௌܰሺݐሻ ோܲሺെݐሻ) average incidence over the same period. Estimating a large 200%
increase in incidence over the last year, the experimenter may consider 0.2 to be a
conservative estimate of the magnitude of ߛଵ (ߛଵ ൌ െ0.1725 for a 200% increase
in incidence, from 1% to 3%, and a 2% annual growth in the susceptible
population, in Scenario 1B).
 Given multiplication of the ߛ଼ term by a factor of around unity in the relative
error, ݁, and multiplication of the ߛଵ term by two factors, one close in value to
two and the other equalling ߚ், an initial estimate of the magnitude of relative
bias, assuming negligible ܶ ൌ 1  year post-infection mortality, could be
0.01 ൅ 2 ൈ 5% ൈ 0.2 ൌ 0.03	for a false-recent rate of approximately 5%. This is
conservative compared to the exact relative error calculated in Scenario 1B, of
magnitude 0.0125.
The estimation of the magnitude of bias, by the experimenter, could be tackled with 
increasing sophistication and detail, depending on the available data – although probably 
with diminishing returns beyond an elementary calculation such as outlined. The ad-hoc 
example demonstrates that the experimenter should reasonably be in a position to 
understand the magnitude of bias and relate the regimes of utility to the current analysis, 
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keeping in mind the inherently imperfect reproducibility in the incidence estimator 
(approximated in Section 2.2.2). In short, whenever cross-sectional incidence estimation 
is at all informative, bias will be small compared to variance. 
Other	factors	impacting	the	incidence	weighting	function	
The exact weighting function, ௌܰሺݐሻ ோܲሺെݐሻ , is never exactly known, as it involves 
complete knowledge of the dynamics of the test for recent infection, rather than merely a 
mean duration of recent infection. For practical purposes, the estimator of this work is a 
useful proxy for a uniformly-weighted mean incidence over the preceding period Ω்.  
Sensitivity and specificity of the ‘diagnostic’ test used to identify HIV-positive 
individuals may be imperfect. In particular, sensitivity will change rapidly from zero to a 
value close to one over a short period post exposure, and thus be highly correlated with 
status on the recent infection test. In the limit that sensitivity approaches unity at some 
time post exposure, even when incidence is varying, the analysis remains consistent if the 
weighting ௌܰሺݐሻ ோܲሺെݐሻ is understood to apply to the rate of detectable infection events – 
which differs from the weighting of underlying exposure events by an epidemiologically 
irrelevant delay – and requires only consistent estimation of the mean duration of recent 
infection.7 If there is correlation between diagnostic delay and the duration of ‘recent’ 
infection, this delay may involve a slight time-dependent blurring, rather than a pure time 
translation, but none of this changes the previously noted heuristic that the estimator is an 
excellent proxy for the uniformly-weighted mean incidence over the period Ω் preceding 
the survey.  
In HIV diagnostics, levels of sensitivity and specificity are exceptionally high, but if 
indeed this analysis were to be contemplated for a context where there is substantially 
imperfect diagnostic performance over the full lifetime post infection, and non-trivial 
correlation with status on the recent infection test, it may warrant further investigation to 
see whether the diagnostic is preferentially misclassifying individuals in the ‘recent’ 
versus ‘non-recent’ categories. 
___________________________ 
7 Estimation of the mean duration of recent infection, using a definition of ‘infection time’ that is 
consistent with the HIV diagnostic algorithm used in the surveillance survey, is further discussed 
in Section 4.3. 
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If the field work for a nominally ‘cross-sectional’ survey takes an extended period of 
time, comparable to Ω், this would introduce additional temporal blurring of the estimate. 
In the limit of fieldwork carried out over a much longer time than Ω் , the resulting 
incidence estimate essentially averages incidence over the period of fieldwork rather than 
over the duration of ‘recent’ infection. 
2.2.2 Moments	of	the	Incidence	Estimator	
Using the delta method [148] together with assumptions of Gaussian uncertainty in the 
sample counts and estimated characteristics of the test for recent infection, the moments 
of the incidence estimator are approximated (see Appendix A.1 for a summary of the 
delta method and its application in this work). The key results are listed, and the 
assumptions and derivation provided thereafter. 
By Equation (2.25), the incidence estimator is: 
ܫመ் ൌ ݊ோ െ ߚ்݊ା݊ௌ ∙ ሺΩ்െߚ்ܶሻ , (2.29)
where ݊ௌ, ݊ோ and ݊ேோ are the counts of uninfected, ‘recently’ infected and ‘non-recently’ 
infected individuals in the cross-sectional sample at ݐ ൌ 0 , ݊ା ൌ ݊ோ ൅ ݊ேோ , and the 
characteristics of the test for recent infection, namely the false-recent rate, ߚ், and mean 
duration of recent infection, Ω், would need to be estimated. The test characteristics are 
typically estimated in separate studies conducted prior to the cross-sectional incidence 
study, though a combined study design, applicable under more restrictive assumptions, 
has been proposed [93, 149]. 
Consider the problem of calculating the mean and the variance of the incidence estimator, 
for a cross-sectional survey of sample size ݊ ൌ ݊ௌ ൅ ݊ோ ൅ ݊ேோ. Let ௌܲ, ோܲ  and ேܲோ	be the 
true population proportions of uninfected, ‘recently’ infected and ‘non-recently’ infected 
individuals. Let ߪஐ෡೅  be the standard deviation of the unbiased estimator for the mean 
duration of recent infection Ω் , and ߪఉ෡೅  be the standard deviation of the unbiased 
estimator for the false-recent rate ߚ். Then the expected value of the incidence estimator 
is 
ܧൣܫመ் ൧ ൎ ோܲ െ ߚ் ାܲ
ௌܲ ∙ ሺΩ் െ ߚ்ܶሻ (2.30)
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and the variance is 
ݒܽݎሺܫመ் ሻ ൎ ൬ ோܲ െ ߚ் ାܲ
ௌܲ ∙ ሺΩ் െ ߚ்ܶሻ൰
ଶ
ൈ
൥	 1݊ ∙ ሺ ோܲ ൅ ேܲோሻ ൬
1
ௌܲ
൅ ோܲ ேܲோሺ ோܲ െ ߚ் ∙ ሺ ோܲ ൅ ேܲோሻሻଶ൰
൅	ߪஐ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ଶ
൅ ߪఉ෡೅ଶ ∙ ቆ
ேܲோΩ் െ ோܲ ∙ ሺܶ െ Ω்ሻ
൫ ோܲ െ ߚ் ∙ ሺ ோܲ ൅ ேܲோሻ൯ሺΩ் െ ߚ்ܶሻቇ
ଶ
൩. 
(2.31) 
The coefficient of variation (ratio of standard deviation to mean) of the incidence 
estimator is c, where: 
ܿଶ ൎ 1݊ ∙ ሺ ோܲ ൅ ேܲோሻ ൬
1
ௌܲ
൅ ோܲ ேܲோሺ ோܲ െ ߚ் ∙ ሺ ோܲ ൅ ேܲோሻሻଶ൰
൅	ߪஐ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ଶ
൅	ߪఉ෡೅ଶ ∙ ቆ
ேܲோΩ் െ ோܲ ∙ ሺܶ െ Ω்ሻ
൫ ோܲ െ ߚ் ∙ ሺ ோܲ ൅ ேܲோሻ൯ሺΩ் െ ߚ்ܶሻቇ
ଶ
. (2.32) 
From this, it is possible to formally explore the trade-off between test characteristics: test 
developers need to find biomarkers for recent infection which have a suitably large mean 
duration  of  recent  infection  and  a  suitably  small  false-recent  rate.8 Note  that  the 
variability of the incidence estimator inflates as the terms ሺΩ் െ ߚ்ܶሻ  and  
൫ ோܲ െ ߚ் ∙ ሺ ோܲ ൅ ேܲோሻ൯	,  which  occur  in  denominators  above,  become  small.  Hence, 
definitions of recent infection, such as being antibody negative while viral RNA or p24 
antigen positive (commonly referred to as ‘acute infection’) are of little use for incidence 
estimation at the population level as the mean duration of recent infection is too short. 
___________________________ 
8  The use of the precision of the incidence estimator, as a summary metric for formally assessing 
the trade-off between the false-recent rate and mean duration of recent infection, was further 
explored in later work, and is presented in Chapter 6. 
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The above results were derived by first assuming Gaussian uncertainty in both the sample 
counts (of uninfected, ‘recently’ infected and ‘non-recently’ infected subjects, ݊ௌ, ݊ோ and 
݊ேோ, respectively) and estimated test characteristics (estimated mean duration of recent 
infection, Ω෡், and estimated false-recent rate, ߚመ்). This allows the counts and estimated 
parameters to be expressed as: 
 ݊ௌ ൌ ݊௦ሺߙଵሻ ൌ ݊ ௌܲ ൅ ߪௌߙଵ,
 ݊ோ ൌ ݊ோሺߙଵ, ߙଶሻ ൌ ݊ ோܲ െ ߪோߙଵ ൅ ߪோ,ேோሺߙଵሻߙଶ,
 ݊ேோ ൌ ݊ேோሺߙଵ, ߙଶሻ ൌ ݊ ேܲோ െ ߪேோߙଵ െ ߪோ,ேோሺߙଵሻߙଶ,
 Ω෡் ൌ 	Ω෡்ሺαଷሻ ൌ Ω் ൅ ߪஐ෡೅ߙଷ	, and
 ߚመ் ൌ 	ߚመ்ሺߙସሻ ൌ ߚ் ൅ ߪఉ෡೅ߙସ,
where 
 ߪௌ ൌ ඥ݊ ௌܲ ∙ ሺ1 െ ௦ܲሻ	,
 ߪோ ൌ ௉ೃ௉ೃା௉ಿೃ ߪ௦, 
 ߪேோ ൌ ௉ಿೃ௉ೃା௉ಿೃ ߪ௦, 
 ߪோ,ேோሺߙሻ ൌ ඥሺ௡ି௡௉ೄିఙೄఈ	ሻ௉ೃ௉ಿೃ௉ೃା௉ಿೃ 	, 
and ߙଵ , ߙଶ , ߙଷ  and ߙସ  are identically and independently distributed standard normal 
random variables. 
The incidence estimator was then expressed as a function of the ߙ௜ (݅ ൌ 1,2,3,4), and a 
multivariate Taylor series expansion around ߙ௜ ൌ 0   ( ݅ ൌ 1,2,3,4 ) was constructed. 
Taking the expected value and variance of this series, retaining powers of ߙ௜ of up to 1, 
led to the results in Equations (2.30) to (2.32). 
The approximation and distributional assumptions are highly accurate in their handling of 
counting error when characteristics of the test for recent infection are known. This was 
verified numerically: assuming a constant historical incidence and a constant prevalence 
to incidence ratio of HIV, as well as known test characteristics, the population 
proportions were calculated and the coefficient of variation of the incidence estimator 
computed by directly enumerating all possible trinomially distributed survey counts. Even 
with a small sample of ݊ ൌ 100 , the maximum error in the coefficient of variation 
obtained using the delta method (that is, the absolute difference between the 
approximated and actual coefficient of variation) is 0.017 for all combinations of 
incidence in [0.1%,3%], prevalence to incidence ratio in [2,10], Ω்	in [100,300] days and 
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ߚ் in [0%,15%]. Matlab code to perform this investigation is provided in Appendix B.2, 
and could be used to explore other regimes of interest. 
The assumption of Gaussian uncertainty in the estimated test characteristics is heuristic, 
and it is difficult to ascertain the accuracy of the approximation provided. When the false-
recent rate is very close to zero, it is likely that a normal distribution will provide a poor 
approximation for the distribution of its estimator, and more sophisticated methods of 
error propagation should be investigated.  
2.2.3 Estimation	of	Test	Characteristics	
The parameters that have been identified to describe the characteristics of the test for 
recent infection required to infer incidence (namely, the false-recent rate, ߚ் , and the 
mean duration of recent infection, Ω்) are intuitively close to those previously proposed. 
The estimation of the characteristics, demonstrating their emergence in longitudinal 
surveillance settings, is discussed below. 
The	false‐recent	rate	
The false-recent rate, ߚ் , is the proportion of ‘recently’ infected individuals among 
individuals infected for a time greater than ܶ.  
Therefore, the binomial maximum likelihood estimator for ߚ் is: 
ߚመ் ൌ ݉ோ݉ , (2.33)
where ݉ோ is the number of ‘recently’ infected individuals in a representative sample of ݉ 
individuals infected for longer than ܶ. 
It would also be possible, although probably more challenging, to estimate ߚ்  from a 
combination of convenience samples, knowledge of the dynamics of anomalous 
subpopulations (who persist in or return to the ‘recent’ state despite being infected for a 
time greater than ܶ) and knowledge of the embedding demography/epidemiology. 
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The	mean	duration	of	recent	infection	
The mean duration of recent infection, Ω், is the average time spent alive and ‘recently’ 
infected while infected for times less than ܶ.  
In an idealised experiment, which revisits initially HIV-negative individuals after a 
time equal to the post-infection time cut-off ܶ and counts the frequency of ‘recent’ results 
in those who have become HIV-positive, a direct estimate for Ω்	is provided, assuming a 
uniform distribution of infection times over the inter-test interval of duration ܶ  (and 
negligible mortality within ܶ  post infection).9 More specifically, the ratio Ω்/ܶ  is the 
probability of a seroconverter providing a ‘recent’ result on the first HIV-positive test, 
and therefore the binomial maximum likelihood estimator for Ω் is: 
Ω෡் ൌ ܶ ݇ோ݇ , (2.34)
where ݇ோ is the number of ‘recently’ infected subjects in the group of ݇ subjects who are 
HIV-positive at follow-up. Such a study would probably need to be prohibitively large to 
capture a reasonably large sample of seroconverters, but it is worth noting that no 
additional input parameters are needed in the estimation, overcoming a key obstacle of 
unknown input parameters to the estimation of previously-defined mean durations of 
recent infection [31]. 
This idea can be further developed to account for varying inter-test intervals, depending 
on available data and knowledge of the dynamics of the test for recent infection. As an 
example, a method of maximum likelihood is outlined below for estimating Ω் from data 
capturing recent infection test classifications at the times of the first HIV-positive tests 
(that is, when there is no follow-up of HIV-positive subjects), and there are varying but 
large intervals between last HIV-negative and first HIV-positive tests, utilising 
assumptions about test dynamics at times post infection in the vicinity of ܶ.  
___________________________ 
9 The estimation of the mean duration of recent infection using only specimens drawn at subjects’ 
first HIV-positive visits, and when inter-test intervals may be large, was formalised and 
demonstrated in earlier work, which is presented in Chapter 3. 
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In general, the probability, ݌௜, that the ݅th seroconverter, with inter-test interval Δ௜, returns 
a ‘recent’ result at the time of the first HIV-positive test is: 
݌௜ ൌ න ݂ሺെݐሻ ோܲሺെݐሻ dݐ
଴
ି∆೔
, (2.35)
where ݂ሺ߬ሻ is the probability density of getting infected at time ߬ before the first HIV-
positive test and ோܲሺ߬ሻ becomes the probability of being ‘recently’ infected when tested 
at time ߬ ሺ൏ Δ௜ሻ after infection, assuming no mortality for at least time Δ௜ post infection. 
More specifically, for a sample of subjects who have inter-test intervals between ܮ and ܷ 
(ܮ ൑ Δ௜ ൑ ܷ), where ܮ and ܷ ሺܮ ൑ ܶ ൑ ܷሻ are chosen so that the probability of testing 
‘recently’ infected is constant at ߠ  for times post infection between ܮ  and ܷ,  and 
assuming that infection times are uniformly distributed in inter-test intervals (that 
is, ݂ሺെݐሻ ൌ 	1/Δ௜ for all ݐ such that ݐ ∈ ሾെΔ௜, 0ሿ), ݌௜ becomes: 
݌௜ ൌ
1
߂௜ ∙ ቆන ோܲሺെݐሻ dݐ
଴
ି்
൅ න ோܲሺെݐሻ dݐ
ି்
ି∆೔
ቇ 
ൌ Ω் ൅ ߠ ∙ ሺ∆௜ െ ܶሻ∆௜ . (2.36)
The likelihood of the entire set of classifications (for all seroconverters) can then be 
maximised to estimate Ω். 
Traditionally, studies aimed at estimating the mean duration of recent infection often 
capture seroconversion panels, obtained from the frequent follow-up and recent infection 
testing of a relatively small sample of seroconverters. A form of survival analysis, or 
regression, can then be used to characterise the time taken to exit the ‘recent’ state, or the 
evolution of the biomarker over time after infection, respectively, thereby estimating the 
mean duration of recent infection.10 For a biomarker that monotonically increases over 
time after infection, what is often measured is the average time from infection to the 
biomarker response crossing a selected threshold (defining the transition from the 
___________________________ 
10  Methods for estimating the mean duration of recent infection from longitudinal data were 
systematically explored in later work, and results are presented in Chapter 4. The dangers of 
neglecting noise in a measured biomarker, by assuming that subjects have single continuous 
sojourns in the ‘recent’ state, implicit in all survival analysis approaches and methods that 
estimate times at which biomarkers ‘cross’ thresholds, are discussed in Chapter 4. However, 
such analyses have been used to estimate the MDRI, and are therefore described here for 
completeness. 
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‘recently’ infected to ‘non-recently’ infected state). Such data and methods may be 
related to estimation of Ω் by decomposing the parameter into two parameters, ߝ and ߱:  
Ω் ൌ ߝܶ ൅ ሺ1 െ ߝሻ߱, (2.37)
where ߱  is the estimated time from seroconversion to threshold-crossing for those 
individuals who do so within ܶ post infection, and ߝ is the proportion of seroconverters 
whose responses are still below the selected threshold at time ܶ post infection. 
In all approaches, the recent infection test classifications of subjects at follow-up are used 
to estimate the mean duration of recent infection. These classifications describe the 
probabilities of being in the ‘recent’ state at times post infection conditional on being 
alive at follow-up, which introduces a relative error in the estimation of Ω்	related to the 
size of ߛଷ	(see Section 2.2.1). 
2.2.4 Simulation	and	Analysis	of	Test	Datasets	
As a further demonstration of the methods presented, 1 000 datasets were simulated and 
used to infer the characteristics of the test for recent infection and incidence, and results 
were presented in Section 2.1.2. The simulation of the datasets is outlined below. 
The model population and test dynamics were constructed so that, at ݐ ൌ 0 and for a time 
cut-off of ܶ ൌ 450 days,  
 HIV prevalence was 15%;
 weighted HIV incidence, ܫ், was 2%;
 the false-recent rate, ߚ், was 2.5%; and
 the mean duration of recent infection, Ω், was 160 days.
The probability of being alive and in the state of ‘recent’ infection at time ߬	post infection 
(measured in years) took the form: 
ோܲሺ߬ሻ ൌ ሺ1 െ ݍሻ݁ିሺఛ ఒ⁄ ሻೖ ൅ ݍ for all ߬ such that ߬ ∈ ቂ0, ଺଴଴ଷ଺ହቃ, (2.38)
where ݍ ൌ 0.0167 , ߣ ൌ 	0.4707  and ݇ ൌ 3.7183 . This set of parameters ensures that 
Ω் ൌ 160 days. It was assumed that there is no death prior to 600 days after infection. 
For each of 1 000 simulations, the following datasets were generated: 
1. A dataset for estimating ߚ்,  which consisted of binomially generated
classifications of 1 000 subjects, representing a random sample of individuals
infected for longer than ܶ ൌ 450 days, as ‘recently’ or ‘non-recently’ infected. In
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the estimation, ߚ்  was measured using the maximum likelihood method 
described by Equation (2.33). 
2. A dataset for estimating Ω் , which consisted of the recent infection test
classifications for 2 000 sampled subjects at their first HIV-positive tests, as well
as the subjects’ inter-test intervals (times between last HIV-negative and first
HIV-positive tests). Infection times for subjects were uniformly distributed in
their inter-test intervals. Inter-test intervals were generated from a uniform
distribution, with a support of 300 to 600 days. The parameter, Ω், was estimated
by maximising a likelihood function based on Equation (2.36), using
ܮ ൌ 300	days, ܷ ൌ 600	days and the estimated false-recent rate as the input ߠ.
Although ߠ and the false-recent rate are different in reality, this approximation is
likely to be made in practice. Uncertainty in the input ߠ, which has a true value of
1.67%, was neglected in estimation of Ω்.
3. A dataset providing the sample counts for inferring incidence, that is, containing
the categorisations of 10 000 subjects, captured in a cross-sectional survey at
ݐ ൌ 0, as uninfected, ‘recently’ infected or ‘non-recently’ infected. This dataset
was produced by calculating the proportion of the population in each of these
three states, based on being consistent with the constructions described above,
and generating classifications for the 10 000 subjects from a trinomial
distribution. The incidence estimator provided in Equation (2.25) was used to
infer incidence.
2.2.5 Prospects	for	Tests	Characterised	by	More	
Than	Two	Parameters	
There are a number of ways one may contemplate summarising test dynamics into a 
greater number of parameters. More complex characterisations of tests for recent 
infection are briefly considered below, and appear to offer limited prospects.  
If the objective of a survey is to provide a single weighted average of recent incidence, 
then the number of infections, in a specified recent period, is formally a ‘sufficient 
statistic’ [150] of this rate – that is, there is no additional benefit in knowing the times of 
occurrence of these infections. The estimation of the numerator in Equation (2.2) is very 
nearly the estimation of the number of infections in the last period Ω். This suggests that 
a finer breakdown, beyond counts of ‘recent’ and ‘non-recent’ cases, of the survey results 
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adds no significant accuracy for obtaining a single point estimate of incidence, though it 
may add significant imprecision. 
The characterisation of an ideal test for recent infection (one with a false-recent rate of 
zero), for the purpose of estimating incidence, requires no parameters other than the mean 
duration of recent infection. When the test exhibits ‘recent’ results at large times post 
infection, an additional parameter, namely a false-recent rate, may be introduced 
(together with the relevant timescale, ܶ, of ‘false-recent’ results) to describe this tail.  No 
assumptions about the dynamics of the ‘false-recent’ results are required. If the ‘false-
recent’ results are distributed over the dynamic range of values for the measured 
biomarker in a known, non-uniform manner, there may be a benefit to characterising this 
dynamic with additional parameters. However, it seems unlikely that the characterisation 
of this dynamic, or its statistically detectable manifestation in a survey, will be feasible, 
given the need for the false-recent rate to be very low. 
One final point that bears mentioning is that data from a single survey for a test for recent 
infection with a long dynamic range could in principle be used to yield multiple incidence 
estimates, using different recent/non-recent thresholds, and perhaps different values of ܶ. 
This would provide, from a single survey, multiple estimates of incidence, each with a 
subtly different weighting scheme. Given how difficult it is to provide even single 
incidence estimates, or to detect differences in incidence using data from separate 
surveys, the effective estimation of an incidence trend from a single survey would require 
daunting sample sizes and tests for recent infection of currently unrealised performance. 
2.3 Online	Resource	and	Analysis	
Tools	for	Practical	Application	
An online resource, maintained by the South African DST/NRF Centre of Excellence in 
Epidemiological Modelling and Analysis (SACEMA), was developed over the course of 
this project. The website, www.incidence-estimation.com, aims to provide users with 
both relevant theoretical background information and supporting analysis tools for HIV 
incidence estimation. Two approaches for estimating incidence are currently supported: 
(1) from cross-sectional surveys using test for recent infection, which is the focus of this 
work as further discussed below, and (2) from age-stratified HIV prevalence data 
A General Theoretical Framework for Incidence Inference  48 
measured at multiple time points, for which methodology and tools were developed by 
other researchers [60]. 
The website’s landing page is captured in Figure 2.3. Users can then navigate to a 
theoretical review of the methodology, a set of analysis tools and an archive of related 
documents. Contact details are also supplied, and investigators from around the world 
have enquired about the applicability and tailoring of the methodology to their particular 
studies, and the choice of inputs for analysis tools and interpretation of outputs. A section 
of the website is dedicated to the Consortium for the Evaluation and Performance of HIV 
Incidence Assays (CEPHIA), facilitating both the consortium’s communication with the 
public, and the internal sharing of documents and data files (access is restricted to 
CEPHIA members). Updates are also regularly posted, describing latest developments in 
the field. 
The current suite of analysis tools, called Assay-Based Incidence Estimation (ABIE) v2.0, 
was developed to support application of the incidence estimation framework presented in 
Section 2.1. The suite provides users with various ‘calculators’, each performing a task-
specific statistical analysis. The toolset replaces and offers some advancements on 
ABIE v1.0, which was both based on the less general incidence inference framework of, 
and created by, McWalter and Welte [25]. 
The objective of ABIE v2.0 was increasing accessibility to the work, and therefore the 
tools were designed to be uncomplicated and user-friendly, allowing a range of potential 
users (such as test developers, individuals designing studies or HIV programme 
managers, and data analysts) to more easily move from the theoretical discourse to 
practical application. The calculators are in the form of Microsoft Excel spreadsheets, 
providing an interface that is familiar to many. All calculations and statistical tests are 
performed using simple closed-form approximations (if not exact solutions) and the most 
straightforward test statistics (differences and ratios of incidences estimates) respectively. 
While the spreadsheets are protected to prevent any accidental modifications of formulae, 
users can unlock the spreadsheets to view all underlying calculations or even purposefully 
tailor the tools to better suit their specific needs. A diverse range of warning and error 
messages appear when inputs suggest inconsistencies or problematic regimes for 
application of this surveillance approach. In a number of the calculators, multiple sets of 
inputs can be provided, enabling the user to consider a range of contexts and analyse the 
sensitivity of outputs to context. 
A General Theoretical Framework for Incidence Inference  49 
Figure 2.3: Online resource for incidence estimation  
The landing page of the incidence estimation website (www.incidence-estimation.com) is 
shown (as it appeared on 16 July 2014). The SACEMA-maintained website was 
developed to provide users with methodological background information and analysis 
tools for HIV incidence estimation. 
Contact | Login
Incidence-Estimation
SACEMA's online resource for incidence estimation
Home
Welcome to the incidence estimation portal, maintained by the South African Department of
Science and Technology / National Research Foundation Centre for Epidemiological Modelling
and Analysis (SACEMA).
Disease incidence, the rate of occurrence of new cases in a population, is typically much more
difficult to estimate than prevalence, the fraction of the population having a condition at a given
point in time. For transient conditions, such as seasonal flu, prevalence is a good proxy for
recent incidence. However, for enduring conditions, such as HIV, current prevalence depends in
detail on historical incidence, demography, and survival.
HIV epidemiology is one of the most urgent contexts in which a difficult-to-measure incidence
plays a crucial role. Reliable estimates of HIV incidence are critical for epidemiological
monitoring, understanding transmission patterns, and in the design and evaluation of
intervention or prevention programs.
Traditionally, epidemiologists have referred to the counting of infection events during the
prospective follow-up of an initially uninfected cohort as producing ‘directly observed’ incidence
estimates. For population-level surveillance, this approach is often impractical and prone to
bias. Indeed, the very definition of incidence, or any other population dynamic rate, is subtle and
potentially problematic, especially when dealing with populations and conditions which are
highly heterogeneous.
Numerous alternatives to cohort studies have attracted wide interest in recent years:
Inferring incidence from cross-sectional surveys testing for biomarkers of ‘recent
infection’
Inferring incidence from population renewal equations, given suitable age-stratified
prevalence and mortality
Estimating incidence by fitting dynamical models to a range of available data
SACEMA is particularly interested in developing and applying new methodology covered by the
first two of these approaches.
UPDATES
Talks given at Department of Health, April
2014
April 18, 2014
Consortium for the Evaluation and
Performance of HIV Incidence Assays
hosts webinar on ‘Recent Infection’ and
the CEPHIA development pipeline for
incidence assays.
Nov 12, 2013
New Paper: Incidence estimation from
prevalence surveys, using age- and time-
dependent prevalence and mortality data.
Nov 5, 2012
New Paper: Incidence estimation from
cross-sectional surveys testing for
biomarkers of 'recent infection'
Nov 5, 2012
The Bill & Melinda Gates Foundation
funded HIV Modelling Consortium
sponsors workshop on characterisation of
biomarkers of recent HIV infection.
July 21, 2012
Read more...
CEPHIA UPDATES
Management Meeting, Stellenbosch, 5-9
May 2014
May 15, 2014
Independent Evaluation of Predicate
Incidence Assays for HIV Surveillance
May 9, 2014
Using Antibodies to Detect HIV
Persistence in Treatment Intensification
and Eradication Studies
May 8, 2014
The Bio-Rad Geenius™ HIV 1/2
Supplemental Assay has been developed
for HIV-1 and HIV-2 differentiation and
confirmation.
May 6, 2014
New single point of contact
Jan 8, 2014
Read more...
Home Theory Tools Archive Contact us CEPHIA
maintains this site with the support of the
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A detailed description of the inputs, outputs and analyses underlying each of the 
calculators is provided in Appendix A. In brief, the following calculators are currently 
available in ABIE v2.0: 
 Incidence and Prevalence Calculator – estimates HIV incidence and prevalence,
from (i) counts of uninfected, ‘recently’ infected and ‘non-recently’ infected
subjects observed in a cross-sectional survey, and (ii) properties of the test for
recent infection (the test’s MDRI and FRR, and the uncertainties with which they
are measured).
 Sample Size Calculator – calculates the number of subjects required in a cross-
sectional incidence study to obtain a specified precision of the incidence
estimator, given the (i) desired precision, (ii) assumed epidemiological context
(HIV incidence and prevalence), and (iii) test properties.
 Incidence Ratio Calculator – estimates the ratio of two incidence values, from
(i) counts of uninfected, ‘recently’ infected and ‘non-recently’ infected subjects
observed in each of two cross-sectional surveys, and (ii) test properties (presumed
to be the same in both populations).
 P-value for Difference Calculator – calculates a conventional p-value to
summarise the discrepancy between two incidence estimates (more specifically,
the probability of obtaining as large a difference between two incidence estimates
as that actually observed), under the null hypothesis of equal incidence in the two
study populations, assuming equal HIV prevalence. Inputs are the (i) counts of
uninfected, ‘recently’ infected and ‘non-recently’ infected subjects observed in
each of the two cross-sectional surveys, and (ii) test properties (presumed to be
the same in both populations).
 Power to Detect Difference Calculator – calculates the probability of inferring a
difference between two incidence values, in the correct direction, when
considering the difference between two incidence estimates, assuming equal HIV
prevalence. Inputs are the (i) assumed epidemiological context, for each study
population, (ii) incidence survey size, for each population, (iii) test properties
(equal in both populations), and (iv) statistical significance level for the test for
difference in incidence.
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 Test Performance Calculator 11  – calculates the precision of the incidence
estimator, given the (i) assumed epidemiological context, (ii) incidence survey
size, and (iii) test properties.
A weakness of cross-sectional incidence surveillance, drawing some criticism, is the 
potentially large samples required to obtain suitably precise incidence estimates in low 
HIV incidence settings, given the current non-ideal performance of tests for recent 
infection. This important topic of sample size considerations is used to illustrate an 
application of the calculators. In Figures 2.4 and 2.5, the Sample Size Calculator is used 
to explore the relationship between sample size and incidence estimation precision, for a 
test for recent infection that has properties closely meeting the ‘Target Product 
Profile’ [14]: an MDRI of 180 days and an FRR of 1%, for ܶ ൌ 1  year. Based on 
experiences from analysing data produced by CEPHIA, the coefficient of variation (CoV) 
for MDRI estimation was taken to be 5%; and the CoV for FRR estimation was set to 
30%, which corresponds to estimation of the FRR in a sample of 1 000 long-infected 
subjects. 
In the screenshot of the Sample Size Calculator provided in Figure 2.4, the tool was used 
to explore an epidemiological setting where the HIV incidence rate is low at 0.5% per 
person year and HIV prevalence is 5%. The incidence value represents the weighted 
incidence that would be measured in the cross-sectional survey (that is, there are no 
assumptions of constant historical incidence). The input specifies that the required CoV 
of the incidence estimator is 20% – roughly equivalent to requiring a 95% probability of 
obtaining an HIV incidence point estimate between 0.3% and 0.7% per person year. The 
calculator output indicates that a sample of 15 400 subjects would be required in the 
incidence study to achieve this level of precision. This can be compared to the 
approximately 11 000 HIV diagnostic tests required to achieve the same precision of 
incidence estimation using a longitudinal study, which identifies HIV-negative subjects in 
a cross-sectional survey of the population and retests these subjects one year later, in the 
described context (5 500 subjects would be tested for HIV at the start of the study, and 
the enrolled HIV-negative subjects retested at the end of the study). 
___________________________ 
11 The Test Performance Calculator was developed to accompany the article presented in 
Chapter 6, in which the precision of the incidence estimator is proposed as a standard metric for 
assessing test performance.  
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Figure 2.4: Example analysis using the Sample Size Calculator contained in the 
ABIE v2.0 tool suite  
In the screenshot of the Sample Size Calculator, the analysis tool output indicates that 
15 401 subjects are needed in a cross-sectional incidence study to obtain the desired 
precision of the incidence estimator, in the specified scenario. Inputs indicate that an 
incidence estimator with a 20% CoV is required, in a population where HIV incidence 
and prevalence are 0.5% per annum and 5% respectively, using a test for recent infection 
that has an MDRI of 180 days, estimated with a 5% CoV, and an FRR of 1%, estimated 
with a 30% CoV, for ܶ ൌ 1 year. 
The required sample size is expected to vary greatly by epidemiological context. The 
calculator, which accommodates multiple sets of inputs, was therefore used to calculate 
the sample sizes required in populations with various HIV incidence and prevalence 
values. The tool output, provided in Figure 2.5, shows that the sample size required to 
obtain the same CoV of the incidence estimator (20%) decreases as HIV incidence 
increases or prevalence decreases. A much smaller survey, of 5 900 subjects, is required 
when incidence is higher, at 1% per annum, and prevalence is lower, at 2.5% (this context 
may capture, for example, an emerging epidemic among teenagers). 
Sample Size Calculator Inputs Outputs
Calculates the sample size required for an incidence es imator CoV using assay characteristics and background incidence
Time cut-off T
Post-infection time cut-off T , separating 'true-recent' from 365
   'false-recent' results (days)
Test for Recent Infection/Assay Characteristics Indicative 95% CIs, using input CoV
Estimated Mean Duration of Recent Infection (MDRI) (days) 180 ( 162.36 - 197.64 )
CoV (Coefficient of Variation) of MDRI estimate (%) 5.0%
Estimated False-Recent Rate (FRR) (%) 1.0% ( 0.41% - 1.59% )
CoV of FRR estimate (%) 30.0%
Reference Epidemic State
Reference incidence (%) 0.5% ( 0.30% - 0.70% )
Reference prevalence (%) 5.0%
CoV of incidence estimator, at an infinite sample, 
Coefficient of Variation Required is 7.8% from test characteristic uncertainty 
Minimum possible incidence estimator CoV at given 7.8% (using reference epidemic state)
   test characteristic uncertainty (%)
CoV required for incidence es imator (%) 20.0%
Population Proportions
HIV-nega ive 0.9500
HIV-positive (classified as 'non-recently' infected) 0.0472
HIV-positive (classified as 'recently' infected) 0.0028
Sample Size Required
Sample size 15401 Warning: Sample size is greater than 5000
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Figure 2.5: Sample size required to obtain a specified CoV for the incidence 
estimator by HIV incidence and prevalence in the study population, using the 
Sample Size Calculator 
The chart, produced by the Sample Size Calculator contained in the toolset ABIE v2.0, 
shows the sample size (in tens of thousands of subjects) required in a cross-sectional 
surveillance study to obtain an incidence estimator with a 20% CoV in each 
epidemiological context considered. The epidemiological contexts capture different 
combinations of HIV incidence (0.25%, 0.5% and 1% per annum) and prevalence (2.5%, 
5% and 10%). The test for recent infection has an MDRI of 180 days, estimated with a 
5% CoV, and an FRR of 1%, estimated with a 30% CoV, for T ൌ 1 year. When HIV 
incidence is 0.25% per annum, and HIV prevalence is at least 7.5%, the uncertainty from 
the estimated test properties already implies a CoV of the incidence estimator greater than 
20%. 
The ABIE analysis tools have been endorsed by the World Health Organisation (WHO) 
HIV Incidence Assays Working Group [13, 130], and are used as part of training delivered 
by the Centers for Disease Control and Prevention (CDC). Locally, the ABIE tools are 
used to analyse data from the South African national household surveys [61]. We, at 
SACEMA, also directly hosted a training workshop, at the request of the WHO, in South 
Africa in 2012 [49, 50]. Participants were primarily epidemiologists and programme 
officers from national health departments and CDC divisions in countries around Africa. 
The theoretical foundations were presented, and the use of each analysis tool 
demonstrated. The WHO has requested that the training is continued, and a second 
workshop was conducted in September 2014. 
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In addition to the standard analysis tools provided online, numerous ad-hoc calculators 
have been created in response to specific requests. For example, the Incidence and 
Prevalence Calculator was tailored to consistently account for the scenario in which not 
all of the HIV-positive subjects identified in the cross-sectional survey were tested for 
‘recent’ infection.12 As another example, a tool was developed to calculate the sample 
size required to achieve a desired statistical power when testing for a difference in 
incidence in two populations, where incidence is estimated from a cross-sectional study 
using a test for recent infection in one population, and by a conventional longitudinal 
study in the other.13 
The next version of the tool suite, ABIE v3.0, is envisioned as providing much greater 
flexibility and more rigorous statistical calculations. The intention is to develop the tools 
in R, which is open-source software that is suited to statistical programming [152]. More 
accurate calculations, requiring more computationally-expensive numerical methods, 
could then be efficiently implemented. For example, in power calculations, the full 
distribution of possible survey counts could be considered (rather than utilising closed-
form approximations that are based on expected counts), and bootstrap resampling could 
be used to estimate uncertainties. A broader range of scenarios, better capturing those that 
may be encountered in reality, could be accommodated, for example by relaxing 
assumptions about equal HIV prevalence and equal test properties in the populations 
being compared; and optimally-powered statistical tests should be developed for 
hypothesis testing. A broader range of input types could also be accommodated (such as 
plausible minimum and maximum values of parameters rather than specifications of 
single values) and more diverse outputs produced (such as files summarising outputs in 
tables or visually through various plots). While such a tool suite would not present the 
simple interface and calculations contained in ABIE v2.0, progressively advancing the 
analytical tools would support the expanding application of this surveillance approach. 
___________________________ 
12The analysis was requested by Medicins Sans Frontiers, for data from an incidence study in 
Kenya, intended to provide a baseline incidence measure for monitoring transmission over time 
[151]. 
13The tool was used by the South African Perinatal HIV Research Unit to design a study intended 
to evaluate the impact of medical male circumcision in Soweto, South Africa. 
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Chapter	3
 
Estimating	the	Mean	Duration	of	
Recent	Infection	I:	Observing	
Subjects	Once	after	Infection		
This chapter formalises and demonstrates the utility of an approach for obtaining 
preliminary estimates of a test’s mean duration of recent infection (MDRI) [143] using 
previously overlooked data. The procedure requires only a single application of the test 
for recent infection per subject, on specimen drawn at the time of the first HIV-positive 
test. No subsequent follow-up of subjects is necessary, and the methodology is suited to 
contexts where times between HIV diagnostic tests may be large (such as a year or two). 
The methodology is explored in Section 3.1, and used to perform initial characterisations 
of two detuned assays using the previously untapped source of specimens provided by 
blood donors. This analysis is a reproduction of a published journal article [31]. 14 
Ancillary details of the analysis, which were published in an appendix to the article, are 
provided in Section 3.2. 
___________________________ 
14The contents of Section 3.1 have been published as: ‘Kassanjee R, Welte A, McWalter TA, 
Keating SM, Vermeulen M, Stramer SL, Busch MP. Seroconverting blood donors as a resource 
for characterising and optimising recent infection testing algorithms for incidence estimation. 
PLOS ONE. 2011; 6(6):e20027’. PLOS applies the Creative Commons Attribution (CC BY) 
license to all works published, and therefore no permission was required to reproduce the work. 
The manuscript was primarily written by RK, who performed all analyses. AW and TAM 
critically reviewed results and assisted in writing the manuscript. Specimen collection and 
laboratory work were performed by MPB, SMK, MV and SLS, and these were led by MPB who 
conceived the design.  
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Two further applications of this approach are presented in Section 3.3, namely the 
characterisation of a newly proposed test for recent infection, based on SMARTubeTM 
technology, and the characterisation of the widely used BED assay for the South African 
context. These applications were presented at HIV conferences [33, 35].15 
At the time of the work described above, the incidence inference framework of McWalter 
and Welte [25] was in use. The more general inference scheme, derived in Chapter 2, had 
not yet been adopted. However, the ideas presented in this chapter are as applicable and 
valuable under the more general framework of Chapter 2, and in fact benefit from it, as 
shown in Section 3.4. 
___________________________ 
15The analysis described in Section 3.3.1 has been previously presented as ‘Kassanjee R, Welte A, 
Jehuda-Cohen T. SMARTube as a test for recent infection. Poster 41 and presentation at the 
2010 HIV Diagnostics Conference. 24-26 March 2010, Florida, USA’. The analysis presented in 
Section 3.3.2 has appeared as ‘Kassanjee R, Welte A, McWalter TA, Viljoen J, Bärnighausen T, 
Newell ML, Fatti, LP. Calibration of BED assay for use in incidence estimation. E-poster 
CDB018 at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 
2009, South Africa’. 
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3.1 Seroconverting	Blood	Donors		
as	a	Resource	for	Characterising	
Tests	for	Recent	Infection	
3.1.1 Introduction	
Incidence, the rate of new infections, provides a more direct and current indication of the 
spread of HIV than prevalence, the fraction of the population in an infected state. 
Incidence estimates are key to monitoring epidemics, assessing outbreaks, and targeting 
and evaluating interventions. Prospective longitudinal studies, which allow for the direct 
counting of new infections in cohorts of individuals, are costly, logistically difficult to set 
up and maintain, and prone to capturing unrepresentative behaviours. Consequently, 
estimation of incidence using cross-sectional surveys [7, 15, 91] has attracted much 
interest over recent years. 
Tests for recent infection, also termed Recent Infection Testing Algorithms (RITAs) [10] 
or Serologic Testing Algorithms for Recent HIV Seroconversion (STARHS) [91], 
classify infections as ‘recently’ or ‘non-recently’ acquired. Incidence is then related to the 
prevalence of test-defined ‘recent’ infection [7, 15-17, 24-26, 91, 92, 143, 145] as 
estimated in a cross-sectional survey. 
Tests for recent infection traditionally employ the laboratory measurement of HIV viral 
or host biomarkers which evolve over time after infection. Antibody avidity, titre, or 
HIV-specific proportion is typically considered, with a measurement below a chosen 
threshold indicative of ‘recent’ infection [8, 9, 107]. 
Immune responses vary for individuals, and so each individual experiences a unique 
evolution of the biomarker. There are two test characteristics of relevance for population-
level incidence estimation. 
1. The test-defined state of ‘recent’ infection should not be too transient. This
ensures that the proportion of the population in this state may be estimated with
good statistical power in surveys with feasible sample sizes. Therefore, the
average time spent in the state of ‘recent’ infection, termed the mean duration of
recent infection (MDRI), ߱, should be large (typically, at least six months [11]).
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2. For many tests, there is evidence that some long-infected individuals are
classified as ‘recently’ infected [8, 9]. Although the phenomenon of ‘false-recent’
results may, in principle, be accounted for without introducing bias, adjustments
result in considerable loss of statistical precision of incidence estimates [11]. The
proportion of long-standing infections classified by the test as ‘recent’, termed the
false-recent rate (FRR), ߝ, should therefore be as low as feasible.
Increasing the threshold (the biomarker cut-off used to discriminate ‘recent’ from ‘non-
recent’ infection) increases the MDRI, but typically also results in a higher FRR. 
Therefore, as the threshold varies, there is a trade-off between the two test characteristics. 
Since population-level surveillance is of interest, rather than each individual’s ‘recent’ or 
‘non-recent’ infection diagnosis, a sensitivity-specificity trade-off (with truly recent 
infection defined by a fixed duration after infection) is not an appropriate threshold 
optimisation criterion.16  
Both calibration data and cross-sectional survey data are required to estimate incidence. 
Calibration data is used to estimate the test characteristics, namely the MDRI, ߱, and 
FRR, ߝ. Cross-sectional  data  is  used  to  estimate  the  proportions  of  susceptible  or 
uninfected, ‘recently’ infected and ‘non-recently’ infected individuals in the population, 
denoted by ௌܲ, ோܲ and ேܲோ, respectively. 
Population proportions and test characteristics are related to incidence, ܫ, by the following 
expression:17 
ܫ ൌ ோܲ െ
ߝ
1 െ ߝ ேܲோ
߱ ௌܲ . 
(3.1)
This has been derived in an analysis by McWalter and Welte [25], shown to be the 
maximum likelihood estimator by Wang and Lagakos [24], and informally generalised by 
Welte et al [11]. McWalter and Welte [23] compare this estimator to the previously 
proposed estimators of McDougal et al [16] and Hargrove et al [17]. 
___________________________ 
16The optimisation of tests for recent infection, using a performance metric that is appropriate to 
their application in HIV incidence surveillance, is discussed in Chapter 6. 
17The general incidence inference framework, which also provides definitions of the test properties 
that are free of assumptions about the test dynamics, as presented in Chapter 2, was still under 
development at the time of this analysis. 
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Ideally, the test should perform similarly in a number of populations, allowing for the 
reuse of test characteristic estimates. However, differences in the stage of the epidemic, 
or viral subtype or clade, may necessitate the estimation of these critical parameters in 
relevant populations for each study. For example, the proportions of individuals who are 
elite controllers (whose immune systems successfully suppress viraemia in the absence of 
treatment), have advanced immunodeficiency or are receiving antiretroviral therapy, may 
vary, and these individuals have a propensity to produce ‘false-recent’ classifications 
[8, 9].  
Traditionally, methods of estimating the MDRI have relied on the testing of serial 
samples from acutely infected subjects [7, 9, 15-17, 24, 91-93]. This typically requires at 
least one pre-seroconversion and multiple post-seroconversion samples, with short 
intervals between follow-up so that the seroconversion and threshold-crossing times may 
be estimated with minimal uncertainty.18 Such panels of data are costly and difficult to 
capture, requiring precisely the demanding longitudinal studies that cross-sectional 
incidence estimation seeks to circumvent. 
Despite being more easily obtained, specimens from seroconverting subjects with 
relatively long intervals between follow-up have been largely overlooked. Obtaining such 
specimens from repeat blood donors provides unique efficiencies as the collection of 
blood for transfusions is ongoing in most countries, and therefore procuring specimens 
does not require the establishment of new surveillance. Although the prevalence and 
incidence of HIV are generally lower in blood donors than the general population, the 
large-scale collection of blood and routine testing of serial donations for HIV provide a 
relatively large sample of seroconverting donors. Furthermore, large volumes of plasma, 
derived from routinely prepared frozen plasma components, are obtained. 
In this investigation, data captured on seroconverting blood donors in South Africa and 
the USA are used to demonstrate the characterisation and optimisation of tests for recent 
infection. 
___________________________ 
18In this chapter, the terms ‘seroconversion’ and ‘infection’ are used interchangeably, and both 
refer to HIV infection being detectable by the HIV diagnostic test (assumed to antibody-based 
here, although the work presented is completely general and any HIV diagnostic could be 
considered). Seroconversion describes the development of antibodies in the subject, in response 
to the virus, specifically to levels that are measurable by a chosen antibody-based HIV test. 
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3.1.2 Methods	
Ethics	statement	
The research and the incidence testing were approved by the University of California, San 
Francisco (UCSF); American Red Cross (ARC) and South African National Blood 
Service (SANBS) institutional review boards or ethics committees. 
Specimen	collection	and	testing	for	‘recent’	infection	
Specimens were collected by the South African National Blood Service (SANBS) of 
South Africa and the American Red Cross (ARC) of the USA, and tested by the Blood 
Systems Research Institute (BSRI) of the USA. Repeat donors who were observed to 
seroconvert were tested for ‘recent’ infection using the specimens collected at the times 
of the first seropositive donations. 
The investigation was performed for the less-sensitive Vironostika assay (LS-
Vironostika) [104], the test for which more data are available, and thereafter, the 
currently-used less-sensitive Vitros assay (LS-Vitros) [153] was characterised. These 
tests are both based on ‘less-sensitive’ versions of diagnostic tests that measure antibody 
titre, a concept introduced by Janssen et al [91]. For each test, ‘recent’ infection is 
indicated by a measured biomarker, namely a standardised optical density (SOD), below 
a chosen threshold. 
LS-Vironostika is a modification of the Vironostika HIV-1 microELISA diagnostic test 
(bioMérieux, Marcy l’Étoile, France) [104]. The laboratory procedures and threshold of 1 
specified by Rawal et al [104] were used. Seroconverting blood donors were tested using 
LS-Vironostika until 2007, as production of the Vironostika assay ceased in the year 
thereafter [9]. Manufacturing of the assay has since been resumed by Avioq Inc 
(Rockville, MD) [154]. 
LS-Vitros is based on the Ortho Vitros ECi anti-HIV 1+2 instrument (Ortho-Clinical 
Diagnostics, Raritan, NJ) [153]. The laboratory conditions were established by BSRI in 
earlier work that sought the closest agreement of classifications by LS-Vitros, using a 
threshold of 20, to those provided by LS-Vironostika [153]. 
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Data consist of the biomarker reading (SOD) at the time of the first seropositive donation, 
and the interval between the last seronegative and first seropositive donation, termed the 
inter-donation (ID) interval, for each seroconverting blood donor. Three datasets (plotted 
in Section 3.2.2) were used for the analysis: LS-Vironostika was applied to samples of 
South African donors (October 2005 to September 2007, sample size of ݊ ൌ 485) and 
North American donors (November 2001 to December 2005, ݊ ൌ 176), and LS-Vitros 
was applied to a sample of South African donors (October 2007 to December 2009, 
݊ ൌ 199). 
Data	analysis	
Test characteristics were estimated using a maximum likelihood method. Rather than 
fitting a curve describing the evolution of the biomarker over time after seroconversion, 
the overall probability of the test classifications at the first seropositive donations in the 
sample was maximised [33]. The likelihood function is derived below (and more detail is 
provided in Section 3.2.1). 
Assuming that the time of seroconversion is uniformly distributed in the ID interval, the 
probability that a seroconverter with ID interval Δ is classified as ‘recently’ infected at 
the time of the first seropositive donation is 
݌ሺΔሻ ൌ 1Δන ܵோሺݐሻ dݐ
୼
଴
, (3.2)
where ܵோሺݐሻ is the probability of being in the test-defined state of ‘recent’ infection when 
tested at time ݐ after seroconversion. For the ݅ th seroconverter in the sample, with ID 
interval Δ௜, the probability of testing ‘recent’ is ݌௜ ൌ ݌ሺΔ௜ሻ. 
The  likelihood,  ܮ,  to  be  maximised,  of  all  test  classifications  in  a  sample  of  ݊ 
seroconverters is 
ܮ ൌෑሺ݌௜ሻ௫೔ ሺ1 െ ݌௜ሻଵି௫೔
௡
௜ୀଵ
, (3.3)
where ݔ௜  is the observed result for the ݅ th seroconverter, and equals 1 if the subject is 
‘recently’ infected and 0 if the subject is ‘non-recently’ infected. 
In the analyses of McDougal et al [16], McWalter and Welte [25] and Wang and Lagakos 
[24], individual biomarker curves either cross the threshold (distinguishing ‘recent’ from 
‘non-recent’ infection) and readings remain above it thereafter, or else fail to reach the 
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threshold,  and  therefore  ܵோሺݐሻ  approaches  some  constant  value, ߙ,  which  is  the 
proportion of biomarker curves that fail to reach the threshold for large ݐ. ܵோሺݐሻ may then 
be expressed as 
ܵோሺݐሻ ൌ ߙ ൅ ሺ1 െ ߙሻܵோᇲሺݐሻ. (3.4)
In the above-mentioned analyses, the MDRI, ߱, is the mean time under the threshold for 
only those biomarkers curves that do cross the threshold, as described by ܵோᇱሺݐሻ. 
Substituting  from  Equation  (3.4)  into  Equation  (3.2),  the  probability  that  the  ݅th 
seroconverter is ‘recently’ infected becomes 
݌ሺΔ୧ሻ ൌ ݌௜ ൌ ߙ ൅ ሺ1 െ ߙሻ 1Δ௜ න ܵோᇱሺݐሻ dݐ
୼೔
଴
. (3.5)
This approach also facilitates non-parametric inference, by considering only subjects with 
large Δ௜. For a time cut-off, ܹ, such that 
ܵோᇲሺݐሻ ൌ 0 ሺor ܵோሺݐሻ ൌ ߙሻ ∀ ݐ ൐ ܹ, (3.6)
if Δ௜ ൐ ܹ, then 
න ܵோᇲሺݐሻ dݐ
୼೔
଴
ൌ න ܵோᇲሺݐሻ dݐ
ஶ
଴
ൌ ߱ (3.7)
is the MDRI. Substituting from Equation (3.7) into Equation (3.5), ݌௜ becomes a function 
of the two test characteristics, 
݌௜ ൌ ߙ ൅ ሺ1 െ ߙሻ ߱Δ௜ , (3.8)
and no assumptions are required about the shape with which the biomarker grows after 
seroconversion (that is, no full specification of ܵோᇲሺݐሻ is required). The estimated test 
characteristics maximise the likelihood, ܮ, which is now a function of ߱, and also of ߙ if 
there is no input estimate of ߙ. 
McDougal et al [16], McWalter and Welte [25] and Wang and Lagakos [24] additionally 
assumed that post-seroconversion survival is independent of the shape of the biomarker 
curves. When the above-mentioned assumptions are obeyed, ߙ ൌ ߝ  in the incidence 
expression in Equation (3.1). More generally, ܵோሺݐሻ may not remain constant for ݐ ൐ ܹ 
for a value of ܹ	used in the analysis. An FRR may then be defined as the proportion of 
individuals, seropositive for longer than ܹ, that are classified as ‘recently’ infected [11]. 
In this case, the above procedure that produces an estimate of ߙ, then considered only a 
proxy ‘FRR’, probably overestimates the FRR if biomarker curves cross the threshold 
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after ܹ or underestimates it if biomarker curves move back below the threshold at times 
since seroconversion greater than that captured in the dataset. The estimated test 
characteristics, ߙ and ߱, therefore provide unrefined estimates for the FRR and MDRI. 
Uniformly distributed seroconversion times are reasonable when the timing of donations 
and exposures to HIV are independent. Test-seeking behaviour (the donation of blood 
soon after exposure specifically to receive HIV testing) or deferral of donations (the delay 
of donations soon after exposure) could therefore bias estimates. In the USA, an 
investigation, which highlighted test-seeking behaviour among homosexual men, noted 
little indication of test-seeking behaviour among blood donors [155], while evidence of 
deferred donations has been observed [156]. Behaviour in the South African donor 
population may vary due to the large scale of the epidemic and stigma associated with 
HIV. 
In this work, various analyses involving the ‘parametric’ and ‘non-parametric’ inference 
of test characteristics by maximising the likelihood function in Equation (3.3) were 
performed for LS-Vironostika and LS-Vitros. In parametric inference, the probability of 
being ‘recently’ infected as expressed in Equation (3.5) was used, assuming forms for 
ܵோᇱሺݐሻ  and including all data in the analysis; and in non-parametric inference, the 
probability in Equation (3.8) was used, including only data satisfying Δ௜ ൐ ܹ . Using 
simulated data, estimates obtained from the parametric and non-parametric approaches 
were compared. Differences in test characteristics for specific subpopulations were 
explored. The utility of the test for obtaining precise incidence estimates was also 
investigated. 
Asymptotic maximum likelihood theory was used to estimate confidence intervals (CIs) 
and confidence regions (CRs) and to test the significance of parameters (based on the 
distribution of the deviance statistic and using the loglikelihood ratio test) [157]. Chi-
squared goodness of fit tests were used to assess agreement between data and 
assumptions [158]. All tests used a significance level of 5%. 
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3.1.3 Results	
Characterisation	of	LS‐Vironostika		
The estimated test characteristics for LS-Vironostika (using a threshold of 1) are shown in 
Figure 3.1, for both estimation of ߱ assuming a known ߙ and simultaneous estimation of 
߱  and ߙ , and analysing South African and American blood donors separately. Non-
parametric estimation was performed, using only observations with Δ௜ ൐ ܹ ൌ 1 year (the 
maximum duration in the state of ‘recent’ infection has been estimated to be 200 days 
[159] and 1 year [93]). The sample sizes for the analyses of South African and American 
donors were ݊ ൌ 282  and ݊ ൌ 106	  respectively. A comparison of the observed 
proportions of seroconverters who were ‘recently’ infected to the expected proportions 
(based on estimated test characteristics), as a function of ID interval, suggests good 
agreement under simultaneous estimation of the parameters (see Section 3.2.2). When 
exploring the sensitivity of results to ܹ , by increasing ܹ  to values up to 2.5 years, 
estimates for South African donors varied by at most 10% (݊ ൌ 189 when ܹ ൌ 2.5 
years), while the large uncertainty in estimates based on the relatively small dataset for 
American donors (݊ ൌ 53 when ܹ ൌ 2.5 years) did not support meaningful inference. 
The estimated ߙ is large, consistent with results from the application of this method to 
assess the BED assay [33 – results not shown]. Estimation of ߱ using an input estimate of 
ߙ is preferable. In the extreme case of all ID intervals being equal, ߱ and ߙ cannot be 
simultaneously estimated as the likelihood function may be kept at its maximum while 
arbitrarily increasing the estimate of ߙ by appropriately decreasing the estimate of ߱. 
Furthermore, using a value of ܹ that is too low (biomarker curves cross the threshold 
after ܹ) would bias estimates of ߙ upwards and ߱ downwards, based on the framework 
of McDougal et al [16], McWalter and Welte [25] and Wang and Lagakos [24]. Note that 
larger values of ܹ would be required at higher thresholds for discriminating between 
‘recent’ and ‘non-recent’ results. 
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Figure 3.1: Estimated test characteristics for LS-Vironostika in the repeat donor 
population 
Estimates of the MDRI, ߱  (days), for LS-Vironostika are shown, under both the 
simultaneous estimation of ߱ and ߙ, and when using an input ߙ, for ܹ ൌ 1 year. For the 
latter estimation, the estimated ߱ is plotted as a function of the assumed ߙ. The 95% 
confidence regions (CRs) for ߱ and ߙ (simultaneous estimation) and confidence intervals 
(CIs) for ߱ (assuming ߙ, and not accounting for uncertainty in ߙ) are displayed. Results 
are shown for repeat blood donors from A) South Africa and B) the USA. 
Legend:  Estimates of ߱ and ߙ from simultaneous estimation of characteristics 
(ߙො ൌ 13%, ෝ߱ ൌ 199 days for South Africa,  
 ߙො ൌ 21%, ෝ߱ ൌ 138 days for USA) 
▬ 95% CR boundary for characteristics from simultaneous estimation 
▬ Estimate of ߱ using an input ߙ 
 95% CI limits for ߱ using an input ߙ 
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The estimated MDRIs, for a number of thresholds (holding ܹ at 1 year), are compared to 
published estimates in Figure 3.2: 
1. Busch et al [160] utilised the directly measured incidence in the repeat donor
population to estimate ߱. Using ‘known’ incidence and proportions ோܲ, ேܲோ and
ௌܲ (measured in the repeat donor population), and assuming a zero FRR, a ‘back-
calculation’ for ߱  using the expression for incidence in Equation (3.1) was
performed. Since the possibility of ‘false-recent’ results was neglected,
overestimation of ߱  is expected, with greater bias at higher thresholds.
Methodologically, estimation of ߱  by back-calculation requires an existing
estimate of the FRR, ߝ , for the same threshold, with such data currently
unavailable. Furthermore, uncertainty in the estimate of ߱ arises from uncertainty
in the estimated incidence; proportions and FRR.
2. The Centers for Disease Control and Prevention (CDC) utilised seroconversion
panels to estimate ߱ in an American population [104, 160].
Parametric	versus	non‐parametric	approach	
The need for parametric assumptions about the shape of the antibody titre response curve, 
summarised into parametric assumptions about the probability of testing ‘recently’ 
infected as a function of time since seroconversion, is circumvented by using only data 
with large ID intervals. Consequently, estimation of ߱ is no longer prone to bias arising 
from poor parametric assumptions, but the dataset used for the estimation is reduced in 
size, decreasing the precision (increasing the variability) of estimates of ߱.  The 
characterisation of LS-Vironostika in the South African repeat donor population was 
revisited, this time using all data and parametric assumptions. 
The probability that a seroconverter is ‘recently’ infected at the first seropositive donation 
is given by Equation (3.5), which can be assessed once a form for ܵோᇱሺݐሻ  is fully 
specified. For ܵோᇱሺݐሻ ൌ ܵோᇱ ቀݐ|߶ቁ, where ߶ is a vector of parameters, the likelihood of the 
data, given by Equation (3.3), becomes a function of ߶ഫ . The MDRI estimator is then 
ෝ߱ ൌ න ܵோᇱ ቀݐ|߶෠ቁ dݐ
ஶ
଴
. (3.9)
where ߶ഫ෠ maximises the likelihood function (in Equation (3.3)). 
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Figure 3.2: Comparison of mean duration of recent infection estimates for  
LS-Vironostika to previously published estimates 
Estimates of the MDRI, ߱  (days), for LS-Vironostika, under both the simultaneous 
estimation of ߱ and ߙ, and when assuming ߙ ൌ 0%, for ܹ ൌ 1 year, are compared to 
published estimates, as a function of test threshold. Published estimates were obtained by 
‘back-calculation’ in the repeat donor population (Busch et al) [160] or using 
seroconversion panels (CDC) [104, 160]. The minimum and maximum ߱ occurring in the 
95% confidence regions (CRs) for ߱  and ߙ  (simultaneous estimation) and 95% 
confidence interval (CI) limits for ߱ (assuming ߙ ൌ 0%, with no uncertainty) are also 
displayed. Estimates pertain to A) South African and B) USA populations. 
Legend:  Estimate of ߱ from simultaneous estimation of characteristics 
 Minimum and maximum ߱ in 95% CR for characteristics 
from simultaneous estimation 
 Estimate of ߱ using an input ߙ ൌ 0% 
 95% CI limits for ߱ using an input ߙ ൌ 0% 
 Published back-calculation estimate of ߱ by Busch et al 
 Published seroconversion panel estimate of ߱ by CDC 
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A number of parametric forms for ܵோᇱሺݐሻ were used in the estimation of the MDRI for 
LS-Vironostika, based on assumptions ranging from a fixed duration of ‘recent’ infection 
for all individuals to a fat-tailed Pareto distribution for the time spent in the state of 
‘recent’ infection. Widely varying estimates of ߱ were obtained, even after excluding 
estimates for which assumptions and data did not agree (and all results are shown in 
Section 3.2.3). Since the true underlying dynamics of the data are unknown, the extent of 
bias from any incorrect parametric assumptions is unclear. 
Simulated data was therefore used to explore the trade-off between precision and bias 
when moving between non-parametric and parametric approaches. Based on each of a 
number of forms for ܵோᇱሺݐሻ, multiple datasets were generated. For each dataset, the MDRI 
was estimated parametrically using each of the forms for ܵோᇱሺݐሻ in turn (including all 
data) as well as non-parametrically (including only data with large ID intervals). 
Agreement between data and parametric assumptions was also assessed. The results of 
the investigation (shown in Section 3.2.3) suggest that power to reject ‘incorrect’ 
parametric assumptions is at times poor and that large bias in estimates may occur. When 
the assumptions leading to Equation (3.8) hold, estimates using the non-parametric 
approach are unbiased, although less precise. 
In the estimation of ߱ for LS-Vironostika using the South African donor sample, by using 
a non-parametric approach, there is a 40% reduction in the sample size from excluding ID 
intervals smaller than ܹ ൌ 1 year. However, potential bias arising from poor parametric 
assumptions is then eliminated, noting that one cannot easily distinguish between 
appropriate and poor parametric assumptions using only the data at hand.  
Population‐specific	test	characteristics	
Significant systematic bias could be introduced to incidence estimates if the test 
characteristics are not evaluated in a population representative of that in which incidence 
estimation is to occur [11, 26]. Since most HIV antibody assays are based primarily on 
clade B antigens, antibody-antigen reactivity may vary when applying assays in 
populations in which other clades occur [161], with differences in the characteristics of 
LS-Vironostika already observed [104, 105, 159, 161, 162]. Other factors, such as the 
association between viral RNA levels and clade, and seroconverters’ genetic 
backgrounds, may also affect results [8, 9, 92, 161].  
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The significance of gender (male and female) and country (South Africa and USA) on the 
characteristics of LS-Vironostika was assessed. Country differences are likely to be 
largely representative of clade differences, as clade C infections are predominant in South 
Africa, and clade B in the USA [163]. Investigations by SANBS on a sample of donors 
(data made available to authors) and studies of North American donors [164, 165] 
indicate that a very small percentage (<5%) of infections are not of the predominant 
clade. 
The null hypothesis, that the characteristics of LS-Vironostika are the same in all four 
groups (each pairing of gender and country), is not rejected with a p-value of 10.48%. 
Estimated test characteristics for the groups are shown in Figure 3.3 (using non-
parametric estimation and ܹ ൌ 1 year). However, in this investigation, large uncertainty 
in estimates, arising from small samples of seroconverters, would result in little power to 
identify significant factors. 
Figure 3.3: Estimated test characteristics for LS-Vironostika in the repeat donor 
population by gender and country 
Estimates of ߱ (days) and ߙ (%) for LS-Vironostika are shown for South African male 
donors, South African female donors, USA male donors and USA female donors. 
Parameters were estimated simultaneously, using ܹ ൌ 1 year, and 95% confidence 
regions (CRs) are indicated. 
Legend  South Africa, males (SA, M): ෝ߱ ൌ 219 days, ߙො ൌ 17%, ݊ ൌ 162 
(  95% CR boundary) 
 South Africa, females (SA, F): ෝ߱ ൌ 185 days, ߙො ൌ 5%, ݊ ൌ 120  
(▬ 95% CR boundary) 
 USA, males (USA, M): ෝ߱ ൌ 42 days, ߙො ൌ 29%, ݊ ൌ 77
(  95% CR boundary) 
 USA, females (USA, F): ෝ߱ ൌ 294 days, ߙො ൌ 6%, ݊ ൌ 29  
(▬ 95% CR boundary) 
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Optimisation	and	comparison	of	tests	for	recent	infection	
The ultimate objective is incidence estimation. The precision of the incidence estimator 
(and hence power to detect changes in incidence) increases with a larger MDRI and 
smaller FRR [11]. However, when optimising a biomarker-based test for recent infection 
by tuning the threshold distinguishing ‘recent’ from ‘non-recent’ infections, there is a 
fundamental trade-off between these two test characteristics as both increase with 
increasing threshold. Figure 3.4 shows the estimated test characteristics of 
LS-Vironostika, in the South African donor population, for a range of thresholds (using 
non-parametric estimation, and ܹ ൌ 1 year). 
The precision of the incidence estimator, given the estimated test characteristics of LS-
Vironostika, is compared to that achieved by a BED-like test for recent infection in 
Figure 3.5.19 The BED-like test has an MDRI of ߱ ൌ 155 days and FRR of ߝ ൌ 5.6% 
(with no uncertainty), as per BED package insert [166], and it is assumed that ߝ ൌ ߙ for 
LS-Vironostika. The coefficient of variation (CoV) of the incidence estimator [25] is 
calculated for a hypothetical population that has an HIV incidence of 1.5% per annum 
and HIV prevalence of 17.5%, loosely based on the South African adult population 
[167, 168]. Since the CoV ratio (LS-Vironostika to BED-like) is indistinguishable from 1, 
at all thresholds considered, the LS-Vironostika appears comparable to a BED-like test 
for recent infection. Additional data, such as captured during the follow-up of 
seropositive individuals awaiting treatment, could be used to explore whether systematic 
artefacts in the estimation occur (for example, from individuals progressing after 
ܹ ൌ 1 year).  
___________________________ 
19This early work, which captures the first article in this thesis that was published, touches on a 
number of ideas that were being further developed at the time. The use of the precision of the 
incidence estimator as a metric for optimising and comparing tests for recent infection is further 
discussed in Chapter 6. 
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Figure 3.4: Estimated test characteristics for LS-Vironostika in the South African 
donor population as a function of test threshold 
Estimates of ߱  and ߙ  for LS-Vironostika, based on the South African repeat donor 
sample, are shown for values of the threshold (discriminating ‘recent’ from ‘non-recent’ 
infection) between 0.2 and 1.5 (in SOD units). The parameters were estimated 
simultaneously, and estimates for A) ߱ (days) and B) ߙ (%) are shown as functions of 
threshold, for ܹ	 ൌ 	1 year. The minimum and maximum ߱ and ߙ occurring in the 95% 
confidence region (CR) for these parameters are also displayed. 
Legend:  Estimated test characteristic from simultaneous estimation 
▬ Estimated test characteristics from simultaneous estimation – smoothed 
(a cubic polynomial was fitted by least squares) 
 Minimum and maximum value of test characteristic in 95% CR for 
characteristics from simultaneous estimation – smoothed 
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Figure 3.5: Relative performance of LS-Vironostika for incidence estimation 
The ratio of the estimated CoV of the incidence estimator, for LS-Vironostika to that of a 
BED-like test for recent infection, is shown as a function of the LS-Vironostika test 
threshold. For LS-Vironostika, test characteristics estimated from the South African 
repeat donor sample were used to calculate the CoV, assuming ߝ ൌ ߙ, while the BED-like 
test was assigned ‘known’ test characteristics of ߱ ൌ 155 days and ߝ ൌ 5.6% [166]. In 
the hypothetical population considered, HIV incidence is 1.5% per annum and HIV 
prevalence is 17.5%. 
Legend:  Estimated CoV ratio  
▬ Estimated CoV ratio – smoothed (a cubic polynomial was fitted by least 
squares) 
 Minimum and maximum CoV ratio in 95% CR for test characteristics 
from simultaneous estimation – smoothed 
Characterisation	of	LS‐Vitros	
Preliminary test characteristic estimates of the currently used LS-Vitros (using a threshold 
of 20), for the South African repeat donor population, are shown in Figure 3.6. 
Simultaneous (non-parametric) estimation of ߱ and ߙ, for a range of ܹ, was performed 
(݊ ൌ 108,  for  ܹ ൌ 1  year, reduces  to 	݊ ൌ 59,  for  ܹ ൌ 2.5  years).  Observed  and 
expected proportions of seroconverters who were ‘recently’ infected were also compared 
(see Section 3.2.2). 
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Figure 3.6: Estimated test characteristics for LS-Vitros in the South African repeat 
donor population as a function of ࢃ 
Estimates of ߱ and ߙ for LS-Vitros, based on the South African repeat donor sample, are 
shown for values of ܹ  between 1 and 2.5 years. The parameters were estimated 
simultaneously, and estimates for A) ߱ (days) and B) ߙ (%) are shown as functions of 
ܹ(years). The minimum and maximum ߱ and ߙ occurring in the 95% confidence region 
(CR) for these parameters are also displayed 
Legend:  Estimated test characteristic from simultaneous estimation 
▬ Estimated test characteristics from simultaneous estimation – smoothed 
(a cubic polynomial was fitted by least squares) 
 Minimum and maximum value of test characteristic in 95% CR for 
characteristics from simultaneous estimation – smoothed 
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For LS-Vitros, the test characteristics were plotted as a function of the time cut-off 
ܹ (Figure 3.6) as no estimates of ܹ  were found in the literature and the estimation 
appeared fairly sensitive to the choice of ܹ for this dataset. Test characteristic estimates 
are highly uncertain and vary widely. This indicates the need for a larger dataset and an 
external estimate of ߙ  for a carefully selected time cut-off ܹ  (large enough for the 
biomarker curves to have crossed the threshold within a time ܹ post infection) to get a 
more accurate and precise estimate of the MDRI. Such data and estimates are currently 
unavailable. A value of ܹ that is too small would bias estimates of ߙ upwards and ߱ 
downwards, under the above-mentioned analysis assumptions. However, as the value of 
ܹ increases, the sample size reduces and ID intervals are more closely clustered together, 
decreasing the power to perform simultaneous estimation. 
The large, albeit highly uncertain, estimates of ߙ suggest that one should be cautious 
about the utility of LS-Vitros for incidence estimation, at this stage of the 
characterisation, while being mindful that ߙ is not the FRR in Equation (3.1) if ܵோሺݐሻ is 
not (approximately) constant for ݐ ൐ ܹ.20 
3.1.4 Discussion	
Traditionally, the characterisation of tests for recent infection (individual assays and 
multiple-test algorithms) has relied on the use of seroconversion panels. The scarcity of 
these panels is therefore an obstacle to the development of tests for incidence estimation. 
In this work, a source of more readily available specimens has been identified, and an 
approach for obtaining preliminary characterisations of tests using these specimens has 
been demonstrated. Further refinement of the characterisation of only the most promising 
tests may thereafter be performed, thus conserving precious longitudinal specimens (for 
MDRI estimation) and specimens from populations with known long-standing infections 
(for FRR estimation) for this purpose. 
Utilising specimens from blood donors provides unique efficiencies as relatively large 
samples of seroconverters and high-volume specimens (125-250ml of plasma per 
seroconverter) are captured during routine blood collection procedures. Furthermore, 
___________________________ 
20 In later work, as part of CEPHIA, a large dataset (which included longitudinal data) was 
produced and analysed to characterise LS-Vitros, and results are presented in Chapter 5. 
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specimens from seropositive subjects around the world are collected, thus providing data 
to investigate whether test characteristics are population-specific. 
The method of estimating the test characteristics (MDRI and a proxy ‘FRR’ for parameter 
estimation purposes) does not require the follow-up of seroconverters. Moreover, by 
using data with large (pre-seroconversion) follow-up intervals, non-parametric estimation 
is supported. To obtain more accurate and precise estimates of the MDRI, an external 
estimate of the proportion of biomarker curves that do not reach the threshold is desirable, 
as well as insight into the maximum time seroconverters otherwise spend in the test-
defined ‘recent’ state. 
For incidence estimation, the utility of LS-Vironostika appears comparable to that of a 
BED-like test for recent infection, over the range of thresholds considered. The precision 
of the incidence estimator provides a criterion for both comparing tests and identifying 
optimal thresholds. While additional data is required for LS-Vitros, preliminary results 
suggest prudence when utilising the assay for incidence estimation. 
The assumptions under which estimates are unbiased are strict. Potential for systematic 
bias in estimates, such as that arising from individuals remaining in the state of ‘recent’ 
infection for prolonged periods, or from non-uniformly distributed seroconversion times, 
should be explored using additional data. This method of estimating the test properties is 
not intended to provide final parameter estimates required for incidence estimation, but 
rather to provide cost-effective and efficient preliminary characterisations of tests using 
previously overlooked data. It is hoped that the concepts and tools demonstrated in this 
work will contribute to the resourceful characterisation, and subsequently focused 
development, of tests for recent infection for population-level incidence estimation. 
3.2 Ancillary	Analysis	Details	
3.2.1 The	Test	Characteristic	Estimators	
In the analyses presented in Section 3.1, two test characteristics were estimated, namely 
the MDRI, ߱, and a proxy ‘FRR’, ߙ , defined according to the analysis constructs of 
McDougal et al [16], McWalter and Welte [25] and Wang and Lagakos [24]. The 
maximum likelihood estimators for the test characteristics are derived below, and their 
distributional properties explored. 
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The function ܵோሺݐሻ denotes the probability that a seroconverter is in the state of ‘recent’ 
infection at time ݐ after seroconversion, conditional on being alive.  
For a given seroconverter, with inter-donation (ID) interval Δ  between the last 
seronegative test and first seropositive test: 
1. The random variable ܺ denotes the result of the test for recent infection at the
time of the first seropositive test, and has a probability mass function ௑݂ሺݔሻ,
where ܺ equals 1 if the subject is ‘recently infected and 0 if the subject is ‘non-
recently’ infected.
2. The random variable ܻ captures the time since seroconversion at the time of the
first seropositive donation, and has a probability density function ௒݂ሺݕሻ, where
0 ൑ ܻ ൏ Δ, and, in particular, is assumed to be uniformly distributed in the ID
interval.
The joint probability function of ܺ and ܻ is denoted by ௑݂,௒ሺݔ, ݕሻ, and the distribution of 
ܺ conditional on ܻ by ௑݂|௒ሺݔ|ݕሻ.  
The probability, ݌, that the seroconverter is classified as ‘recently’ infected at the time of 
the first seropositive donation is 
݌ሺΔሻ ൌ ௑݂ሺ1ሻ 
ൌ න ௑݂,௒ሺ1, yሻ dݕ
୼
଴
ൌ න ௒݂ሺݕሻ ௑݂|௒ሺ1|ݕሻ dݕ
୼
଴
ൌ 1Δන ܵோሺݐሻ dݐ
୼
଴
, (3.10)
since ௒݂ሺݕሻ ൌ 1/Δ	for all ݕ such that 0 ൑ ݕ ൑ Δ, and ௑݂|௒ሺ1|ݐሻ ൌ ܵோሺݐሻ. 
The likelihood, ܮ, of all test classifications in a sample of ݊ seroconverters is 
ܮ ൌෑሺ݌௜ሻ௫೔ሺ1 െ ݌௜ሻଵି௫೔
௡
௜ୀଵ
, (3.11)
where the subscript ݅ denotes quantities relating to the ݅th seroconverter in the sample and 
ݔ denotes the observed values of ܺ. The ݅th seroconverter has ID interval Δ௜ and therefore 
݌௜ ൌ ݌ሺΔ௜ሻ. 
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The analyses of McDougal et al [16], McWalter and Welte [25] and Wang and Lagakos 
[24] assume that individual biomarker curves either cross the threshold (distinguishing 
‘recent’ from ‘non-recent’ infection) and readings remain above it thereafter, or else fail 
to reach the threshold. Therefore ܵோሺݐሻ approaches some constant value, ߙ, which is the 
proportion of biomarker curves that fail to cross the threshold, for ݐ larger than some time 
cut-off ܹ, and 
ܵோሺݐሻ ൌ ߙ ൅ ሺ1 െ ߙሻܵோᇲሺݐሻ . (3.12)
In the above-mentioned analyses, the MDRI, ߱, is defined as the mean time under the 
threshold for those curves that do cross the threshold, which is described by ܵோᇲሺݐሻ. 
Substituting from Equation (3.12) into Equation (3.10), the probability that a 
seroconverter (with ID interval Δሻ  is ‘recently’ infected at the time of the first 
seropositive donation becomes 
݌ሺΔሻ ൌ ߙ ൅ ሺ1 െ ߙሻ 1Δන ܵோᇲሺݐሻ
୼
଴
dݐ. (3.13)
For ܵோᇲሺݐሻ ൌ ܵோᇲ ቀݐቚ߶ቁ, ܮ is a function of the unknown parameters ߶ and ߙ (if there is no 
input estimate for ߙሻ, which are estimated to maximise ܮ. The estimate of the MDRI is 
then  
ෝ߱ ൌ න ܵோᇱ ቀݐ|߶෠ቁ
ஶ
଴
dݐ, (3.14)
where  ߶෠ is the estimate of ߶. 
This likelihood approach also facilitates non-parametric inference, by considering only 
individuals with large Δ. Since 
ܵோᇲሺݐሻ ൌ 0 ሺsince ܵோሺݐሻ ൌ ߙሻ ∀ ݐ ൐ ܹ, (3.15)
if Δ ൐ ܹ, then 
න ܵோᇲሺݐሻ dݐ
୼
଴
ൌ න ܵோᇲሺݐሻ dݐ
ஶ
଴
ൌ ߱ (3.16)
is the MDRI. 
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Substituting from Equation (3.16) into Equation (3.13), ݌ሺΔሻ  relies only on the test 
characteristics:  
݌ሺΔሻ ൌ ߙ ൅ ሺ1 െ ߙሻ߱Δ , (3.17)
and the likelihood function becomes 
ܮ ൌ ෑሺ݌௜ሻ௫೔
௡∗
௜ୀଵ
ሺ1 െ ݌௜ሻଵି௫೔ where ݌௜ ൌ ݌ሺΔ௜ሻ ൌ ߙ ൅ ሺ1 െ ߙሻ ߱Δ୧ (3.18)
and ݊∗ሺ൑ ݊ሻ is the size of the sample consisting of only seroconverters with ID intervals 
larger than ܹ  (and the subscript ݅  denotes quantities relating to the ݅ th subject in this 
smaller sample). The estimated test characteristics maximise the likelihood ܮ, which is 
now a function of ߱, and of ߙ if there is no input estimate of ߙ. 
Simultaneous estimation of the test characteristics is less feasible in samples with closely 
clustered ID intervals. In the extreme case of Δ௜ ൌ Δ∗ ൐ ܹ  for all ݅  ( ݅ ൌ 1,2, … ݊∗ ), 
simultaneous estimation is not possible as there are no unique estimates of ߱ and ߙ which 
maximise the likelihood function. More specifically, the likelihood function, 
ܮ ∝ ቀߙ ൅ ሺ1 െ ߙሻ ߱Δ∗ቁ
∑ ௫೔೙∗೔సభ ቆ1 െ ቀߙ ൅ ሺ1 െ ߙሻ ߱Δ∗ቁቇ
∑ ሺଵି௫೔ሻ೙∗೔సభ
, (3.19)
is maximised when 
∑ ݔ௜௡∗௜ୀଵ
݊∗ ൌ ߙ ൅ ሺ1 െ ߙሻ
߱
Δ∗ . (3.20)
The left-hand side of the equation depends on the observed data. The maximum 
likelihood estimate for ߱ appearing in the right-hand side of the equation can be chosen 
arbitrarily by selecting a corresponding estimate of ߙ that ensures the equation holds. 
A maximum likelihood estimator, ߦመ, is asymptotically normally distributed around the 
true parameter value, ߦ , with variance equal to the inverse of the expected Fisher's 
Information Matrix, under regularity conditions [157]: 
ߦመ ௗ→ 		ܰ
ۉ
ۇߦ, ൦െܧ ൮
߲ଶ ln ൬ܮ ቀߦቁ൰
߲ߦଶ ൲൪
ିଵ
ی
ۊ as ݉ → ∞, (3.21)
where ݉ is the size of the sample used in the estimation procedure, ܧሺ. ሻ is the expected 
value and ܮሺ. ሻ  is the likelihood function (and ln൫ܮሺ. ሻ൯  the natural logarithm of the 
likelihood function). Using this property of maximum likelihood estimators, large sample 
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approximations for the distribution and moments of the test characteristic estimators 
follow. 
When ߙ is known, the distribution of the estimator for ߱ is  
ෝ߱ ~ሶ ܰ ቌ߱, ቎෍൬1 െ ߙΔ୧ ൰
ଶ 1
݌௜ሺ1 െ ݌௜ሻ
௡∗
௜ୀଵ
቏
ିଵ
ቍ. (3.22)
When ߙ is unknown, the bivariate distribution for the joint estimator for ߱ and ߙ is 
ۏێ
ێێ
ۍ ෝ߱
ߙො ےۑ
ۑۑ
ې
~ሶ ܰ
ۉ
ۈ
ۇ
ۏێ
ێێ
ۍ߱
ߙ ےۑ
ۑۑ
ې
,
ۏ
ێ
ێ
ۍ
െܧ
ۉ
ۇ
߲ଶ lnሺܮሻ
߲߱ଶ
߲ଶ lnሺܮሻ
߲߲߱ߙ
߲ଶ lnሺܮሻ
߲߲߱ߙ
߲ଶ lnሺܮሻ
߲ߙଶ ی
ۊ
ے
ۑ
ۑ
ې
ିଵ
ی
ۋ
ۊ, (3.23)
where the covariance matrix is 
ۏ
ێ
ێ
ێ
ێ
ۍ෍൬1 െ ߙΔ௜ ൰
ଶ 1
݌௜ሺ1 െ ݌௜ሻ
௡∗
௜ୀଵ
෍ 1Δ௜݌௜
௡∗
௜ୀଵ
෍ 1Δ௜݌௜
௡∗
௜ୀଵ
෍൬1 െ ߱Δ௜൰
ଶ௡∗
௜ୀଵ
1
݌௜ሺ1 െ ݌௜ሻے
ۑ
ۑ
ۑ
ۑ
ې
ିଵ
(3.24)
and ݌௜ ൌ ݌ሺΔ௜ሻ and ܮ ൌ ܮሺ߱, ߙሻ are given in Equation (3.18). 
3.2.2 The	Observed	Data	and	Fitted	Models		
Plots of the data used to perform the analyses presented in Section 3.1 are provided, and 
the fitted models informally assessed by visually comparing observed and expected 
proportions of ‘recent’ results.  
The data for each of the two tests for recent infection, LS-Vironostika and LS-Vitros, are 
shown in Figure 3.7, stratified by country (South Africa and the USA). Each 
seroconverting blood donor’s biomarker reading at the time of the first seropositive 
donation and inter-donation interval (time between the last seronegative and first 
seropositive donation) are shown. 
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Figure 3.7: Observed biomarker readings for LS-Vironostika and LS-Vitros in 
seroconverting blood donors, and corresponding inter-donation intervals  
Each subject’s biomarker reading at the first seropositive donation, expressed as a 
standardised optical density (SOD), and inter-donation interval (time between last 
seronegative and first seropositive donation, in days) are shown (for inter-donation 
intervals less than 4 years), for A) LS-Vironostika for donors in South Africa, B) LS-
Vironostika for donors in the USA and C) LS-Vitros for donors in South Africa. 
Measurements below test thresholds (horizontal dashed lines) produce ‘recent’ 
classifications. 
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The method of maximum likelihood, outlined in Section 3.2.1 above, was used to 
characterise the tests. In Figures 3.8 to 3.11, observed proportions of seroconverters who 
were ‘recently’ infected at the first seropositive donations are compared to expected 
proportions, for each primary analysis presented in Section 3.1. For each analysis, firstly, 
the MDRI, ߱, was estimated assuming a known ߙ, and secondly, simultaneous estimation 
of ߱  and ߙ  was performed. Non-parametric estimation was applied, using data on 
seroconverters with inter-donation (ID) intervals larger than the chosen time cut-off ܹ.  
The probability of testing ‘recently’ infected declines with increasing ID interval. 
Subjects with similar ID intervals were therefore grouped together (at least 20 subjects 
per group), and, for each group, the observed and expected proportions were plotted 
against the average ID interval. Expected proportions were obtained by substituting 
estimated (or input) test characteristics into Equation (3.17), and averaging the 
probabilities obtained for subjects in the group. When assuming a known ߙ (Part A of 
figures), the 95% confidence interval limits for the expected proportion were obtained by 
instead substituting the 95% confidence interval limits for ߱ into Equation (3.17). When 
simultaneously estimating ߱ and ߙ (Part B of figures), the plotted limits for the expected 
proportion indicate the minimum and maximum values for this proportion that were 
obtained when considering all pairs of values for the test characteristics within the 95% 
confidence region for ߱ and ߙ.  
Figure 3.8 and Figure 3.9 capture results for LS-Vironostika, for the South African 
(݊ ൌ 282) and American repeat donor (݊ ൌ 106) samples, respectively, using ܹ ൌ 1 
year. In Figure 3.10 and Figure 3.11, observed and expected proportions are compared for 
LS-Vitros  in  the  South  African  donor  sample  for  ܹ ൌ 1 year  (݊ ൌ 108)  and 
ܹ ൌ 2.5 years (݊ ൌ 	59), respectively. 
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A) Estimation of ࣓ using input ࢻ
B) Simultaneous estimation of ࣓ and ࢻ (࣓ෝ ൌ ૚ૢૢ days and ࢻෝ ൌ ૚૜%)
Figure 3.8: Comparison of observed and expected proportions of ‘recently’ infected 
seroconverters for LS-Vironostika, South Africa, ࢃ ൌ ૚ year 
Observed and expected proportions of ‘recently’ infected subjects, at first seropositive 
donations, are shown as a function of inter-donation (ID) intervals (days) for LS-
Vironostika, for the South African repeat blood donor sample. Expected proportions are 
based on estimated test characteristics when A) estimating only ߱ and assuming a known 
ߙ, and B) simultaneously estimating ߱ and ߙ, using ܹ ൌ 1 year. Proportions are plotted 
against average ID intervals for groups of at least 20 subjects. 95% CI limits or 
uncertainty bounds for expected proportions are also indicated. 
Legend:  Observed proportion of ‘recent’ infection 
 Expected proportion of ‘recent’ infection 
 95% CI limits / uncertainty bounds for expected proportion 
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A) Estimation of ࣓ using input ࢻ
B) Simultaneous estimation of ࣓ and ࢻ (࣓ෝ ൌ ૚૜ૡ days and ࢻෝ ൌ ૛૚%)
Figure 3.9: Comparison of observed and expected proportions of ‘recently’ infected 
seroconverters for LS-Vironostika, USA, ࢃ ൌ ૚ year 
Observed and expected proportions of ‘recently’ infected subjects, at first seropositive 
donations, are shown as a function of inter-donation (ID) intervals (days) for LS-
Vironostika, for the American repeat blood donor sample. Expected proportions are based 
on estimated test characteristics when A) estimating only ߱ and assuming a known ߙ, and 
B) simultaneously estimating ߱ and ߙ, using ܹ ൌ 1 year. Proportions are plotted against
average ID intervals for groups of at least 20 subjects. 95% CI limits or uncertainty 
bounds for expected proportions are also indicated. 
Legend:  Observed proportion of ‘recent’ infection 
 Expected proportion of ‘recent’ infection 
 95% CI limits / uncertainty bounds for expected proportion 
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A) Estimation of ࣓ using input ࢻ
B) Simultaneous estimation of ࣓ and ࢻ (࣓ෝ ൌ ૠ૟ days and ࢻෝ ൌ ૝૚%)
Figure 3.10: Comparison of observed and expected proportions of ‘recently’ 
infected seroconverters for LS-Vitros, South Africa, ࢃ ൌ ૚ year 
Observed and expected proportions of ‘recently’ infected subjects, at first seropositive 
donations, are shown as a function of inter-donation (ID) intervals (days) for LS-Vitros, 
for the South African repeat blood donor sample. Expected proportions are based on 
estimated test characteristics when A) estimating only ߱ and assuming a known ߙ, and B) 
simultaneously estimating ߱  and ߙ , using ܹ ൌ 1 year. Proportions are plotted against 
average ID intervals for groups of at least 20 subjects. 95% CI limits or uncertainty 
bounds for expected proportions are also indicated. 
Legend:  Observed proportion of ‘recent’ infection 
 Expected proportion of ‘recent’ infection 
 95% CI limits / uncertainty bounds for expected proportion 
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A) Estimation of ࣓ using input ࢻ
B) Simultaneous estimation of ࣓ and ࢻ (࣓ෝ ൌ ૞૟ૢ days and ࢻෝ ൌ ૛૝%)
Figure 3.11: Comparison of observed and expected proportions of ‘recently’ 
infected seroconverters for LS-Vitros, South Africa, ࢃ ൌ ૛. ૞ years 
Observed and expected proportions of ‘recently’ infected subjects, at first seropositive 
donations, are shown as a function of inter-donation (ID) intervals (days) for LS-Vitros, 
for the South African repeat blood donor sample. Expected proportions are based on 
estimated test characteristics when A) estimating only ߱ and assuming a known ߙ, and B) 
simultaneously estimating ߱ and ߙ, using ܹ ൌ 2.5 years. Proportions are plotted against 
average ID intervals for groups of at least 20 subjects. 95% CI limits or uncertainty 
bounds for expected proportions are also indicated. 
Legend:  Observed proportion of ‘recent’ infection 
 Expected proportion of ‘recent’ infection 
 95% CI limits / uncertainty bounds for expected proportion 
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The expected proportions of ‘recent’ results are sensitive to the input value for ߙ as well 
as ܹ. Expected proportions are relatively well aligned to observed proportions when ߙ is 
estimated together with ߱ (rather than being provided as an input), but uncertainty in the 
estimation procedure becomes large when the parameters are jointly estimated. This 
highlights the need for external and accurate data to guide choices of ߙ and ܹ. Also, in 
this work, the probability of testing ‘recently’ infected, conditional on being alive, is 
understood  to  be  approximately  constant  (and  equal  to  ߙ)  for  all  times  after 
seroconversion greater than ܹ, based on the analysis constructs of McDougal et al [16], 
McWalter and Welte [25] and Wang and Lagakos [24]. The behaviours of LS-
Vironostika and LS-Vitros may violate this assumption, potentially leading to 
misalignment between observed and expected proportions. 
3.2.3 Parametric	Versus	Non‐Parametric	
Estimation	
The need for parametric assumptions about the probability of testing ‘recently’ infected 
as a function of time since seroconversion is circumvented by using only data with 
sufficiently large ID intervals (see Section 3.2.1). While this protects against bias arising 
from poor parametric assumptions, the sample size is reduced.  
The test characteristics of LS-Vironostika, in the South African repeat donor population, 
were therefore also estimated using all data and a number of parametric assumptions, 
captured by specifying various forms for ܵோᇲሺݐሻ ൌ ܵோᇲሺݐ|߶ሻ , where ߶  is a vector of 
parameters to be estimated from the data. The six assumed forms for ܵோᇲሺݐ|߶ሻ are plotted 
in Figure 3.12. For simplicity, by design, ߶ ൌ ߱ for each form. Estimates of the MDRI, 
߱, using the various parametric assumptions, are provided in Table 3.1. Results of a chi-
squared goodness of fit test [158], used to assess agreement between data and 
assumptions, are also provided. Widely varying estimates of ߱ were obtained, even after 
discarding those estimates for which data and assumptions did not agree. 
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Figure 3.12: Parametric forms for ࡿࡾᇲሺ࢚|ࣘഫሻ  used in MDRI estimation and data 
generation 
Each of the six forms for ܵோᇲሺݐ|߶ഫሻ used in the analysis is plotted as a function of time 
since seroconversion (days), where ܵோᇲሺݐ|߶ഫሻ  is the probability of being ‘recently’ 
infected when tested at time ݐ  after seroconversion (for those individuals who do 
transition out of the ‘recent’ state). The function ܵோᇲሺݐ|߶ഫሻ  contains the parameter ߶ഫ , 
which is estimated to maximise the likelihood of observed data for test characterisation 
purposes, or for which a value is specified for data generation purposes. By design, 
߶ഫ ൌ ߱  for each form. The functions are plotted using ߶ഫ ൌ ߱ ൌ 150  days.
*Form 6 uses a (suitably scaled and shifted) sine function to obtain an s-shaped curve that
reaches zero at time 2߱ after seroconversion. 
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Input ࢻ (%) 
0 5 10 15
Estimated ࣓, in 
   days (95% CI) 
Parametric form 1 *84 (82-84) *83 (81-84) *83 (81-84) *83 (80-84)
Parametric form 2 316 (266-374) 278 (233-333) 251 (209-301) 229 (188-276) 
Parametric form 3 *237 (217-249) 228 (204-246) 219 (192-242) 208 (180-235) 
Parametric form 4 *429 (355-520) 379 (309-464) 338 (273-418) 303 (242-378) 
Parametric form 5 650 (528-802) *579 (464-721) 516 (409-649) *461 (361-585)
Parametric form 6 268 (232-309) 241 (207-281) 221 (188-259) 205 (173-242)
Non-parametric 274 (234-313) 245 (199-289) 216 (165-266) 186 (132-241)
Goodness of fit  
   p-valuea 
Parametric form 1 0.00 0.00 0.00 0.00
Parametric form 2 0.29 0.10 0.56 0.73
Parametric form 3 0.03 0.57 0.65 0.80
Parametric form 4 0.02 0.12 0.16 0.09
Parametric form 5 0.09 0.02 0.08 0.03
Parametric form 6 0.05 0.56 0.69 0.90
a Null hypothesis: The data is consistent with the assumed form for ܵோᇲሺݐ|߶ഫሻ 
Table 3.1: Estimated mean duration of recent infection for LS-Vironostika, South 
Africa, using various parametric assumptions 
Estimates of the MDRI, ߱ (days), for LS-Vironostika in the South African repeat donor 
population are shown, using both parametric and non-parametric estimation approaches 
and an input value of ߙ  (%). 95% CI limits are also provided. For the parametric 
estimation, each of the six forms for ܵோᇲሺݐ|߶ഫሻ shown in Figure 3.12 was assumed in turn 
(Parametric form 1 to 6) and all data were included. P-values from a chi-squared 
goodness of fit test used to assess agreement between data and parametric assumptions 
are also shown, and an estimate of ߱ that corresponds to a p-value below 0.05 is indicated 
by an asterisk (*). For non-parametric estimation, only seroconverters with ID intervals 
larger than ܹ ൌ 1 year were included in the analysis.  
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Since the underlying dynamics of the data are unknown, the extent of any bias in the 
results is unclear. Simulated data was therefore used to investigate the trade-off between 
the increased precision from larger samples and increased potential for bias from poor 
parametric assumptions, when moving from a non-parametric to parametric approach. A 
number of datasets were generated, each consisting of ID intervals and test classifications 
for 500 seroconverters. For each seroconverter, the ID interval was drawn from a (kernel 
density) non-parametric distribution that was fitted to the ID intervals contained in the 
real-world dataset (for LS-Vironostika, South Africa); the infection time was drawn from 
a uniform distribution spanning the subject’s ID interval; and the test classification was 
generated from a chosen specification of ܵோᇲሺݐ|߶ሻ and ߙ ൌ 0%. Each of the six forms for 
ܵோᇲሺݐ|߶ሻ in Figure 3.12, using ߶ ൌ ߱ ൌ 150 days, was used to generate 100 datasets. 
For each simulated dataset, seven estimates of ߱ were obtained: six by assuming each of 
the parametric forms for ܵோᇲሺݐ|߶ሻ in turn and using all data in the estimation procedure, 
and one by non-parametric estimation using only ID intervals greater than ܹ ൌ 1 year 
and assuming ߙ ൌ 0%. For each parametric estimation, a chi-squared goodness of fit test 
was performed to assess agreement between data and parametric assumptions. When data 
were generated from a form of ܵோᇲሺݐ|߶ሻ that is non-zero at times greater than ܹ ൌ 1 
year, underestimation of ߱ is expected. To assess the performance of MDRI estimation, 
estimates of ߱ were compared to its true value, which was 150 days throughout this 
investigation, and the ability to distinguish between correct and incorrect parametric 
assumptions was considered. 
The results of the investigation, summarised in Table 3.2, indicate that, although moving 
to a parametric approach allows all data to be exploited, there is the potential for 
introducing large bias in estimates from poor parametric assumptions. The results of the 
goodness of fit tests suggest that it is challenging to distinguish between appropriate and 
poor parametric assumptions, using a given dataset. The average 95% confidence interval 
(CI) widths, when using the correct parametric assumption or the non-parametric 
approach, are also provided (Table 3.2). CIs were obtained using large sample maximum 
likelihood theory (in particular, properties of the deviance statistic) [157]. The increased 
CI width when moving to the non-parametric approach illustrates the loss of precision 
incurred when discarding data with insufficiently large ID intervals. 
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Parametric form used for data generation 
1 2 3 4 5 6
Average estimated 
   ࣓, in days (95%   
   CI width)a 
Parametric form 1 153 (27) -  102 -  -  108 
Parametric form 2 187 153 (51) 154 122 90 164 
Parametric form 3 197 129 151 (42) 105 78 154 
Parametric form 4 -  191 197 151 (59) 110 207 
Parametric form 5 -  273 286 212 151 (68) 295 
Parametric form 6 174 138 140 106 84 151 (44) 
Non-parametric 150 (79) 153 (79) 148 (79) 144 (78) 128 (74) 149 (79) 
Percentage of 
   estimates 
   rejected 
Parametric form 1 2 100 94 100 100 96 
Parametric form 2 87 2 10 19 68 5
Parametric form 3 23 67 3 80 92 16
Parametric form 4 100 7 37 5 13 35
Parametric form 5 100 22 68 9 3 79
Parametric form 6 28 32 7 77 97 2
a Includes only estimates not rejected (p-value≥0.05) by goodness of fit test 
Table 3.2: Summary of results from investigation of parametric versus  
non-parametric estimation using simulated data 
Average estimates of the MDRI, ߱  (days), and percentages of estimates rejected by 
goodness of fit tests (p-values below 0.05) are shown for groups of 100 simulated 
datasets. The parametric form for ܵோᇲ൫ݐห߶ഫ൯ used to generate the datasets is captured by 
the table columns (Parametric form 1 to 6, see Figure 3.12). The MDRI was estimated 
parametrically (assumed form for ܵோᇲ൫ݐห߶ഫ൯  captured by table rows) and non-
parametrically (using ܹ=1 year). For each group of datasets and estimation method, the 
average estimate of ߱  was calculated after excluding those estimates rejected by the 
goodness of fit test, and the average width of the 95% CI is provided when the assumed 
parametric form is correct or non-parametric estimation was applied. In both data 
generation and MDRI estimation, ߙ ൌ 0%. 
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3.3 Further	Applications	
Two further applications of the methodology presented are described below. While this 
approach is not intended to provide highly accurate and precise estimates of the MDRI, it 
serves an important role in obtaining initial estimates using previously neglected sources 
of specimens when that is all that is available.  
3.3.1 A	Biomarker	for	Recent	Infection		
Using	SMARTubeTM		
The sensitivity of an HIV diagnostic test (probability of correctly detecting virus) is 
expected to increase from zero to, ideally, 100% over some short period after HIV 
transmission. An antibody-based diagnostic test is unable to detect HIV infection in the 
period between acquiring the infection and seroconversion, where the seroconversion 
time captures when the antibody response reaches a measurable level. Therefore, an HIV-
positive subject tested in this ‘seronegative window period’ will produce a false-negative 
HIV diagnosis. To reduce this period, SMART Biotech Ltd [169] developed the 
Stimulating Maximal Antibody Response Tube (SMARTubeTM). The technology 
stimulates in-vivo primed immune cells to produce antibodies in-vitro. By incubating a 
specimen in a SMARTubeTM before applying the HIV diagnostic test, antibodies reach 
detectable levels sooner after infection [170, 171]. 
As illustrated in Figure 3.13 (Part A), stimulation of antibody in an incubated specimen is 
expected to fade over time after infection. This suggests that a measure of the increase in 
signal could provide a novel biomarker for recent infection. In this analysis, one such 
measure is defined and its potential explored: the ‘Stimulation Index’ (SI) is the ratio of 
stimulated to unstimulated antibody levels (Part B of Figure 3.13). A test for recent 
infection is constructed by introducing a threshold, where an SI measurement above the 
threshold is interpreted as indicating ‘recent’ infection. As the threshold is varied, there is 
the familiar trade-off between test characteristics: while a lower threshold improves 
(increases) the MDRI, a higher threshold typically improves (decreases) the FRR. 
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A) Antibody signal
B) The ‘Stimulation Index’
Figure 3.13: The impact of SMARTubeTM on antibody signal, and the 
‘Stimulation Index’ 
The schematic diagram illustrates the increase in antibody signal resulting from 
incubating a specimen in a SMARTubeTM, and the proposed measure of this increase, 
each as a function of time since HIV acquisition. A) Antibody signal, as measured by a 
standard semi-quantitative HIV diagnostic test, is shown, without (‘unstimulated’) and 
with (‘stimulated’) the use of a SMARTubeTM, and the difference in the ‘seronegative 
window period’ reflected. B) The ‘Stimulation Index’ (SI) is shown, and is the ratio of the 
stimulated to unstimulated antibody levels.  
As is typically the case for new biomarkers, very little data to characterise the test were 
available, and opportunities to generate further, tailored, data would be contingent on 
demonstrating sufficient promise of the candidate biomarker. An initial, preliminary 
characterisation of the test was therefore performed, using existing available specimens. 
The specimens were obtained from subjects in various regions of China by the Centers 
for Disease Control and Prevention (CDC) and the National Institute for the Control of 
Pharmaceutical and Biological Products in Beijing (NICPBP). Intervals between HIV 
tests were large (the exact sizes were unknown) and there was little background 
information on the subjects, and therefore such specimen sets have typically been 
overlooked. Data on the SI biomarker were generated by testing (subsets of) specimens 
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using two semi-quantitative HIV diagnostic tests, developed by Abbott Diagnostics and 
Beijing Wantai Biological Pharmacy. Each specimen was tested both using the standard 
diagnostic procedure (to obtain an ‘unstimulated’ antibody measurement) and after 
incubation in a SMARTubeTM (to obtain a ‘stimulated’ antibody measurement), and SI 
values were calculated. 
The FRR, ߝ, was estimated using specimens drawn from non-recently infected subjects 
attending CDC clinics (݊ ൌ 59 for Abbott and ݊ ൌ 73 for Wantai). The decreasing FRR, 
as function of increasing threshold, is illustrated in Figure 3.14. Results suggest that a 
suitably low FRR may be achievable by a choice of threshold of around 1.2 or larger. 
The MDRI, ߱, was estimated using specimens collected during surveys of a high-risk, 
injecting-drug-using population (݊ ൌ 57 for Wantai). There was no follow-up of subjects, 
and specimens included in the analysis were drawn at the times of first HIV-positive tests. 
Since the times between last HIV-negative and first HIV-positive tests were unknown, 
these were crudely all assumed to be Δ∗  in the analysis. The maximum likelihood 
approach presented in Sections 3.1 and 3.2 above was used to estimate the MDRI, for a 
range of thresholds beginning at 1.2 and assuming a zero FRR (based on the results 
above), and for a range of values of Δ∗ beginning at 1 year (assuming Δ∗ ൐ ܹ , where ܹ 
is the maximum time after infection that an individual may remain in the ‘recent’ state). 
The point estimate for ߱, as a function of threshold and inter-test interval Δ∗, is shown in 
Figure 3.15, and increases with decreasing threshold or increasing Δ∗. At a high threshold 
of 1.5 (SI units) and small Δ∗ of 1 year, ߱ is estimated to be 0.2 years (70 days), and ߱ 
increases to 1.1 years (404 days) when the threshold decreases to 1.2 and Δ∗ increases to 
3 years. 
Hypothesis tests for superiority or non-inferior of the test characteristics (compared to 
those of existing tests or reference values) would have little statistical power due to the 
small sample sizes. Instead, for the FRR, data were used to assess the null hypothesis 
ߝ ൌ 5% against the alternative hypothesis ߝ ൐ 	5%. Even at a relatively low threshold 
of 1.1 (the estimate for ߝ increases as the threshold decreases), the null hypothesis was 
not rejected (p-values of 0.80 and 0.71 for Abbott and Wantai kits, respectively). 
Similarly, for the MDRI, data were used to evaluate the null hypothesis ߱ ൌ 155 days 
against the alternative hypothesis ߱ ൏ 155 days, where 155 days is the MDRI of the 
(then) widely used BED assay as per package insert [166]. Even at a high threshold of 1.4 
and conservatively assuming an FRR of 5% (the estimate for ߱ decreases as the threshold 
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or input FRR increases), the null hypothesis was not rejected (p-value of at least 0.46 for 
an assumed Δ∗ of at least 2 years for the Wantai kit). These results suggest that there is a 
lack of evidence that the FRR is particularly large or MDRI is small. This analysis 
suggests that efforts should be made to capture a larger set of specimens, appropriate for 
test characterisation and including relevant background information, to further investigate 
the potential of using SMARTubeTM to construct a biomarker for recent infection. More 
generally, the investigation strengthens the case for broadening the spectrum of 
biomarkers conventionally considered. 
A) Abbott
B) Wantai
Figure 3.14: Estimated false-recent rate of a test using the ‘Stimulation Index’ 
biomarker, as a function of the ‘recent’/‘non-recent’ threshold and stratified by HIV 
diagnostic test 
The estimate of the FRR, ߝ (%), and its 95% (Clopper-Pearson) confidence interval are 
shown for a recent infection test that is based on the ‘Stimulation Index’ (SI), as a 
function of test threshold (above which an SI value indicates ‘recent’ infection). Antibody 
levels were measured using HIV diagnostic tests by A) Abbott Diagnostics and B) Beijing 
Wantai Biological Pharmacy. 
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Figure 3.15: Estimated mean duration of recent infection of a test using the 
‘Stimulation Index’ biomarker, as a function of the ‘recent’/‘non-recent’ threshold 
and assumed inter-test interval 
The point estimate for the MDRI, ߱ (days), is shown for a recent infection test that is 
based on the ‘Stimulation Index’ (SI), as a function of both test threshold (above which 
an SI value indicates ‘recent’ infection) and the assumed inter-test interval (time between 
last HIV-negative and first HIV-positive tests, in years). An input FRR of zero was used, 
and antibody levels were measured using an HIV diagnostic test by Beijing Wantai 
Biological Pharmacy. 
This analysis suggests that efforts should be made to capture a larger set of specimens, 
appropriate for test characterisation and including relevant background information, to 
further investigate the potential of using SMARTubeTM to construct a biomarker for 
recent infection. More generally, the investigation strengthens the case for broadening the 
spectrum of biomarkers conventionally considered. 
3.3.2 Local	Characterisation	of	the	BED	Assay		
Potential regional variation in the behaviour of tests for recent infection brings into 
question the ability to recycle estimates of the MDRI across different incidence studies. 
In this analysis, existing specimens, captured as part of an ongoing population-based 
demographic surveillance study in rural South Africa, were used to estimate the MDRI of 
the BED assay [92, 107], developed in the USA, for a South African context. 
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Ongoing HIV surveillance is conducted by the Africa Centre for Health and Population 
Studies, University of KwaZulu-Natal [172]. The surveillance area is located near the 
rural market town of Mtubatuba in KwaZulu-Natal. HIV incidence in the area has 
remained at a high rate of approximately 3.4 infections per 100 person years since 2003 
[173], and individuals in the area are eligible for HIV testing as part of the routine study 
surveillance. For this analysis, the BED assay was applied to specimens (stored as dried 
blood spots) drawn at times of first HIV-positive tests, for women aged 15-49 and men 
aged 15-54 who were tested between June 2003 and June 2006. Intervals between last 
HIV-negative and first HIV-positive tests were large, ranging from 0.5 years to 3 years, 
with a median interval of 1.3 years. The utility of such data had been previously 
overlooked, due to the infrequent observation of subjects.  
The MDRI was estimated using the approach described in Sections 3.1 and 3.2 above. A 
local FRR for the BED assay had previously been measured in the same population, and 
was estimated to be 1.69% (95% CI: 1.00%-2.66%) for a maximum time in the ‘recent’ 
state of ܹ ൌ 306  days for test ‘progressors’ [131]. This estimated FRR and the 
corresponding ܹ were used as inputs in the MDRI estimation. The maximum likelihood 
estimates of the MDRI, by gender and age, are provided in Table 3.3. 
Number of subjects Estimated ࣓ in days (95% CI) 
All data 274 115 (90-139)
Male 72 98 (50-146)
Female 202 120 (91-149)
Ages 15 - 24 138 103 (70-136)
Ages 25 + 136 128 (91-165)
Table 3.3: Estimated mean duration of recent infection for the BED assay in a South 
African surveillance population, by gender and age 
Estimates of the MDRI, ߱  (days), for the BED assay in a surveillance population in 
KwaZulu Natal, South Africa, are tabulated. Estimation used an input FRR of 1.96% and 
ܹ ൌ 306 days. 95% confidence intervals (CIs) are also provided (based on large sample 
maximum likelihood estimator properties). The MDRI was calculated using all data, 
stratifying data by gender, and stratifying data by age, in turn. 
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The likelihood functions for the MDRI are shown in Figures 3.16 to 3.18 (using 
ܹ ൌ 306  days throughout). The impact of varying assumptions for the FRR is 
considered in Figure 3.16, where each of a number of FRR inputs were used in turn: the 
local estimate of 1.69% described above; an external estimate of 5.6%, which was 
measured in populations in North America and the Netherlands [16]; and zero. The 
estimated MDRIs varied by 21 days. In Figure 3.17 and Figure 3.18, the likelihood 
functions for the MDRI are shown when stratifying data by gender and age respectively 
(using an input FRR of 1.69%). Age and gender differences were not significant (using a 
likelihood ratio test and significance level of 5%). 
Figure 3.16: Likelihood function for the mean duration of recent infection of the 
BED assay by input false-recent rate 
The likelihood of observing the data (scaled to have a maximum of 1) is shown as a 
function of the MDRI, ߱  (days), for the BED assay in the studied South African 
surveillance population. Data with inter-test intervals larger than ܹ ൌ 306 days were 
included in the analysis, and various FRR inputs were used in turn: the local measurement 
of 1.69%, an external measurement of 5.60%, and zero. 
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Figure 3.17: Likelihood function for the mean duration of recent infection of the 
BED assay by gender 
The likelihood of observing the data (scaled to have a maximum of 1) is shown as a 
function of the MDRI, ߱ (days), for the BED assay in the studied South African 
surveillance population. Data with inter-test intervals larger than ܹ ൌ 306 days were 
included in the analysis, and an input FRR of 1.69% was used. Data were stratified by 
gender (Male and Female). 
Figure 3.18: Likelihood function for the mean duration of recent infection of the 
BED assay by age 
The likelihood of observing the data (scaled to have a maximum of 1) is shown as a 
function of the MDRI, ߱  (days), for the BED assay in the studied South African 
surveillance population. Data with inter-test intervals larger than ܹ ൌ 306 days were 
included in the analysis, and an input FRR of 1.69% was used. Data were stratified by age 
(Ages 15-24 and Ages 25+). 
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This analysis provides the first MDRI estimate for the BED assay using specimens 
collected as part of population-based HIV surveillance in Southern Africa. These 
preliminary results suggest that, on average, infected individuals remain in the BED 
assay-defined state of ‘recent’ infection for 115 days (95% CI: 90-139 days) in the South 
African surveillance population. Previously published estimates range from 133 or 153 
days in a North American cohort [16]  to 187 days in a cohort of Zimbabwean women 
[17]. Use of these externally obtained MDRI estimates would decrease incidence 
estimates by between 14% and 39% respectively. Just as other work has cautioned against 
the generalisation of FRR estimates [131], this work cautions against the use of an MDRI 
that is not validated in the survey population. 
3.4 Estimation	within	the	General	
Incidence	Inference	Framework	
Throughout this chapter thus far, test characteristics have been defined based on the 
analyses of McDougal et al [16], McWalter and Welte [25] and Wang and Lagakos [24]. 
The definitions of the MDRI and FRR emerging from their work rely on specific 
assumptions about the dynamics of tests for recent infection, known to be violated in 
reality. These assumptions have since been relaxed and a general incidence inference 
framework has been developed [29].21 Estimation of the MDRI that is defined within this 
general framework is explored below.  
The probability that a seroconverter, who tests seropositive at time Δ  after testing 
seronegative, is ‘recently’ infected at the time of the first seropositive test is 
݌ሺΔሻ ൌ ݌൫Δ|߶ഫ൯ ൌ 1Δන ܵோ൫ݐ|߶ഫ൯ dݐ
୼
଴
, (3.25)
where it is assumed that seroconversion is equally likely to have occurred at any time 
between the two tests, and ܵோሺݐ|߶ഫሻ, which is the probability of testing ‘recent’ at time ݐ 
after seroconversion, depends on the parameter ߶ഫ . The likelihood of observing the test 
classifications in a sample of ݊ seroconverters is then 
ܮሺഫ߮ሻ ൌ 	ෑ൫݌ሺΔ௜| ߶ഫሻ൯௫೔
௡
௜ୀଵ
൫1 െ ݌ሺΔ௜| ߶ഫሻ൯ଵି௫೔, (3.26)
___________________________ 
21The derivation of the general framework for incidence inference is presented in Chapter 2. 
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where Δ௜ and ݔ௜ capture the observed data (݅ ൌ 1,2, … , ݊), and ߶ഫ  is the (unknown) model 
parameter. More specifically, for the ݅th seroconverter, Δ௜ is the inter-test interval and ݔ௜ is 
the observed classification at the first seropositive test, where ݔ௜ equals 1 if the subject is 
‘recently’ infected and equals 0 if the subject is ‘non-recently’ infected. 
Any definition of a mean duration in the ‘recent’ state would involve some averaging of 
ܵோሺݐ|߶ഫሻ over time ݐ, and therefore the MDRI is generally a function of ߶ഫ . Estimation of 
the  MDRI  then  naturally  proceeds  by  specifying  a  functional  form  for  ܵோሺݐ|߶ഫሻ, 
estimating ߶ഫ  by maximising the likelihood function, and calculating the implied MDRI 
estimate. However, poor assumptions about ܵோ൫ݐ|߶ഫ൯  could lead to substantial bias in 
results, and therefore a large part of this chapter has been dedicated to finding special 
cases of this estimation procedure which require less extensive or no parametric 
assumptions. More specifically, cases have been sought where ݌ሺΔሻ, and therefore the 
likelihood function, depend only on the test characteristics of interest, and, if required, a 
small number of ‘nuisance’ parameters (that restrict the form of ܵோ൫ݐ|߶ഫ൯ less than a full 
specification of the function in terms of ߶ഫሻ . In all cases considered, large sample 
maximum likelihood theory can be used to obtain properties of the MDRI estimator. 
Under the assumptions of McDougal et al [16], McWalter and Welte [25] and Wang and 
Lagakos [24], ܵோ൫ݐ|߶ഫ൯ can be expressed as 
ܵோ൫ݐ|߶ഫ൯ ൌ ߝ ൅ ሺ1 െ ߝሻܵோᇲሺݐ|߶ഫ∗ሻ, (3.27)
where ܵோᇲ൫ݐ|߶ഫ∗൯ ൌ 0 for sufficiently large ݐ (ݐ ൐ ܹ), and the parameter ߝ is the FRR. 
The MDRI is defined as ߱ ൌ ׬ ܵோᇲ൫ݐ|߶ഫ∗൯ஶ଴ dݐ  (assuming guaranteed survival until ܹ 
after infection). For a subject with a sufficiently large inter-test interval Δ (Δ ൐ ܹ), the 
probability of testing ‘recently’ infected becomes 
݌ሺΔሻ ൌ ݌ሺΔ|ߝ, ߱ሻ ൌ ߝ ൅ ሺ1 െ ߝሻ߱Δ . (3.28)
Therefore, by including only subjects with large inter-test intervals in the analysis dataset 
(Δ௜ ൐ ܹ, ݅ ൌ 1,2, … , ݊), the likelihood becomes a function of only the test characteristics 
ߝ and ߱, which can be estimated directly by maximising the likelihood function. While 
the test characteristics can be jointly estimated in principle, results from the sections 
above show that estimation of the MDRI, ߱, is challenging without an input value of ߝ 
for a carefully chosen value of ܹ. 
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The more general analysis of Kassanjee et al [29] relaxes all assumptions about test 
dynamics by introducing a post-infection time cut-off ܶ  in the construction of the 
incidence  estimator.  The  MDRI, Ω்,  is  now  the  average  time  that  an  individual  is 
‘recently’  infected  and  alive,  while  infected  for  less  than  ܶ.  The  FRR,  ߚ்,  is  the 
probability that an individual who is infected for longer than ܶ will return a ‘recent’ 
result. The probability of testing ‘recently’ infected, ݌ሺΔሻ, can be expressed in a form that 
contains Ω் directly (assuming guaranteed survival until ܶ after infection): 
݌ሺΔሻ ൌ 1Δቆන ܵோ൫ݐ|߶ഫ൯ dݐ
்
଴
൅ න ܵோ൫ݐ|߶ഫ൯ dݐ
୼
்
ቇ 
ൌ Ω்Δ ൅
1
Δන ܵோ൫ݐ|߶ഫ൯ dݐ.
୼
்
 (3.29)
When Δ ൌ ܶ, this probability reduces to 
݌ሺΔ ൌ ܶሻ ൌ ݌ሺΔ ൌ ܶ|Ω்ሻ ൌ Ω்ܶ . (3.30)
Therefore, by designing a study (or constructing a dataset) where all inter-test intervals 
are equal to ܶ (Δ௜ ൌT, ݅ ൌ 1,2, … , ݊), the likelihood function is expressed in terms of only 
the MDRI, Ω், which can then be estimated directly by maximising the likelihood of the 
data. In particular, the likelihood function, which now captures a binomial process, will 
be maximised when the observed probability of a ‘recent’ classification at the first 
seropositive test is used as an estimate of the true probability that is given in 
Equation (3.30). That is, the estimated MDRI is  
Ω෡் ൌ ܶ 1݊෍ݔ௜
௡
୧ୀଵ
, (3.31)
where ∑ ݔ௜௡୧ୀଵ  is the total number of ‘recent’ results among the ݊  available results. 
Importantly, no external estimates of any parameters are required to guide data inclusion 
rules or assess the likelihood function.  
The HIV surveillance data on the BED assay, described in Section 3.3.2, was re-analysed 
to demonstrate estimation of the MDRI, Ω். A time cut-off of ܶ ൌ 548 days (1.5 years) 
was chosen for the exploratory analysis, which aimed to provide preliminary estimates of 
the MDRI using two simplifications of Equation (3.29). 
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Figure 3.19: Estimated mean duration of recent infection for the BED assay using 
subjects with inter-test intervals close to ࢀ 
The estimate of the MDRI, Ω் (days), for the BED assay in a South African surveillance 
population is shown as a function of ݔ (%), where subjects with inter-test intervals within 
ሾܶ ∙ ሺ1 െ ݔሻ, ܶ ∙ ሺ1 ൅ ݔሻሿ are included in the analysis and ܶ ൌ 548 days. In the likelihood 
function approximation, all inter-test intervals are treated as being equal to ܶ . 95% 
confidence interval limits are also indicated (dashed lines). 
Firstly, all subjects with inter-test intervals close to ܶ were included in the analysis, and 
the simplification given by Equation (3.30) – which requires inter-test intervals to be 
exactly equal to ܶ – was nevertheless used. A subject was included in the analysis if his 
inter-test interval, Δ, was within ሾܶ ∙ ሺ1 െ ݔሻ, ܶ ∙ ሺ1 ൅ ݔሻሿ for a chosen value of ݔ. The 
estimated MDRI, as a function of ݔ, is shown in Figure 3.19. Point estimates appear 
relatively stable, and range from 138 days to 175 days for ݔ between 5% and 20%. As the 
value of ݔ increases from zero, bias is introduced as the likelihood function is no longer 
exact. However, the number of subjects included in the analysis increases and therefore 
the confidence interval width decreases (݊ ൌ 32, for ݔ ൌ 5%, increases to ݊ ൌ 101, for 
ݔ ൌ 20%).  
Secondly, all subjects with inter-test intervals in some range ሾܮ, ܷሿ, which contains ܶ, 
were included in the analysis, and it was assumed that ܵோ൫ݐ|߶ഫ൯ remains constant at some 
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value ߠ for all ݐ such that ݐ ∈ ሾܮ, ܷሿ.22 The probability of a seroconverter, with inter-test 
interval Δ, being ‘recently’ infected is then 
݌ሺΔሻ ൌ ݌ሺΔ|Ω், ߠሻ ൌ Ω் ൅ ߠ ∙ ሺΔ െ ܶሻΔ . (3.32)
The likelihood function now contains Ω் and ߠ, where the value of ߠ was specified as an 
input in the estimation. Using ܮ ൌ ܶ and ܷ ൌ 3 years (݊ ൌ 115), the estimated MDRI, as 
a function of ߠ, is shown in Figure 3.20. The point estimate drops from 150 days for 
ߠ ൌ 0% to 130 days for ߠ ൌ 15%. The sensitivity of results to the choice of ܮ, ܷ and ߠ 
was explored by repeating the estimation for all combinations of values of ܮ between 300 
days and 550 days inclusive (in 25 day increments), ܷ between 600 days and 1100 days 
(25 day increments), and ߠ between 0% and 15% (1% increments). A histogram of all 
resulting MDRI point estimates is provided in Figure 3.21, where the minimum, 
25th percentile, median, 75th percentile and maximum point estimates are 113, 131, 137, 
146 and 170 days, respectively (the sample size ranged from ݊ ൌ 37 to ݊ ൌ 275).  
Figure 3.20: Estimated mean duration of recent infection for the BED assay using 
subjects with inter-test intervals larger than ࢀ 
The estimate of the MDRI, Ω் (days), for the BED assay in a South African surveillance 
population is shown as a function of ߠ (%), where the probability of testing ‘recent’ is 
assumed to be constant at ߠ for times since infection in ሾܮ, ܷሿ. Subjects with inter-test 
intervals within ሾܮ, ܷሿ  are included in the analysis, and ܮ ൌ ܶ ൌ 548  days and 
ܷ ൌ 3 years. 95% confidence intervals are also indicated (dashed lines).  
___________________________ 
22This simplification was also used in the analysis of simulated data in Section 2.1 and 2.2. 
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Figure 3.21: Distribution of mean duration of recent infection estimates for the BED 
assay when varying estimation input parameters 
A histogram of estimates for the MDRI, Ω் (days), for the BED assay in a South African 
surveillance population is shown. Subjects with inter-test intervals within ሾܮ, ܷሿ  are 
included in the analysis, and the probability of testing ‘recent’ is assumed to be constant 
at ߠ for times since infection in ሾܮ, ܷሿ. The MDRI was estimated for combinations of 
ܮ in [300,550] days, ܷ in [600,1100] days and ߠ in [0%,15%]. 
While the focus of this chapter is MDRI estimation using specimens from subjects who 
are observed only once after seroconversion, the approach presented could be generalised 
to  contexts  where  subjects  contribute  multiple  specimens  after  seroconversion.23 
Estimation of the MDRI without making parametric assumptions about ܵோ൫ݐ|߶ഫ൯ is of 
particular interest. A generalisation of the non-parametric estimation approach described 
above (captured by Equations (3.30) and (3.31)), to contexts where inter-test intervals can 
be smaller than ܶ and subjects are followed up over time, is therefore briefly outlined 
below. 
___________________________ 
23The estimation of the MDRI from longitudinal data, using alternative estimation methods, is 
discussed in Chapter 4. The generalisation of the approach for MDRI estimation that is presented 
in this chapter (using single specimens from infected subjects), to the context where there are 
follow-up specimens, is presented here for completeness. 
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The inter-test interval Δௗ should be a divisor of ܶ – that is, there must exist some natural 
number ݊ௗ  such that ܶ/Δௗ ൌ ݊ௗ . For example, for ܶ ൌ 1  year, some possible values 
for Δௗ are 2 months (݊ௗ ൌ 6), 4 months (݊ௗ ൌ 3) and 1 year (݊ௗ ൌ 1). Subjects should 
have ݊ௗ  specimens drawn, Δௗ  apart, from (and inclusive of) the time of the first 
seropositive test (although subjects can miss draws and some subjects can be lost to 
follow-up). Assuming seroconversion events are uniformly distributed between last 
seronegative and first seropositive tests, the probability of a ‘recent’ classification at the 
first seropositive test is 
݌ሺΔௗሻ ൌ ݌൫Δௗ|߶ഫ൯ ൌ 1Δௗ න ܵோ൫ݐ|߶ഫ൯ dݐ
୼೏
଴
, (3.33)
as before (see Equation (3.25)). More generally, the probability of a ‘recent’ classification 
at draw ݇  ( ݇ ൌ 1,2, … , ݊ௗ ), which occurs at time Δௗ ∙ ሺ݇ -1) when using the first 
seropositive visit as reference time 0, is 
݌∗ሺ݇, Δௗሻ ൌ ݌∗൫݇, Δௗ|߶ഫ൯ ൌ 1Δௗ න ܵோ൫ݐ|߶ഫ൯ dݐ
୼೏∙௞
୼೏∙ሺ௞ିଵሻ
. (3.34)
The MDRI can be written in terms of these probabilities: 
Ω் ൌ න ܵோ൫ݐ|߶ഫ൯ dݐ
்
଴
ൌ ෍න ܵோሺݐሻ dݐ
୼ౚ∙௞
୼೏∙ሺ௞ିଵሻ
௡೏
௞ୀଵ
ൌ Δௗ ෍݌∗ሺ݇, Δୢሻ
௡೏
௞ୀଵ
, (3.35)
and estimated using the observed probabilities of ‘recent’ results by 
Ω෡் ൌ Δௗ ෍ ݕ௞݉௞
௡೏
௞ୀଵ
, (3.36)
where ݉௞  results are observed for visit ݇ , and ݕ௞  of those are ‘recent’. Note that a 
subject’s classifications (for various visits) would not be independent, and the estimated 
uncertainty for the MDRI estimator should consistently account for this – for example, by 
using the observed correlations between results as proxies for true correlations in an 
analytical expression for ݒܽݎሺΩ෡்ሻ, or through bootstrap resampling at a subject level 
[174]. 
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In summary, the approach for obtaining preliminary MDRI estimates, using specimens 
from subjects observed only once after infection, is still as applicable and valuable when 
defining test characteristics using the general incidence inference framework. By 
assuming a parametric form for the probability of testing ‘recent’ as a function of time 
since infection, all inter-test intervals can be accommodated. However, there are special 
cases where, by restricting the inter-test intervals included in the analysis, the extent of 
any parametric assumptions (and potential bias arising from these) can be reduced. When 
all inter-test intervals are exactly equal to the time cut-off ܶ (or some divisor of ܶ when 
infected subjects are in fact followed-up), the MDRI can be estimated non-parametrically 
and directly, without any ‘nuisance’ parameters or the need for any external knowledge of 
test dynamics. 
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Chapter	4	
 
Estimating	the	Mean	Duration	of	
Recent	Infection	II:	Longitudinal	
Follow‐Up	of	Infected	Subjects	
Traditionally, estimation of the mean duration of recent infection (MDRI) has relied on 
longitudinal data, which provides results for the test for recent infection at multiple time 
points after infection for each subject. Various approaches have been used in the literature 
to analyse such data, leading to questions about best practices and the implications of 
methodological differences. This chapter therefore systematically investigates various MDRI 
estimation methods, and presents some ideas for potentially reducing artefacts in analyses.  
A detailed benchmarking of estimation methods was performed using a data simulation 
platform, and is presented in Section 4.1. The investigation forms part of a project 
involving an international group of researchers and analysts brought together by the HIV 
Modelling Consortium [53]. The analysis presented here forms a substantial portion of the 
full body of work by the group, on which a manuscript is currently being prepared.24 
___________________________ 
24The analysis presented in Section 4.1 contributes to work being published by the following 
authors, listed alphabetically and publishing on behalf of an HIV Modelling Consortium working 
group: Daniela De Angelis (Medical Research Council, and Cambridge University – United 
Kingdom), Marian Farah (Medical Research Council, and Cambridge University – United 
Kingdom),  Debra Hanson (Centers for Disease Control and Prevention – USA), Reshma 
Kassanjee (SACEMA – South Africa), Phillip Labuschagne (SACEMA – South Africa), Oliver 
Laeyendecker (National Institute of Allergy and Infectious Diseases – USA), Stepháne Le Vu 
(French Public Health Institute – France), Brian Tom (Medical Research Council, and 
Cambridge University – United Kingdom), Rui Wang (Harvard University – USA), Alex Welte 
(SACEMA – South Africa) and Ping Yan (Public Health Agency of Canada – Canada). 
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The unknown infection times of subjects in the sample pose a particularly subtle obstacle 
to accurate MDRI estimation, and potential approaches for limiting bias are explored in 
the remainder of the chapter. Firstly, by redefining the effective ‘HIV-positive’ state 
through the introduction of an artificially high ‘diagnostic detectability’ threshold on a 
semi-quantitative assay, the time of entry into this state could potentially be more 
accurately estimated by reducing extrapolation required in analyses given typically 
available data. The concept is demonstrated in Section 4.2 using simulated data from the 
benchmarking exercise, and was first presented in a conference poster [34] using actual 
data.25 Secondly, when estimating a subject’s infection time, diagnostic testing history 
data should be carefully analysed, and the context-dependent definition of (perforce, 
detectable) infection considered. These topics, inspired by the CEPHIA data preparation 
process, are briefly explored in Section 4.3. A summary of the ideas presented has been 
included in a manuscript by CEPHIA.26 
___________________________ 
25The concept presented in Section 4.2 was first published in the following conference poster: 
‘Kassanjee R, Hargrove J, Marinda E, Humphrey J, McWalter TA and Welte A. New criteria for 
defining biomarker-derived ‘recent HIV infection’ for the purposes of incidence estimation. 
E-poster CDC0474 at the XVIII International AIDS Conference, 18 – 23 July 2010, Austria’. 
26Some of the ideas presented in Section 4.3, which were developed while preparing and analysing 
CEPHIA data, are summarised in a (currently unpublished) manuscript by CEPHIA, authored 
by: Christopher D Pilcher (University of San Francisco, California – USA), Sheila M Keating 
(Blood Systems Research Institute – USA), Reshma Kassanjee (SACEMA – South Africa), 
Elaine McKinney (Public Health England – United Kingdom), Shelley N Facente (University of 
San Francisco, California – USA), Kara Marson (University of San Francisco, California – 
USA), Alex Welte (SACEMA – South Africa), Michael P Busch (Blood Systems Research 
Institute – USA) and Gary Murphy (Public Health England – United Kingdom). 
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4.1 Benchmarking	Estimation	
Approaches	Using	Simulated	
Data	
4.1.1 Introduction	
Conventionally, estimation of the MDRI has relied on longitudinal data, which captures 
the dynamics of the test for recent infection as a function of time after infection. 
Constructing such datasets requires specimens from (initially HIV-negative) subjects to 
be collected regularly over time before and after infection. Such specimens are costly and 
logistically difficult to obtain, 27  and, when available, a number of approaches for 
analysing the resulting longitudinal data could be considered. While different 
methodologies have been adopted by various research groups [16, 17, 91-103], robust 
(and widely-accepted) methods for estimating the MDRI are essential for the success of a 
cross-sectional incidence surveillance approach as unbiased incidence estimation requires 
unbiased test characterisation. It is important to identify factors that significantly 
influence test dynamics, and disentangling the variation in MDRI estimates caused by 
study population differences (such as the subtype of HIV infections) from that caused by 
analytical differences requires careful consideration of the estimation methods employed. 
Also, to optimally design studies for characterising tests for recent infection, the 
relationships between features of the data, such as sample sizes and visit gaps, and the 
performance of MDRI estimation methods need to be understood. 
Consequently, in 2012, the HIV Modelling Consortium tasked SACEMA with 
coordinating a collaborative project to investigate the performance of MDRI estimation 
approaches using simulated data [53]. The project team consists of researchers from 
SACEMA, the Centers for Disease Control and Prevention (CDC), the National Institute 
of Allergy and Infectious Diseases (NIAID), the British Medical Research Council 
(MRC), Cambridge University, the French Public Health Institute, Harvard School of 
Public Health and the Public Health Agency of Canada. The working group gathered at 
___________________________ 
27 In an attempt to address the bottleneck created by the reliance on longitudinal data, the 
preliminary estimation of the MDRI, using specimens from subjects observed only once after 
infection, is discussed in Chapter 3. 
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Harvard University in Boston in July 2012 to discuss the theoretical framework for 
estimating incidence (and thus defining the MDRI), outline the project scope and 
methodology, and interpret preliminary outputs. Thereafter, a teleconference was held 
every second week, so that each step of the process could be critically reviewed and tasks 
allocated to team members. Online structures were developed to efficiently share relevant 
documents, datasets, MDRI estimation outputs and drafts of the manuscript (to be 
published). 
In principle, the ‘recent’ or ‘non-recent’ classification produced by a test for recent 
infection may rely on multiple measured biomarkers and clinical indicators [10]. This 
investigation was restricted to considering a test for recent infection based on a single 
biomarker. The biomarker need not represent the measurement of a single quantity, but 
may be a single summary metric of multiple measurements. In line with currently used 
‘incidence assays’, a measurement below a chosen threshold, ܻ , was interpreted as 
indicating ‘recent’ infection. The MDRI summarises the average time that biomarker 
measurements are below this threshold – more specifically, the MDRI, Ω், of relevance 
for incidence estimation, is the average time ‘recently’ infected and alive while infected 
for less than some chosen time cut-off ܶ [29]. 
A defining feature of this project is the use of simulated data: by simulating data, not only 
is the true underlying MDRI computable (against which MDRI estimates can be 
compared), but experiments can be replicated thousands of times and therefore the 
behaviour of estimation methods fully understood. The SACEMA team developed a 
comprehensive simulation platform that automated the generation and storage of datasets, 
application of estimation methods, and storage of outputs in a database. 
A large number of MDRI estimation methods were implemented, including both 
approaches previously used and some new approaches proposed by the project team 
members. The accuracy and precision of methods were assessed in a number of modelled 
scenarios that capture essential features of what could be encountered in reality, such as 
different underlying biomarker dynamics (for example, forms of the biomarker signals 
post infection and levels of measurement noise) and different study designs or subject 
behaviours (for example, sample sizes, intended visit schedules and tendency of subjects 
to miss visits). 
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4.1.2 Design 
In practice, an analyst would typically be provided with a single dataset for estimation of 
the MDRI. However, to understand the performance of any given MDRI estimation 
method, this ‘experiment’ needs to be repeated a large number of times and the collection 
of MDRI estimates considered. The simulation platform28 that was developed as a part of 
this project allowed for efficient replication of experiments through the automated 
generation of datasets and application of estimation methods. Detailed discussions follow 
about the (i) generation of data, (ii) MDRI estimation methods, and (iii) metrics of 
performance used. 
Broadly outlining the approach taken, the performance of MDRI estimation methods was 
assessed in a ‘base case’ scenario and then in each of a number of comparison scenarios. 
The base case scenario captures a somewhat optimistic study design and high adherence 
by subjects, and a biomarker dynamic inspired by experiences of researchers in the group. 
Comparison scenarios were generated by systematically varying aspects of this base case 
scenario, and capture features of processes that could be encountered in practice. For each 
scenario, 1 000 datasets were generated and each method of MDRI estimation was 
applied to each of the datasets (other than for the non-linear mixed models, which were 
each applied to a common subset of 250 datasets due to the computational expense of the 
estimation approach). Summary measures of accuracy and precision were used to assess 
the performance of the MDRI estimation methods, relative to one another and by context.  
___________________________ 
28 The simulation platform was implemented and administered by Phillip Labuschagne of 
SACEMA. The platform automated the generation of data, the application of MDRI estimation 
methods (which were provided by others in the group, including myself, in the form of Matlab, R 
or SAS scripts) and the storage of all results.  The system was developed using Python, R and 
MySQL. Due to the large run times involved, computing resources provided by Amazon Web 
Services were utilised. 
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Data	generation	
The underlying processes that produce a real-world dataset for MDRI estimation can be 
considered in two parts. Firstly, the study design, adherence to the protocol and subject 
behaviour would drive the visit times and infection times of subjects in the sample. 
Secondly, particulars of the biological signal (as a function of time since infection) and 
the noise around the signal (from fluctuations within the host or simply imperfect 
measurement in the laboratory) would drive the observed biomarker readings for the 
visits (according to when the subjects got infected). Based on imitating these real-world 
processes, stochastic models were constructed for generating the visit times, infection 
times and biomarker readings of subjects. The models, inspired by experiences of 
researchers in the project team, were designed to be simple and rely on relatively few 
input parameters, yet provide sufficient flexibility to explore the features to be 
investigated. The base case scenario was defined by choosing particular values for the 
data generation parameters, based on an idealistic adherence to a somewhat optimistic 
study design and insights into existing biomarkers for recent infection. Data generation 
parameters were then systematically varied to create the comparison scenarios.  
The model used to generate visit times was intended to portray a study where initially 
HIV-negative subjects are visited regularly over time, and the intended visit gaps and 
total follow-up times are specified, but the realised visits that are generated also account 
for variability, missed visits and loss to follow-up. More specifically, the starting point is 
to specify, for all subjects in the study, the intended time between visits while HIV-
negative, the intended visit gap once observed to be HIV-positive, and the intended total 
follow-up time from a subject’s first HIV-positive test. To then account for loss to follow-
up (for example, due to participants moving out of the study area or termination of the 
study period), a proportion of subjects are lost earlier than intended, and allocated 
reduced total follow-up times. To account for variability in visit gaps, the potential visit 
gaps (in the absence of missed visits) fluctuate around the intended or mean visit gaps. To 
account for missed visits, there is a chance that a subject misses any potential visit. Since 
one may expect some subjects to miss visits more frequently than others, subject-specific 
probabilities of missing visits deviate from some population average probability. A total 
sample size (or number of subjects who become HIV-positive) is selected, which, in 
reality, results from factors such as the scale of study, observed HIV incidence, and 
recruitment and retention rates.  
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The timing of infection within the ‘infection interval’, used to refer to the time interval 
from the last HIV-negative visit to the first HIV-positive visit, will depend on both the 
study design and subject behaviour. For example, if visit times are specified by the study 
administrators and strictly maintained, it is valid to assume that a subject is equally likely 
to have been infected (as defined by the HIV diagnostic test used) at any time in the 
infection interval. However, subjects may exhibit test-seeking behaviours (advancing 
visits after exposures specifically to obtain HIV tests) or test-deferring behaviours 
(delaying visits after exposures, possibly out of fear or from illness with acute HIV) 
[155, 156, 175, 176]. This complexity was summarised by specifying a distribution for 
generating infection times within infection intervals. 
The model for generating a biomarker reading for each visit aimed to mimic a process 
whereby realised biomarker readings consist of both signal and noise, and the biomarker 
evolves differently in different subjects. For example, the signal may grow quickly and 
saturate at a high value in one subject, and grow slowly and settle at a low level in 
another. Based on plausible behaviour of a viral or host-response biomarker in a subject, 
a flexible sigmoid curve was chosen to capture the biomarker signal as a function of time 
after infection, thus allowing for a period of little growth, clear evolution, and then 
levelling-off of the signal. To allow for subject-specific evolutions, the three parameters 
(asymptote, scale and shape) defining the signal were independently generated for each 
subject, with each subject’s parameters drawn from some common multivariate 
population-level distribution. A flexible noise structure allowed the magnitude of the 
noise to depend on the value of the signal. While this biomarker model was used to 
generate readings for almost all scenarios considered (including the base case), an 
alternative model was implemented for exploring the sensitivities of MDRI estimation 
results to the true form of the underlying biomarker. In this alternative biomarker model, 
the biomarker signal was based on a power of time, with a time lag between infection and 
when the signal was observed 
The described models for the simulation of data are formally outlined below, in terms of 
input parameters and the specific functional forms and statistical distributions used to 
generate the data. Values for the input parameters for the base case scenario are also 
specified. The models produce sets of visit times ሼݐ௜,௝ሽ , infection times ሼݐ௜௡௙,௜ሽ , and 
biomarker  readings  ሼݔ௜,௝ሽ,  where  ݐ௜,௝  is  the  time  of  the  ݆th  HIV-positive  visit 
( ݆ ൌ 1,2, …݊௜ ) for subject ݅  ( ݅ ൌ 1,2, … , ݊ ) and ݔ௜,௝  is the corresponding biomarker 
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reading, and ݐ௜௡௙,௜ is the time of infection for subject ݅. For each subject, the time of the 
last HIV-negative visit provides the reference time of 0. 
The generation of visit times, ሼݐ௜,௝ሽ, depends on eleven parameters which are introduced 
in order below, namely ݊, ܨ௠௔௫ , ݌௟௧௙௨ , ߤ௩௚௡ , ߪ௩௚௡ ,	ߙ௩௠௣௡ , ߚ௩௠௣௡ , ߤ௩௚௣ , ߪ௩௚௣ , ߙ௩௠௣௣ , 
and ߚ௩௠௣௣. 
For any given subject ݅ (݅ ൌ 1,2, … , ݊, where ݊ is specified as an input), the total follow-
up  time  from  the  first  HIV-positive  visit,  ݑ௜, is  drawn  from  the  following  mixed 
distribution: 
݂ሺݔሻ ൌ ൞
1 െ ݌௟௧௙௨ if ݔ ൌ ܨ௠௔௫݌௟௧௙௨
ܨ௠௔௫ if ݔ ∈ ሺ0, ܨ௠௔௫ ሻ
0 elsewhere
, (4.1) 
where ܨ௠௔௫ is the intended and maximum follow-up time and ݌௟௧௙௨ is the proportion of 
subjects lost to follow-up. The distribution treats follow-up times as uniformly 
distributed. in (0,ܨ௠௔௫	) for those subjects who are lost to follow-up. 
The time of the first HIV-positive visit for subject ݅, relative to the last HIV-negative 
visit, depends on the study protocol and behaviour of the subject while HIV-negative. The 
first  HIV-positive  visit  time,  ݐ௜,ଵ,  is  drawn  from  a  normal  distribution  with  mean 
ߤ௩௚௡ ∙ ሺ݊௩௠௡,௜ ൅ 1ሻ and variance ߪ௩௚௡ଶ ∙ ሺ݊௩௠௡,௜ ൅ 1ሻ (truncated to exclude values below 
zero), where ߤ௩௚௡  is the mean visit gap while HIV-negative and ߪ௩௚௡	 captures the 
variability in the gap, and ݊௩௠௡,௜ is the number of visits that are missed (before the first 
HIV-positive visit). The count ݊௩௠௡,௜  is drawn from a geometric(݌௩௠௡,௜ ) distribution 
(݊௩௠௡,௜ ൌ 0,1,2, …), where ݌௩௠௡,௜  is the subject’s probability of independently missing 
any visit. This probability, ݌௩௠௡,௜, is drawn from a population-level betaሺߙ௩௠௣௡, ߚ௩௠௣௡) 
distribution. 
Denoting the realised visit gap after the ݇௧௛ HIV-positive visit by ߜ௜,௞ (݇ ൌ 1,2, … ሻ, the 
time of the subsequent HIV-positive visit, ݐ௜,௞ାଵ, is generated using ݐ௜,௞ାଵ ൌ ݐ௜,௞ ൅ ߜ௜,௞, 
where ߜ௜,௞ depends on the study protocol and subject behaviour while HIV-positive. The 
visit gap, ߜ௜,௞, is drawn from a normal distribution with mean ߤ௩௚௣ ∙ ሺ݊௩௠௣,௜,௞ ൅ 1ሻ and 
variance ߪ௩௚௣ଶ ∙ ሺ݊௩௠௣,௜,௞ ൅ 1ሻ (truncated to exclude values below zero), where ߤ௩௚௣ is the 
mean visit gap while HIV-positive and ߪ௩௚௣	captures variability in the gap, and ݊௩௠௣,௜,௞ 
is the number of visits that are missed (after the ݇௧௛ HIV-positive visit). The number of 
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visits  missed,  ݊௩௠௣,௜,௞ ,  is  drawn  from  a  geometric( ݌௩௠௣,௜ )  distribution 
 (݊௩௠௣,௜,௞ ൌ 0,1,2, …), where ݌௩௠௣,௜ is the subject’s probability of independently missing 
any visit. This probability, ݌௩௠௣,௜, is drawn from a population-level betaሺߙ௩௠௣௣, ߚ௩௠௣௣) 
distribution. 
Only visits occurring within the subject’s total follow-up time are retained – that is, ݊௜ is 
the largest value such that ݐ௜,௡೔ െ ݐ௜,ଵ ൑ ݑ௜.  
The generation of infection times, ሼݐ௜௡௙,௜ሽ , depends on two parameters, namely ߙ௜௡௙ 
and	ߚ௜௡௙. The infection time for the ݅௧௛ subject, ݐ௜௡௙,௜, is ݐ௜,ଵ ∙ ݑ௜ where ݑ௜ is drawn from a 
betaሺߙ௜௡௙, ߚ௜௡௙)  distribution.  Setting  ߙ௜௡௙ ൌ ߚ௜௡௙ ൌ 1  recovers  uniformly  distributed 
infection times, and ߙ௜௡௙ ൌ ߚ௜௡௙ , ߙ௜௡௙ ൐ ߚ௜௡௙  and ߙ௜௡௙ ൏ ߚ௜௡௙  produce average test-
neutral, test-seeking and test-deferring behaviours respectively.  
The generation of biomarker readings, ሼݔ௜,௝ሽ , depends on the thirteen parameters 
contained in the inputs ߤപ௕ , 	Σ௕ , and പ݁ . For the ݅௧௛  subject, the signal at time ݐ  post 
infection is given by: 
ݕ௜ሺݐሻ ൌ ݕሺݐ|പܾ௜ሻ ൌ ܾ௜,ଵ ∙ ൭1 ൅ ቆ ݐܾ௜,ଶቇ
ି௕೔,య
൱
ିଵ
, (4.2) 
where ܾ௜,ଵ captures the maximum height or asymptote, ܾ௜,ଶ captures a horizontal scaling, 
and ܾ௜,ଷ describes the shape, of the signal which is anchored at zero at infection. The 
subject’s  signal  parameters,  contained  in  പܾ௜ ൌ ሾܾ௜,ଵ, ܾ௜,ଶ, ܾ௜,ଷሿ,  are  drawn  from  a 
population-level multivariate ܰሺߤപ௕, Σ௕ሻ  distribution (truncated to have only a non-
negative support for each parameter). Allowing for noise, a biomarker measurement, ݔ௜,௝, 
for the visit at time ݐ௜,௝, is drawn from a 
ܰቆݕ௜൫ݐ௜,௝∗ ൯, ቀ݁଴ ൅ ݁ଵ ∙ ݕ௜൫ݐ௜,௝∗ ൯ ൅ ݁ଶ ∙ ቀݕ௜൫ݐ௜,௝∗ ൯ቁ
௘యቁ
ଶ
ቇ 
distribution (and non-positive values are censored to be 0), where the noise parameters 
are contained in പ݁ ൌ ሾ݁଴, ݁ଵ, ݁ଶ, ݁ଷሿ and ݐ௜,௝∗ ൌ ݐ௜,௝ െ ݐ௜௡௙,௜ is the time since infection at the 
visit.  
For the alternative biomarker model, the data depends on the five inputs ܾଵ,௟, ܾଵ,௨, ܾଶ,௟, 
ܾଶ,௨ and ݁. The signal for subject ݅ at time ݐ post infection is: 
ݕ௜ሺݐሻ ൌ ݕሺݐ|പܾ௜ሻ ൌ 8 ∙ max൫0, t െ b୧,ଵ൯௕೔,మ , (4.3)
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where ܾ௜,ଵ ൐ 0 captures the time between infection and the appearance of signal, and 
ܾ௜,ଶ ൐ 0 describes the shape of signal growth. The subject’s lag parameter, b୧,ଵ, is drawn 
from  a  uniformሺܾଵ,௟, ܾଵ,௨ሻ  distribution,  and  the  shape  parameter  is  drawn  from  a 
uniformሺܾଶ,௟, ܾଶ,௨ሻ distribution. Including noise, a biomarker measurement, ݔ௜,௝ , for the 
visit at time ݐ௜,௝, is drawn from a ܰ൫ݕ௜൫ݐ௜,௝∗ ൯, ݁ଶ൯ distribution (and non-positive values are 
censored to be 0), where ݐ௜,௝∗ ൌ ݐ௜,௝ െ ݐ௜௡௙,௜ is the time since infection at the visit. 
For each dataset generated, the above mechanisms produce ሼݐ௜,௝ሽ, ሼݐ௜௡௙,௜ሽ and ሼݔ௜,௝ሽ for 
݅ ൌ 1,2, … , ݊  and ݆ ൌ 1,2, … ݊௜ . The infection times, ሼݐ௜௡௙,௜ሽ , would be unknown in 
practice, and only the observable visit times and biomarker readings, ൛൫ݐ௜,௝, ݔ௜,௝൯ൟ, are 
passed to the MDRI estimation methods.  
The base case scenario is described below, and values of the data generation input 
parameters are provided. For each of the 50 subjects captured in the sample (݊ ൌ 50ሻ, the 
intended visit gaps were 3 months and 1 month while HIV-negative and HIV-positive 
respectively (ߤ௩௚௡ ൌ 3 months and ߤ௩௚௣ ൌ 1 month), and intended follow-up time was 
2 years (ܨ௠௔௫ ൌ 2  years). There was a 10% coefficient of variation for visit gaps 
(ߪ௩௚௡ ൌ 3  days and ߪ௩௚௣ ൌ 9  days), and no missed visits and no loss to follow-up 
(ߙ௩௠௣௡ → 0,  ߚ௩௠௣௡ ൌ 1,  	ߙ௩௠௣௣ → 0,  ߚ௩௠௣௣ ൌ 1,  ݌௟௧௙௨ ൌ 0).  Visit  times  were 
considered to be fixed by study design and independent of infection, and therefore 
infection times were uniformly distributed in infection intervals (ߙ௜௡௙ ൌ 1 and	ߚ௜௡௙ ൌ 1). 
In terms of the biomarker dynamics, for visit times measured in days, the mean signal 
parameter values were given by ߤപ௕ ൌ ሾ85,190,5ሿ (capturing height, scale and shape, in 
order). The covariance matrix for subject-specific deviations, Σ௕ , was such that the 
standard deviations of the height, scale and shape parameters were 7.5, 50 and 1.4 
respectively; and there was a correlation of -0.4 between the shape and scale parameters, 
0.3 between the shape and height parameters, and -0.12 between the scale and height 
parameters (arising from the relationship of each parameter with shape, without any 
additional or partial correlation). The noise inputs were പ݁ ൌ ሾ2,0,0.3,0.5ሿ, producing a 
standard deviation that began at 2 at infection and levelled off at 4.7 (based on the 
average asymptote of 85). One or more parameters were varied to produce each of the 
comparison scenarios, and details are specified in the tables of results. 
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Approaches	for	estimating	the	mean	duration	of	recent	infection	
Based on the general incidence inference framework [29], the MDRI can be expressed 
mathematically as Ω் ൌ ׬ ோܲሺݐሻ	dݐ்଴ , where ோܲሺݐሻ is the probability of being ‘recently’ 
infected and alive at time ݐ after infection. 29 Estimation of the MDRI therefore inevitably 
entails using the longitudinal data to make inferences about the function ோܲሺݐሻ. This can 
be achieved either directly by fitting a chosen model for ோܲሺݐሻ to the ‘recent’ and ‘non-
recent’ classifications of subjects, or indirectly by modelling the biomarker measurements 
and then subsequently computing the implied probability of obtaining a measurement 
below the threshold ܻ  (that is, obtaining a ‘recent’ result). Throughout this work, 
ܶ ൌ 1 year and ܻ ൌ 40, and negligible mortality within ܶ after infection was assumed in 
the estimation of the MDRI. 
Various approaches for estimating the MDRI appear in the literature [16, 17, 91-103]. For 
this benchmarking exercise, a number of methods were implemented, intended to be 
representative of those previously published and to provide some extensions. The 
methods are represented in the mind map in Figure 4.1, and were broadly divided into 
three categories, capturing (i) interpolation methods, (ii) survival analysis, and 
(iii) parametric regression. Those methods that were implemented by others in the project 
team appear in grey text (Methods 18-24) and are not discussed in this thesis (additional 
interpretation of all results will be provided in the manuscript to be published by the 
group). Specific implementations within each category of methods are described in more 
detail below. 
___________________________ 
29 The derivation of the general incidence inference framework and the definitions of test 
characteristics appearing in the incidence estimator are presented in Chapter 2. 
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Figure 4.1. Mind map of the mean duration of recent infection estimation 
approaches included in the benchmarking exercise  
The 24 MDRI estimation methods that were implemented and evaluated are captured in 
the mind map (each numbered and labelled in bold). Methods shown in grey text 
(Methods 18-24) were implemented by other members of the team, and are therefore not 
discussed in this thesis. When parametrically modelling biomarker measurements, the 
three forms for the biomarker signal that were used (Signal 1-3) are given by
1) ܽሺ1 ൅ ሺݐ ∙ expሺܾሻሻ௖ሻିଵ, 2) ܽሺ1 െ expሺെሺݐ ∙ expሺܾሻሻ௖ሻሻ, and
3) ܽ൫1 െ exp൫െሺݐ ∙ expሺܾሻሻ൯൯ where ݐ is time since infection and ܽ, ܾ and ܿ are model
parameters; and the two noise structures that were used (Noise 1-2) specify that the 
standard deviation of noise is 1) a linear function of the signal, or 2) constant. 
MDRI estimation approaches
Parametric
regression
- Subject-level linear regressions
- Response: biomarker reading
in vicinity of test threshold
- Infection times by multiple imputation
- Non-linear regression
- Response: biomarker reading
- Including random effects
Bayesian
(Winbugs and R)
Uniform priors
for infection
times
3) - Signal 3
- Noise 2
2) - Signal 2
- Noise 2
1) - Signal 1
- Noise 2
3) - Signal 3
- Noise 2
2) - Signal 2
- Noise 2
1) - Signal 1
- Noise 2
Frequentist
maximum likelihood
(Matlab)
3) - Signal 3
- Noise 1
2) - Signal 2
- Noise 1
1) - Signal 1
- Noise 1
- Linear regression
- Response: probability of
'recent' infection
- No random effects
Frequentist
maximum likelihood
(Matlab)
4) - Link: identity
- Predictor: interval of time
3) - Link: loglog
- Predictor: linear in ln(time)
2) - Link: logit
- Predictor: natural cubic spline
1) - Link: logit
- Predictor: cubic polynomial
Survival analysis
Non-parametric
Turnbull's algorithm
(single interval
censoring)
Kaplan Meier
with interpolation Nearest neighour
Linear
Parametric
(double interval
censoring) Lognormal
Gamma
Weibull 5. Surv_Par_Weibull
Interpolation
Nearest neighbour Multiple transitions 4. Interp_Midp_ME
Single exit  3. Interp_Midp_SE
Linear Multiple transitions 2. Interp_Linear_ME
Single exit 1. Interp_Linear_SE
6. Surv_Par_Gamma
7. Surv_Par_Lognormal
8. Surv_NonPar_KM_Lin
9. Surv_NonPar_KM_Midp
10. Surv_NonPar_Turnbull
11. Binomial_Logit_Cubic
12. Binomial_Logit_Spline
13. Binomial_LogLog_Linear
14. Binomial_Ident_Interval
15. Mixed_MLE_Sig1
16. Mixed_MLE_Sig2
17. Mixed_MLE_Sig3
18. Mixed_Bayes_Sig1
19. Mixed_Bayes_Sig2
20. Mixed_Bayes_Sig3
21. Mixed_Bayes_Sig1_Unif
22. Mixed_Bayes_Sig2_Unif
23. Mixed_Bayes_Sig3_Unif
24. Mixed_Linear_MI
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Generally, a challenge faced when estimating the MDRI from longitudinal data is the 
uncertainty of subjects’ infection times. It is only known that infection (as defined by the 
HIV diagnostic test being used) occurs somewhere between the last HIV-negative and 
first HIV-positive visits, and explicitly allowing for this uncertainty substantially 
increases the complexity of estimation methods. One simple approach is to approximate 
each subject’s infection time by some expected infection time, but even this relies on 
assumptions about subject behaviour. In studies where visits times are fixed by design, it 
is valid to assume that the infection time is uniformly distributed in the infection interval. 
In this case, an infection time could be estimated by the midpoint of the infection interval. 
A number of the MDRI methods outlined below use this ‘midpoint infection time’ 
approach. 
Interpolation methods (Methods 1-4) use mathematical interpolation for each subject to 
obtain a biomarker reading at every time point after infection (using a ‘midpoint infection 
time’, assuming a biomarker reading of zero at infection, and without any extrapolation 
beyond the subject’s last data point). At every time ݐ post infection, the proportion of 
those subjects with available biomarker readings (namely those that have not been lost to 
follow-up) that have measurements below the test threshold ܻ provides an estimate of 
ோܲሺݐሻ. Biomarker readings were interpolated either linearly or by a nearest neighbour 
approach (implying that transitions between states occur at the midpoints of periods 
between visits). Furthermore, the approach was implemented either using all data as is or 
assuming a subject’s readings remain above the threshold, ܻ, after a first measurement 
above ܻ. The first implementation allows for multiple transitions between the ‘recent’ 
and ‘non-recent’ states, while the second assumes and enforces single exits from the state 
of ‘recent’ infection (disregarding information contained in later data points), as done in 
some of the literature [91, 93-96, 98-100, 102]. This class of methods provides a basic, 
informal approach for analysing the longitudinal data. The Matlab function that was 
developed to implement Methods 1 and 2 is provided in Appendix B.3. 
Conventional statistical survival analysis techniques are used to model the time from 
entering to exiting a state of interest. For this application, even if the biomarker signal is 
monotonically increasing over time after infection (at least until the time cut-off ܶ), 
measurement noise implies that subjects may fluctuate in and out of the state of ‘recent’ 
infection many times, and therefore this single sojourn view of ‘recent’ infection is too 
restrictive. These statistical methods have nevertheless been employed in this area [93, 
94, 96, 98-100, 102] and can be easily implemented using standard software, and were 
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therefore included in this benchmarking exercise. To utilise the survival analysis 
framework, all data points beyond a subject’s first ‘non-recent’ data point were 
effectively discarded.  
Survival analysis methods are also more amenable to accommodating (at least some cases 
of) data censoring. In this application, data is double interval censored as both entry and 
exit times are interval censored. More specifically, a subject’s entry time lies within the 
infection interval, and exit time lies in what is referred to here as the ‘exit interval’. The 
exit interval is taken to be the time interval either between the subject’s first ‘non-recent’ 
visit and the preceding visit, or between the latest visit and infinity (or some very large 
time) if there is no ‘non-recent’ result (typically referred to as a right censored exit time). 
The first set of survival analysis methods (Methods 5-7) are based on fitting a parametric 
distribution (Weibull, Gamma or Lognormal distribution) to the time in the ‘recent’ state, 
treating the time in the state as double interval censored (that is, the infection time is 
uniformly distributed in the infection interval, and then the exit time is uniformly 
distributed in the exit interval). A maximum likelihood approach was used to estimate the 
distribution’s parameters, and the integration required to assess the likelihood function 
was performed numerically (using the composite trapezoidal rule). 
Parametric assumptions about the distribution of times in the ‘recent’ state were avoided 
by using a Kaplan-Meier or Product-Limit estimator [177, 178] of the survival function 
(Methods 8 and 9), where the estimated survival function is a step function that 
maximises the likelihood of the observed data. The standard Kaplan-Meier approach 
accommodates only right censored data, and therefore ‘midpoint infection times’ were 
used and exit times were estimated by interpolation between biomarker readings on either 
side of the exit interval (assuming a zero biomarker measurement at infection), either 
linearly or by a nearest neighbour approach. If the last visit of the subject was ‘non-
recent’, the exit time was treated as right censored. The MDRI estimates obtained from 
these methods will be equal to those produced by the corresponding single-exit 
interpolation methods (Methods 1 and 3) when there are no right censored exit times 
within ܶ after infection. 
Founded on the principle of an Expectation-Maximisation algorithm, Turnbull's algorithm 
[178, 179] extends the Kaplan-Meier estimator of the survival function to allow for 
interval censored data (Method 10). The double interval censoring in the data implies that 
a trapezoidal distribution should be used to describe the uncertainty in the time in the 
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‘recent’ state, while the single interval censoring accommodated by Turnbull’s algorithm 
utilises a uniform distribution. Therefore, while not formally exact, to facilitate 
application of this approach and reproduce previous implementations [98], the data was 
interpreted as capturing single interval censored times in the ‘recent’ state, with bounds 
given by the minimum and maximum possible times in the ‘recent’ state implied by the 
data. In this implementation, the survival function was taken to evolve piecewise linearly 
(rather than being piecewise constant, as is conventionally assumed). 
In parametric regression (Methods 11-17), a particular form for the expected response, 
as a function of predictors, is fitted to the data. In this application, time since infection (or 
transformations thereof) provide the predictor(s), and either the biomarker reading or test 
classification (‘recent’ versus ‘non-recent’) provides the response. Different classes of 
parametric regression can be considered, depending on the following, for example: the 
method of model fitting (such as whether a Bayesian or Frequentist approach is used, and 
the specific software or algorithms utilised); whether the response is the biomarker 
reading or test classification; whether the defined model forms are linear or non-linear in 
the parameters; whether subject-level clustering of data is accounted for by random 
effects; and how the unknown infection times are accommodated. The choices made 
greatly impact the statistical complexity, and computational stability and expense, of the 
approach. Two classes of parametric regression models were employed and are discussed 
below, namely linear binomial regression models and non-linear (normal-response) 
mixed models, both using ‘midpoint infection times’. 30 
The linear binomial regression models (Methods 11-14) assumed functional forms for 
ோܲሺݐሻ, with parameters estimated to maximise the likelihood of classifications in the data 
(using Matlab’s ‘glmfit’ tool). The models were of the form ݃൫ ோܲሺݐሻ൯ ൌ ߚഫ்ݔപሺݐሻ, where 
݃ሺ. ሻ is the link function, and ߟ ൌ 	ߚഫ்ݔപሺݐሻ		is the linear predictor containing both the 
model parameters in ߚഫ and the predictors, which are functions of time since infection, in 
ݔപሺݐሻ . This class of models neglects the subject-level clustering of data points. Four 
parametric forms of the model were implemented (Forms 1-4), intended to provide 
varying degrees of flexibility: 1) ݃ሺ. ሻ is a logit link and ߟ is a cubic polynomial of time (a 
four-parameter model); 2) ݃ሺ. ሻ is a logit link and ߟ is a linear combination of the basis 
___________________________ 
30Additional classes of parametric regression models were implemented by other members of the 
project team, and are to be presented in the group’s manuscript. 
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functions of a natural cubic spline that has six equally spaced knots within ሾ0, ܶሿ (a six-
parameter model); 3) ݃ሺ. ሻ  is a loglog link and ߟ  is a linear function of the natural 
logarithm of time (a two-parameter model, with ோܲሺݐሻ resembling a Weibull survival 
function); and 4)	݃ሺ. ሻ and ߟ are such that ோܲሺݐሻ is constant within each of six equally-
sized subintervals segmenting the post-infection time interval ሾ0, ܶሿ (six parameters). In 
some scenarios considered, the sparseness of data did not support meaningful use of 
Forms 2 and 4. For Form 4, when fewer than five subjects contributed data points to any 
subinterval, the number of subintervals was reduced in decrements of one (to a minimum 
of one). 
Non-linear mixed models (Methods 15-17) for the biomarker measurements are 
substantially more complex and difficult to implement than any of the approaches 
discussed above, but are able to capture various features of the data. In general, a 
parametric form for the biomarker signal over time since infection is chosen, as is a 
measurement noise structure, and subject-level clustering or correlation of data is 
accounted for through subject-specific deviations (random effects) of signal parameters 
from the population-level average signal parameters (fixed effects).  
More specifically, the chosen model structure specified that the biomarker measurement 
for subject ݅ at time ݐ after infection was given by 
௜݂ሺݐሻ ൌ ݂ሺݐ|പܽ௜ሻ ൌ ݕሺݐ|പܽ௜ሻ ൅ ൫݇ଵ ൅ ݇ଶݕሺݐ|പܽ௜ሻ൯ ∙ ߝ, (4.4)
where the signal was described by ݕሺݐ|പܽ௜ሻ and the noise was captured by ߝ, which is a 
standard normal random variable (independently drawn for every biomarker 
measurement). The subject’s ݊௔ signal parameters contained in പܽ௜ followed a multivariate 
normal distribution, with mean ߤപ௔ (the fixed effects) and covariance matrix Σ௔ (capturing 
the variability of the random effects or subjects’ deviations). The model parameters were 
contained in ߤപ௔, Σ௔ and പ݇ ൌ 	ሾ݇ଵ, ݇ଶሿ.  
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Three forms for the signal were implemented (Signals 1-3). Signal 1 is 
ݕሺݐ|പܽ௜ሻ ൌ 	ܽ௜,ଵ ∙ ቀ1 ൅ ቀݐ ൈ ݁ݔ݌൫ܽ௜,ଶ൯ቁ
௔೔,యቁ
ିଵ
, (4.5) 
and Signal 2 is 
ݕሺݐ|പܽ௜ሻ ൌ 	ܽ௜,ଵ ∙ ቀ1 െ expቀെ൫ݐ ൈ ݁ݔ݌൫ܽ௜,ଶ൯൯௔೔,యቁቁ, (4.6) 
and both result in eleven-parameter models (݊௔ ൌ 3). Signal 3, a special case of Signal 2, 
is  
ݕሺݐ|പܽ௜ሻ ൌ 	ܽ௜,ଵ ∙ ቀ1 െ exp ቀെ൫ݐ ൈ ݁ݔ݌൫ܽ௜,ଶ൯൯ቁቁ (4.7) 
and produces a seven-parameter model (݊௔ ൌ 2ሻ. Signal 1 matches the biomarker signal 
used to generate base case scenario data, up to transformations of the parameters. 
The mixed model parameters were estimated to maximise the likelihood of the data. The 
large search space and complex likelihood function can cause instabilities when using 
optimisation algorithms to search for the parameters’ maximum likelihood estimates, and 
therefore Markov Chain Monte Carlo (MCMC) approaches are often used. For this 
exercise, stability of processes was important as estimation was performed for several 
thousands of datasets through an automated system, and therefore the MCMC approach 
provided by Matlab’s ‘nlmefitsa’ tool was used. Also, while (in practice) convergence 
criteria would be carefully assessed when analysing any given dataset (as would the choice 
of parametric forms), here the number and lengths of the chains (which aim to converge 
to the maximum likelihood estimates) used in a single estimation were increased until a 
balance was found between feasible run times and suitably small variation in MDRI 
estimates if analysing the same dataset multiple times (three chains of 1 000 steps were 
used, each with its own starting value, and the parameter estimates providing the largest 
likelihood value were considered to be the maximum likelihood estimates). 
For the parametric approaches above (Methods 5-7, 11-17), data points occurring at large 
times after infection, relative to the time cut-off ܶ, were discarded before model fitting, in 
an attempt to achieve the best model fit specifically to data over post-infection times in 
ሾ0, ܶሿ. More specifically, data points were excluded which were beyond ܶ  plus some 
margin (ranging from 0 to 0. 5 ∙ ܶ across methods). Since the maximum follow-up time 
for subjects was 2 years and biomarkers were well behaved over that time by design, this 
data exclusion may have limited impact here. However, in practice, biomarker dynamics 
may become less predictable years after infection, and therefore care should be taken in 
choosing data to train models that are intended to describe early test dynamics. 
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The output of each method of estimation described above can be expressed as an 
estimated ோܲሺݐሻ – possibly after some transformation of output model parameters. The 
MDRI was then estimated by the area under this inferred curve, from ݐ ൌ 0 to ݐ ൌ ܶ, 
either analytically or numerically (using the composite trapezoidal rule). 
In practice, when any parameter is inferred, the reported estimate has little meaning 
without an estimate of uncertainty, typically expressed as a confidence interval. However, 
for this exercise, confidence intervals were not reported. By operating within a simulation 
environment where experiments could be replicated, the bias and variance of point 
estimates were directly measured. These metrics inform the coverage and widths of 
confidence intervals that may be produced. Furthermore, for any given estimation 
method, it is possible that a number of methods could be used to obtain confidence 
intervals. The optimisation of the confidence interval approach, and finding a balance 
between its complexity or computational expense and its performance, would extend this 
benchmarking exercise well beyond its already broad scope. 
Metrics	of	performance	for	estimation	methods	
For each scenario and each MDRI estimation method, a large number of MDRI estimates 
were obtained by analysing each of the 1 000 datasets that were generated. The 
distribution of point estimates provides information about the behaviour and performance 
of the estimation method. Many metrics could be considered for summarising this 
distribution, and potentially how it relates to the true MDRI – for example, percentiles, 
variance, the expected value, bias, or the mean squared error could be computed. For each 
scenario and each estimation method, two such performance statistics are reported here: 
(i) accuracy is summarised by relative bias (difference between average MDRI estimate 
and true MDRI, relative to the true MDRI), and (ii) precision is captured by the relative 
standard deviation or coefficient of variation (standard deviation of estimates relative to 
the mean estimate). 
To quantify the bias in estimation, the average MDRI estimate needs to be compared to 
the true MDRI, which was therefore computed for each scenario considered. The MDRI, 
Ω், depends on the dynamics of the underlying biomarker as a function of time since 
infection.  
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For scenarios where data was generated using the primary, base case biomarker model, 
the MDRI was calculated using the following expression (substituting in the scenario’s 
data generation parameter values): 
Ω் ൌ 	න න ௕݂ഫሺപܾሻ Φ൭ ܻ െ ݕ
ሺݐ|പܾሻ
݁଴ ൅ ݁ଵ ∙ ݕሺݐ|പܾሻ ൅ ݁ଶ ∙ ൫ݕሺݐ|പܾሻ൯௘య
൱	
௕ഫ∈ோయ
dപܾ	dݐ
௧ୀ்
௧ୀ଴
, (4.8) 
where ܻ ൐ 0 is the test threshold used to distinguish between ‘recent’ and ‘non-recent’ 
results, ܶ is the time cut-off appearing in the definition of the MDRI, ݕሺݐ|പܾሻ is the signal 
given by Equation (4.2), Φሺ. ሻ is the standard normal cumulative distribution function, 
and ௕݂ഫሺപܾሻ  is a multivariate normal probability density function with mean ߤപ௕  and 
covariance matrix Σ௕, truncated to have only a positive support. 
For the alternative data generation biomarker form discussed, the MDRI was computed 
by: 
Ω் ൌ න න න ௕݂భ ሺܾଵሻ ௕݂మሺܾଶሻΦቆ
ܻ െ ݕሺݐ|പܾሻ
݁ ቇ dܾଶ	dܾଵ	dݐ
௕మୀ௕మ,ೠ
௕మୀ௕మ,೗
௕భୀ௕భ,ೠ
௕భୀ௕భ,೗
௧ୀ்
௧ୀ଴
, (4.9) 
where പܾ ൌ ሾܾଵ, ܾଶሿ, ݕሺݐ|പܾሻ is the signal given by Equation (4.3), 
௕݂భ	ሺܾଵሻ ൌ ൫ܾଵ,௨ െ ܾଵ,௟൯
ିଵ
if ܾଵ,௟ ൑ ܾଵ ൏ ܾ௟,௨ (0 elsewhere) and ௕݂మ	ሺܾଶሻ ൌ ൫ܾଶ,௨ െ ܾଶ,௟൯
ିଵ
if ܾଶ,௟ ൑ ܾଶ ൏ ܾଶ,௨ (0 elsewhere). 
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4.1.3 Results	
The results from each method of MDRI estimation are plotted for the base case scenario 
in Figure 4.2, and summary performance statistics for all scenarios are provided in 
Tables 4.1 to 4.4 – namely the relative bias of the estimation procedure (accuracy) and the 
relative standard deviation or coefficient of variation of point estimates (precision). The 
contents of each of the tables are outlined below, and then some qualitative insights 
gained from interpreting the results are highlighted.  
The base scenario is somewhat idealistic, capturing monthly visits for 50 HIV-positive 
subjects over two years after infection and infection times that are uniformly distributed 
in intervals of 3 months. For this scenario, all categories of estimation methods appear to 
provide useful estimates (Figure 4.2), but there is a clear sensitivity to parametric 
assumptions when considering the mixed model results (Methods 15-17). Therefore, an 
initial investigation into parametric assumptions for the mixed models was performed, 
and is presented in Table 4.1. This investigation was used to down select and fine tune the 
(computer-intensive) mixed models that were to be subsequently assessed alongside the 
remaining estimation methods (and resulted in Signal 3 being abandoned). For each of the 
three fitted signal forms (Methods 15-17), four variations of the mixed model were 
implemented for this auxiliary investigation, based on assumptions about the noise 
structure and correlation between random effects (Table 4.1). The scenarios that were 
used to assess performance captured alternative forms of the underlying biomarker, and 
variations of the noise structure and levels of correlation between random effects 
(compared to the base case biomarker dynamic).  
Features of the data related to study protocol and subject behaviour (that is, the generation 
of visit and infection times) are considered in Table 4.2 and Table 4.3. The performance 
of estimation methods when varying the number of subjects and mean visit gaps, while 
HIV-negative and HIV-positive in turn, is summarised in Table 4.2; while the impact of 
(increasing levels) of missed visits, loss to follow-up and non-uniformity of infection 
times is explored in Table 4.3. The impact of features of the underlying biomarker 
dynamic is investigated in Table 4.4, where the levels of measurement noise and inter-
subject variability are varied (for the base case biomarker form) and the alternative 
biomarker form is considered. 
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Figure 4.2. Box-and-whisker plots of the mean duration of recent infection point 
estimates for the base case scenario by method of estimation
Box-and-whisker plots of the point estimates for the MDRI, Ω் (days), are provided for 
the base case scenario, for each of the MDRI estimation methods (ܶ ൌ 1 year). The box 
and dividing line indicate the central 50% and median of estimates respectively, and 
whiskers and circles capture remaining data points and outliers respectively (outliers are 
more than 1.5 times the interquartile range or box length away from the central box). The 
vertical black line indicates the true MDRI.  
* Methods 15-17 appear to have fewer outliers because fewer experiments were replicated
(250 instead of 1 000). 
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1 Alternative biomarker form specified in text, ܾଵ,௟ ൌ ܾଵ,௨ ൌ 0, ܾଶ,௟ ൌ 0.3, ܾଶ,௨ ൌ 0.35 and ݁ ൌ 4, where 
   time is measured in days 
2 Alternative biomarker form specified in text, ܾଵ,௟ ൌ 15, ܾଵ,௨ ൌ 25, ܾଶ,௟ ൌ 0.3, ܾଶ,௨ ൌ 0.35 and ݁ ൌ 4,  
  where time is measured in days 
3 Noise standard deviation increases and then decreases with growing signal: പ݁ ൌ ሾ4, -0.26, 2.8, 0.5ሿ  
4 Noise standard deviation increases and then decreases with growing signal: പ݁ ൌ ሾ4, -0.22, 10, 0.25ሿ  
Table 4.1: Performance of variations of mixed models in scenarios constructed for 
exploring sensitivities to parametric assumptions 
The estimated relative bias (%) and relative standard deviation (%) for each MDRI 
estimation procedure are shown, for variations of the non-linear mixed models for the 
biomarker readings. Scenarios capture different underlying biomarker forms, and changes 
in the noise structure and the correlations between signal ‘random effects’ (relative to the 
base case).  * Scenario corresponds to base case. 
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FITTED MODEL
   SPECIFICATIONS
Noise standard deviation
Correlation between 
   'random effects'
RELATIVE BIAS (%)
Underlying biomarker
   form
Base case* -1 0   -0 2   -6 1   -1 1   -0 4   -6 0   -0 6   0 9    -6 7   -0 7   0 9    -6 7   
Power function, 
   no time lag1
-0 8   -0 1   -2 8   -0 7   -0 1   -2 8   -0 4   0 2    -3 3   -0 3   0 1    -3 4   
Power function, 
   with time lag2
1 7    2 2    -1 1   1 7  2 2    -1 1   -1 1   0 0    -1 8   -1 1   -0 0   -1 8   
Noise structure
Base case* -1 0   -0 2   -6 1   -1 1   -0 4   -6 0   -0 6   0 9    -6 7   -0 7   0 9    -6 7   
Alternative 13 -0 6   0 3    -7 0   -0 6   0 3    -7 0   -0 4   0 9    -6 8   -0 4   1 0    -6 8   
Alternative 24 -1 7   -1 4   -8 7   -1 4   -0 4   -8 7   -1 6   -1 0   -8 1   -1 5   -0 0   -8 2   
Correlation between
   signal 'random effects'
No correlation -0 3   0 6  -4 6 -0 4 0 5  -4 7 -0 3 1 3  -5 7 -0 3  1 3    -5 6   
Base case* -1 0   -0 2 -6 1 -1 1 -0 4 -6 0 -0 6 0 9  -6 7 -0 7  0 9    -6 7   
Double correlation
   coefficients
-1 4   -0 6   -6 8   -1 4   -0 8   -6 8   -0 6   1 0    -7 2   -0 7   0 9    -7 2   
RELATIVE STANDARD
   DEVIATION (%)
Underlying biomarker
   form
Base case* 4 0    4 0    4 1    4 1  4 1    4 1    4 1    4 1  4 7    4 8    4 8    4 7   
Power function, 
   no time lag1
4 3    4 3    4 4    4 3  4 4    4 4    4 4    4 4  3 5    3 5    3 6    3 6   
Power function, 
   with time lag2
3 8    3 8    3 4    3 3  3 7    3 6    3 3    3 3  3 3    3 3    3 4    3 4   
Noise structure
Base case* 4 0    4 0    4 1    4 1  4 1    4 1    4 1    4 1  4 7    4 8    4 8    4 7   
Alternative 13 4 4    4 4    4 5    4 5  4 3    4 4    4 5    4 5  5 4    5 4    5 2    5 1   
Alternative 24 4 5    5 1    4 5    5 3  4 4    4 5    4 4    4 5  5 1    5 3    5 0    5 1   
Correlation between
   signal 'random effects'
No correlation 4 6    4 6  4 5  4 6  4 6  4 6  4 5  4 6  5 1  5 2   5 1    5 0   
Base case* 4 0    4 0    4 1    4 1  4 1    4 1    4 1    4 1  4 7    4 8    4 8    4 7   
Double correlation
   coefficients
4 0    3 9    4 0    4 0  3 9    3 8    4 0    4 0  4 9    4 9    4 8    4 7   
 None  None  Included  Included 
 Constant Linear in signal Constant  Linear in signal 
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1 Convergence issues arose for Methods 5-7, which were run on only 250 datasets and 80% of runs 
   produced outputs 
2 The standard deviation for visit gaps (ߪ௩௚௡ and ߪ௩௚௣) was 10% of the mean 
3 Convergence issues were encountered for Methods 15 and 16; and Methods 12 and 14 utilised 
 unrealistic model forms given the sparseness of data 
Table 4.2: Performance of the mean duration of recent infection estimation methods 
in scenarios capturing various study designs 
The estimated relative bias (%) and relative standard deviation (%) for each of the MDRI 
estimation procedures are shown. Scenarios capture varying numbers of (HIV-positive) 
subjects and average visit gaps, while HIV-negative and HIV-positive. 
* Scenario corresponds to base case.
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RELATIVE BIAS (%)
Number of subjects
51 -0 0  0 5    -0 1  0 5    -0 3  0 1    -0 2  0 0   -0 1  -0 0  0 4    -0 9   0 7    0 9    0 3   1 8     
10 -0 6  -0 0  -0 8  -0 1 -0 7 -0 7 -0 7 -0 6 -0 8 -0 8 -0 2 -0 2 0 1    0 3    -0 5  1 1     
20 -0 3  0 1    -0 5  0 0    -0 4  -0 5  -0 5  -0 3  -0 5  -0 5  0 0    -0 0   0 3    0 5    -0 6  0 9     
50* -0 4  0 1    -0 7  -0 1  -0 7  -0 7  -0 7  -0 4  -0 7  -0 9  -0 1  -0 1   0 3    0 4    -0 7  0 9     
100 -0 4  0 1    -0 7  -0 0 -0 6 -0 7 -0 7 -0 4 -0 6 -0 9 -0 0 -0 0 0 3    0 4    -0 3  1 2     
150 -0 3  0 2    -0 5  0 1    -0 5  -0 5  -0 6  -0 3  -0 5  -0 8  0 1    0 1     0 4    0 6    -0 2  1 3     
Mean HIV-negative 
   visit gap2
1 week -0 4  0 1    -0 6  0 0  -0 7 -0 6 -0 5 -0 4 -0 6 -0 6 0 1  0 0   0 5    0 5    -0 2  1 5     
2 weeks -0 5  -0 0  -0 7  -0 1  -0 8  -0 7  -0 6  -0 5  -0 7  -0 8  -0 1  -0 1   0 3    1 3    -0 2  1 6     
1 month -0 5  -0 0  -0 6  -0 1  -0 7  -0 6  -0 5  -0 5  -0 6  -0 6  -0 0  -0 0   0 3    0 6    0 1   1 8     
3 months* -0 4  0 1    -0 7  -0 1  -0 7  -0 7  -0 7  -0 4  -0 7  -0 9  -0 1  -0 1   0 3    0 4    -0 7  0 9     
6 months -0 4  0 1    -1 5  -0 9  -0 8  -0 6  -0 6  -0 4  -1 5  1 6    -0 5  -1 0   0 2    -2 4   -0 5  -0 2   
Mean HIV-positive
   visit gap2
1 week -2 4  0 1    -2 7  0 2    -2 6  -2 7  -2 7  -2 4  -2 6  -2 6  0 2   0 2     0 5    0 0    -0 1  1 2     
2 weeks -1 3  0 1    -1 5  0 1    -1 5  -1 5  -1 5  -1 3  -1 5  -1 5  0 1   0 1     0 4    -0 0   -0 8  0 6     
1 month* -0 4  0 1    -0 7  -0 1  -0 7  -0 7  -0 7  -0 4  -0 7  -0 9  -0 1  -0 1   0 3    0 4    -0 7  0 9     
3 months 1 0    1 1    0 1    0 2    0 1    0 0    -0 0  1 0   0 1    0 4    -0 2  1 8     0 4    -1 8   -1 5  0 9     
6 months3 1 1   1 1    -3 5  -3 5  0 1    0 4    0 2    1 1   -3 5  14 1  -3 2  -24 5 -0 1  -10 3 -8 8  -19 4 
RELATIVE STANDARD
   DEVIATION (%)
Number of subjects
51 14 1  14 1  14 4  14 4 14 8 14 1 14 6 14 1 14 4 14 9 14 5 13 9 14 6  14 6  13 8  13 9   
10 9 7    9 8    9 8    9 9    9 8    9 8    9 8    9 7   9 8    10 2  10 0  9 9     10 0  9 9    9 0   8 9     
20 7 0    7 0    7 1    7 1    7 1    7 1    7 1    7 0   7 1    7 5    7 1    7 2     7 2    7 2    7 3   7 2     
50* 4 4   4 4    4 5    4 5    4 5    4 5    4 4    4 4   4 5    4 6    4 5   4 5     4 6    4 5    4 1   4 1     
100 2 9   3 0    3 0    3 0  3 0  3 0  3 0  2 9  3 0  3 1  3 0  3 0   3 1    3 0    2 9   2 9     
150 2 5   2 5    2 6    2 6    2 6    2 6    2 6    2 5   2 6    2 7    2 6   2 6     2 6    2 6    2 4   2 4     
Mean HIV-negative 
   visit gap2
1 week 4 0   4 0    4 1    4 1    4 1    4 1    4 0    4 0   4 1    4 1    4 1   4 1     4 2    4 1    3 9   3 8     
2 weeks 4 1   4 1    4 1    4 2    4 1    4 1    4 1    4 1   4 1    4 2    4 2   4 2     4 3    4 1    4 2   4 1     
1 month 4 0   4 1    4 1    4 2  4 1  4 1  4 1  4 0  4 1  4 2  4 2  4 2   4 3    4 1    3 9   3 9     
3 months* 4 4   4 4    4 5    4 5  4 5  4 5  4 4  4 4  4 5  4 6  4 5  4 5   4 6    4 5    4 1   4 1     
6 months 5 3   5 3    5 6    5 6    5 6    5 5    5 4    5 3   5 6    4 9    5 6   6 3     5 4    6 4    5 0   5 1     
Mean HIV-positive
   visit gap2
1 week 4 2   4 3    4 2    4 3  4 2  4 2  4 2  4 2  4 2  4 2  4 3  4 3   4 3    4 3    4 2   4 2     
2 weeks 4 2   4 3    4 3    4 3    4 3    4 3    4 3    4 2   4 3    4 4    4 4   4 4     4 4    4 4    4 1   4 1     
1 month* 4 4   4 4    4 5    4 5    4 5    4 5    4 4    4 4   4 5    4 6    4 5   4 5     4 6    4 5    4 1   4 1     
3 months 4 4   4 4    4 9    4 8  4 9  5 0  4 9  4 4  4 9  6 1  4 9  7 1   5 0    6 1    5 1   4 4     
6 months3 4 4   4 4    6 1    6 1  6 2  6 9  7 4  4 4  6 1  4 8  22 2 37 7 6 5    8 8    13 6  16 1   
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1 Reported as the mean of the population-level distribution for the probability of missing a visit, which has 
   an absolute standard deviation of 5%, for HIV-negative subjects and HIV-positive subjects in turn 
2 Reported as the percentage of subjects lost within the specified maximum follow-up time 
3 Methods 2 and 4 require that at least one subject is followed-up until ܶ ൌ 1 year after infection, and  
   therefore 2% of estimations could not be completed 
4 Infection times occur a third of the infection interval away from the first HIV-positive visit on average, 
 and 80% of infection times occur closer to the first HIV-positive visit than the last HIV-negative visit 
Table 4.3: Performance of the mean duration of recent infection estimation methods 
in scenarios capturing various non-ideal features of subject visits 
The estimated relative bias (%) and relative standard deviation (%) for each of the MDRI 
estimation procedures are shown. Scenarios capture varying levels of missed visits and 
loss to follow-up, and non-uniformity of infection times. 
* Scenario corresponds to base case.
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RELATIVE BIAS (%)
Missed visit
   probability1
0% and 0%* -0 4  0 1    -0 7  -0 1 -0 7 -0 7 -0 7 -0 4 -0 7 -0 9 -0 1 -0 1 0 3    0 4    -0 7  0 9     
50% and 0% 1 5    1 9    -0 2  0 3    -0 5  -0 5  -0 5  1 5   -0 2  1 1    2 2    2 2   2 5   1 9  2 1    2 6     
75% and 0% 11 0  11 3  7 9    8 3    -0 7  -0 6  -0 6  11 0  7 9    3 5    4 8    4 8   4 7   4 2  7 7    7 2     
0% and 50% 1 1    1 3    0 6    0 9    -0 2  -0 4  -0 5  1 1   0 6    -0 6  -0 1  -0 1   0 2    0 3    -0 5  1 4     
0% and 83% 13 3  13 7  14 2  14 8  0 6    -0 2  -0 6  13 5  14 5  -0 2  0 0    -0 2   0 4    0 6    -1 3  -0 5   
50% and 50% 2 9   3 1    1 3    1 5  -0 1 -0 2 -0 3 2 9  1 3  0 7  1 9  1 8   2 4   2 0  1 5    2 6     
50% and 83% 12 4  12 8  13 2  13 7  0 3    -0 3  -0 6  12 5  13 4  -1 6  1 4    1 2     2 2    1 8    0 5    2 7     
Loss to follow-up2
0% within 2 years* -0 4  0 1    -0 7  -0 1  -0 7  -0 7  -0 7  -0 4  -0 7  -0 9  -0 1  -0 1   0 3    0 4    -0 7  0 9     
100% within 2 years -2 0  -0 0  -2 2  -0 2 -0 7 -0 7 -0 7 -0 6 -0 8 -1 0 -0 1 -0 2 0 2    0 8    -0 0  1 1     
100% within 1 5 years -2 6  0 0    -2 9  -0 1  -0 7  -0 7  -0 6  -0 5  -0 7  -1 9  -0 1  -0 1   0 3    1 1    -0 0  0 8     
100% within 1 year3 -4 1  0 1    -4 5  -0 1  -0 6  -0 2  0 0    -0 7  -0 9  -2 9  -0 0  -0 0   0 1    1 8    1 0    1 3     
Infection times
Uniformly distributed* -0 4  0 1    -0 7  -0 1 -0 7 -0 7 -0 7 -0 4 -0 7 -0 9 -0 1 -0 1 0 3    0 4    -0 7  0 9     
Test-seeking behaviour4 7 8    8 2    7 6    8 1  7 6  7 5  7 5  7 8  7 6  7 4  8 2  8 1   8 6   8 7  7 9    9 6     
RELATIVE STANDARD
   DEVIATION (%)
Missed visit
   probability1
0% and 0%* 4 4   4 4    4 5    4 5  4 5  4 5  4 4  4 4  4 5  4 6  4 5  4 5   4 6   4 5  4 1    4 1     
50% and 0% 5 2   5 2    5 5    5 5    5 0    5 1    5 0    5 2   5 5   5 1    5 1    5 1   5 2   5 2  5 0    5 0     
75% and 0% 6 0   6 0    6 4    6 4  6 5  6 5  6 5  6 0  6 4  6 6  6 6  6 6   6 7   6 8  6 7    6 6     
0% and 50% 4 4   4 4    4 8    4 8    4 9    5 0    4 9    4 4   4 8   5 4    5 1    5 1   5 1   5 0  4 2    4 1     
0% and 83% 4 6   4 6    5 2    5 2    6 8    7 0    7 0    4 6   5 2   8 4    7 2    7 3   7 2   7 2  6 6    7 1     
50% and 50% 5 4   5 4    5 8    5 8    5 8    5 8    5 8    5 4   5 8   6 3    6 0    6 0   6 0   6 0  5 5    5 4     
50% and 83% 5 6   5 6    6 3    6 3    7 6    7 6    7 6    5 6   6 3   9 7    8 0    8 0   7 9   8 0  6 3    5 9     
Loss to follow-up2
0% within 2 years* 4 4   4 4    4 5    4 5    4 5    4 5    4 4    4 4   4 5   4 6    4 5    4 5   4 6   4 5  4 1    4 1     
100% within 2 years 5 0   5 0    5 1    5 2  5 0  5 0  5 0  4 9  5 0  5 2  5 1  5 1   5 2   5 1  4 9    4 8     
100% within 1 5 years 4 9   5 1    5 0    5 2    5 0    4 9    4 9    4 9   4 9   5 1    5 1    5 1   5 2   5 1  4 9    4 8     
100% within 1 year3 5 4   5 8    5 5    5 9    5 6    5 6    5 7    5 5   5 6   5 7    5 8    5 8   5 8   5 7  5 4    5 5     
Infection times
Uniformly distributed* 4 4   4 4    4 5    4 5  4 5  4 5  4 4  4 4  4 5  4 6  4 5  4 5   4 6   4 5  4 1    4 1     
Test-seeking behaviour4 4 0   4 0    4 0    4 1  4 1  4 1  4 1  4 0  4 0  4 2  4 1  4 1   4 2   4 1  4 0    3 9     
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1 Reported as the (constant) standard deviation of noise, with values representing 10%, 25% and 50% of 
   the test threshold (or 5%, 12% and 24% of the average range of the signal) 
2 Described in terms of the standard deviations of signal ‘random effects’, maintaining their correlations 
3 Alternative biomarker form specified in text, ܾଵ,௟ ൌ ܾଵ,௨ ൌ 0, ܾଶ,௟ ൌ 0.3, ܾଶ,௨ ൌ 0.35 and ݁ ൌ 4, where 
   time is measured in days 
4 Alternative biomarker form specified in text, ܾଵ,௟ ൌ 15, ܾଵ,௨ ൌ 25, ܾଶ,௟ ൌ 0.3, ܾଶ,௨ ൌ 0.35 and ݁ ൌ 4,  
  where time is measured in days 
Table 4.4: Performance of the mean duration of recent infection estimation methods 
in scenarios capturing various features of the underling biomarker dynamics  
The estimated relative bias (%) and relative standard deviation (%) for each of the MDRI 
estimation procedures are shown. Scenarios capture varying magnitudes of measurement 
noise, levels of inter-subject variability, and underlying biomarker forms. 
* Scenario corresponds to base case.
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RELATIVE BIAS (%)
Magnitude of noise1
4 -0 4    0 2    -0 6   0 0    -0 6   -0 6    -0 6    -0 4   -0 6   -0 8   0 1   0 0   0 4   0 5   -0 5  1 1   
10 -3 9    -0 2  -4 5   -0 2  -4 5   -4 5    -4 5    -3 9   -4 5   -4 7   -0 1  -0 2  0 6   0 3   -0 3  1 0   
20 -15 9  -0 2  -17 3 -0 1  -17 2  -17 3  -17 1  -15 9 -17 2 -17 4 -0 2  -0 3  1 2   -0 1  -3 0  -0 1  
Inter-subject
   variability2
Base case* -0 4    0 1    -0 7   -0 1  -0 7   -0 7    -0 7    -0 4   -0 7   -0 9   -0 1  -0 1  0 3   0 4   -0 7  0 9   
Doubled -0 8    0 5    -1 2   0 2    -1 1   -1 8    -2 1    -0 8   -1 2   -0 6   -0 1  -0 0  0 4   -0 0  -3 4  -2 5  
Tripled -1 4    -0 0  -1 8   -0 3  -2 5   -3 3    -4 6    -1 4   -1 8   -0 5   -0 8  -0 8  -0 3  -1 0  -6 3  -5 3  
Underlying biomarker
   form
Base case* -0 4    0 1    -0 7   -0 1  -0 7   -0 7    -0 7    -0 4   -0 7   -0 9   -0 1  -0 1  0 3   0 4   -0 7  0 9   
Power function, 
   no time lag3 -10 1  -0 9  -11 6 -0 4  -11 5  -11 4  -11 4  -10 1 -11 5 -11 8 -0 4  -0 4  0 1   -0 0  -0 3  0 1   
Power function, 
   with time lag4 -8 7    -0 6  -9 9   -0 1  -9 9   -9 9    -9 9    -8 7   -9 9   -10 0 -0 0  -0 1  0 5   0 5   -1 1  -0 0  
RELATIVE STANDARD
   DEVIATION (%)
Magnitude of noise1
4 4 5     4 5    4 5     4 6    4 5    4 5   4 5     4 5     4 5     4 7     4 6   4 6   4 7   4 6   4 7   4 7   
10 4 4     4 5    4 6     4 5    4 6    4 6   4 5     4 4     4 6     4 8     4 5   4 5   4 6   4 6   4 3   4 3   
20 5 5     4 5    5 9     4 6    5 9    5 8   5 7     5 5     5 9     6 0     4 6   4 6   4 6   4 7   6 9   4 7   
Inter-subject
   variability2
Base case* 4 4     4 4    4 5     4 5    4 5    4 5   4 4     4 4     4 5     4 6     4 5   4 5   4 6   4 5   4 1   4 1   
Doubled 6 9     6 8    7 0     6 9    7 1    7 0   6 9     6 9     7 0     7 0     7 0   7 0   6 9   7 1   6 1   6 1   
Tripled 7 6     7 5    7 7     7 6    7 6    7 5   7 2     7 6     7 7     7 6     7 8   7 8   7 6   7 9   7 6   7 6   
Underlying biomarker
   form
Base case* 4 4     4 4    4 5     4 5    4 5    4 5   4 4     4 4     4 5     4 6     4 5   4 5   4 6   4 5   4 1   4 1   
Power function, 
   no time lag3 4 8     4 6    5 1     4 8    5 1    5 1   5 1     4 8     5 1     5 3     4 7   4 8   4 8   4 9   4 3   4 4   
Power function, 
   with time lag4 4 3     4 1    4 6     4 2    4 6    4 6   4 6     4 3     4 6     4 8     4 2   4 2   4 3   4 2   3 3   3 3   
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Single sojourn assumptions. A primary cause of bias in MDRI estimation is the 
assumption of a single sojourn in the ‘recent’ infection state, as contained in all single-
exit and survival analysis methods (Methods 1 and 3, 5-10). The underestimation of the 
MDRI became more pronounced as measurement noise was increased and HIV-positive 
visit gaps were reduced – both of these features made it more likely that an (increasingly) 
‘early’ upward fluctuation above the test threshold would be observed, artificially 
clipping a subject’s sojourn in the ‘recent’ state. In principle, the level of bias (for a given 
visit schedule) would depend on both the magnitude (and structure) of noise and the 
growth in the signal (such as captured by its slope), in a vicinity of the threshold (namely, 
over the time when noise may cause biomarker readings to fluctuate across the threshold). 
For example, when data was generated using the alternative biomarker form, the 
relatively small gradient of the signal at the test threshold resulted in greater 
underestimation of the MDRI by the single sojourn approaches, even though the 
magnitude of measurement noise around the threshold remained similar to that for the 
base case scenario. Given the limitations of single sojourn approaches, the interpretations 
below mainly focus on the results from the remaining estimation approaches.  
Variability of estimates. The various methods of estimation exhibited similar variability 
(relative standard deviations) in a given context (neglecting the most extreme contexts). 
Results indicate that the standard deviation of estimates varies approximately inversely 
proportionally to the square root of the number of subjects, and proportionally to the 
standard deviation of the distribution of individual durations in the ‘recent’ state (see 
investigation into inter-subject variability). Larger visit gaps, more frequently missed 
visits, increased loss to follow-up, and greater measurement noise all added to the 
variability in more nuanced ways.  
Loss to follow-up. Increased loss to follow-up would be expected to increase the 
variability of estimates, as the biomarker behaviour at later times after infection is 
inferred from fewer subjects. In the extreme case that no subjects are followed until ܶ 
after (an estimated) infection, only approaches that extrapolate beyond the latest data 
points can be used. When there is drop-out, those subjects that are observed to transition 
out of the ‘recent’ state would over-represent the shorter sojourns, and therefore biases 
arise when using methods that naïvely average over data (see Methods 1 and 3). 
Parametric assumptions for biomarker mixed models. When considering the 
parametric assumptions used in the mixed models, Signal 3 produced large biases and 
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was removed early on in the benchmarking exercise (Table 4.1). This bias was anticipated 
as Signal 3 is concave downwards and does not allow for a period of little growth in the 
biomarker signal immediately after infection. Models using Signals 1 and 2 (Methods 15 
and 16), allowing for varying noise magnitude and non-zero correlations between random 
effects, were retained for the remainder of the investigation. Signal 1 exactly matched the 
data generation process (up to transformations of parameters), although this ideal 
alignment of assumptions with reality would not occur in practice. When analysing any 
given dataset, knowledge of the underlying process, plots of the data, and statistical 
model fitting diagnostic tools would be used to select a reasonable parametric form. A 
comparison of the results for Signal 1 and 2 suggests that, while the true underlying form 
would never be known, similar inferences can be made even when fitting the ‘wrong’ 
parametric model by choosing a form is that reasonably aligned with the data and 
sufficiently flexible. The model fit (and therefore biases from incorrect parametric 
assumptions) depends on factors such as the frequency of visits and magnitude of noise. 
Noise structure. Many statistical models assume noise has either a constant standard 
deviation (additive noise) or a constant coefficient of variation (proportional noise). 
When incorrectly assuming the latter noise structure (or even when correctly assuming it, 
while having an incorrect assumption for the biomarker signal), performance of the 
estimation approach would be poor – models are forced to describe the data points with 
near-zero signal values very well, at the expense of fitting the rest of the data very poorly. 
A constant coefficient of variation noise structure was therefore not implemented, after 
some preliminary explorations (not shown). 
Binomial regression models. The binomial regression models appear to be particularly 
stable across scenarios, with performance typically at least on par with that of the mixed 
models. While the binomial models were computationally stable and easy to implement, 
they do not account for all the data features that are captured by the mixed models – 
notably, the subject-level clustering of data points – and also assume that data is missing 
completely at random. Results appear to be less sensitive to parametric assumptions, with 
all four models (ranging from two-parameter to six-parameter models) providing similar 
results (excluding scenarios where data were insufficient to fit certain parametric forms). 
Intuitively, many different biomarker dynamics could potentially be summarised into 
fewer (suitably flexible) forms for ோܲሺݐሻ – a topic that could now be further investigated 
using this simulation platform.  
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Large visit gaps. All methods of estimation were inaccurate when infection intervals 
were very large (compared to the duration of ‘recent’ infection). The number of (HIV-
positive) data points captured in any dataset could be reduced by either a higher 
probability of missed visits, or larger intended visit gaps. Methods employing subject-
specific biomarker interpolation were vulnerable to high missed visit probabilities (some 
subjects then had very large realised visit gaps and their times in the ‘recent’ state were 
particularly poorly estimated). On the other hand, population-level model fitting became 
challenging and inaccurate with large scheduled visit gaps for all subjects (as there was 
then no data to describe the dynamic over certain intervals of post-infection time after 
anchoring infection times).  
Infection times. Unknown infection times pose a fundamental obstacle to MDRI 
estimation as substantial bias can be introduced when the assumptions about infection 
times are violated. All methods of estimation introduced a bias (in absolute terms) equal 
to the difference between the mean infection time in reality and the mean infection time 
under model assumptions (namely uniformly distributed infection times within infection 
intervals).  
Correlation between estimates. Lastly, the MDRI estimates produced by any two 
estimation procedures in a chosen scenario were highly correlated (Pearson correlation 
coefficients averaged around 0.95 after excluding single-exit estimation methods and 
contexts with extremely sparse data). This suggests that (the unbiased) estimation 
procedures should give similar results when applied to any given dataset (keeping in mind 
the similarities in precision), and limited benefit can be gained from averaging the results 
of multiple methods. 
4.1.4 Discussion	
For tests for recent infection to be of utility for cross-sectional incidence surveillance, 
tests must first be characterised – that is, test properties of relevance for incidence 
estimation must be measured. Through the development of a theoretical framework for 
incidence inference [29], two generally-defined test properties have emerged: the mean 
duration of recent infection (MDRI), which is the average time ‘recently’ infected and 
alive while infected for less than some time cut-off ܶ, and the false-recent rate (FRR), 
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which is the probability that a person who is infected for a time larger than ܶ will produce 
a ‘recent’ result.31 While the FRR in principle captures a mixture of test dynamics and 
epidemiological and demographic history (and is therefore expected to be context-
dependent), the MDRI captures (primarily) the early biological dynamics of the test for 
recent infection (and should therefore be stable across contexts, which is critical to the 
overarching concept that a once-calibrated test should be useful if transferred to other 
contexts). 
Estimation of the MDRI has traditionally relied on longitudinal data, consisting of test 
results observed over time after some (estimable) infection times for a sample of subjects. 
Through an extensive benchmarking exercise using simulated data, the accuracy and 
precision of various methods for estimating the MDRI from such longitudinal data were 
assessed in a number of modelled scenarios capturing what may be encountered in 
practice. In this exercise, incidence assays, or tests for recent infection based on single 
biomarkers, were considered, where measurements below a chosen test threshold indicate 
‘recent’ infection. The methods of estimation therefore model either the biomarker 
measurements or the ‘recent’ and ‘non-recent’ classifications, as functions of time since 
infection. 
Results highlight the danger of using estimation procedures that assume single continuous 
sojourns in the state of ‘recent’ infection, such as conventional survival analysis 
approaches. Simplistic approaches, such as the interpolation of biomarker readings (while 
allowing for multiple transitions between the ‘recent’ and ‘non-recent’ states) are useful 
for obtaining ‘quick and dirty’ estimates provided the times between visits are sufficiently 
small.  
Formal regression approaches were generally the strongest. While non-linear mixed 
models for the biomarker readings most comprehensively captured the expected real-
world features of the data (such as subject-specific evolutions of the biomarker), they 
were computationally demanding and required a higher level of analytical sophistication. 
Furthermore, when analysing any given dataset, knowledge of the biomarker, plots of the 
data, and model fit diagnostics should be carefully used to inform parametric 
assumptions, at the risk of large bias occurring otherwise. While not accounting for the 
___________________________ 
31The general framework for inferring incidence and defining test characteristics of relevance for 
incidence estimation is presented in Chapter 2. 
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subject-level clustering of the data, the linear binomial regression models proved 
particularly useful – they provided accurate results, were potentially less sensitive to 
parametric assumptions, were computationally stable, and could be fitted using standard 
statistical software. The benefits of including random effects or changing to non-linear 
model forms could be considered, although results suggest current implementations of 
binomial regression perform well. However, these extensions may become important 
when operating in scenarios outside of those considered. For example, if study drop-out 
depends on the observed biomarker readings (that is, data is missing at random) over the 
relevant post-infection timescale set by ܶ, then random effects could be included to 
control for bias that may otherwise arise. Other potential sensitivities, for example, to 
non-normal distributions of random effects, could also be explored in more detail. 
Uncertainty in infection times, or rather the violation of assumptions about infection 
times, poses a particular challenge to obtaining unbiased MDRI estimates. While 
computationally demanding, some research groups have formally accounted for this 
uncertainty in infection times, by using a marginal likelihood function (integrating out the 
infection times) [97, 103], sampling infections times [101], or incorporating prior 
distributions for infection times in a Bayesian model fitting [94]. However, assumptions 
about the timing of infection are still required (to inform the distributions used). Other 
groups have attempted to use the biomarker readings themselves to estimate infection 
times [17, 92, 96, 100, 102]. In this exercise, a single, standard diagnostic test, such as an 
enzyme immunoassay (EIA), was assumed to be used at all visits, and therefore the 
analyst would only know that a subject’s infection (as defined by the diagnostic test) 
occurred between the last HIV-negative and first HIV-positive visit. In settings where 
various HIV diagnostic tests are used and the testing histories of subjects are documented, 
this external data could be used to inform the distributions of infection times.32 For 
example, a subject with detectable p24 antigens and undetectable antibodies at a visit 
would have been infected within the preceding few weeks [101, 180, 181]. 
As guidance for MDRI estimation is further developed, the nature of tests for recent 
infection that are expected to be used in the future should be kept in mind. For example, 
as the field moves towards tests that rely on multiple biomarkers, some methods for 
estimating the MDRI (such as those that utilise the dichotomous test classifications) 
___________________________ 
32 The inference of infection times using diagnostic testing histories is briefly explored in 
Section 4.3. 
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would be more amenable to this extension than others (such as those that model 
biomarker measurements, where many parameters would be needed to describe the 
multiple biomarkers and the relationship among them). Also, biomarkers may represent 
complex summary metrics of multiple responses, or quantify biological processes that are 
not well-understood, and thus approaches for choosing and testing parametric 
assumptions may require particular attention. Another nuance worth noting is the 
assumption of guaranteed survival until ܶ  after infection implicit in most MDRI 
estimations. This assumption may often lead to little bias in the MDRI for small values of 
ܶ, but, in settings where early mortality is high or the value of ܶ is chosen to be relatively 
large (to capture an enduring ‘recent’ state), analyses to estimate the MDRI should 
incorporate data on survival.  
It is hoped that the results presented here will help inform the design of studies, which are 
costly and challenging to conduct. For example, particularly in low HIV incidence 
settings, hundreds of HIV-negative subjects need to be followed to obtain just a handful 
of subjects who become HIV-positive. While limited resources will always restrict study 
design options, useful MDRI estimates can be obtained in a range of realistic scenarios. It 
was only in the extreme scenarios of sparse data that all methods of estimation became 
problematic. The results of this benchmarking exercise can therefore provide guidance on 
how best to direct efforts – for example, by drawing attention to the varying benefits of 
increasing the sample size versus increasing the number of visits per subject, or of having 
stringent visits times that are the same for all subjects versus allowing for variability 
among subjects.  
The simulation platform that has been developed can now be used to extend this 
benchmarking exercise, for example, to include other hypothetical scenarios, assess future 
proposed estimation procedures, or investigate confidence interval coverage. The 
simulation approach also holds the promise of extending the use of this environment to 
explore other topics related to cross-sectional incidence surveillance, particularly those 
that are intractable to being explored analytically – such as the detection of incidence 
trends in populations. 
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4.2 Redefining	Entry	into	‘Recent’	
Infection	for	More	Accurate	Test	
Characterisation	
An obstacle to accurate estimation of the MDRI is the unobservable infection times of 
subjects in the sample, where infection typically refers to detectable infection as defined 
by the HIV diagnostic test being used. As highlighted by the results in Section 4.1, 
substantial biases can arise when incorrect assumptions are made about subjects’ testing 
behaviours. Whether simply using expected infection times in analyses [95, 96, 100, 102] 
or formally accounting for their uncertainty [91, 94, 97, 101, 103], assumptions about the 
relationship between infection and visit times are inevitably required. Alternatively, 
infection times could be estimated from the observed recent infection test biomarker 
measurements [17, 92, 96, 100, 102], rather than relying on external assumptions about 
the distributions of infection times between visits. However, the extrapolation of 
biomarker readings to times earlier than the first HIV-positive visit requires assumptions 
or knowledge about the very early dynamics of the biomarker. 
An approach for redefining the ‘HIV-negative’, ‘HIV-positive and recently infected’ and 
‘HIV-positive and non-recently infected’ states is therefore proposed, and is intended to 
reduce the reliance on assumptions about testing behaviour and on extrapolation of 
biomarker readings back in time when estimating the MDRI. The concept is demonstrated 
using the data simulation platform and estimation methods that have been presented in 
Section 4.1. While the approach can be generalised, a test for recent infection based a 
single biomarker is considered below. 
The approach entails redefining the empirically observed ‘HIV-positive’ state by 
introducing a lower ‘diagnostic’ threshold on the dynamic of the biomarker for recent 
infection. In a cross-sectional survey, a subject who is classified as infected by the HIV 
diagnostic test (which may be, for example, a standard enzyme immunoassay or Western 
blot) must also return a recent infection biomarker measurement above this diagnostic 
threshold to be classified as ‘HIV-positive’ for purposes of estimating incidence. 
Effectively, an artificially less-sensitive HIV diagnostic algorithm is created. When 
estimating the MDRI from longitudinal data, benefits are gained if ‘infection’ times, 
defined consistently with the diagnostic algorithm described, can be more accurately 
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modelled. As illustrated in Figure 4.3, a subject is now ‘HIV-positive and recently 
infected’ when the biomarker measurement is between some lower threshold ௅ܻ (acting as 
a diagnostic threshold) and upper threshold ௎ܻ (distinguishing ‘recent’ from ‘non-recent’ 
infection as before), and the MDRI summarises the average time that this occurs (within 
time ܶ of entering the ‘HIV-positive’ state). 
A) Conventional definition
 
B) Alternative definition
 
Figure 4.3: Conventional and alternative definitions of the ‘HIV-negative’, ‘HIV-
positive and recently infected’ and ‘HIV-positive and non-recently infected’ states 
The three states of relevance for incidence estimation, namely the ‘HIV-negative’, ‘HIV-
positive and recently infected’ and ‘HIV-positive and non-recently infected’ states, as 
defined by the HIV diagnostic test and the biomarker for recent infection, are shown. 
In A), which illustrates the conventional definition used, a subject is ‘HIV-positive’ if 
diagnosed as infected by the HIV diagnostic test, and then ‘recently’ infected if the 
biomarker for recent infection is below a threshold ௎ܻ . In B), which illustrates the 
alternative definition of states proposed, a subject is ‘HIV-positive’ if diagnosed as 
infected by the HIV diagnostic test and the biomarker for recent infection is above a 
threshold ௅ܻ, and is then ‘recently’ infected if the biomarker is between ௅ܻ and ௎ܻ. 
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The simulation platform described in Section 4.1 was used to generate datasets, for 
estimation of the MDRI using both the conventional and alternative definitions of ‘HIV-
positive and recently infected’. Visits times for subjects were generated as in the base 
case scenario, and the distribution of infection times between HIV-negative and HIV-
positive visits (all defined according to some standard HIV diagnostic test) was tuned to 
create three scenarios which capture: (i) test-neutral behaviour where infection times were 
uniformly distributed in the infection interval (ߙ௜௡௙ ൌ ߚ ௜௡௙ ൌ 1), (ii) test-seeking 
behaviour where infection times were closer to the first HIV-positive visits on average 
(ߙ௜௡௙ ൌ 3 ,	 ߚ௜௡௙ ൌ 1 . 5 ), and (iii) test-deferring behaviour where infection times were 
closer to the last HIV-negative visits on average (ߙ௜௡௙ ൌ 1 . 5 ,	ߚ௜௡௙ ൌ 3 ). In all three 
scenarios, biomarker measurements were generated from the base case biomarker model, 
using parameters that produced a slowly evolving signal and little inter-subject variability 
(ߤപ௕=[100,250,2.7], the standard deviations of the height, scale and shape random effects 
were 5, 5 and 0.5 respectively, there was no correlation between random effects, and 
measurement noise had a constant standard deviation of 2 biomarker units).  
The MDRI was estimated by linear interpolation of biomarker readings, as described in 
Section 4.1.2 (Method 2). The average time a biomarker is between two thresholds ௅ܻ and 
௎ܻ  can be expressed as the difference between (i) the average time the biomarker is 
below ௎ܻ, and (ii) the average time the biomarker is below ௅ܻ. Therefore, conveniently, 
no modification of the estimation method was required, although it outputs an estimate of 
the average time that a biomarker is below a specified threshold (rather than between two 
thresholds). To estimate the MDRI under the conventional definition of states, the 
estimation method was applied using a threshold of ௎ܻ ൌ 60. To estimate the MDRI 
under the alternative definition of states, the estimation method was then also applied 
using a threshold of ௅ܻ ൌ 10 and the difference between the results for ௎ܻ and ௅ܻ taken. 
By design, the ‘recently’ infected state persists for less than a couple of years, and 
therefore ܶ was chosen to be large enough for the MDRI to capture all ‘recent’ results.  
Results from estimating the MDRI, from the 1 000 datasets generated for each of the 
three scenarios, are shown in Figure 4.4. Bias in estimation of the MDRI was reduced by 
moving from the conventionally-defined MDRI (biomarker readings below ௎ܻ  indicate 
‘recent’ infection) to the alternatively-defined MDRI (readings between ௅ܻ  and ௎ܻ 
indicate ‘recent’ infection). For the alternatively-defined MDRI, there was little bias 
because the vast majority of subjects (82%) had readings below ௅ܻ  at their first HIV-
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positive visits (where, for purposes of referring to the data, last HIV-negative and first 
HIV-positive visits still relate the standard HIV diagnostic test). For these subjects, the 
‘infection’ times now of interest (that is, when biomarkers exceeded ௅ܻ) were estimated 
by interpolating between observed biomarker measurements (which were one month 
apart). In other words, for the vast majority of subjects in the sample, no assumptions 
were made about when infections became detectable by the HIV diagnostic test (in the 
three month intervals between the last HIV-negative and first HIV-positive visits) nor 
was there any extrapolation of biomarker readings to times earlier than first HIV-positive 
visits. These assumption and extrapolations were unavoidable in estimation of the 
conventionally-defined MDRI. 
Figure 4.4: Box-and-whisker plots of the mean duration of recent infection point 
estimates, using conventional and alternative definitions of the ‘HIV-positive and 
recently infected’ state, in scenarios capturing different testing behaviours 
Box-and-whisker plots summarise the 1 000 point estimates for the MDRI, Ω் (days), in 
test-neutral, test-seeking and test-deferring scenarios, where the MDRI was estimated 
using each of two definitions for the ‘HIV-positive and recently infected’ state. The 
MDRI was estimated using linear interpolation (ܶ ൌ 2 years). In A), a biomarker reading 
below ௎ܻ ൌ 60  indicates ‘recent’ infection (conventional definition), while in B), a 
biomarker reading between ௅ܻ ൌ 10 and ௎ܻ ൌ 60 indicates ‘recent’ infection (alternative 
definition). For each scenario, the box and dividing line indicate the central 50% and 
median of estimates respectively, and whiskers and circles capture remaining data points 
and outliers respectively (outliers are more than 1.5 times the interquartile range away 
from the central box). The vertical black line indicates the true MDRI. 
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The definitions of the MDRI and FRR are now anchored by an ‘infection’ time that 
captures when a subject’s biomarker for recent infection crosses above the threshold ௅ܻ. 
This is familiar in design – previously, the infection time captured when some viral or 
host response (that grows after HIV transmission) crossed above some ‘detectability’ 
threshold of an HIV diagnostic test (for example, when seroconversion occurs if 
considering an antibody-based test). The differences are that a biomarker for recent 
infection produces a signal that will more slowly evolve and has a more useful dynamic 
range, compared to that of a diagnostic test, and the ‘diagnostic’ or ‘detectability’ 
threshold is set higher than necessary to detect the virus or an immune response. 
By creating a less-sensitive HIV diagnostic algorithm, a time lag is introduced to 
incidence estimation as subjects who are infected in the weeks preceding a surveillance 
survey (and therefore return biomarker measurements below ௅ܻ) would not contribute to 
the measured incidence. However, the weighting of incidence that is measured is already 
stretched over several months prior to a study, and therefore any blurring or shifting of 
this weighting over a few weeks (for suitable choices of ௅ܻ) would not be meaningful. 
Also, while it is a fine detail that relates to any definition of ‘infection’, it is possible that 
a subject can fluctuate in and out of the ‘HIV-positive’ state for some short period 
(although this is unlikely to be observed in practice given reasonable visit gaps), leading 
to some negligible blurring of the weighting function.33 
By introducing the lower threshold ௅ܻ, there is a trade-off between increased accuracy 
and decreased precision of incidence estimation. As the discussion above highlights, 
MDRI estimates become less prone to bias, and will therefore bias incidence estimates 
less. However, the state of ‘recent’ infection becomes more transient, and therefore the 
variance of incidence estimates increases (as it becomes more difficult to observe subjects 
in this state). This gain in accuracy and loss in precision would grow as the threshold ௅ܻ is 
increased, and therefore a suitable balance between these would need to be found. 
___________________________ 
33Section 2.2.1 provides some discussion about the relationship between the weighting function for 
past incidence and diagnostic sensitivity. Subtleties around the detection of HIV are noted in 
passing here merely for completeness, but the impact of these is considered to be negligible for 
the analyses presented. 
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The potential of this approach would also depend on the particular dynamics of the 
biomarker for recent infection and subjects’ visit gaps. Frequent testing is not feasible for 
the large numbers of HIV-negative subjects enrolled in a prospective study, and therefore 
frequent follow-up is typically initiated only after a subject presents as HIV-positive. To 
restrict bias in MDRI estimation, namely by reducing the reliance on assumptions about 
(standard diagnostic) infection times and on extrapolation of biomarker readings, the 
threshold ௅ܻ should be large enough for subjects’ biomarker measurements to have not 
evolved far beyond it, preferably still be well below it, at their first HIV-positive visits. It 
should also be large enough to lie above any early noisy biomarker dynamics, so that the 
evolution of the biomarker in its vicinity can be confidently modelled from the data. All 
of this needs to be achieved while keeping the value of ௅ܻ  small enough to obtain a 
suitably enduring state of ‘recent’ infection (for an appropriate choice of the upper 
threshold ௎ܻ for distinguishing between ‘recent’ and ‘non-recent’ infections). 
In principle, the framework for cross-sectional incidence estimation allows for arbitrary 
definitions of the ‘HIV-negative’, ‘HIV-positive and recently infected’ and ‘HIV-positive 
and non-recently infected’ states (although not all definitions will provide useful 
weightings of past incidence). Accurate incidence estimation then requires only that tests 
for recent infection are consistently characterised and applied in cross-sectional incidence 
studies. This illustrative analysis shows how alternative definitions of HIV diagnostic 
states and classifications of infections as ‘recent’ or ‘non-recent’ could be considered, in 
an attempt to reduce artefacts in test characterisations arising from modelling unknown 
infection times. As with estimating any parameter, there is unavoidable uncertainty in 
both MDRI and incidence estimates, and therefore any gains in accuracy should be 
viewed in the light of this sampling variability. While the dynamics of biomarkers 
developed in the future may make this approach more appealing, current experiences with 
data suggest there may be limited benefit to this strategy.  
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4.3 Estimation	of	Infection	Times	
from	Diagnostic	Testing	
Histories	
Throughout this thesis, ‘infection’ has consistently referred to ‘detectable infection’, 
which is largely sufficient for the needs at hand. In this section, some finer points about 
estimating infection times are considered, and this warrants a review of the applicable 
terminology. The time of exposure refers to the time of HIV acquisition or transmission 
(for example, during a sexual contact), while the time of infection or test conversion 
refers to when HIV becomes detectable by some HIV diagnostic test (which is typically 
only weeks after exposure). While subjects can only be tested for detectable infection in a 
study, results are dependent on the particular diagnostic test used, and therefore exposure 
provides a useful general reference event for analytical purposes. 
In a prospective study intended to generate longitudinal data for estimation of the MDRI, 
a subject’s exact time of infection is unknown, but constrained to lie between the 
subject’s last HIV-negative visit and first HIV-positive visit. When HIV exposures do not 
influence the visit times of subjects, it is reasonable to assume that infection is equally 
likely to have occurred at any time in this interval. This leads to uniform distributions or 
flat priors for the infection times [91, 94, 97, 101, 103], often summarised into expected 
infection times at the midpoints of intervals between visits  [95, 96, 100, 102]. Implicit in 
this approach is the assumption that the same HIV diagnostic test is used at all visits, and 
that no staging information is produced by the diagnostic test (that would further 
influence the analyst’s view on when a subject was infected). Furthermore, by using the 
estimated MDRI for incidence estimation, it is also assumed that the same diagnostic test 
(or one with the same sensitivity) is used in the incidence survey. This section aims to 
consider briefly these important analytical subtleties, which are overlooked in the 
literature. The estimation of exposure or infection times from subjects’ diagnostic testing 
histories is briefly explored, and the need for consistent use of diagnostic rules for both 
test characterisation and surveillance application is highlighted. 
A large number of HIV diagnostic tests have been developed, each based on the detection 
of specific components of the virus itself or specific host antibody responses (or both) 
[182]. Tests may also differ by type of specimen analysed (such as plasma, dried blood 
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spots or saliva) and whether they need to be performed in a laboratory or can be 
completed on site (‘rapid tests’). Classes of diagnostic tests that detect antibodies include 
enzyme immunoassays (EIAs) – sometimes called enzyme-linked immunosorbent assays 
(ELISAs), Western blot and immunofluorescence assays (IFAs); while those that measure 
the virus itself include assays to detect p24 antigens and nucleic-based assays to detect 
HIV ribonucleic acid (RNA). Also, to reduce diagnostic misclassification, algorithms of 
HIV diagnostic tests are often used – for example, two EIAs may be performed, and if at 
least one detects HIV infection, a confirmatory Western blot test is conducted.  
Despite the large variety of HIV diagnostics that are available and in use, in principle, the 
behaviour of any given HIV diagnostic test (or component of a diagnostic algorithm) that 
is applied to a subject who has acquired HIV can be summarised into the test sensitivity 
as a function of time since exposure. The sensitivity of a test is the probability that it 
correctly detects HIV, and is shown for a hypothetical test in Figure 4.5 (part A). It is 
possible that this function is not monotonically increasing – for example, p24 antigens 
may decline to undetectable levels after an initial period of detectability. When a subject 
(who acquires HIV at some time, during the study) is tested for HIV at a study visit, the 
result of the diagnostic test can be combined with the test’s sensitivity to infer likely HIV 
exposure times, as shown in Figure 4.5 (part B).  
Expressing this formally, the likelihood of observing the diagnostic test result ݀  at 
calendar time ݐ௧௘௦௧ (choosing an arbitrary reference time 0), as a function of the subject’s 
HIV exposure time ݑ, is  
ܮሺ݀|ݑሻ ൌ ൫ ାܲሺݐ௧௘௦௧ െ ݑሻ൯ௗ൫1 െ ାܲሺݐ௧௘௦௧ െ ݑሻ൯ଵିௗ, (4.10) 
where ݀ equals 1 if the diagnostic result is HIV-positive and 0 if it is HIV-negative, and 
ାܲሺݏሻ is the sensitivity of the test at time ݏ after HIV exposure. This concept can be 
extended to account for the subject’s full diagnostic testing history. Various HIV 
diagnostic tests (or algorithms) may be applied at each visit, and all visits times and 
individual diagnostic test results then collectively used to infer the subject’s exposure 
time, as outlined below. 
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A) Diagnostic sensitivity
 
B) Likelihood for exposure time
 
Figure 4.5: Sensitivity of a hypothetical HIV diagnostic test and implied likelihood 
function for a subject’s HIV exposure time 
In A), the sensitivity of a hypothetical HIV diagnostic test is shown as function of time 
since HIV exposure, where the test’s sensitivity is its probability of correctly detecting 
HIV. In B), the likelihood function for a subject’s exposure time is shown. This provides 
the probability of observing a result for the diagnostic test, which is applied at some 
time ݐ௧௘௦௧, as a function of the HIV exposure time, and depends on the test’s sensitivity. 
The solid and dashed curves are the likelihood functions when the observed diagnostic 
results are HIV-positive and HIV-negative respectively. 
To simplify some of the interpretations that follow, it is now assumed that a subject has a 
single time of entering the infected state (defined by some diagnostic test) and remains in 
the state thereafter (this view can be relaxed, as captured by the generality of 
Equation (4.10)). The sensitivity function is now viewed as the cumulative distribution 
function for the time from exposure to (detection of) infection. The calendar time of the 
subject’s ݆௧௛  visit is denoted by ݐ௝  and the result of diagnostic test ݇  at that visit 
(if available) by ௝݀,௞, which equals 1 if the result is HIV-positive and 0 if HIV-negative 
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(݆ ൌ 1,2, … ௝݊  and ݇ ൌ 1,2, … , ݊௞ ). First considering a particular diagnostic test ܭ , the 
likelihood of observing its results at all visits, as a function of exposure time ݑ, can be 
derived: 
ܮ൫ሼ ௝݀,௄ሽ௝|ݑ൯ ൌ ௄ܲା൫ݐ௣௢௦ െ ݑ൯ െ ௄ܲା൫ݐ௡௘௚ െ ݑ൯, (4.11) 
where ௄ܲାሺݏሻ is the sensitivity of diagnostic test ܭ at time ݏ after exposure, ݐ௣௢௦  is the 
earliest visit time where the diagnostic test produced an HIV-positive result, and ݐ௡௘௚ is 
the latest visit time where the diagnostic test produced an HIV-negative result. If there are 
no negative test results,	ݐ௡௘௚ can be set to negative infinity ൫ ௄ܲା൫ݐ௡௘௚ െ ݑ൯ ൌ 0൯ and if 
there are no positive test results, ݐ௣௢௦ can be set to positive infinity ൫ ௄ܲା൫ݐ௣௢௦ െ ݑ൯ ൌ 1൯.  
Assuming independence of diagnostic tests, the overall likelihood function for the time of 
HIV exposure ݑ is 
ܮሺݑሻ ൌ ܮ൫ሼ ௝݀,௞ሽ௝,௞|ݑ൯ ൌෑܮ൫ሼ ௝݀,௄ሽ௝|ݑ൯
௡ೖ
௄ୀଵ
, (4.12) 
where ܮ൫ሼ ௝݀,௄ሽ௝|ݑ൯ is given by Equation (4.11). 
Examples of obtaining this net likelihood function from a subject’s testing history are 
provided in Figure 4.6. In general, the lower bound for feasible exposure times is driven 
by the most-sensitive of the diagnostic tests that returned HIV-negative results, at the 
latest visit where any HIV-negative result was produced. Conversely, the upper bound for 
feasible exposure times is driven by the least-sensitive of the diagnostic tests that returned 
HIV-positive results, at the earliest visit where any HIV-positive result was produced. 
A limitation of the framework presented above is the assumption of independence of HIV 
diagnostic tests. For example, it is conceivable that the virus and host response matures 
rapidly in some subjects (resulting in relatively early detection of HIV by a number of 
diagnostic tests) and slowly in other subjects (resulting in relatively late detection by 
multiple tests). A completely general framework would capture a multivariate distribution 
for the times from exposure to (detection of) infection by various HIV diagnostic tests, 
and a similar likelihood approach could be used to infer likely exposure times. However, 
the practical use of such a framework would rely on (currently unrealistic) inputs to 
describe the relationship among multiple tests. The analysis presented above may already 
be challenging to implement without further simplifications (discussed below), as it relies 
on full specifications of tests’ sensitivity functions. 
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Figure 4.6: Likelihood functions for HIV exposure times for a number of 
hypothetical diagnostic testing histories 
Three hypothetical diagnostic testing histories and resulting likelihood functions for a 
subject’s HIV exposure time are provided. In A), presumed sensitivities of three 
diagnostic tests are shown as a function of time since exposure. In order of decreasing 
sensitivity, the three tests are an RNA-detection assay (dashed line), an EIA (solid line) 
and Western blot (dotted line). Possible testing histories for a subject are captured in 
B) to D). In each figure, the (dashed, solid and dotted) lines capture the likelihood
functions for the exposure time based on the individual diagnostic tests, and these are 
then used to obtain the overall likelihood function shown by the curve with shaded area 
(scaled to have a height of one). Diagnostic test results and the times of visits are captured 
on the x-axis. In B), the subject has a single visit with both HIV-positive and HIV-
negative results; in C), the subject has multiple test dates and diagnostic test results; and 
in D), a single diagnostic test is used and only the last HIV-negative and first HIV-
positive visits are shown. 
0
0
0.25
0.5
0.75
1
A) Diagnostic sensitivity
Time since HIV exposure
Te
st
 se
ns
iti
vi
ty
RNA
EIA
WB
0
0.25
0.5
0.75
1
EIA−
WB−
RNA+
Time of HIV exposure, u
Li
ke
lih
oo
d 
of
ex
po
su
re
 ti
m
e
L(
u
)
B) Likelihood function for exposure time, diagnostic history I
0
0.25
0.5
0.75
1
EIA− EIA−WB−
EIA+
RNA+
Li
ke
lih
oo
d 
of
ex
po
su
re
 ti
m
e
L(
u
)
Time of HIV exposure, u
C) Likelihood function for exposure time, diagnostic history II
0
0.25
0.5
0.75
1
EIA− EIA+
Li
ke
lih
oo
d 
of
ex
po
su
re
 ti
m
e
L(
u
)
Time of HIV exposure, u
D) Likelihood function for exposure time, diagnostic history III
Estimating the Mean Duration of Recent Infection II: Longitudinal Follow-Up of Infected Subjects  149 
The discussion above has been framed in terms of inferring a subject’s HIV exposure 
time from the testing history. In practice, for unbiased incidence estimation, the MDRI 
should be estimated using a definition of infection that is consistent with what is 
detectable in the incidence surveillance study. For example, if a subject’s HIV status is to 
be determined by Western blot in the surveillance survey, then the (estimated) time of 
becoming Western blot positive should be used as the infection time when analysing data 
to estimate the characteristics of the test for recent infection. The framework presented 
above (summarised by Equation (4.12)) can still be used, but now the reference time 
needs to be the time of test conversion by the diagnostic algorithm used in the incidence 
study, rather than the exposure time. In other words, ௄ܲାሺݏሻ appearing in Equation (4.11) 
should provide the sensitivity of diagnostic test ܭ at time ݏ after test conversion (when 
using the test used in the incidence study), and a likelihood function ܮሺݓሻ  for the 
appropriately-defined test conversion or infection time ݓ would be obtained.  
Given typical visit gaps (of a few months) and the much shorter times from exposure to 
infection by diagnostic tests, likelihood functions may often plateau (implying non-
unique maximum likelihood estimates of test conversion times). One approach for 
interpreting the information contained in the likelihood function is through a posterior 
distribution for the test conversion time of the subject. Using a uniform prior distribution 
for the test conversion time, its posterior distribution is proportional to the likelihood 
function (by Bayes theorem). Analyses for estimating the MDRI could make use of the 
posterior expected test conversion time, or formally incorporate the full distribution – for 
example, as prior knowledge, for purposes of sampling possible test conversion times, or 
for producing a marginal likelihood function for the MDRI model parameters [91, 94, 97, 
101, 103]. 
In the case that the same diagnostic test is used at all visits in the MDRI study (such as in 
Part D of Figure 4.6) and in the incidence study, the above analysis recovers a uniform 
posterior distribution for the test conversion time in the interval between the last HIV-
negative and first HIV-positive visits. This is the special case encountered in many of the 
published analyses [91, 94, 97, 101, 103], although one may expect that more complex 
diagnostic testing histories often arise, and therefore efforts should be made to document 
these and incorporate them into analyses. 
Given sufficient information about the sensitivities of diagnostic tests, a subject’s full 
testing history could be used to formally make inferences about the ‘infection’ time. The 
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empirical category of ‘infected’ will depend on the diagnostic algorithm, and should be 
consistent across MDRI estimation and incidence studies. Given that limited knowledge 
about the sensitivities of diagnostic tests may be available, simplifications of the 
framework presented here may be required. For example, for a diagnostic test which is 
expected to have a sensitivity that rapidly climbs from 0 to 1, after some period of 
undetectability of HIV following exposure, the test dynamic could be summarised by the 
average time from exposure to (detection of) infection, thus neglecting any inter-subject 
variability. Inputs describing these average durations could be obtained from studies that 
have assessed diagnostic test performance (for example, see [180, 181, 183-185]). In this 
case, all posterior distributions for infection times would be uniform distributions (with 
bounds determined by the data and average durations).34  
The preceding analysis also highlights that more sensitive diagnostic tests naturally 
extend the MDRI for any recent infection test. The trade-off between the added expense 
of a more sensitive diagnostic test and more precise incidence estimation from a 
(probably only very marginally) larger MDRI would need to be assessed in practice. 
___________________________ 
34This simplification for estimating the (posterior distribution of the) infection time, using a 
subject’s diagnostic testing history, is applied in the analysis presented in Chapter 5. 
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Chapter	5
 
Theory	to	Practice:	
Characterisation	of	Candidate	
Tests	for	Recent	Infection	
An important, practical application of the framework and methodology for test 
characterisation described in the previous chapters is presented here. Over the last four 
years, the Consortium for the Evaluation and Performance of HIV Incidence Assays 
(CEPHIA) has established a vast repository of specimens and produced a large volume of 
data to characterise, optimise and compare proposed tests for recent infection. The 
consortium’s first primary analysis outputs, which describe the behaviours of five 
prominent incidence assays, are presented in Section 5.1. The report is a reproduction of a 
published journal article [32].35  
___________________________ 
35  Section 5.1 presents a manuscript that has been published as: ‘Kassanjee R, Pilcher CD, 
Keating SM, Facente SN, McKinney E, Price MA, Martin JN, Little S, Hecht FM, Kallas EG, 
Welte A, Busch MP, Murphy G, on behalf of the Consortium for the Evaluation and 
Performance of HIV Incidence Assays (CEPHIA). Independent assessment of candidate HIV 
incidence assays on specimens in the CEPHIA repository. AIDS. 2014; 28(16):2439-2449’. The 
manuscript was published under the terms of the Creative Commons License Attribution-Non-
commercial No Derivative 3.0 (CCBY NCND), and therefore no permission was required from 
the publishers to reproduce the work. The manuscript was written by RK. GM, AW, CDP and 
MPB conceived the study design and sourced funding. RK and AW led the data analysis. CDP, 
SNF, SJL, MAP, JNM, EGK and FMH led on specimen acquisition and related data collection. 
GM, MPB, SMK and EM led on assay performance and quality, and assay results reporting. All 
authors assisted in the interpretation of findings, provided input and suggestions for analysis, and 
reviewed the manuscript. Funding for CEPHIA was provided by the Bill and Melinda Gates 
Foundation (grant OPP1017716). 
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5.1 Independent	Assessment	of	
Candidate	HIV	Incidence	Assays	
on	Specimens	in	the		
CEPHIA	Repository	
5.1.1 Introduction	
Reliable measurement of HIV incidence (the rate of new infections) is essential for 
monitoring the epidemic, assessing interventions and planning studies. Traditionally, 
incidence is measured by counting the number of new infections acquired in a cohort of 
subjects followed-up over time. However, such longitudinal studies are often costly, time 
consuming, and unrepresentative. Therefore, the estimation of incidence from cross-
sectional surveys, using ‘incidence assays’ that distinguish ‘recent’ from ‘non-recent’ 
infection, has attracted wide interest [9, 10, 12-14]. 
Cross-sectional surveillance is founded on the heuristic that a high prevalence of ‘recent’ 
infection indicates a high incidence [7, 15]. However, current incidence assays that 
provide a reasonably enduring state of ‘recent’ infection also tend to produce substantial 
‘false-recent’ results at large times after infection [9, 10, 12-14, 75-77, 79, 81, 112]. As 
methodology matured [11, 16-27, 29, 82, 186], a general theoretical framework was 
developed that supports the consistent analysis of ‘false-recent’ results [29].36 However, 
there have not been independent assessments of candidate assays, or consensus metrics of 
an assay’s utility for incidence estimation. 
In 2010, the Bill and Melinda Gates Foundation supported the establishment of the 
Consortium for the Evaluation and Performance of HIV Incidence Assays 
(CEPHIA) [47]. Over the last four years, CEPHIA has entered into collaborations and 
material transfer agreements to establish a large repository of valuable plasma specimens 
with sufficient clinical background data. Test developers can apply for access to a small 
___________________________ 
36The derivation of the general incidence inference framework, performed as part of earlier work, 
is presented in Chapter 2. 
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‘qualification panel’ of specimens, and, if the assay is suitably promising, the assay can 
be independently applied (by a CEPHIA laboratory) to a much larger ‘evaluation panel’. 
Results are presented below for the first five assays that have successfully passed through 
the full evaluation, namely Limiting Antigen-Avidity (LAg) [98], BED [92], Less-
Sensitive or Detuned Vitros [100], Vitros Avidity [100] and BioRad Avidity [187]. In 
principle, a test for recent infection can be arbitrarily complex in design [9, 10, 12-14], 
and can be optimised by tuning numerous parameters. The present evaluation is of tests 
for recent infection which are based on single biomarkers, termed incidence assays, 
applied according to developers’ test conditions and interpretive guidelines. Test 
optimisation, by the application of alternative thresholds in the interpretation of results, 
and using the assays in combination with one another or with supplemental markers (such 
as viral load), is ongoing. 
Translating survey counts (of HIV-negative, ‘recently’ HIV-positive and ‘non-recently’ 
HIV-positive subjects) into incidence estimates [29] requires knowledge of two test 
properties: 
 The mean duration of recent infection (MDRI), which is the average time spent
alive and ‘recently’ infected, while infected for less than some time cut-off
denoted by ܶ.
 The false-recent rate (FRR), which is the probability that a randomly chosen
subject, who is infected for longer than ܶ, will produce a ‘recent’ result.
A ‘Target Product Profile’ for tests for recent infection has been developed and attracted 
some attention [13, 14, 188], and provides a number of objectives that incidence assays 
should meet to be of utility for incidence estimation. To achieve usefully precise 
incidence estimates, in real-world household surveys in high incidence settings, an 
incidence assay should have a sufficiently enduring MDRI (of around one year) and small 
FRR (definitely less than 2%, and ideally zero). Furthermore, for feasible widespread use 
of the assay, results should be highly reproducible, and the training, equipment and 
sample type requirements should be modest.  
In this analysis, each assay’s MDRI and FRR were evaluated. As the behaviour of 
incidence assays may vary across subpopulations [75-77, 79, 189], the characteristics of 
the incidence assays in various specimen sets were also explored. 
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5.1.2 Methods	
The	CEPHIA	specimen	repository	and	the	evaluation	panel	
The CEPHIA repository is housed at Blood System Research Institute (San Francisco; 
CA) and currently consists of more than 5000 plasma specimens obtained from over 1200 
subjects. The specimens used in this analysis were obtained through collaborations with 
blood banks, and clinical research studies enrolling and following subjects over time: 
American Red Cross [190]; Blood Centers of the Pacific [191]; South African National 
Blood Service [192]; Hemocentro do São Paulo [193]; the University of California, San 
Francisco, Options study [194]; San Francisco Men’s Health Study [195]; the San Diego 
Primary Infection Cohort [196]; the multi-centre AMPLIAR cohort [197]; the multi-centre 
International AIDS Vaccine Initiative (IAVI) African Early Infection Cohort (Protocol C) 
[198]; and the University of California, San Francisco, SCOPE study [199]. 
Two ‘panels’ of specimens were created for the present purpose: a 250-member 
‘qualification panel’ for preliminary assessments (see [41] for results); and a 2500-
member ‘evaluation panel’ for the full assessments of assays showing suitable promise, 
which forms the basis of this investigation. 
The evaluation panel specimens were drawn from 928 subjects and 60% of subjects 
contributed multiple specimens over time (these subjects contributed up to 13 specimens 
and a median of 3 specimens each). Follow-up after infection ranged from 1 week to 
more than 10 years, and the median follow-up time was 3 years (for subjects with 
estimable infection dates, as discussed below). 
Laboratory	procedures	and	interpretation	of	assay	results	
Each of the five assays measures an aspect of an individual’s immune response, with 
measurements below some threshold interpreted as indicative of ‘recent’ infection.  
BED [92, 166] and LAg [98, 113, 200] (Sedia Biosciences Corporation; Portland; OR) 
were developed specifically as incidence assays by the Centers for Disease Control and 
Prevention (CDC). The immunoglobulin G (IgG) capture BED enzyme immunoassay 
(EIA) measures the proportion of IgG that is specific to HIV, and a normalised optical 
density (ODn) below 0.8 indicates ‘recent’ infection. The single-well Limiting Antigen-
Avidity EIA is responsive to the avidity of HIV-1 specific IgG, as it presents marginally 
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low concentrations of a multi-subtype recombinant HIV-1 antigen, typically affording 
just a single binding site to the multivalent IgG or IgM antibodies. While a ‘recent’/‘non-
recent’ threshold of 1.0 ODn was initially proposed, this was recently revised to 1.5 [200, 
201], following a review of the assay in which CEPHIA participated.  
Both less-sensitive Vitros (LS-Vitros) and Vitros Avidity [100] are based on the Vitros 
ECi/ECiQ Immunodiagnostic System, a chemiluminescence assay that gives a 
quantitative measure of HIV antibodies (Ortho-Clinical Diagnostics, Inc.; Rochester; 
NY). For LS-Vitros, a reported signal-to-cutoff (S/C) below 20, for a diluted specimen, is 
interpreted as a ‘recent’ result. For Vitros Avidity, the ratio of the S/C in an aliquot 
treated with a chaotropic agent (guanidine) to that in an aliquot not thus treated yields an 
avidity index (AI), and a ‘recent’/‘non-recent’ threshold of 60% is used to classify the 
infection. 
The BioRad Avidity test [187] is based on a modification of the Genetic Systems HIV-
1/HIV-2 plus O EIA (Bio-Rad Laboratories, Inc.; Hercules; CA), which involves the 
testing of each specimen in the presence and absence of a chaotropic agent 
(Diethylamine). The ratio of the reactivity of the treated to untreated aliquot produces an 
avidity index (AI), with values below 40% indicating ‘recent’ infection.  
All assays were applied according to developers’ standard operating procedures and 
package inserts [92, 98, 100, 166, 200], and protocols are available on the CEPHIA 
project website [47]. Testing was performed independently in CEPHIA laboratories, by 
technicians trained by the test developers and blinded to specimen background 
information. Three large volume ‘control’ specimens (obtained from blood donations, and 
chosen to represent a range of serological responses) were supplied to laboratory 
technicians with each panel, for regular confirmation of reproducibility and stability of 
assays. 
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Data	analysis	
All data captured within CEPHIA are stored in a (MySQL) relational database. 37 
Database queries linked assay results to the background information on subjects and 
specimens for data analysis (performed in Matlab R2013b, the MathWorks Inc.).  
Test properties were evaluated in specimen sets defined by stratifying on treatment 
history, viral load, CD4 cell count, time from infection to specimen draw, and HIV 
subtype (based on country, for the 48% of specimens which lack explicit laboratory 
subtype confirmation). The performance of assays in ‘elite controllers’ (ECs), broadly 
defined as subjects who maintain undetectable or very low HIV viral loads without 
antiretroviral therapy (ART), is of particular interest. As the SCOPE study purposefully 
recruited ECs, specimens from these subjects were analysed separately. The subjects were 
ART-naïve (or without ART for at least 6 months), with all off-treatment viral load 
measurements (HIV-1 RNA) below 200 copies/ml and at least 50% of these 
measurements below 75 copies/ml.  
The definitions of the MDRI and FRR rely on the previously mentioned construct of a 
post-infection time cut-off ܶ [29]. If ܶ is chosen to be too short, this limits the possible 
MDRI and typically raises the FRR. If ܶ is chosen to be too long, it becomes difficult to 
obtain sufficient data to characterise the test with sufficient precision over this time post 
infection, and the MDRI will also develop variation by time and place (properties 
inevitable for the FRR) rather than capture stable biological properties of the test. A cut-
off of ܶ ൌ 2 years was used throughout this analysis.  
In practice, the notion of ‘infection’ implicit in the test property definitions refers to 
‘detectable infection’ – which depends on the particular HIV diagnostic test used in the 
incidence study. In this analysis, ‘detectable infection’ was defined as the time of 
seroconversion on an HIV viral lysate-based Western blot assay. Based on a methodology 
described elsewhere,38 infection dates were estimated for the 56% of subjects who had 
recorded dates of last HIV-negative and first HIV-positive tests (not more than 120 days 
___________________________ 
37 The CEPHIA database is currently administered by David Matten of SACEMA. 
38 Members of CEPHIA have prepared a (currently unpublished) manuscript describing the work 
of CEPHIA and outlining the envisioned development pathway for new biomarkers for recent 
infection. The framework for estimating infection dates from diagnostic test data, summarised in 
the manuscript, is presented in Section 4.3. 
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apart) and descriptions of the diagnostic assays used. Average durations of Fiebig stages 
[180, 181] were used to estimate times at which subjects seroconverted (corresponding to 
entering Fiebig stage 5). Subjects with unambiguous acute retroviral syndrome (ARS) 
symptoms onset dates [202-205] between their last HIV-negative and first HIV-positive 
test dates, were estimated to seroconvert 17 days after ARS onset (based on the 
observation that the incubation period of ARS symptoms is about 14 days [206-209], and 
that the time from exposure to Western blot seroconversion averages 31 days [180, 181]). 
A number of methods can reasonably be used to estimate the MDRI, each with its own 
accuracy, precision and complexity – as explored in a separate, detailed benchmarking 
exercise [53].39 In this analysis, binomial regression was applied; this is an approach that 
was found to be robust across a number of scenarios explored in the benchmarking 
project and has been previously used for MDRI estimation [101]. The model form is 
݃ሺ ோܲሺݐሻሻ ൌ ݂ሺݐሻ , where ோܲሺݐሻ  is the probability of testing ‘recent’ at time t after 
infection, ݃ is the chosen link function and ݂ሺݐሻ contains the model parameters, which 
are estimated by a maximum likelihood approach. Results from a four-parameter model 
form are presented, where ݃  is the logit link, and ݂ሺݐሻ  is a cubic polynomial in ݐ 
(Model A). Data points more than 1.1 ൈ ܶ  post (estimated) infection were discarded 
before model fitting (Data Exclusion Rule I), with the aim of achieving the best fit of the 
model over [0,ܶ] post-infection, while avoiding diluting the data around the boundary at 
ܶ. The sensitivity of results when increasing the data exclusion cut-off to 2 ൈ ܶ (Data 
Exclusion Rule II) was also considered. Variation in results was explored when fitting 
two other model forms, namely (i) a more restrictive two-parameter model where ݃ is the 
log-log link and ݂ሺݐሻ is a linear function of lnሺݐሻ (Model B), and (ii) a flexible seven-
parameter model where ݃ is the logit link and ݂ሺݐሻ is a linear combination of the natural 
cubic spline basis functions with interior knots occurring every 3 months after infection, 
between 0 and ܶ ൌ 2 years after infection (Model C). In all cases, the MDRI, expressed 
mathematically as ׬ ோܲሺݐሻ	dݐ்଴ , was estimated using the fitted ோܲሺݐሻ ൌ ݃ିଵሺ݂ሺݐሻሻ 
(negligible mortality within ܶ post infection was assumed). 
To correctly account for the structure of the data, in the absence of explicit subject-level 
clustering in the fitted models, bootstrapping was performed by sampling subjects (not 
___________________________ 
39 The benchmarking of approaches for estimating the MDRI from longitudinal data is presented in 
Section 4.1. 
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observations) with replacement. The 2.5th and 97.5th percentiles of 10 000 MDRI estimate 
replicates provided 95% confidence interval (CI) limits [174].  
A population-level FRR is inherently dependent on the epidemiological and demographic 
history of a study population [29], and so a set of specimens, such as in the CEPHIA 
repository, can only be used to estimate the FRR in well-defined subpopulations. 
Therefore, specimens from long-infected subjects were identified (specimens drawn at 
least ܶ after the subject’s first recorded HIV-positive visit and estimated Western blot 
infection time), and the proportion of ‘recently’ infected subjects estimated in each of the 
specimen sets described above. To capture subject-level clustering, when a subject 
provided more than one result to any FRR estimate, the most frequent classification was 
used (few subjects had equal numbers of ‘recent’ and ‘non-recent’ results, and each such 
subject contributed half to the aggregate count of subjects with majority ‘recent’ 
classifications). Exact Clopper-Pearson 95% CIs [210] are provided. 
5.1.3 Results	
The incidence assay dynamics, excluding specimens from treated subjects and SCOPE 
elite controllers, are shown in Figures 5.1 to 5.3. The evolution of assay readings by time 
since infection is shown in Figure 5.1. The distribution of results for specimens drawn 
more than ܶ ൌ 2 years after infection is shown in Figure 5.2. In Figure 5.3, the proportion 
of ‘recent’ results (assay measurements below the ‘recent’/‘non-recent’ threshold) is 
plotted by time since infection and stratified by HIV subtype (A1, B, C and D). Note that 
(i) there is natural variability in biomarker maturation, leading to a significant number of 
subjects reaching the standard ‘recent’/‘non-recent’ threshold more than one year, but 
often less than two years, post infection; and (ii) there is significant delay or failure to 
achieve maturation to ‘non-recent’ status among specimens of subtypes A1 and D.  
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Figure 5.1: Spaghetti plots and box-and-whisker plots of incidence assay 
measurements observed over time after infection for LAg, BED, LS-Vitros, 
Vitros Avidity and BioRad Avidity  
Incidence assay measurements are shown as a function of (estimated) time since infection 
(years), excluding treated subjects and identified elite controllers, for A) LAg, B) BED, 
C) LS-Vitros, D) Vitros Avidity and E) BioRad Avidity (1376 data points from 418
subjects). A spaghetti plot (left) shows subjects’ trajectories, and box-and-whisker plots 
(right) show percentiles of measurements in 6-monthly intervals of time post infection 
(the central 50% and median of measurements are captured by the box and dividing line 
respectively, and whiskers and ‘+’ symbols capture remaining measurements and outliers 
respectively; there are 40-450 data points in each group). ‘Recent’/‘non-recent’ thresholds 
are shown by horizontal solid lines. 
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Figure 5.2: Distribution of incidence assay measurements for specimens from long-
infected subjects for LAg, BED, LS-Vitros, Vitros Avidity and BioRad Avidity 
The empirical distribution of incidence assay measurements for specimens drawn more 
than ܶ ൌ 2  years after infection, excluding treated subjects and identified elite 
controllers, is shown for A) LAg, B) BED, C) LS-Vitros, D) Vitros Avidity and 
E) BioRad Avidity (665 data points from 316 subjects). ‘Recent’/‘non-recent’ thresholds
are shown by vertical solid lines.  
* The peak of BioRad Avidity results at 100% is due to a large proportion of (treated and
untreated) aliquots returning the maximum possible S/C on the equipment used. 
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Figure 5.3: The proportion of ‘recent’ results stratified by time since infection and 
HIV subtype for LAg, BED, LS-Vitros, Vitros Avidity and BioRad Avidity 
The proportion of ‘recent’ results (%) as a function of time since infection (years) and 
stratifying by HIV subtype (A1, B, C and D), excluding treated subjects and identified 
elite controllers, is shown for A) LAg, B) BED, C) LS-Vitros, D) Vitros Avidity and 
E) BioRad Avidity. Circles show observed proportions and lines capture 95% confidence
intervals. Specimens are grouped by 6-monthly intervals of time since infection until 
2 years, after which all specimens are grouped together (there are 25 to 665 data points 
per group, other than for subtype D, which has fewer than 20 points 1-2 years after 
infection). 
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Table 5.1 provides estimated test properties for the various specimen sets. LAg has an 
estimated MDRI of 188 days (95% CI: 165-211), while remaining assays have MDRI 
estimates of 285 to 333 days (the CI limits range from 254 to 363 days). Results were 
insensitive (less than a 2% change in results) to whether ARS onset dates were used to 
adjust estimated infection dates, a change to Data Exclusion Rule II, and the use of 
alternative Model C. MDRI estimates increased by 2% to 4% when changing to Model B, 
which was the most sensitive to the data exclusion rules (there was a 4% to 10% increase 
in estimates when changing to Data Exclusion Rule II).  
Excluding treated subjects and SCOPE elite controllers, and analysing all remaining 
specimens drawn more than ܶ ൌ 2 years after infection, the measured FRR ranges from 
1% (95% CI: 0.3%-3%) for LAg, to 6% to 10% (95% CIs span 3% to 14%) for the 
remaining assays. 
When stratifying by time since infection, the varying persistence of ‘recent’ 
classifications across assays is evident, with LAg exhibiting the leanest tail of persistence 
of ‘recent’ infection. 
The FRR among elite controller specimens is high for all assays, and averages 25% 
(minimum of 13% to a maximum of 48% across assays). The FRR among treated subjects 
is even higher, averaging 65% (minimum of 50% to a maximum of 76% across assays). 
Further stratifying treated subjects by time from infection to treatment initiation, the FRR 
decreases as the time to treatment initiation increases: for early treatment initiation 
(within 6 months of infection) the average FRR is 84% (64% to 93%), while for later 
treatment initiation (more than 6 months after infection) it is 41% (27% to 57%). 
The FRR for subjects with low viral loads, here defined as below 75 copies/ml, is high, 
averaging 55% (41% to 69%). This is consistent with results above, as 92% of this 
specimen set is made up of specimens from the identified elite controllers and treated 
subjects (and 94% of specimens from SCOPE elite controllers and treated subjects have a 
low viral load). 
Lastly, the FRR among subjects with low CD4 cell counts, namely less than 200 cells/µl 
and acting as a proxy for AIDS identification, was relatively low, averaging 2% (0% to 
4%). Further stratifying this group by CD4 cell count (not shown) did not reveal any 
patterns. 
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Table 5.2 lists MDRI and FRR estimates by subtype. The most significant pairwise 
differences in the MDRIs were between subtype A1 and any other, on the Vitros 
platform. With one exception, notably small p-values for subtype pairwise differences in 
the FRRs involve A1 or D and a non-A1, non-D subtype, dominated by LS-Vitros, Vitros 
Avidity and BioRad Avidity results. While these initial results highlight potential subtype 
differences, a more definitive analysis (beyond the present scope) should be based on a 
large number of subtype D and A1 specimens and estimation procedures specifically 
adapted to this stratification.  
5.1.4 Discussion	
The application of cross-sectional HIV incidence surveillance, utilising tests for recent 
infection, has been hampered by the lack of high performance incidence assays and the 
lack of independent, rigorous and consistent evaluations of candidate assays [9, 10, 12-
14]. Over the last four years, CEPHIA [47] has developed a substantial repository of 
precious specimens, and begun using these specimens to characterise the most promising 
incidence assays. Results for LAg, BED, LS-Vitros, Vitros Avidity and BioRad Avidity 
are presented above. 
Assays can be evaluated against a ‘Target Product Profile’ (TPP) [13, 14, 188]: Not only 
should the technology be affordable, practical and transferable to other laboratories, but 
the mean duration of recent infection (MDRI) should be sufficiently long (of around one 
year) and the false-recent rate (FRR) small (ideally zero, and less than 2%). Results 
suggest that incidence assays continue to struggle to simultaneously achieve these two 
test property goals, with no single assay unequivocally meeting the criteria set out in the 
TPP. Compared to the increasingly used LAg assay, the other assays provide larger 
MDRIs but also higher FRRs. 
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While a stable, high-performance incidence assay should ideally produce a consistently 
small FRR, regardless of the study population, data from this work helps to understand 
some of the reasons why an assay’s performance could be unstable and FRRs may be 
large. All assays produce particularly high FRRs among elite controllers (>10%) and 
treated subjects (>50%), and the size of these subpopulations will vary by region and 
time. In a surveillance study, identifying these subjects is problematic, as there is no 
universal definition of, or test for, elite controllers, and self-reported treatment status may 
be unreliable. Furthermore, earlier initiation of treatment is associated with a higher FRR, 
in line with varying impacts of treatment on immune responses by treatment timing [72, 
78, 213]. Context strongly affects when patients begin treatment – for example, in some 
states in the USA, patients are offered treatment immediately following HIV diagnosis 
[214], while in South Africa most HIV-positive patients are unable to access treatment 
until CD4 cell counts drop below 350 copies/µl [215]. In this study, 94% of specimens 
from elite controllers and treated subjects also had a low viral load (<75 copies/ml), and 
so viral load testing provides a potential tool to screen for these high-FRR subjects – 
specimens with viral loads below an optimised threshold would be classified as ‘non-
recent’ (regardless of the incidence assay measurement). Note that such a change in the 
‘recent’ infection classification rule will also impact (reduce) the MDRI. Surveys could 
also directly test for the presence of antiretroviral drugs to identify treated subjects [216]. 
Properties for each assay have been estimated here on the standardised basis of a Western 
blot being used to identify HIV-positive subjects. However, other diagnostic screening 
tests are likely to be used in incidence studies, and the time between HIV exposure and 
reactivity on these tests can differ by several weeks [180, 181, 185]. Therefore, for 
application to incidence studies, the base case MDRI reported here would need to be 
increased or decreased – depending on the particular screening test or algorithm used in 
the study to classify a specimen as HIV-positive, and hence eligible for ‘recent’ infection 
testing.  
The results presented here should not be viewed as discouraging, as they provide a 
consistent, independent characterisation of these candidate incidence assays. Large FRRs 
continue to limit the utility of single incidence assays, and subtype-specific test behaviour 
should be further explored. This analysis provides the basis for exploring optimisation 
through such adjustments as variation of ‘recent’/‘non-recent’ thresholds, inclusion of 
supplemental tests (in particular, viral load), and the use of multiple incidence assays, all 
of which is the subject of ongoing work within and beyond CEPHIA [10, 12, 13, 86, 88, 
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101, 102]. Optimisation should also consider the time cut-off ܶ , to distinguish ‘true-
recent’ from ‘false-recent’ results. Although ܶ should be not be too large, the value of ܶ 
was increased from 1 year, as used in preliminary analyses [42], to 2 years in this 
analysis, to better capture the tails of persisting ‘recent’ results and thus reduce FRRs. 
Ongoing analyses also include the evaluation of tests for recent infection, using the 
precision of the incidence estimator as a summary performance metric [30].40 In addition, 
efforts are being made to capture more detailed information on cohorts’ diagnostic testing 
protocols and more complete testing histories of subjects, thus providing the required data 
to further refine estimated infection dates for later analyses of assay results. 
The repository of specimens and data that has been generated by CEPHIA provide a 
unique opportunity to further advance the investigation and refinement of markers of 
‘recent’ HIV infection. Specimens and datasets are well-maintained, samples sizes are 
large, specimen background information is recorded, and multiple incidence assays and 
potential supplemental tests have been applied to the same specimens. 
CEPHIA has begun testing the ‘evaluation panel’ using other assays, with the aim of 
evaluating ten incidence assays in its first phase. A second phase of CEPHIA, known as 
CEPHIA II and also funded by the Bill and Melinda Gates Foundation (BMGF), was 
launched in the beginning of 2013. Under CEPHIA II, the repository is being expanded to 
include non-plasma specimens (such as linked whole blood, oral fluid, urine and stool) 
that are being prospectively collected through collaborations with various study sites. 
CEPHIA is also supporting biomarker discovery projects funded by the BMGF and US 
National Institute of Health (NIH), with a focus on earlier steps in the development 
pathway. Further updates on CEPHIA activities can be found on the project website 
(http://www.incidence-estimation.com/page/cephia). 
___________________________ 
40The use of the precision of the incidence estimator, as a standard metric for assessing test 
performance, was formally outlined in earlier work, and is presented in Chapter 6. 
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Chapter	6	
 	
Measuring	and	Optimising	Test	
Performance		
In principle, any test for recent infection can be characterised and applied in an incidence 
surveillance study. Earlier chapters of this work have both developed the theoretical 
framework and explored the practical methodology for doing this. However, the lack of 
standard metrics for assessing the utility of recent infection tests has been an obstacle to 
test development, and therefore the measurement and optimisation of test performance 
are the focus of this final contribution of the thesis. 
While it has been increasingly recognised that tests should provide an enduring state of 
‘recent’ infection and rarely (ideally, never) return ‘recent’ results at large times post 
infection, formal metrics for trading off these two test properties have not been widely 
adopted. An appropriate metric for assessing and optimising tests for recent infection, 
namely the precision of the incidence estimator, is presented in Section 6.1, which is a 
reproduction of a published article providing guidance to developers [30].41 
As the discourse increasingly moves towards practical application, efforts are being made 
to develop high-performance biomarkers for recent infection. Some important practical 
considerations are highlighted in Section 6.2, which explores the scope of the test 
optimisation, the context-dependence of test performance, and other test design criteria of 
relevance. 
___________________________ 
41The contents of Section 6.1 have been published as: ‘Kassanjee R, McWalter TA, Welte A. 
Defining optimality of a test for recent infection for HIV incidence surveillance. AIDS Res Hum 
Retroviruses. 2014; 30(1): 45-49’. The article was reproduced with permission from AIDS 
Research and Human Retroviruses, published by Mary Ann Liebert, Inc., New Rochelle, NY. 
The manuscript was primarily written by RK, who also performed all analyses. AW and TAM 
helped conceive the ideas, reviewed the analyses, and assisted in writing the manuscript. 
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6.1 Defining	Optimality	of	a		
Test	for	Recent	Infection	for		
HIV	Incidence	Surveillance		
The measurement of HIV incidence, the rate of new infections, is essential in most 
surveillance and intervention contexts. Recognising the practical challenges presented by 
longitudinal studies, the estimation of incidence from cross-sectional surveys using tests 
for recent infection has attracted considerable interest [8-11, 14, 147, 217]. However, the 
performance and optimisation of a test that aims to categorise infections as ‘recent’ or 
‘non-recent’, specifically for population-level surveillance, requires a shift from 
conventional diagnostic thinking about test performance. 
When individual-level detection of a condition is of primary interest, sensitivity, 
specificity and predictive values are appropriate metrics of performance. These metrics 
improve as inter-subject variability decreases. However, when estimating a population-
level summary parameter, such as incidence, the appropriate performance metrics are 
accuracy and precision of the statistic measured. Here, incidence estimation utilises 
information on the average behaviour of biomarkers, and is relatively insensitive to the 
variability underlying this averaging. While the appropriate optimisation of tests for 
recent infection has been noted in passing [10, 11, 14, 147, 217], there is neither 
consensus nor guidance for developers. 
As with any diagnostic, elements of a test for recent infection may be adjusted to alter its 
performance. In the context of HIV recent infection tests, typically some quantitative host 
or viral biomarkers are measured, and the infection is categorised as ‘recent’ or ‘non-
recent’ by reference to thresholds [8-10]. For example, the widely used BED assay 
measures the proportion of HIV-specific immunoglobulin G (IgG) antibodies in total IgG, 
and a measurement below some threshold classifies the infection as ‘recent’ [107]. While 
a test may be comprised of many elements that can be varied, from the underlying 
biological processes measured to the assay platforms and specific kits, ultimately, the 
optimisation will involve the fine tuning of thresholds. 
It is increasingly recognised that the lack of high performance recent infection tests poses 
a major obstacle to the widespread implementation of cross-sectional incidence 
surveillance [14, 217]. The World Health Organisation (WHO) has maintained a WHO 
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Working Group on HIV Incidence Assays since 2006, the Consortium for the Evaluation 
and Performance of HIV Incidence Assays (CEPHIA) was established in 2010, and both 
the Bill and Melinda Gates Foundation and the National Institutes of Health have 
provided substantial funding for the development of better tests [13, 47, 52, 188, 218]. 
Given the current surge in the development of candidate tests for recent infection, it is 
important to have clarity and consensus on robust metrics of performance, and in 
particular to avoid the pitfalls of traditional diagnostic thinking. 
Prevalence, the fraction of a population with a condition, can at times be substantially 
informative about incidence. For example, for transient conditions, such as influenza, it is 
well known that near demographic equilibrium: 
Incidence ൎ PrevalenceMean duration of condition , (6.1)
where incidence is expressed as a rate of cases per person time in the entire population, 
not just per person time at risk. However, when a condition is enduring, and survival in 
the state is poorly known and evolving, as is the case with HIV, prevalence becomes 
uninformative about incidence. In this case, it makes sense to find ways of defining and 
detecting a robust early phase post infection, and using a more refined version of the 
above heuristic to infer incidence from the prevalence of ‘recent’ infection.  
Under simplistic assumptions, HIV incidence, expressed as a rate of infection per person 
time at risk, is then formally estimated, in a cross-sectional setting, by [7]:  
ܫመ ൌ ݌ோ݌ௌΩ , (6.2) 
where pR and pS are the proportions of ‘recently’ infected and susceptible or HIV-negative 
subjects in the sample, and Ω is the mean duration of recent infection. Currently available 
tests (and perhaps all conceivable tests) for recent infection present a subtle problem in 
that some individuals who have been infected for long periods of time may nevertheless 
yield spurious ‘recent’ results [77, 78, 213]. With some simplifying assumptions, it has 
been shown how this ‘false-recent’ phenomenon can be intuitively understood as 
requiring a ‘subtraction’ of the estimated number of ‘false-recent’ results from the 
observed number of ‘recent’ results [16, 17, 25, 29]. 
More recently, a very general analysis has been obtained by introducing a convenience 
time cut-off ܶ, which represents the time, post infection, after which a ‘recent’ test result 
is a ‘false-recent’ result [29]. The test properties then are (i) a false-recent rate (FRR), ߚ், 
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which is the (population-dependent) proportion of those individuals infected for more 
than time ܶ who produce ‘recent’ test results, and (ii) a somewhat subtly-defined mean 
duration of recent infection (MDRI), Ω் , which is the average time spent ‘recently’ 
infected while infected for less than ܶ  [29]. 42  Note that 1 െ ߚ்  is the (population-
dependent) specificity of the test if it aimed to identify infections that have occurred 
within the preceding period ܶ. This leads to the following incidence estimator [29]: 
ܫመ் ൌ ݌ோ െ ߚ்݌ା݌ௌ ∙ ሺΩ் െ ߚ்ܶሻ , (6.3)
which depends on the proportions of subjects in the sample who are classified as 
‘recently’ infected, HIV-positive and HIV-negative, denoted by ݌ோ, ݌ା and ݌ௌ ൌ 1 െ ݌ା, 
respectively; and the test properties, Ω் and ߚ், for a chosen time cut-off ܶ. When there 
are no ‘false-recent’ results (ߚ் ൌ 0), Equation (6.3) reduces to Equation (6.2), noting 
that Ω ൌ Ω் in the absence of an explicit time cut-off ܶ. In terms of epidemiological and 
demographic context, the applicability of Equation (6.3) requires only that the susceptible 
population size does not vary substantially over a period of duration ܶ  [29]. The 
biomarkers underlying the test for recent infection should mainly capture stable 
biological, as opposed to environmentally-dependent, factors over the period ܶ  post 
infection (that is, the MDRI should not vary significantly by context, but be a true 
property of the test) [29]. It is understood that the FRR will have contextual variability.  
Uncertainty in the incidence estimate arises from statistical fluctuations of the proportions 
of subjects in the sample in the various classes as well as from uncertain test properties. 
The uncertainty of the incidence estimator, described here by its coefficient of variation 
(ratio of standard deviation to mean), ܿ, can be approximated using the delta method [29]:  
ܿଶ ൌ 1݊ ାܲ ∙ ൬
1
ௌܲ
൅ ோܲ ேܲோሺ ோܲ െ ߚ் ାܲሻଶ൰
൅	ߪஐ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ଶ
൅ߪఉ෡೅ଶ ∙ ቆ
ேܲோΩ் െ ோܲ ∙ ሺܶ െ Ω்ሻ
ሺ ோܲ െ ߚ் ାܲሻ ∙ ሺΩ் െ ߚ்ܶሻቇ
ଶ
, (6.4)
___________________________ 
42The general framework for incidence inference, producing these definitions of the MDRI and 
FRR, was developed as part of earlier work, and is presented in Chapter 2. 
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where ோܲ 	 and ேܲோ  are the proportions of ‘recently’ and ‘non-recently’ infected 
individuals in the study population; ାܲ ൌ ோܲ ൅ ேܲோ and ௌܲ ൌ 1 െ ାܲ are the proportions 
of infected (or HIV-positive) and susceptible (or HIV-negative) individuals in the 
population; and ߪஐ෡೅  and ߪఉ෡೅  are the uncertainties (standard deviations) with which the 
test properties Ω்  and ߚ்  are measured. It is certainly possible that the normality 
assumptions intrinsic to deriving Equation (6.4) could be violated in practice, in which 
case the same underlying theory can be used as a basis for a numerically more complex 
calculation of the variance of incidence estimates, such as by bootstrap resampling 
methods [174]. Whether or not one uses Equation (6.4) to estimate the coefficient of 
variation is not fundamental to the present discussion about optimisation. 
The familiar statistical objective when estimating any parameter is to find a sample 
statistic that estimates the parameter with the greatest accuracy (least bias) and greatest 
precision (smallest variance). As shown in the general derivation of Equation (6.3) [29], 
the bias is negligible compared to variance in the epidemiologically and demographically 
relevant regime, using any reasonable test for recent infection. The remaining goal is 
therefore the minimisation of variance. The apparent bias reported by other researchers 
[27] is a result of an alternative summary parameterisation of biomarker dynamics, which 
declares the FRR to be zero. This leads to an MDRI which is complex, context-dependent 
and difficult to estimate; and hence produces a similarly context-dependent implicit 
weighting over historical incidence. 
To minimise variance, the state of ‘recent’ infection should not be too transient, so that a 
realistically sized cross-sectional survey can capture a sufficient number of ‘recent’ cases 
for the estimation of the ‘recent’ proportion to be statistically robust (and therefore the 
MDRI should be large). The larger the adjustment for ‘false-recent’ results, the greater 
the overall uncertainty arising from fluctuations of the sample proportions (and therefore 
the FRR should be small). However, the two test properties cannot be independently 
adjusted, as test modifications that increase the MDRI typically also increase the FRR. 
Hence, the central goal of test design is an optimal balance between these two properties. 
An ideal test would have a near-zero FRR and an MDRI of around a year, if considering a 
setting where one is interested in the average incidence over approximately the last year. 
Figure 6.1 illustrates this trade-off between the MDRI,	Ω், and FRR, ߚ். The contours 
show the coefficient of variation (CoV) of the incidence estimator as a function of the 
MDRI and FRR, in an example context. In the context,  HIV incidence is 1% per annum 
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and HIV prevalence is 10%, Ω்  and ߚ்  are estimated with a 5% and 30% CoV 
respectively and ܶ ൌ 1 year, and incidence is measured in a cross-sectional survey of 
5 000 subjects. Moving to the right (to a large MDRI) and down (to a low FRR) in the 
contour plot, the CoV of the incidence estimator decreases (that is, precision increases). 
For a test to begin to move into a regime of usefulness, the MDRI should be at least 6 
months and the FRR below 2% [11, 14, 188]. In the context described by the figure, this 
implies a CoV of the incidence estimator of 30%, which implies that one can be 95% 
confident of estimating the true incidence of 1% per annum as a point estimate between 
0.4% and 1.6% per annum.  
Figure 6.1: Performance of a test for recent infection as a function of test properties, 
in an example context 
The contour plot captures the coefficient of variation (CoV) of the incidence 
estimator (%), as a function of the mean duration of recent infection, Ω்  (days), and 
false-recent rate, ߚ் (%), for an example context. HIV incidence is 1% per annum and 
HIV prevalence is 10%, Ω் and ߚ் are estimated with a 5% and 30% CoV respectively 
and ܶ ൌ 1 year, and incidence is measured in a cross-sectional survey of 5 000 subjects. 
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To illustrate the optimisation of test design in a simplistic scenario, consider a biomarker 
where the reading at time ݐ after infection (years) is 
ݕሺݐሻ ൌ 1 െ expሺെ2ݐሻ ൅ 0.2 ∙ ߝ, (6.5)
where ߝ captures noise and is a standard normal random variable, and readings below 
some chosen threshold indicate ‘recent’ infection. Here, the only source of variability is 
noise in the biomarker, while in reality there is often substantial inter-subject variability, 
and effects due to immune system decline and treatment. Nevertheless, this simple model 
captures the same trade-off – that increasing the threshold increases both the MDRI and 
FRR – observed with more complex biomarker dynamics. In Figure 6.2 the precision of 
the incidence estimator is plotted as a function of test threshold, and the optimal threshold 
indicated, for an example context. In the context, there is epidemiological and 
demographic equilibrium of 1% per annum HIV incidence and 10% HIV prevalence, Ω் 
and ߚ்  are exactly known, ܶ ൌ 1  year, incidence is measured in a survey of 10 000 
subjects, and all individuals survive for (exactly) 10 years from infection. Note that the 
FRR, ߚ் , depends on the survival dynamics and epidemiological and demographic 
history of the population (up until the maximum post-infection survival time). A tool to 
calculate the CoV of the incidence estimator is available at http://www.incidence-
estimation.com/page/tools.43 
Unfortunately, there is no single test design that will be optimal in all settings. This is 
because uncertainty in incidence estimation is determined by both the dynamics of the 
recent infection test and the context-specific epidemiological and demographic history 
(captured by HIV incidence and prevalence). Therefore, a range of anticipated contexts 
should be considered in evaluating a candidate test, or in fine tuning test design. This 
context-specific performance may be discouraging and regrettably complicated, but it is 
not unique to this surveillance application: even in a conventional simplistic diagnostics 
setting, the sensitivity and specificity of a test, if these can be assumed to be context-
independent, must be combined with a contextual prevalence to determine the predictive 
value performance of the test. 
The minimisation of the variance of the incidence estimator, or maximisation of 
precision, by trading the MDRI off against the FRR, provides a completely general 
___________________________ 
43The Test Performance Calculator is part of the online ABIE v2.0 tool suite, and is described in 
Section 2.3 and Appendix A. 
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criterion for optimising test design, regardless of the complexity of the test. For example, 
there is a trend towards using multiple biomarkers in a single test for recent infection, 
where various approaches for combining the individual biomarker results to produce a 
classification could be employed. For example, the final classification could be based on 
the sum of biomarkers readings, or on the number of individual readings below 
biomarker-specific thresholds [86, 88, 95, 101, 102]. The optimal test design is that which 
provides the lowest variance of incidence estimates across intended contexts. 
Obtaining the most precise incidence estimates also consistently captures the optimisation 
that would be appropriate in studies that aim to test for differences in incidence or 
identify risk factors for HIV acquisition. Statistical tests for differences among groups 
(for example, capturing different ages, genders or social and sexual behaviours) are more 
highly powered when incidence is more precisely estimated in each group. 
Figure 6.2: Optimal threshold for a hypothetical biomarker for recent infection, for 
an example context 
The coefficient of variation (CoV) of the incidence estimator (%) is shown, as a function 
of the threshold used to distinguish between ‘recent’ and ‘non-recent’ infection, for a 
hypothetical biomarker and example context. A biomarker measurement at time ݐ (years) 
after infection is given by 1 െ expሺെ2ݐሻ ൅ 0.2 ∙ ߝ, where ߝ is a standard normal random 
variable. HIV incidence and prevalence have remained at 1% per annum and 10% 
respectively, Ω் and ߚ் are exactly known, ܶ ൌ 1 year, incidence is measured in a cross-
sectional survey of 10 000 subjects, and post-infection survival is 10 years. 
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Much of the literature introducing new tests for recent infection has attempted to assess 
their utility in terms of sensitivity and specificity [92, 109, 111, 112, 125, 187, 219]. As 
would be appropriate in the more familiar diagnostic applications, values close to 100% 
have been regarded as realistic targets, with these two measures summarised into, for 
example, Receiver Operating Characteristic (ROC) curves and the overall classification 
accuracy. However, three major obstacles are encountered when extending the use of 
these diagnostic metrics to this surveillance application. (i) Any workable definition of 
sensitivity and specificity requires a notion of truly recent infection that is defined by a 
strict threshold on time since infection, and a fully specified distribution of times since 
infection in a population. (ii) Even if thus defined, sensitivity and specificity cannot be 
accurately estimated from interval censored seroconverter data sets. (iii) Inter-subject 
variability of infection-related biomarkers naturally increase with time post infection; and 
therefore diagnostic optimisation will tend to motivate for a category of ‘recent’ infection 
restricted to the lower variability period close to infection, whereas incidence estimation 
requires the most enduring notion of ‘recent’ infection which does not bring a substantial 
false-recent rate.  
In a clinical setting there may be substantial value in having some evidence of time since 
infection, at the time of HIV diagnosis. This opens up a multitude of new questions 
beyond the scope of this discussion. Most importantly, there needs to be further work to 
support reporting and interpreting individual biomarker values, beyond a ‘recent’ or ‘non-
recent’ categorical result, and the appropriate optimisation of a test may not be the fine 
tuning of a threshold for this clinical context.  
Any evaluation and optimisation of a test for recent infection should be based on the 
specific purpose for which the test is to be used, with the current work focusing on 
incidence estimation. The goal of HIV incidence estimation from cross-sectional surveys, 
using tests for recent infection, has attracted the interest of test developers. However, the 
assessment and optimisation of these tests, for purposes of estimating a population-level 
average, requires a fundamental shift from traditional criteria for measuring performance. 
The relevant performance metric of such tests is the precision of incidence estimates 
produced in an intended context. The central goal of the test developer, then, is the 
minimisation of the variance of the incidence estimator through a trade-off between the 
mean duration of recent infection and false-recent rate. 
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6.2 Some	Important		
Practical	Considerations		
for	Test	Optimisation	
Following the development of the theoretical and methodological foundations for 
characterising and applying tests for recent infection, discourse in the field has shifted 
towards the practical application of biomarker-based incidence surveillance. Topics of 
growing interest are therefore the identification and optimisation of the most promising 
tests, and the development of improved tests. In support of these efforts, a single 
summary measure of test performance was introduced in the previous section. This 
metric, namely the precision of the incidence estimator, provides a formal framework for 
balancing the needs for a large mean duration of recent infection (MDRI) and small false-
recent (FRR). When utilising this metric in practice, a number of important 
considerations arise. The scope of the optimisation, the context-dependence of test 
performance, and other criteria for assessing tests are briefly discussed below.  
Defining	the	scope	of	the	test	optimisation	
When optimising the design of a test for recent infection, one needs to choose which rules 
or parameters capturing the test design may be varied and how. While it is important to 
allow for sufficient flexibility to achieve high test performance, this goal needs to be 
balanced with practical limitations. For one, tests based on very complex schemes may be 
difficult to understand and consistently apply in surveillance studies. Also, if there are 
many parameters that can be tuned, an exhaustive exploration of possible test designs 
may become computationally daunting and the test design becomes vulnerable to being 
over-fitted to the data at hand. Some aspects to consider when defining the scope of the 
test optimisation are therefore briefly explored.  
For an incidence assay consisting of a single quantitative measurement that increases (or 
decreases) over time after infection, one may reasonably restrict the test design to rely on 
only one parameter – namely a threshold for distinguishing between ‘recent’ and ‘non-
recent’ infections. The optimisation of the test is then straightforward, and entails finding 
the value of the threshold that maximises the precision of incidence estimates. However, 
the uncertain or poor performance of existing incidence assays has led to increasing 
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interest in tests for recent infection based on multiple markers, in which case the 
optimisation search space can become high-dimensional, large and complex.  
To illustrate this expansion of the search space, Figure 6.3 shows some possible test 
designs when using just two quantitative biomarkers, each increasing over time after 
infection. A test design specifies how to map the two quantitative readings onto 
dichotomous ‘recent’ and ‘non-recent’ classifications, and relies on a number of tuneable 
parameters. The optimisation procedure would need to select both an approach for 
mapping the measured markers onto classifications and the particular parameter values.  
More generally, for ݉ biomarkers (quantitative or otherwise), a region (possibly made up 
of a number of disjoint regions) in the ݉-dimensional space describing the ݉  results 
needs to be defined as representing ‘recent’ infection. The boundary of this region could 
be described by an arbitrarily large number of parameters, and should be optimised so 
that individuals remain within it for sufficiently enduring times after infection on average 
(large MDRI), but are rarely still within it once infected for some time, such as a couple 
of years (small FRR). Some examples of test designs for multiple biomarkers can be 
found in the literature: proposed ‘multi-assay algorithms’, which utilise a number of 
incidence assays and measures of viral load and CD4 cell counts, classify infections as 
‘recently’ acquired if each biomarker is below or above some biomarker-specific 
threshold [13, 61, 88, 89, 95, 101, 126]. Generalising this design, ‘recent’ infection may 
be identified by at least a specified number of all biomarkers being below (or above) their 
respective thresholds, as applied in the interpretation of the multiple immune responses 
produced by the Bio-Plex platform [102]. 
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Figure 6.3: Examples of test designs for two biomarkers that increase over time 
after infection 
Six possible test designs are shown for creating ‘recent’ and ‘non-recent’ infection 
classifications from two (non-negative) quantitative biomarkers (Biomarkers 1 and 2) that 
increase over time after infection. Each mapping of measurements onto classifications 
relies on at most two parameters, ܽ and ܾ. In A), a Biomarker 1 measurement below ܽ 
produces a ‘recent’ result, while in B), a Biomarker 2 measurement below ܾ produces a 
‘recent’ result. In C), both biomarker measurements must be below their corresponding 
thresholds for a ‘recent’ classification, while in D), at least one biomarker measurement 
must be below its corresponding threshold. In E), a linear combination of the readings 
below a chosen threshold indicates ‘recent’ infection (summarised here by specifying the 
two intercepts of the dividing line shown). Lastly, in F), a linear combination of the 
squares of the two readings below a chosen threshold indicates ‘recent’ infection 
(summarised here by the two intercepts of the dividing elliptical boundary). 
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It is worth noting that some familiar tests for recent infection are based on quantities that 
are themselves already summaries of multiple biomarkers. Such a test therefore captures a 
specific mapping of multi-dimensional space onto a one-dimensional quantitative metric, 
which is then used to classify infections based on a single threshold parameter. For 
example, this is the case for antibody avidity assays which measure the ratio of antibody 
signal in a sample treated with a chaotropic agent to that in an untreated sample [100, 
113, 115, 116, 119, 121]. A ratio, or ‘avidity index’, below a chosen threshold indicates 
‘recent’ infection. The interpretation of the treated and untreated sample antibody signals, 
as a region in two-dimensional space representing ‘recent’ infection, is shown in 
Figure 6.4. Also, genetic diversity assays provide summary measures of very large 
amounts of complex data that collectively describe virus heterogeneity – for example, in 
the work of Park et al [125], the assay reading is the lower 10th percentile of the 
Hamming distance distribution of sequences; and in the work of Cousins et al [220], a 
High Resolution Melting (HRM) score captures the melting peak width. 
Figure 6.4: The ‘recent’ infection region implied by a conventional ‘avidity index’ 
interpretation of two antibody signals 
A conventional avidity assay produces an ‘avidity index’, which is the ratio of antibody 
signal in a sample treated by a chaotropic agent (Biomarker 2) to that in a sample not thus 
treated (Biomarker 1), and a value of the avidity index below a chosen threshold ܾ is 
interpreted as indicating ‘recent’ infection. The figure shows the ‘recent’ and ‘non-recent’ 
infection regions of the two-dimensional space that describes the two biomarker 
measurements. 
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Importantly, an understanding of the biomarker dynamics and the relationship among 
biomarkers should be used to inform which test designs should be considered in the 
optimisation. For example, in the extreme case that one biomarker can be expressed as a 
monotonic transformation of another, there can be no benefit from using both biomarkers. 
In the case that the two biomarkers are sufficiently different (uncorrelated or orthogonal), 
the performance of a test utilising both biomarkers will depend on the test design and the 
relationship between the biomarkers. 
Continuing this example, first consider a test based on one biomarker, where a 
measurement below threshold ܽ is interpreted as indicating ‘recent’ infection (Part A in 
Figure 6.3). Then stipulating that the second biomarker measurement must also be below 
threshold ܾ for the ‘recent’ classification to be retained (Part C in Figure 6.3) would 
decrease both the MDRI and FRR (as the size of the ‘recent’ infection region is reduced). 
This test design would be best suited to two biomarkers that are closely related soon after 
infection (little impact on the MDRI), but poorly associated at large times post infection 
(large reduction in the FRR). Alternatively, stipulating that an infection is considered to 
be ‘recent’ if the first biomarker measurement is below ܽ  or the additional second 
biomarker measurement is below ܾ (Part D in Figure 6.3) would increase both the MDRI 
and FRR. This design would be suited to biomarkers that are independent soon after 
infection (large increase in the MDRI) but highly related at large times post infection 
(small increase in the FRR). In practice, the optimal choice of threshold for the first 
biomarker is likely to change once the second biomarker is introduced.  
As another example of how knowledge of individual biomarker dynamics can be used to 
select a plausible test design, consider a set of biomarkers where each aims to detect a 
different type of host immune response (capturing a particular type of antibody 
responding to a specific component of the virus). These responses may be transient, each 
growing and waning over a short and different time after infection, as captured in 
Figure 6.5 (Part A). By identifying which of these responses occur within a year or two 
after infection, and which occur later, it may be possible to construct a rule that provides 
a useful definition of ‘recent’ infection. A suitably enduring state of ‘recent’ infection 
could be obtained by requiring the detection of at least one early response, while the FRR 
could be kept low by also requiring that none of the later responses are detectable (Part B 
of Figure 6.5). 
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Figure 6.5: The dynamic of a hypothetical test for recent infection based on the 
detection of transient immune responses observed at different times after infection  
The dynamic of a hypothetical test for recent infection, based on the detection of each of 
seven transient responses, is shown. In A), the probability of detecting each response is 
shown as a function of time since infection. In B), the dynamic of the test for recent 
infection is summarised by the probability of testing ‘recently’ infected as a function of 
time since infection. A ‘recent’ classification is produced if at least one of the five earlier 
responses (solid lines in Part A) is observed, and neither of the two later responses 
(dashed lines) is observed. 
When considering a large number of complex biomarkers that are not well understood, 
more data-driven approaches may be required to inform test designs. Formal supervised 
learning methods may be considered, such as support vector machines, discriminant 
analysis, classification trees and generalised additive models. These machine learning 
techniques are used to find predictive rules – in this case, to classify an infection as 
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probably recently or non-recently acquired, based on the individual biomarkers. In 
addition to being critical of assumptions and the interpretability of the models, it is 
essential that the methods for fitting these models are appropriately adapted to this 
surveillance application. 
Supervised learning approaches conventionally seek model parameters that maximise the 
probability of a ‘correct’ classification. This frames the optimisation in terms of metrics 
that are useful for individual diagnostic settings (namely sensitivity, specificity and 
predictive values), rather than those that are directly meaningful for incidence 
surveillance (namely those capturing the precision of the incidence estimator). For 
argument’s sake, suppose that a test for recent infection is viewed as a test for identifying 
infections that have occurred in the preceding period ܶ. The ratio of the MDRI to ܶ could 
then be described as the average sensitivity of the test, specifically when the true time 
since infection is uniformly distributed between 0 and ܶ, and the FRR could be described 
as one minus the context-dependent test specificity. For incidence surveillance, a high-
performance test should then have a specificity close to 100%, but, critically, does not 
require a sensitivity close to 100%, and values larger than 50% would probably be 
difficult to achieve. This performance regime, though excellent for surveillance purposes, 
would be considered far from optimal by machine learning approaches that aim to 
maximise overall classification accuracy (and also conventionally assign the same ‘costs’ 
to ‘false-positive’ and ‘false-negative’ results). 
Another aspect of defining a test for recent infection is choosing the post-infection time 
cut-off T, separating ‘true-recent’ from ‘false-recent’ results. A larger ܶ would typically 
produce better test performance, as a larger ܶ implies a larger (or unchanged) MDRI and 
(typically, but not always) a smaller FRR. However, ܶ determines the maximum period in 
the past over which incidence is averaged, and allows for the decoupling of early test 
dynamics (summarised into the MDRI) from later dynamics which become convolved 
with the population’s epidemiological and demographic history (captured by the FRR).44 
Therefore, while ܶ should be large enough for the overwhelming majority of individuals 
to no longer return ‘recent’ results beyond ܶ after infection, it should not be chosen much 
larger than necessary to achieve this. While not envisioned as being a parameter that is 
___________________________ 
44
 The decoupling of short-term and long-term test dynamics, achieved by introducing the post-
infection time cut-off ܶ into the framework for incidence estimation, is explored in Chapter 2.  
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finely tuned during test optimisation, choosing a suitable value of ܶ  is an important 
aspect of test design. For example, a value of one, two or three years might be chosen, 
depending on the test dynamics, surveillance study objectives, and availability of test 
characterisation data. 
All of the discussion above has focused specifically on the interpretation of quantitative 
biomarker measurements to produce ‘recent’ and ‘non-recent’ classifications. Stepping 
further upstream into the development process, the optimisation of the technology that 
produces the measurements themselves should be considered. For example, tests for 
recent infection based on ‘detuned’ or ‘less-sensitive’ versions of standard HIV 
diagnostic assays were developed by modifying laboratory procedures, such as dilution 
specifications and incubation times. The modifications were introduced so that the 
measured biomarker grew more slowly over time post infection and produced a dynamic 
that supported the introduction of a threshold to distinguish ‘recent’ from ‘non-recent’ 
infection [91, 100, 104-106]. The laboratory procedures for these and other biomarkers 
for recent infection could be further modified to provide more optimal evolutions of 
quantitative measurements. 
In principle, the optimisation of a test for recent infection, aiming to maximise the 
precision of incidence estimates, could be pushed arbitrarily far back into the 
development process. However, to be practical, early test development would simply seek 
biomarkers that appear predictive of the timing of infection, and that could potentially 
produce tests for recent infection with large MDRIs and small FRRs. It is in these earlier 
development stages that simple performance targets, such as those provided by the 
‘Target Product Profile’ [13, 14, 188], are particularly useful. In fact, funding agencies 
are currently supporting the development of a collection of ‘Target Product Profiles’, 
each tailored to a particular use of a biomarker for recent infection (for example, as a 
stand-alone test for recent infection, or as part of a ‘multi-assay algorithm’ [88, 101]). It 
is only later on in the development process, when a limited number of well-defined 
parameters are to be tuned and sufficient data on test dynamics have been captured, that 
statistical analysis of the precision of the incidence estimator would be most practical and 
likely to add the most value. Even at this late stage, the scope of the optimisation should 
be carefully chosen, balancing sufficient flexibility of test design with practical needs.  
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The	context‐dependence	of	test	performance	
A subtlety when assessing the performance of tests for recent infection, based on the 
precision of the incidence estimator, is the dependence on context. The precision of the 
incidence estimator depends on (i) the size of the incidence surveillance survey, (ii) the 
proportions of HIV-negative, ‘recently’ infected and ‘non-recently’ infected subjects in 
the population, and (iii) the mean duration of recent infection (MDRI) and false-recent 
rate (FRR) and the uncertainties with which these test properties are measured (as well as 
ܶ ). The population proportions, and FRR, depend on the full epidemiological and 
demographic history of the population, convolved with the complete dynamics of the test 
for recent infection. Therefore, to assess the performance of any given test, hypothetical 
contexts need to be chosen, and should closely resemble the real-world contexts of 
interest. 
Given any hypothetical context, various approaches could then be considered for 
calculating the precision of the incidence estimator. In the extreme case, when given 
complete knowledge of the population history and test dynamics, analytical or 
simulation-based approaches could be used to translate this information into inputs to a 
calculation of the precision of the incidence estimator, which could be performed using 
general methods for estimating uncertainties, such as bootstrap resampling [174]. 
However, such approaches are impractical for a number of reasons – they require 
unrealistic inputs, the calculations are unnecessarily complicated and computer intensive, 
and it is likely that highly uncertain results will be produced (given the uncertainties in 
the inputs). Therefore, various simplifications could be used, guided by what information 
is available and the applicability of analytical approximations in a particular setting. 
For example, in the test performance calculations presented in Section 6.1 above, two 
simplifications were used. Firstly, population histories were summarised into the HIV 
prevalence and HIV incidence of the population at the time of the incidence study, where 
HIV incidence refers to the average incidence measured in the survey. Using the general 
expression for incidence (that leads to the estimator in Equation (6.3)), the population 
proportions were then calculated from the input test properties (and ܶ), HIV incidence 
and HIV prevalence. Secondly, a closed form approximation for the precision of the 
incidence estimator was used, obtained by applying the delta method and assuming 
Gaussian uncertainty in all inputs (see Equation (6.4)).   
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In the calculation of precision, the context-specific (estimated) test properties need to be 
used. While the MDRI should capture only biological dynamics of the test over ܶ after 
infection, and therefore ideally not rely on context, the FRR is expected to change by time 
and region [29, 189]. If a direct measurement of the FRR is not available for the 
population of interest (or one suitably similar), then knowledge about the population and 
test dynamics could be used to inform an FRR input. More specifically, the proportion of 
‘recent’ results produced by a test will vary by subpopulation, as highlighted by the 
results in Section 5.1. Based on views about the prevalence of these subpopulations in the 
long-infected population at the time of the survey, and the probability of ‘recent’ results 
in each subpopulation, an appropriately averaged context-specific FRR can be calculated. 
The stability of the test dynamics will determine how context-dependent the test 
properties are. For example, if test behaviour varies by HIV subtype, then the subtype-
composition of the study population needs to be taken into account. This has the 
consequence that even the MDRI can become context-dependent, and, since the 
distribution of subtypes in a population may change over time, even time-dependent. This 
limitation on transferability of test characteristics undermines key benefits of biomarker-
based cross-sectional surveillance. On the other hand, if a test for recent infection is not 
affected by factors such as subtype, and has a zero FRR in all subpopulations that could 
be considered, then the MDRI and (zero) FRR would be same in any context. Therefore, 
as more robust tests for recent infection are developed, with smaller FRRs, it is 
anticipated that the context-dependence of test properties will be reduced, making test 
performance assessment more straightforward.  
While the context-dependence of the precision of incidence estimation is unavoidable, a 
test for recent infection would be most practical if it performs well across a range of 
epidemiologically relevant contexts. While context will affect the exact value of the 
incidence estimator precision, it is expected that context will only mildly affect 
determination of the optimal design for a test (such as the choice of threshold for 
distinguishing between ‘recent’ and ‘non-recent’ infections). Also, it is important that all 
relevant uncertainties are propagated through the calculation of test performance, to avoid 
misguided over-commitment to very particular test designs – for example, a confidence 
interval for the coefficient of variation of the incidence estimator should be reported. It is 
anticipated that the optimisation procedure will indicate a space of optimal test designs 
(for a range of contexts), rather than advocate exact (context-specific) test designs, given 
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the inevitable uncertainties of and sensitivities to inputs (for example, the precision of the 
incidence estimator is sensitive to the input uncertainties in test properties).  
To demonstrate some of the ideas presented above, potential designs for a test for recent 
infection based on biomarkers measured by the Bio-Plex platform [86, 102] are compared 
in Table 6.1. The platform provides a number of measures of titre and avidity for 
antibodies responding to each of a number of specific HIV proteins. Published estimates 
of test properties (in treatment naïve populations) [102], for thirteen possible test designs 
(Tests 1 to 13), were used to estimate the coefficient of variation (CoV) of the incidence 
estimator in four hypothetical contexts (Contexts A-D in Table 6.1). The contexts capture 
different incidence and prevalence values, incidence study sizes, and uncertainties in test 
properties (and it is assumed that the published test properties can be recycled in these 
contexts). 
The relative ordering of the candidate tests, according to their performances, remains 
similar across the contexts considered. The tests based on multiple biomarkers generally 
perform similarly to one another and outperform the tests based on single biomarkers, 
with the exception of Test 1, which provides relatively high performance yet utilises only 
a single biomarker (measuring the avidity of antibodies responding to the gp160 HIV 
protein). Sometimes, when moving from one test design to another, both test properties 
improve (or worsen), and the decrease (or increase) in the CoV is then useful for 
quantifying the size of the performance gain (or loss), which can be weighed against 
factors such as changes in costs and test complexity. In other cases, the changes in the 
MDRI and FRR counteract each other (they both increase or decrease), and the direction 
of the change in the CoV then indicates which of the two effects is stronger. 
In Context D, which is the only context that accounts for uncertainties in test properties, 
the CoVs for the different test designs become more dispersed, highlighting the 
importance of correctly accounting for test property uncertainties. While a high, but 
known, FRR decreases the precision of the incidence estimator, it is the uncertainty about 
the test property that substantially penalises a test with a high FRR. 
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Biomarkers 
includedi 
Threshold/ 
ruleii 
MDRI 
(days) 
FRR 
(%) 
Coefficient of variation of 
incidence estimator (%),  
by context 
A B C D 
1 160a 25 235 1.1 22 15 15 26
2 120a 20 265 4.5 27 19 18 35
3 41a 35 224 3.4 28 20 19 37
4 66a 10 279 27.8 61 43 38 92
5 160n 5 164 0.3 24 17 17 26
6 120n 7 176 8.4 50 35 32 72
7 160n, 120n, 66a, 120a, 160a, 41a 4/6 228 0.3 20 14 15 22
8 160n, 66a, 120a, 160a, 41a 3/5 257 1.1 21 15 15 24
9 120n, 66a, 120a, 160a, 41a 3/5 264 2.3 23 16 16 28
10 160n, 120n, 120a, 160a, 41a 3/5 239 0.3 20 14 14 21
11 120n, 120a, 160a, 41a 2/4 278 3.1 23 16 16 30
12 160n, 120a, 160a, 41a 2/4 266 1.4 21 15 15 25
13 120a, 160a, 41a 2/3 250 1.4 22 15 15 26
i Lists which biomarkers are included in the test for recent infection, where each biomarker  
  identifier consists of a number that represents the HIV protein used and letter that indicates  
  whether antibody titre (n) or avidity (a) is measured 
ii If a single biomarker is used, this provides the biomarker-specific threshold (below which a 
  measurement indicates ‘recent’ infection); if multiple biomarkers are used, this indicates the   
  minimum number of biomarker measurements that must be below their biomarker-specific    
  thresholds to obtain a ‘recent’ result (out of the total number of biomarkers considered) – for 
  example, for Test 7, ‘4/6’ indicates that at least 4 out of the 6 biomarkers must return  
  measurements below their thresholds to produce a ‘recent’ result 
Table 6.1: Coefficient of variation of the incidence estimator, for thirteen potential 
tests for recent infection based on multiple biomarkers produced by the Bio-Plex 
platform, for different contexts  
The coefficient of variation of the incidence estimator (%) was calculated for each of four 
hypothetical contexts (A-D) using previously published estimates of test properties [102]. 
In Context A, HIV incidence was 1.5% per annum, HIV prevalence was 15%, the 
incidence study contained 5 000 subjects and there was no uncertainty in input test 
properties. Contexts B to D are each obtained by changing specific aspects of Context A. 
In Context B, the sample size was increased to 10 000 subjects. In Context C, HIV 
incidence and prevalence were increased to 2% per annum and 20% respectively. In 
Context D, non-zero uncertainties in test properties were accommodated – assuming a 5% 
coefficient of variation for the MDRI estimator, and that the FRR was measured as a 
binomial proportion in a sample of 500 subjects. The delta method approximation for the 
coefficient of variation of the incidence estimator was used. 
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Given the similarity of many of the CoVs, it is likely to be challenging to distinguish 
between many of these test designs (especially once uncertainties in the CoVs are 
formally accounted for). However, the scope of the optimisation could be vastly 
broadened, by allowing biomarker-specific thresholds to be tuned, considering all 
possible subsets of biomarkers for inclusion in the algorithm, and exploring other rules 
for defining the ‘recent’ region in the multi-dimensional space describing the multiple 
biomarkers. 
Throughout the discussion above, test dynamics were combined with features of 
hypothetical populations and incidence study sizes to produce measures of precision of 
the incidence estimator. It is worthwhile keeping in mind that this relationship could 
instead be used in the opposite direction, by specifying the precision and making any of 
the inputs the subject of the equation to then be solved. For example, sample sizes 
required to produce suitably powered incidence studies could be calculated to inform 
study design. Alternatively, one could solve for the test properties that provide sufficient 
precision of incidence estimation, in chosen contexts, to inform guidelines for test 
development. Similarly, one could explore in which epidemiological contexts this 
surveillance approach is of utility, given currently available tests. The context-
dependence of the performance of recent infection tests recent infection is unavoidable, 
and understanding this analytical subtlety and correctly accounting for it is an important 
aspect of optimising test design and understanding the utility of biomarker-based 
incidence surveillance.  
Other	criteria	for	assessing	recent	infection	tests	
While the variability of incidence estimates provides a sound metric for evaluating tests 
for recent infection for incidence surveillance from a theoretical point of view, this is not 
the only measure that would be considered in practice. A few examples of other criteria 
that are of importance are listed below. 
The deployment of a test for recent infection into surveillance systems should be 
logistically feasible. This is also reflected in the ‘Target Product Profile’ [13, 14, 188], 
which stipulates objectives related to the type of sample and method of sample collection 
that are required, infrastructure and training needs, and test costs. 
A central concept behind biomarker-based incidence surveillance is the transferability of 
test properties. Results should therefore be robust with regard to small variations in 
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procedures that may inevitably occur in practice. Biomarker dynamics should also be 
insensitive to factors such as HIV clade or gender, which would substantially vary across 
populations and in time, and could limit the transferability of even the MDRI. The FRR 
should ideally be close to zero in all possible subpopulations (such as treated subjects and 
elite controllers), as this would limit its variation by context.   
Results from the analysis of the precision of the incidence estimator would need to be 
weighed against practical requirements. For example, the improvement in precision 
obtained by moving from one test design to another would need to be viewed alongside 
any increase in costs or test complexity.  
Also, once a test that produces high precision incidence estimates has been identified, 
other aspects of operations research could be explored. For example, for tests that are 
based on algorithms of multiple biomarkers, where not all biomarker measurements 
always need to be known to unambiguously classify an infection, the order in which the 
biomarkers are applied could be optimised to minimise costs.  
As highlighted by the examples above, while there is now a clear framework for defining 
and estimating test properties of relevance for incidence estimation, and converting these 
into direct metrics of test performance, there are numerous operational issues (mainly 
summarised by cost and robust transferability) which also influence test selection and 
optimisation. Ongoing developments in biomarker discovery and optimisation can 
reasonably be expected to lead to meaningful improvements in availability and 
practicality of recent infection tests for surveillance. 
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Chapter 7 
 
Conclusion		
As HIV epidemics continue to sweep across nations, typically disproportionately 
affecting those most in need, governments and public health organisations continue to 
commit themselves to the fight against the virus. Monitoring the spread of HIV and 
assessing the impact of interventions require reliable and practical methods for measuring 
infection rates. In the real world, new infections occur in a population at various points in 
time through a time-dependent, stochastic process. For the purpose of mathematically 
analysing the spread of the virus, incidence is thus defined in a continuum model world as 
the risk or hazard of infection per unit time per susceptible individual.  
The measurement of this parameter is challenging as incidence is a rate, the 
consequences of which are only observable over time (rather than a state, which has a 
prevalence that can be directly estimated at any point in time). The estimation of 
incidence from single cross-sectional surveys has therefore attracted much interest: by 
application of a test for recent infection, to distinguish between ‘recently’ and ‘non-
recently’ acquired infections, the prevalence of ‘recent’ HIV infection, together with 
estimated properties of the test, may be used to infer (average past) incidence. 
This work presents a number of important theoretical and methodological advances, 
together with some practical applications and related corollaries, and addresses key 
obstacles that have been hampering the widespread use of this surveillance approach.  
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Firstly, a general theoretical framework was derived for inferring incidence from the 
cross-sectional application of a test for recent infection. 
In the derivation of the general incidence estimator, assumptions about test dynamics 
were relaxed. These assumptions were used to develop earlier estimators although they 
are known to be violated in practice. Previously used assumptions of equilibrium 
conditions were also avoided by defining the measured incidence as a particular 
weighting of past incidence, determined by the early post-infection test dynamics and 
variation in the population size over recent times. Any residual biases were explicitly 
summarised into a set of mathematical terms, which an experimenter could examine to 
assess whether a study is in a regime of utility.  
Through  the  introduction  of  a  post-infection  time  cut-off  ܶ,  completely  general 
definitions of the two test properties that are required for incidence inference emerged 
from the analysis. The mean duration of recent infection (MDRI) is the average time alive 
and classified as ‘recently’ infected while infected for less than ܶ, and the false-recent 
rate (FRR) is the probability that an individual who is infected for longer than ܶ will 
produce a ‘recent’ result.  
The general framework was compared to that of the competing school of thought, in 
which there is no cut-off ܶ and test dynamics are summarised into a single property, 
namely the MDRI [7, 15, 27]. The primary benefit of introducing ܶ and the FRR is that 
this creates a clear separation between (i) a carefully defined weighting of only recent 
incidence measured in the survey, which is loosely captured by the (stable) MDRI; and 
(ii) the full population history, which is neatly captured by the (context-dependent) FRR 
rather than obscuring the meaning of the incidence that otherwise would be measured. 
Secondly, attention was turned to estimation of a test’s MDRI: new approaches, current 
practices, and some ideas for reducing artefacts in analyses were investigated.  
To address the bottleneck in test development posed by the reliance on longitudinal 
specimens that are collected by following subjects over time, the use of alternative 
specimen sets to obtain preliminary estimates of MDRIs was formalised and 
demonstrated. Only the classification of a subject’s infection (as ‘recent’ or ‘non-recent’) 
at the time of HIV diagnosis is required, together with the time since the last HIV-
negative test. The approach is suited to settings where infection and testing times are 
approximately independent and the times between HIV tests are large. In this work, two 
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previously untapped sources of specimens, namely blood donors and subjects tested as 
part of routine surveillance, were used to perform initial test characterisations. 
Moving beyond preliminary characterisations of tests, accurate and precise MDRI 
estimates are required for use in surveillance studies. Therefore a detailed benchmarking 
of approaches for estimating the MDRI from longitudinal data was performed. Using 
simulated data, the performance of a range of methods that could be used in practice was 
thoroughly assessed in a number of modelled scenarios that capture essential features of 
what could be encountered in reality, including various underlying test dynamics, study 
designs, and subject behaviours. The dangers of neglecting noise in biomarkers or 
choosing inappropriate parametric forms were highlighted; and, while formal methods for 
analysing repeated-measures data most comprehensively captured data structures, simpler 
interpolation and regression approaches were also found to be of practical value. High 
performance of MDRI estimation was achieved across a range of realistic scenarios. 
As highlighted by the results of the benchmarking exercise, the unknown infection times 
of subjects pose a particular challenge to the accurate estimation of the MDRI from 
longitudinal data. An analysis was presented that demonstrates some benefit from 
artificially controlling, by definition, entry into the ‘HIV-positive and recently infected’ 
state, provided that times of entry into this state can be accurately estimated given 
typically available data. Also, a straightforward, general approach was outlined for 
leveraging potentially complex testing history data to obtain the most informative 
possible estimates of infection times. 
Thirdly, an important practical application, entailing the analysis of the characteristics of 
five prominent tests for recent infection, was presented. 
The analysis was performed as a member of the Consortium for the Evaluation and 
Performance of HIV Incidence Assays (CEPHIA). CEPHIA was established in 2010 as an 
independent body, tasked with fostering consensus in the field and providing clear 
guidance to the public. The analysis of the first five tests to undergo a full evaluation by 
CEPHIA represents an important milestone, and captures more than three years of 
collaborations, specimen collection, laboratory testing, and data management and analysis 
by the team – all applying stringent quality control measures which it is hoped will guide 
standards in the field. 
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The results represent the first independent and consistent characterisation of multiple 
candidate tests. The analysis provides the basis for exploring the optimisation of the tests 
(an ongoing exercise by CEPHIA and other groups), as the struggle continues to achieve 
simultaneously, for all five tests, the goals of a large MDRI and small FRR, particularly 
among virally suppressed subjects. 
Lastly, to support the ongoing development of tests for recent infection, a framework for 
measuring and optimising test performance was outlined. 
In principle, any test can be consistently characterised and applied in a surveillance study 
to obtain valid incidence estimates, and therefore a standard metric for assessing the 
utility of tests for this surveillance application was needed. The precision of the incidence 
estimator was presented as a measure for formally and consistently balancing the needs 
for a large MDRI and small FRR. The guidance aimed to counter the use of more familiar 
metrics (sensitivity, specificity and predictive values) that are suited specifically to 
individual diagnostics settings and would lead to spurious evaluations of tests for 
estimating population-level average incidence rates. 
When optimising the design of a test by maximising the precision of incidence 
estimation, a number of practical considerations arise, and some key aspects of these were 
briefly explored. The scope of any optimisation should be carefully defined – while it 
should be broad enough for high performance designs to be discovered, it should be 
suitably restricted so that the analysis remains tractable and tests are not overly 
complicated. Also, test performance is unavoidably dependent on context, and the ideal 
test would perform well across a range of epidemiologically relevant contexts. 
Importantly, the selection and optimisation of a test to be integrated into surveillance 
studies would also be influenced by operational factors, primarily related to cost and 
transferability of the technology. 
Collectively, the contributions made within this work provide essential theoretical and 
methodological foundations for the application, characterisation and optimisation of 
recent infection tests for HIV incidence surveillance. An important aspect of this research 
was the sharing of ideas – in journals, at conferences, through collaborations and at 
meetings of working groups, by providing training, and by developing online resources 
[29-50, 52, 53]. Through these efforts, this research has already had demonstrable impact 
in shaping discussion in the area and building consensus. 
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Focus in the field has now shifted towards the practical application of cross-sectional 
incidence surveillance. In March 2014, the Centers for Disease Control and Prevention 
(CDC) and US President’s Emergency Fund for AIDS Relief (PEPFAR) announced a 
funding opportunity worth 125 million US dollars for improving the monitoring of HIV 
and assessment of interventions [221]. One of the funding goals is the complete 
integration of cross-sectional HIV incidence estimation, using tests for recent infection, 
into general population-based surveillance systems in a number of resource-limited 
countries. 
Ongoing endeavours to develop and optimise candidate tests for recent infection should 
continue to be supported, as well as efforts to meticulously characterise and deploy 
chosen tests. There have been increasing funding opportunities for test developers over 
recent years [188, 218], and CEPHIA is currently supporting the work of a number of 
biomarker discovery groups. Also, more general and sophisticated analysis tools will 
need to be developed and made available, and individuals trained in their use. The tools 
should support a range of analyses that may be required, from the characterisation of 
recent infection tests to sophisticated power calculations for detecting incidence trends by 
repeating incidence studies over time. 
Tests for recent infection find application in a number of closely related areas of work, 
which are beyond the scope of this thesis. In some countries, incidence is estimated by 
applying recent infection tests to subjects who are diagnosed with HIV in health-care 
settings (rather than to HIV-positive subjects identified in a survey), using inputs about 
testing behaviours and at-risk population sizes [134-138]. Also, an area that is currently 
largely undeveloped, but is starting to attract interest, is the estimation of incidence from 
multiple sources of data – that is, by combining measurements of the prevalence of 
‘recent’ HIV infection with, for example, sentinel surveillance data and national 
household survey data. Countries have also begun using tests for recent infection in 
clinical settings, to provide individual feedback on the likely time since infection at the 
time of diagnosis [139-141]. While approaches for interpreting and reporting results still 
require much refinement, this clinical application is important as staging information 
could be used effectively to support contact-tracing and the tailoring of counselling and 
treatment plans. As all of these applications of recent infection tests, including cross-
sectional incidence surveillance, are further developed and their uptake increases, tests 
will become more marketable. Perceived profitability would be an important driver of the 
required product development.  
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This thesis has focused on estimating HIV incidence using tests for recent HIV infection. 
As a closing remark, it is possible that transient early stages of other conditions could be 
defined and their prevalence measured in surveys to infer incidence. The nuances and 
limitations of each application would need to be carefully investigated, and it will be 
interesting to explore how other conditions’ biomarkers for recent infection fit into the 
framework for application and characterisation that has been established for HIV. A 
practical challenge will be the development of suitable tests for recent infection in this 
wider context. Even for HIV, high-performance and practical recent infection tests 
continue to be sought, despite HIV being the focus over the last two decades. The 
community needs to continue to translate knowledge into practice, so that the impact of 
the presented advances in incidence surveillance can be fully realised.  
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Appendix	A	
Statistical	Expressions	
Underlying	Online	Tools	
A suite of analysis tools, called Assay-Based Incidence Estimation (ABIE) v2.0, has been 
made available online to support application of the theoretical and methodological 
frameworks presented in this work (www.incidence-estimation.com) [48].The toolset 
consists of a number of ‘calculators’, each designed to perform a particular analysis 
related to the application of tests for recent infection for incidence surveillance. The 
calculation of outputs from users’ inputs is described in this appendix. Uncertainties and 
distributions of estimators appearing in the tools are approximated using the delta 
method and other large-sample results, which are summarised in Section A1. 
Each of the remaining sections, A2 to A7, outlines the objective, inputs and 
outputs of a single calculator in the tool suite.  
The calculators in this version of the ABIE toolset are in the form of Microsoft Excel 
spreadsheets, and were designed to be particularly uncomplicated by utilising closed-form 
approximations (if not exact analytical expressions) for all calculations and the most 
straightforward test statistics (differences and ratios of incidences estimates), as discussed 
in Section 2.3. 
All inputs that are measurements of time, namely the post-infection time cut-off ܶ and the 
mean duration of recent infection (MDRI), are in units of years. The incidence rate is 
expressed as the hazard of infection per person year. A sample count is in units of 
subjects. The false-recent rate (FRR), prevalence, and the risk of infection over a 
specified period, are all dimensionless and bounded by 0 and 1. Any coefficient of 
variation (CoV) is also dimensionless.  
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A1	 Uncertainties	and	Distributions	
of	Estimators	
The approximations for the uncertainties and distributions of statistics used in the 
calculators rely on results obtained from Taylor polynomial approximations, the delta 
method and maximum likelihood theory. The main results used are summarised below. 
Three statistics appear in the calculators: the incidence estimator, the difference between 
two incidence estimators, and the ratio of two incidence estimators. Each of these 
statistics can be expressed in terms of (i) random variables contained in the vector 
ߙഫ ൌ ሾߙଵ, ߙଶ, …ߙ஺ሿ், which capture sampling variability, and (ii) fixed parameters which 
capture properties of the study population(s), test for recent infection and study design. 
The stochastic nature of the scalar statistic can therefore be fully captured by its 
representation as ݃ሺߙഫሻ. 
In all cases considered in the calculators, ߙഫ  captures variability in sample counts (of 
uninfected, ‘recently’ infected and ‘non-recently’ infected subjects) and variability in 
estimated test characteristics (the MDRI and FRR). By construct (by using conditional 
distributions), the ߙ௜  are always independent. In particular, the ߙ௜  are defined to be 
(identically and independently distributed) standard normal random variables, and this is 
expected to provide a reasonable distributional approximation, in most regimes, when 
sample sizes for the incidence study and test characterisation studies are large. It is 
recognised that a Gaussian distribution for the estimated FRR may have limited 
applicability as improved tests for recent infection are developed and FRRs become very 
small. 
To begin, the properties of the statistic can be explored by approximating the statistic by a 
first-order Taylor polynomial in ߙ௜ . A multivariate Taylor series expansion of ݃ሺߙഫሻ 
around ܧሾߙഫሿ ൌ ߙഫ଴ is given by 
݃ሺߙഫሻ ൌ ݃ሺߙഫ଴ሻ ൅ ሺߙഫ െ ߙഫ଴ሻ୘ ∙ ܦ݃ሺߙഫ଴ሻ 
൅ 12! ሺߙഫ െ ߙഫ଴ሻ
் ∙ ܦଶ݃ሺߙഫ଴ሻ ∙ ሺߙഫ െ ߙഫ଴ሻ ൅ ⋯, (A1) 
where ܦ݃ሺߙഫ଴ሻ ൌ ׏݃ሺߙഫ଴ሻ is the gradient of ݃ሺߙഫሻ evaluated at ߙഫ ൌ ߙഫ଴, 
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׏݃ሺߙഫ଴ሻ ൌ ቈ߲݃
ሺߙഫሻ
߲ߙଵ ,
߲݃ሺߙഫሻ
߲ߙଶ , … ,
߲݃ሺߙഫሻ
߲ߙ஺ ቉
்
อ
ఈഫୀఈഫబ
, (A2) 
and ܦଶ݃ሺߙഫ଴ሻ ൌ ܪ൫݃ሺߙഫ଴ሻ൯ is the Hessian matrix of ݃ሺߙഫሻ evaluated at ߙഫ ൌ ߙഫ଴, 
ൣH൫݃ሺߙഫ଴ሻ൯൧௜,௝ ൌ
߲݃ଶሺߙഫሻ
߲ߙ௜߲ߙ௝ ቤఈഫୀఈഫబ
. (A3) 
Retaining only the first two terms of the Taylor series expansion yields the following 
approximation for ݃ሺߙഫሻ: 
݃ሺߙഫሻ ൎ ݃ሺߙഫ଴ሻ ൅ ሺߙഫ െ ߙഫ଴ሻ୘ ∙ D݃ሺߙഫ଴ሻ. (A4) 
Applying the mean and variance operator on both sides of Equation (A4), in turn, 
produces the following expressions for the moments of the statistic: 
ܧሾ݃ሺߙഫሻሿ ൎ ݃ሺߙഫ଴ሻ (A5)
ܸܽݎ൫݃ሺߙഫሻ൯ ൎ D݃ሺߙഫ଴ሻ் ∙ ܸܽݎሺߙഫሻ ∙ D݃ሺߙഫ଴ሻ. (A6) 
The approximations captured by Equations (A4) to (A6) will improve as ݃ሺߙഫሻ  is 
increasingly linear in ߙഫ  near ߙഫ଴ . By introducing distributional properties for ߙഫ , the 
distributional properties of ݃ሺߙഫሻ can be explored. For normally distributed ߙ௜, it follows 
that ݃ሺߙഫሻ is also (approximately) normally distributed. 
Formally, the delta method (for example, see [148]) shows that functions of 
asymptotically multivariate-normally distributed random variables are often themselves 
asymptotically normally distributed. More specifically, if 
√݊ ∙ ሺߙഫ െ ߙഫ଴ሻ ௗ→ ܰሺ0പ, Σሻ as some sample size ݊ → ∞, (A7) 
then, for ݃ሺߙഫሻ that has a non-zero differential at ߙഫ଴,  
√݊ ∙ ൫݃ሺߙഫሻ െ ݃ሺߙഫ଴ሻ൯ ௗ→ ܰ ቀ0പ, D݃ሺߙഫ଴ሻ୘ ∙ Σ ∙ D݃ሺߙഫ଴ሻቁ as ݊ → ∞. (A8) 
Leaning on the results above, since ߙഫ is defined to have a ܰሺ0പ, ܫ஺ሻ distribution where ܫ஺ is 
an ܣ  by ܣ  identity matrix (based on the anticipated limiting distribution of ߙഫ  as all 
relevant sample sizes tend to infinity), the large-sample distribution of the statistic ݃ሺߙഫሻ 
is 
݃ሺߙഫሻ~. ܰ ቌ݃ሺ0പሻ,෍ቆ߲݃ሺߙഫሻ߲ߙ௜ ቇ
ଶ
อ
ఈഫୀ଴ഫ
஺
௜ୀଵ
ቍ. (A9)
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The large-sample approximate normality of the statistic also follows from maximum 
likelihood theory (for example, see [222]), namely from the results that (i) maximum 
likelihood estimators are asymptotically normally distributed (subject to regularity 
conditions), and (ii) functions of maximum likelihood estimators are themselves 
maximum likelihood estimators (the ‘invariance property’). The incidence estimator 
(based on Equations (2.23) and (2.25)) can be expressed as 
ܫመ் ൌ ܫመ் ൫ ෠ܲௌ, ෠ܲା, ෠ܲோ, Ω෡், ߚመ்൯ ൌ
෠ܲோ െ ߚመ் ෠ܲା
෠ܲௌ ∙ ൫Ω෡் െ ߚመ்ܶ൯ , (A10)
where ෠ܲௌ , ෠ܲା  and ෠ܲோ  are estimators for ௌܲ , ାܲ  and ோܲ , which are the proportions of 
individuals in the population who are susceptible (HIV-negative), infected and ‘recently’ 
infected respectively ( ௌܲ ൅ ାܲ ൌ 1ሻ, and Ω෡் and ߚመ் are estimators for Ω் and ߚ், which 
are the test MDRI and FRR respectively for a time cut-off ܶ. If the required inputs ( ෠ܲௌ, 
෠ܲା , ෠ܲோ , Ω෡்  and ߚመ் ) are obtained using a maximum likelihood approach (as would 
typically be the case), it follows that the incidence estimator is a maximum likelihood 
estimator, and is therefore asymptotically normally distributed. 
In the calculators, the expression provided in Equation (A9) is used to approximate the 
distribution and moments of the incidence estimator, incidence difference estimator, and 
incidence ratio estimator. In the descriptions of the calculators in the sections below, to 
obtain compact equations, uncertainty for an estimator is expressed as either a CoV (ratio 
of standard deviation to mean) or standard deviation (or the square thereof). The CoV or 
standard deviation depends on (typically) unknown parameters (population proportions, 
test characteristics, and uncertainties of test characteristic estimates) that appear in ݃ሺߙഫሻ, 
and, in all applications, the estimated (or assumed) values of these parameters are used as 
proxies of the true values so that uncertainties can be assessed. 
A2	 Incidence	Prevalence	Calculator	
Objective 
This calculator estimates HIV incidence and prevalence from the input sample counts 
observed in the cross-sectional survey and test characteristics. 
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Inputs 
 Post-infection time cut-off ܶ
 Estimated (or assumed) test characteristics
o Estimated MDRI Ω෡்
o Estimated FRR ߚመ்
o Estimated CoV of MDRI estimator ܿ̂ஐ෡೅
o Estimated CoV of FRR estimator ܿ̂ఉ෡೅
 Observed sample counts in the survey of ݊ subjects
o Number of HIV-negative subjects ݊௦  versus HIV-positive subjects ݊ା ,
where ݊ௌ ൅ ݊ା ൌ ݊
o Number of ‘recently’ infected subjects ݊ோ versus ‘non-recently’ infected
subjects ݊ேோ, where ݊ோ ൅ ݊ேோ ൌ ݊ା
HIV prevalence, ࡼା 
The point estimate for HIV prevalence is 
෠ܲା ൌ ݊ା݊ . (A11)
The limits of the 95% confidence interval for HIV prevalence, ሾ ෠ܲା,௟ , ෠ܲା,௨ሿ, are equal to 
෠ܲା,௟ ൌ ൞
0 if ݊ା ൌ 0
ݒଵ,௟ ∙ ܨሺݒଵ,௟, ݒଶ,௟ , ߙ2ሻ
ݒଶ,௟ ൅ ݒଵ,௟ ∙ ܨሺݒଵ,௟, ݒଶ,௟ , ߙ2ሻ
if ݊ା ൐ 0 (A12)
෠ܲା,௨ ൌ ൞	
ݒଵ,௨ ∙ ܨሺݒଵ,௨, ݒଶ,௨, 1 െ ߙ2ሻ
ݒଶ,௨ ൅ ݒଵ,௨ ∙ ܨሺݒଵ,௨, ݒଶ,௨, 1 െ ߙ2ሻ
if ݊ା ൏ ݊	
1 if ݊ା ൌ ݊
, (A13)
where ܨሺݒଵ, ݒଶ, ݍሻ is the lower ݍth percentile of an ܨ distribution with ݒଵ and ݒଶ degrees 
of  freedom,  ߙ ൌ 0.05,  ݒଵ,௟ ൌ 2 ∙ ݊ା,  ݒଶ,௟ ൌ 2 ∙ ሺ݊ െ ݊ା ൅ 1ሻ,  ݒଵ,௨ ൌ 2 ∙ ሺ݊ା ൅ 1ሻ  and 
ݒଶ,௨ ൌ 2 ∙ ሺ݊ െ ݊ାሻ.  This  Clopper-Pearson  ‘exact’  binomial  proportion  confidence 
interval provides a conservative coverage of least 95% [210]. 
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HIV incidence rate, ࡵࢀ 
The point estimate for the incidence rate is 
ܫመ் ൌ ݊ோ െ ߚመ்݊ା݊ௌ ∙ ൫Ω෡்െߚመ்ܶ൯ . (A14)
While the true incidence in the study population is non-negative, the incidence estimator 
can take on any real value as a result of variability in input counts and estimated test 
characteristics, as well as potential biases in inputs (for example, that may occur if test 
characteristics are estimated in populations that are not representative of the study 
population). 
The limits of the 95% confidence interval for incidence, ൣܫመ் ,௟ , ܫመ் ,௨൧, are given by 
ܫመ் ,௟ ൌ ܫመ் െ ݖଵିఈ/ଶ ∙ ܿ̂ூመ೅ ∙ ܫመ் (A15)
ܫመ் ,௨ ൌ ܫመ் ൅ ݖଵିఈ/ଶ ∙ ܿ̂ூመ೅ ∙ ܫመ் , (A16)
where  ݖ௤ ൌ Φିଵሺݍሻ  is  the  lower  ݍth  percentile  of  a  standard  normal  distribution, 
ߙ ൌ 0.05, and ܿ̂ூመ೅  is the estimated CoV of the incidence estimator. The CoV of the 
incidence estimator, ܿூመ೅ , is approximated (see Section A.1) by 
ܿ̂ூመ೅ଶ  ൌ
1
݊ ෠ܲା ∙ ൭
1
෠ܲௌ ൅
෠ܲோ ෠ܲேோ
൫ ෠ܲோ െ ߚመ் ෠ܲା൯ଶ
൱ 
൅	ߪොஐ෡೅ଶ ∙ ቆ
1
Ω෡் െ ߚመ்ܶቇ
ଶ
൅	ߪොఉ෡೅ଶ ∙ ቆ
෠ܲାΩ෡் െ ෠ܲோܶ
൫ ෠ܲோ െ ߚመ் ෠ܲା൯൫Ω෡் െ ߚመ்ܶ൯ቇ
ଶ
, (A17)
where 
෠ܲௌ ൌ 1 െ ෠ܲା ൌ ݊ௌ݊ (A18)
෠ܲା ൌ ݊ା݊
(A19)
෠ܲோ ൌ ݊ோ݊
(A20)
෠ܲேோ ൌ ݊ேோ݊
(A21)
are the estimated proportions of susceptible, infected, ‘recently’ infected and ‘non-
recently’ infected individuals in the population. 
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The result for the uncertainty of the incidence estimator was obtained by expressing 
sample counts and estimated test characteristics in terms of independently distributed 
standard normal random variables ߙ௜ (݅ ൌ 1,2,3,4) as follows (outlined in Section 2.2.2, 
but reproduced here for completeness): 
݊ௌ ൌ ݊௦ሺߙଵሻ ൌ ݊ ௌܲ ൅ ߪௌߙଵ (A22)
݊ோ ൌ ݊ோሺߙଵ, ߙଶሻ ൌ ݊ ோܲ െ ߪோߙଵ ൅ ߪோ,ேோሺߙଵሻߙଶ (A23)
݊ேோ ൌ ݊ேோሺߙଵ, ߙଶሻ ൌ ݊ ேܲோ െ ߪேோߙଵ െ ߪோ,ேோሺߙଵሻߙଶ (A24)
Ω෡் ൌ Ω෡்ሺαଷሻ ൌ Ω் ൅ ߪஐ෡೅ߙଷ (A25)
ߚመ் ൌ ߚመ்ሺߙସሻ ൌ ߚ் ൅ ߪఉ෡೅ߙସ, (A26)
where ௌܲ , ோܲ  and ேܲோ  are the proportions of susceptible, ‘recently’ infected and ‘non-
recently’ infected individuals in the population respectively; ߪஐ෡೅ and ߪఉ෡೅ are the standard 
deviations of the (unbiased) estimators for Ω் and ߚ் respectively; and  
ߪௌ ൌ ඥ݊ ௌܲ ∙ ሺ1 െ ௦ܲሻ (A27)
ߪோ ൌ ோܲோܲ ൅ ேܲோ ߪ௦ (A28)
ߪேோ ൌ ேܲோோܲ ൅ ேܲோ ߪ௦ (A29)
ߪோ,ேோሺߙሻ ൌ ඥ
ሺ݊ െ ݊ ௌܲ െ ߪௌߙ ሻ ோܲ ேܲோ
ோܲ ൅ ேܲோ .
(A30)
The resulting approximation for the CoV of the incidence estimator is 
ܿூመ೅ଶ  ൎ
1
݊ ାܲ ∙ ൬
1
ௌܲ
൅ ோܲ ேܲோሺ ோܲ െ ߚ் ାܲሻଶ൰
൅	ߪஐ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ଶ
൅	ߪఉ෡೅ଶ ∙ ൬
ାܲΩ் െ ோܲܶ
ሺ ோܲ െ ߚ் ାܲሻሺΩ் െ ߚ்ܶሻ൰
ଶ
. (A31)
In Equations (A15) to (A17), the estimated CoV, ܿ̂ூመ೅, is negative if the point estimate for 
incidence (used as a proxy for the mean estimate) is negative. 
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Annual risk of HIV infection, ࡾࢀ  
The annual risk of infection is the probability that a susceptible individual will get 
infected over the period of a year. The point estimate for this annual risk is  
෠்ܴ ൌ 1 െ exp൫െܫመ் ൯, (A32)
based on a constant hazard of infection of ܫመ்  over the year.  
The limits of the 95% confidence interval for the annual risk of infection, ൣ ෠்ܴ,௟ , ෠்ܴ,௨൧, are 
obtained by applying an equivalent transformation to the confidence interval limits for the 
incidence rate:  
෠்ܴ,௟ ൌ 1 െ exp൫െܫመ் ,௟൯   (A33)
෠்ܴ,௨ ൌ 1 െ exp൫െܫመ் ,௨൯. (A34)
A3	 Sample	Size	Calculator	
Objective 
This tool calculates the sample size required to achieve a desired precision of incidence 
estimation in a surveillance survey from the input test characteristics, epidemiological 
context, and desired precision of the incidence estimator. 
Inputs 
 Post-infection time cut-off ܶ
 Estimated (or assumed) test characteristics
o Estimated MDRI Ω෡்
o Estimated FRR ߚመ்
o Estimated CoV of MDRI estimator ܿ̂ஐ෡೅
o Estimated CoV of FRR estimator ܿ̂ఉ෡೅
 Assumed epidemiological context
o HIV incidence ܫ
o HIV prevalence ܲ
 Desired CoV of the incidence estimator ܿூመ೅
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Sample size, ࢔  
The (estimated) sample size, required to achieve the desired CoV for the incidence 
estimator, is  
෤݊ ൌ 1෨ܲା ∙ ൭
1
෨ܲௌ ൅
෨ܲோ ෨ܲேோ
൫ ෨ܲோ െ ߚመ் ෨ܲା൯ଶ
൱ ൈ 
൭ܿூመ೅ଶ െ ߪොஐ೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ଶ
െ ߪොఉ෡೅ଶ ∙ ቆ
෨ܲାΩ෡் െ ෨ܲோܶ
൫ ෨ܲோ െ ߚመ் ෨ܲା൯൫Ω෡் െ ߚመ்ܶ൯ቇ
ଶ
൱
ିଵ
(A35)
where 
෨ܲௌ ൌ 1 െ ܲ (A36)
෨ܲା ൌ ܲ (A37)
෨ܲோ ൌ ܫ ∙ ሺ1 െ ܲሻ൫Ω෡் െ ߚመ்ܶ൯ ൅ ߚመ்ܲ (A38)
෨ܲேோ ൌ ܲ െ ෨ܲோ (A39)
are the proportions of susceptible, infected, ‘recently’ infected and ‘non-recently’ infected 
individuals in the population for the input context (based on input test characteristic 
estimates). This result is obtained by solving for ݊ in the CoV of the incidence estimator 
given in Equation (A31). 
A4	 Incidence	Ratio	Calculator	
Objective  
This calculator estimates the ratio between the incidence values in two study populations, 
from input sample counts observed in the cross-sectional survey performed in each of the 
two study populations and test characteristics. Test characteristics are assumed to be the 
same in both populations. 
Inputs 
 Estimated (or assumed) test characteristics
o Estimated FRR ߚመ்
o Estimated CoV of FRR estimator ܿ̂ఉ෡೅
 Observed sample counts in the survey of ݊௞  subjects in study population ݇
(݇ ൌ 1,2)
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o Number of HIV-negative subjects ݊ௌ,௞ versus HIV-positive subjects ݊ା,௞,
where ݊ௌ,௞ ൅ ݊ା,௞ ൌ ݊௞
o Number of ‘recently’ infected subjects ݊ோ,௞  versus ‘non-recently’
infected subjects ݊ேோ,௞, where ݊ோ,௞ ൅ ݊ேோ,௞ ൌ ݊ା,௞
No knowledge of the time cut-off ܶ or MDRI is required, as the term containing ܶ and 
the MDRI appearing in the incidence estimator cancels out in the ratio of two incidence 
estimators (assuming equal values of ܶ and test characteristics in the populations). 
Incidence ratio, ࡵࡾ  
The incidence ratio, the ratio of the incidence in study population 2 to the incidence in 
study population 1, is equal to 
ܫܴ ൌ ோܰ,ଶ െ ߚ் ାܰ,ଶ
ௌܰ,ଶ ∙ ሺΩ் െ ߚ்ܶሻ ൊ
ோܰ,ଵ െ ߚ் ାܰ,ଵ
ௌܰ,ଵ ∙ ሺΩ் െ ߚ்ܶሻ 
ൌ ோܰ,ଶ െ ߚ் ାܰ,ଶ
ோܰ,ଵ െ ߚ் ାܰ,ଵ ∙
ௌܰ,ଵ
ௌܰ,ଶ
, (A40)
where ௌܰ,௞  and ାܰ,௞  are the numbers of susceptible (or uninfected) and infected 
individuals respectively, in study population ݇ (݇ ൌ 1,2) of total size ௞ܰ ൌ ௌܰ,௞ ൅ ାܰ,௞, 
and ோܰ,௞ is the number of ‘recently’ infected individuals in the population. 
The point estimate for this parameter is 
ܫ෢ܴ ൌ ݊ோ,ଶ െ ߚመ்݊ା,ଶ݊ோ,ଵ െ ߚመ்݊ା,ଵ ∙
݊ௌ,ଵ
݊ௌ,ଶ . (A41) 
The limits of the 95% confidence interval for the incidence ratio, ൣܫ෢ܴ௟, ܫ෢ܴ௨൧, are given by 
ܫ෢ܴ௟ ൌ ܫ෢ܴ െ ݖଵିఈ/ଶ ∙ ܿ̂ூோ෢ ∙ ܫ෢ܴ (A42)
ܫ෢ܴ௨ ൌ ܫ෢ܴ ൅ ݖଵିఈ/ଶ ∙ ܿ̂ூோ෢ ∙ ܫ෢ܴ, (A43)
where  ݖ௤ ൌ Φିଵሺݍሻ  is  the  lower ݍth  percentile  of  a  standard  normal  distribution, 
ߙ ൌ 0.05 and ܿ̂ூோ෢  is the estimated CoV of the incidence ratio estimator.  
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The CoV of the incidence ratio estimator, ܿூோ෢ , is estimated (see Section A.1) by: 
ܿ̂ூோ෢ଶ  ൌ
1
݊ ෠ܲା,ଵ ∙ ൭
1
෠ܲௌ,ଵ ൅
෠ܲோ,ଵ ෠ܲேோ,ଵ
൫ ෠ܲோ,ଵ െ ߚመ் ෠ܲା,ଵ൯ଶ
൱ 
൅	 1݊ ෠ܲା,ଶ ∙ ൭
1
෠ܲௌ,ଶ ൅
෠ܲோ,ଶ ෠ܲேோ,ଶ
൫ ෠ܲோ,ଶ െ ߚመ் ෠ܲା,ଶ൯ଶ
൱
൅	ߪොఉ෡೅ଶ ∙ ቆ
෠ܲା,ଵ
෠ܲோ,ଵ െ ߚመ் ෠ܲା,ଵ െ
෠ܲା,ଶ
෠ܲோ,ଶ െ ߚመ் ෠ܲା,ଶቇ
ଶ
, (A44)
where 
෠ܲௌ,௞ ൌ ݊ௌ,௞݊௞ (A45)
෠ܲା,௞ ൌ ݊ା,௞݊
(A46)
෠ܲோ,௞ ൌ ݊ோ,௞݊௞
(A47)
෠ܲேோ,௞ ൌ ݊ேோ,௞݊௞
(A48)
are the estimated proportions of susceptible, infected, ‘recently’ infected and ‘non-
recently’ infected individuals in study population ݇. 
The CoV approximation was obtained by expressing the sample counts and estimated test 
characteristics as functions of independently distributed standard normal random 
variables ߙ௜ (݅ ൌ 1,2, … 5) as follows: 
݊ௌ,ଵ ൌ ݊ௌ,ଵሺߙଵሻ ൌ ݊ଵ ௌܲ,ଵ ൅ ߪௌ,ଵߙଵ (A49)
݊ோ,ଵ ൌ ݊ோ,ଵሺߙଵ, ߙଶሻ ൌ ݊ଵ ோܲ,ଵ െ ߪோ,ଵߙଵ ൅ ߪோ,ேோ,ଵሺߙଵሻߙଶ (A50)
݊ேோ,ଵ ൌ ݊ேோ,ଵሺߙଵ, ߙଶሻ ൌ ݊ଵ ேܲோ,ଵ െ ߪேோ,ଵߙଵ െ ߪோ,ேோ,ଵሺߙଵሻߙଶ (A51)
݊ௌ,ଶ ൌ ݊ௌ,ଶሺߙଷሻ ൌ ݊ଶ ௌܲ,ଶ ൅ ߪௌ,ଶߙଷ (A52)
݊ோ,ଶ ൌ ݊ோ,ଶሺߙଷ, ߙସሻ ൌ ݊ଶ ோܲ,ଶ െ ߪோ,ଶߙଷ ൅ ߪோ,ேோ,ଶሺߙଷሻߙସ (A53)
݊ேோ,ଶ ൌ ݊ேோ,ଶሺߙଷ, ߙସሻ ൌ ݊ଶ ேܲோ,ଶ െ ߪேோ,ଶߙଷ െ ߪோ,ேோ,ଶሺߙଷሻߙସ (A54)
ߚመ் ൌ ߚመ்ሺߙହሻ ൌ ߚ் ൅ ߪఉ෡೅ߙହ, (A55)
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where ௌܲ,௞  ோܲ,௞ , ேܲோ,௞  are the proportions of susceptible, ‘recently’ infected and ‘non-
recently’ infected individuals in population ݇ respectively, ௌܲ,௞ ൅ ோܲ,௞ ൅ ேܲோ,௞ ൌ 1; ߪఉ෡೅ 
is the standard deviation of the (unbiased) estimator for ߚ்; and 
ߪௌ,௞ ൌ ට݊௞ ௌܲ,௞ ∙ ൫1 െ ௌܲ,௞൯ (A56)
ߪோ,௞ ൌ ோܲ,௞ோܲ,௞ ൅ ேܲோ,௞ ߪௌ,௞ (A57)
ߪேோ,௞ ൌ ேܲோ,௞ோܲ,௞ ൅ ேܲோ,௞ ߪௌ,௞ (A58)
ߪோ,ேோ,௞ሺߙሻ ൌ
ට൫݊௞ െ ݊௞ ௌܲ,௞ െ ߪௌ,௞ߙ൯ ோܲ,௞ ேܲோ,௞
ோܲ,௞ ൅ ேܲோ,௞ .
(A59)
The approximation for the CoV of the incidence ratio estimator that is produced is 
ܿூோ෢ଶ  ൎ
1
݊ ାܲ,ଵ ∙ ൭
1
ௌܲ,ଵ
൅ ோܲ,ଵ ேܲோ,ଵ൫ ோܲ,ଵ െ ߚ் ାܲ,ଵ൯ଶ
൱ 
൅	 1݊ ାܲ,ଶ ∙ ൭
1
ௌܲ,ଶ
൅ ோܲ,ଶ ேܲோ,ଶ൫ ோܲ,ଶ െ ߚ் ାܲ,ଶ൯ଶ
൱
൅	ߪఉ෡೅ଶ ∙ ቆ
ାܲ,ଵ
ோܲ,ଵ െ ߚ் ାܲ,ଵ െ
ାܲ,ଶ
ோܲ,ଶ െ ߚ் ାܲ,ଶቇ
ଶ
. (A60)
In Equations (A42) to (A44), the estimated CoV, ܿ̂ூோ෢ , is negative if the point estimate for 
the incidence ratio (used as a proxy for the mean estimate) is negative. 
A5	 P‐value	for	Difference	Calculator	
Objective 
This tool calculates a p-value (probability of obtaining a result as extreme as that 
observed) for the difference between incidence estimates for two study populations, under 
a hypothesis of equal HIV incidence, from input sample counts observed in the cross-
sectional survey performed in each study population and test characteristics. Test 
characteristics are the same in the two populations, and equal HIV prevalence is also 
assumed. 
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Inputs 
 Estimated (or assumed) test characteristics
o Estimated FRR ߚመ்
 Observed sample counts in the survey of ݊௞  subjects in study population ݇
(݇ ൌ 1,2)
o Number of HIV-negative subjects ݊ௌ,௞ versus HIV-positive subjects ݊ା,௞,
where ݊ௌ,௞ ൅ ݊ା,௞ ൌ ݊௞
o Number of ‘recently’ infected subjects ݊ோ,௞  versus ‘non-recently’
infected subjects ݊ேோ,௞, where ݊ோ,௞ ൅ ݊ேோ,௞ ൌ ݊ା,௞
No knowledge of the time cut-off  ܶ , MDRI, or uncertainty in test characteristics is 
required, as these parameters appear in common factors in the incidence difference or fall 
away given the particular approximations used. 
P-value for difference between incidence estimates, ࢖ 
The parameter about which inference is of interest is the incidence difference, ܫܦ, which 
is given by 
ܫܦ ൌ ܫଵ െ ܫଶ 
ோܰ,ଵ െ ߚ் ାܰ,ଵ
ௌܰ,ଵ ∙ ሺΩ் െ ߚ்ܶሻ െ
ோܰ,ଶ െ ߚ் ାܰ,ଶ
ௌܰ,ଶ ∙ ሺΩ் െ ߚ்ܶሻ ,
(A61) 
where ௌܰ,௞  and ାܰ,௞  are the numbers of susceptible (or uninfected) and infected 
individuals respectively, in study population ݇ (݇ ൌ 1,2) of size ௞ܰ ൌ ௌܰ,௞ ൅ ାܰ,௞, and 
ோܰ,௞ is the number of ‘recently’ infected individuals in the population. This parameter is 
estimated by 
ܫܦ෢  ൌ ݊ோ,ଵ െ ߚ
መ்݊ା,ଵ
݊ௌ,ଵ ∙ ሺΩ෡் െ ߚመ்ܶሻ െ
݊ோ,ଶ െ ߚመ்݊ା,ଶ
݊ௌ,ଶ ∙ ൫Ω෡் െ ߚመ்ܶ൯
ൌ 1Ω෡் െ ߚመ்ܶ ∙ ቆ
݊ோ,ଵ െ ߚመ்݊ା,ଵ
݊ௌ,ଵ െ
݊ோ,ଶ െ ߚመ்݊ା,ଶ
݊ௌ,ଶ ቇ. (A62) 
For ܫܦ෢~ܰሺܫܦ, ߪூ஽෢ଶ ሻ, the two sided p-value is 
݌ ൌ 2 ∙ ൭1 െ Φቆቤܫܦ෢ െ ܫܦ௢ߪூ஽෢,଴ ቤቇ൱, (A63)
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where Φሺ. ሻ is the cumulative distribution function of a standard normal random variable, 
and ܫܦ଴		and ߪூ஽෢,଴ଶ  are the expected value and variance of ܫܦ෢  under the null hypothesis.
Here, the null hypothesis is that HIV incidence is the same in the two populations, and 
therefore ܫܦ଴ ൌ 0. Assuming equal HIV prevalence and tests characteristics, under the 
null hypothesis the proportions of susceptible, infected, ‘recently’ infected and ‘non-
recently’ infected individuals, ௌܲ,௞, ାܲ,௞, ோܲ,௞ and ேܲோ,௞, respectively, are the same in the 
two populations. The variance of the incidence difference under the null hypothesis, 
ߪூ஽෢,଴, is estimated (see Section A.1) by: 
ߪොூ஽෢,଴ଶ 	ൌ ቆ
෠ܲோ,଴ െ ߚመ் ෠ܲା,଴
෠ܲௌ,଴ ∙ ሺΩ෡் െ ߚመ்ܶሻቇ
ଶ 1
෠ܲା,଴ ∙ ൭
1
෠ܲௌ,଴ ൅
෠ܲோ,଴ ෠ܲேோ,଴
൫ ෠ܲோ,଴ െ ߚመ் ෠ܲା,଴൯ଶ
൱ ൬ 1݊ଵ ൅
1
݊ଶ൰, (A64)
where 
෠ܲ௃,଴ ൌ ݊௃,ଵ ൅ ݊௃,ଶ݊ଵ ൅ ݊ଶ (A65)
is  the  estimated  proportion  of  individuals  in  state  ܬ,  ܬ ∈ ሼܵ, ൅, ܴ, ܴܰሽ.  Substituting 
ܫܦ଴ ൌ 0  and Equation (A64) into their corresponding terms in Equation (A63), the 
reported p-value is  
݌෤ ൌ 2 ∙ ൭1 െ Φቆቤ ܫܦ෢ߪොூ஽෢,଴ቤቇ൱. (A66)
The variance for the incidence difference was obtained by expressing sample counts and 
estimated test characteristics as functions of independently distributed standard normal 
random variables ߙ௜ (݅	 ൌ 1,2… ,6) as follows: 
݊ௌ,ଵ ൌ ݊ௌ,ଵሺߙଵሻ ൌ ݊ଵ ௌܲ,ଵ ൅ ߪௌ,ଵߙଵ (A67)
݊ோ,ଵ ൌ ݊ோ,ଵሺߙଵ, ߙଶሻ ൌ ݊ଵ ோܲ,ଵ െ ߪோ,ଵߙଵ ൅ ߪோ,ேோ,ଵሺߙଵሻߙଶ (A68)
݊ேோ,ଵ ൌ ݊ேோ,ଵሺߙଵ, ߙଶሻ ൌ ݊ଵ ேܲோ,ଵ െ ߪேோ,ଵߙଵ െ ߪோ,ேோ,ଵሺߙଵሻߙଶ (A69)
݊ௌ,ଶ ൌ ݊ௌ,ଶሺߙଷሻ ൌ ݊ଶ ௌܲ,ଶ ൅ ߪௌ,ଶߙଷ (A70)
݊ோ,ଶ ൌ ݊ோ,ଶሺߙଷ, ߙସሻ ൌ ݊ଶ ோܲ,ଶ െ ߪோ,ଶߙଷ ൅ ߪோ,ேோ,ଶሺߙଷሻߙସ (A71)
݊ேோ,ଶ ൌ ݊ேோ,ଶሺߙଷ, ߙସሻ ൌ ݊ଶ ேܲோ,ଶ െ ߪேோ,ଶߙଷ െ ߪோ,ேோ,ଶሺߙଷሻߙସ (A72)
ߚመ் ൌ ߚመ்ሺߙହሻ ൌ ߚ் ൅ ߪఉ෡೅ߙହ (A73)
Ω෡் ൌ Ω෡்ሺߙ଺ሻ ൌ Ω் ൅ ߪஐ෡೅ߙ଺, (A74)
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where ௌܲ,௞  ோܲ,௞ , ேܲோ,௞  are the proportions of susceptible, ‘recently’ infected and ‘non-
recently’ infected individuals in population ݇ respectively, ௌܲ,௞ ൅ ோܲ,௞ ൅ ேܲோ,௞ ൌ 1; ߪఉ෡೅ 
and ߪஐ෡೅  are the standard deviations of the (unbiased) estimators for ߚ்  and Ω் 
respectively; and 
ߪௌ,௞ ൌ ට݊௞ ௌܲ,௞ ∙ ൫1 െ ௌܲ,௞൯ (A75)
ߪோ,௞ ൌ ோܲ,௞ோܲ,௞ ൅ ேܲோ,௞ ߪௌ,௞ (A76)
ߪேோ,௞ ൌ ேܲோ,௞ோܲ,௞ ൅ ேܲோ,௞ ߪௌ,௞ (A77)
ߪோ,ேோ,௞ሺߙሻ ൌ
ට൫݊௞ െ ݊௞ ௌܲ,௞ െ ߪௌ,௞ߙ൯ ோܲ,௞ ேܲோ,௞
ோܲ,௞ ൅ ேܲோ,௞ .
(A78)
The delta method then provides the following approximation for the variance of ܫܦ෢ :  
ߪூ஽෢ଶ  ൎ ቆ ோܲ,ଵ
െ ߚ் ାܲ,ଵ
ௌܲ,ଵ ∙ ሺΩ் െ ߚ்ܶሻቇ
ଶ 1
݊ଵ ାܲ,ଵ ∙ ൭
1
ௌܲ,ଵ
൅ ோܲ,ଵ ேܲோ,ଵ൫ ோܲ,ଵ െ ߚ் ାܲ,ଵ൯ଶ
൱ 
൅ቆ ோܲ,ଶ െ ߚ் ାܲ,ଶ
ௌܲ,ଶ ∙ ሺΩ் െ ߚ்ܶሻቇ
ଶ 1
݊ଶ ାܲ,ଶ ∙ ൭
1
ௌܲ,ଶ
൅ ோܲ,ଶ ேܲோ,ଶ൫ ோܲ,ଶ െ ߚ் ାܲ,ଶ൯ଶ
൱ 
൅	ߪஐ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ସ
ቆ ோܲ,ଵ െ ߚ் ାܲ,ଵ
ௌܲ,ଵ
െ ோܲ,ଶ െ ߚ் ାܲ,ଶ
ௌܲ,ଶ
ቇ
ଶ
൅	ߪఉ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ସ
ቆ ାܲ,ଵΩ் െ ோܲ,ଵܶ
ௌܲ,ଵ
െ ାܲ,ଶΩ் െ ோܲ,ଶܶ
ௌܲ,ଶ
ቇ
ଶ
. (A79)
This tool aims to provide a simple interpretation of an observed difference between two 
incidence estimates. However, the statistic used to test for a difference in incidence 
should be optimised. Under the assumption of equal HIV prevalence and test 
characteristics, fluctuations in observed HIV prevalence or the estimated test 
characteristics create unnecessary variability in the incidence difference, and the 
difference between the proportions of ‘recently’ infected individuals among those 
individuals who are infected, which directly captures differences in only incidence, could 
instead be considered.  
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A6	 Power	to	Detect	Difference	
Calculator	
Objective 
This tool calculates the ‘power’ to correctly reject the null hypothesis of equal incidence 
in two study populations, when considering the difference between two incidence 
estimates, from input test characteristics, epidemiological context, sample sizes for the 
incidence surveys that would be performed in the study populations, and the significance 
level used for testing for a difference in incidence. Test characteristics are the same in the 
two populations, and equal HIV prevalence is also assumed. 
Inputs 
 Post-infection time cut-off ܶ
 Estimated (or assumed) test characteristics45
o Estimated MDRI Ω෡்
o Estimated FRR ߚመ்
o Estimated CoV of MDRI estimator ܿ̂ஐ෡೅
o Estimated CoV of FRR estimator ܿ̂ఉ෡೅
 Assumed epidemiological context
o HIV incidence I௞ in study population ݇	ሺ݇ ൌ 1,2), where ܫଵ ൐ ܫଶ
o HIV prevalence ܲ (the same in both populations)
 The survey size ݊௞ in study population ݇	ሺ݇ ൌ 1,2)
 Significance level ߙ
‘Power’ to reject null hypothesis of equal incidence, ࣖ 
This calculator is closely related to the P-value for Difference Calculator described in 
Section A5. The parameter about which inference is of interest is again the incidence 
difference, provided in Equation (A61), and the estimator for the parameter and its 
uncertainty are provided in Equations (A62) and (A79) respectively. While a p-value 
___________________________ 
45The current version of the calculator assumes ܿ̂ஐ෡೅ ൌ 0 and ܿ̂ఉ෡೅ ൌ 0, but these uncertainties are
explicitly accounted for here, for completeness.  
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(probability of obtaining a difference as extreme as that observed, under a null hypothesis 
of equal incidence) was previously calculated, here an inferential ‘power’ (probability of 
obtaining a small p-value in an assumed context where the null hypothesis is in fact false) 
is provided. This tool aims to calculate the probability of correct inference, or, more 
specifically, the probability of both 
(i) rejecting the null hypothesis of equal incidence in a two-tailed hypothesis test 
based on the incidence difference (that is, observing a two-sided p-value 
below the specified significance level); and  
(ii) observing an incidence difference in the correct direction (that is, obtaining a 
higher incidence estimate for population 1 than for population 2).  
The ‘power’ defined here would be smaller than the power conventionally calculated in 
statistics, which captures the probability of (i) above alone. The decrease in ‘power’ is 
expected to be negligible, unless the difference between incidence values in the two study 
populations is particularly small. 
For ܫܦ෢~ܰሺܫܦ, ߪூ஽෢ሻ, the ‘power’ is given by: 
ߴ ൌ ܲ ቆூ஽෢ିூ஽బఙ಺ವ෢,బ ൐ ݖଵିఈ/ଶቤ ܫܦ෢~ܰ൫ܫܦଵ, ߪூ஽෢,ଵ
ଶ ൯ቇ
ൌ Φቆݖଵିఈ/ଶߪூ஽෢,଴ ൅ ܫܦ଴ െ ܫܦଵߪூ஽෢,ଵ ቇ, (A80)
where Φሺ. ሻ is the cumulative distribution function of a standard normal random variable, 
ݖ௤ ൌ Φିଵሺݍሻ is the lower ݍth percentile of the standard normal distribution, ܫܦ଴ ൌ 0 and 
ߪூ஽෢,଴ଶ  are the (presumed) expected value and variance of the incidence difference
estimator under the null hypothesis of equal incidence, and ܫܦଵ and ߪூ஽෢,ଵଶ  are the expected
value and variance of the incidence difference estimator in reality. 
For the input epidemiological context, in reality, the proportions of uninfected, infected, 
‘recently’ infected and ‘non-recently’ infected individuals in population ݇ (݇ ൌ 1,2) are 
෨ܲௌ,௞ ൌ 1 െ ܲ (A81)
෨ܲା,௞ ൌ ܲ (A82)
෨ܲோ,௞ ൌ ܫ௞ ∙ ሺ1 െ ܲሻ൫Ω෡் െ ߚመ்ܶ൯ ൅ ߚመ்ܲ (A83)
෨ܲேோ,௞ ൌ ܲ െ ෨ܲோ,௞. (A84)
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The variance of the incidence difference estimator in reality, ߪூ஽෢,ଵଶ , is therefore estimated 
by 
ߪ෤ூ஽෢,ଵଶ  ൌ ቆ
෨ܲோ,ଵ െ ߚመ் ෨ܲା,ଵ
෨ܲௌ,ଵ ∙ ሺΩ෡் െ ߚመ்ܶሻቇ
ଶ 1
݊ଵ ෨ܲା,ଵ ∙ ൭
1
෨ܲௌ,ଵ ൅
෨ܲோ,ଵ ෨ܲேோ,ଵ
൫ ෨ܲோ,ଵ െ ߚመ் ෨ܲା,ଵ൯ଶ
൱ 
൅	ቆ ෨ܲோ,ଶ െ ߚመ் ෨ܲା,ଶ෨ܲௌ,ଶ ∙ ሺΩ෡் െ ߚመ்ܶሻቇ
ଶ 1
݊ଶ ෨ܲା,ଶ ∙ ൭
1
෨ܲௌ,ଶ ൅
෨ܲோ,ଶ ෨ܲேோ,ଶ
൫ ෨ܲோ,ଶ െ ߚመ் ෨ܲା,ଶ൯ଶ
൱ 
൅	ߪොஐ෡೅ଶ ∙ ቆ
1
Ω෡் െ ߚመ்ܶቇ
ସ
ቆ ෨ܲோ,ଵ െ ߚመ் ෨ܲା,ଵ෨ܲௌ,ଵ െ
෨ܲோ,ଶ െ ߚመ் ෨ܲା,ଶ
෨ܲௌ,ଶ ቇ
ଶ
	
൅	ߪොఉ෡೅ଶ ∙ ቆ
1
Ω෡் െ ߚመ்ܶቇ
ସ
ቆ ෨ܲା,ଵΩ෡் െ ෨ܲோ,ଵܶ෨ܲௌ,ଵ െ
෨ܲା,ଶΩ෡் െ ෨ܲோ,ଶܶ
෨ܲௌ,ଶ ቇ
ଶ
. (A85)
By substituting Equations (A81) to (A84) into Equation (A85), the variance could instead 
be written directly in terms of input parameters:  
ߪ෤ூ஽෢,ଵଶ  ൌ ൬
1
݊ଵ ൅
1
݊ଶ൰ ൭
ܲߚመ் ∙ ൫1 െ ߚመ்൯
൫Ω෡் െ ߚመ்൯ଶሺ1 െ ܲሻଶ
൱ 
൅ ቆܫଵ
ଶ
݊ଵ ൅
ܫଶଶ
݊ଶቇ ൬
1
1 െ ܲ൰ 
൅൬ܫଵ݊ଵ ൅
ܫଶ
݊ଶ൰ ቆ
1 െ 2ߚመ்
൫Ω෡் െ ߚመ்ܶ൯ሺ1 െ ܲሻቇ 
൅ ߪොஐ෡೅ଶ ∙ ቆ
1
Ω෡் െ ߚመ்ܶቇ
ଶ
ሺܫଵ െ ܫଶሻଶ
൅ ߪොఉ෡೅ଶ ∙ ቆ
ܶ
Ω෡் െ ߚመ்ܶቇ
ଶ
ሺܫଵ െ ܫଶሻଶ. (A86)
Under the null hypothesis of equal HIV incidence, assuming equal HIV prevalence and 
test characteristics, the proportions of susceptible and infected individuals, ௌܲ,௞ and ାܲ,௞, 
and ‘recently’ and ‘non-recently’ infected individuals, ோܲ,௞ and ேܲோ,௞, would be the same 
in the two populations. Therefore, the ‘expected’ estimate of ߪூ஽෢,଴ଶ  is 
ߪ෤ூ஽෢,଴ଶ 	ൌ ቆ
෨ܲோ,଴ െ ߚመ் ෨ܲା,଴
෨ܲௌ,଴ ∙ ൫Ω෡் െ ߚመ்ܶ൯ቇ
ଶ 1
෨ܲା,଴ ∙ ൭
1
෨ܲௌ,଴ ൅
෨ܲோ,଴ ෨ܲேோ,଴
൫ ෨ܲோ,଴ െ ߚመ் ෨ܲା,଴൯ଶ
൱ ൬ 1݊ଵ ൅
1
݊ଶ൰, (A87)
where  
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෨ܲ௃,଴ ൌ ݊ଵ
෨ܲ௃,ଵ ൅ ݊ଶ ෨ܲ௃,ଶ
݊ଵ ൅ ݊ଶ (A88)
is the expected estimate of ௃ܲ,଴, which is understood to equal both ௃ܲ,ଵ and ௃ܲ,ଶ under the 
null hypothesis, for each state ܬ, ܬ ∈ ሼܵ, ൅, ܴ, ܴܰሽ. 
Substituting ܫܦ଴ ൌ 0 , ܫܦଵ ൌ ܫଵ െ ܫଶ , and Equations (A85) and (A87) into their 
corresponding terms in Equation (A80), the reported ‘power’ is therefore 
ሚߴ ൌ Φቆݖଵିఈ/ଶߪ෤ூ஽෢,଴ െ ሺܫଵ െ ܫଶሻߪ෤ூ஽෢,ଵ ቇ. (A89)
While this tool aims to provide straightforward guidance on the interpretation of a 
difference between two incidence estimates, further refinement of the analysis tool should 
include the optimisation of the statistic used to test for a difference between two 
incidence values. 
A7	 Test	Performance	Calculator	
Objective 
This tool calculates the performance of a test for recent infection, from input test 
characteristics, epidemiological context and the incidence survey size. The reported 
metric of performance is the CoV of the incidence estimator. 
Inputs 
 Post-infection time cut-off ܶ
 Assumed test characteristics
o MDRI Ω்
o FRR ߚ்
o CoV of MDRI estimator ܿஐ෡೅
o CoV of FRR estimator ܿఉ෡೅
 Assumed epidemiological context
o HIV incidence ܫ
o HIV prevalence ܲ
 The survey size ݊
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Coefficient of variation of the incidence estimator, ࢉࡵ෠ࢀ 
The CoV of the incidence estimator is reported as  
ܿ̃ூመ೅ଶ  ൌ
1
݊ ෨ܲା ∙ ൭
1
෨ܲௌ ൅
෨ܲோ ෨ܲேோ
൫ ෨ܲோ െ ߚ் ෨ܲା൯ଶ
൱ 
൅	ߪஐ෡೅ଶ ∙ ൬
1
Ω் െ ߚ்ܶ൰
ଶ
൅	ߪఉ෡೅ଶ ∙ ቆ
෨ܲାΩ் െ ෨ܲோܶ
൫ ෨ܲோ െ ߚ் ෨ܲା൯ሺΩ் െ ߚ்ܶሻቇ
ଶ
, 
(A90) 
where  
෨ܲௌ ൌ 1 െ ܲ (A91)
෨ܲା ൌ ܲ (A92)
෨ܲோ ൌ ܫ ∙ ሺ1 െ ܲሻሺΩ் െ ߚ்ܶሻ ൅ ߚ்ܲ (A93)
෨ܲேோ ൌ ܲ െ ෨ܲோ (A94)
are the proportions of susceptible, infected, ‘recently’ infected and ‘non-recently’ infected 
individuals in the population for the input context (using input test characteristics). This 
result is based on Equation (A31). 
It is recognised that there are some regimes in which the above closed-form 
approximation for the CoV would be poor. For example, for tests with particularly small 
FRRs, the FRR estimator’s distribution is likely to deviate substantially from the assumed 
normal distribution, even when sample sizes are large for FRR estimation. Later versions 
of the tool could therefore utilise more general methods for estimating the CoV of the 
incidence estimator, such as bootstrap resampling [174]. Also, the current version of the 
calculator treats all inputs as known, hypothetical parameter values, and therefore does 
not report any uncertainty around the calculated CoV. In practice, when assessing the 
performance of an available test in a real-world population of interest, the inputs to the 
CoV calculation would be uncertain, and all such uncertainties should be propagated 
through the calculation (for example, to produce confidence intervals for the CoV of the 
incidence estimator). Approaches that could be used to account for the variability include 
those summarised in Section A1 (if using closed-form approximations for the CoV) or 
general, computationally-demanding approaches (such as bootstrap resampling). 
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Appendix	B	
Selected	Matlab	Code	
Code blocks to reproduce some of the analyses presented in the main body of text are 
provided below. Programming was performed in Matlab (R2013b, 8.2.0.701, 64-bit), and 
the Statistic and Optimisation toolboxes were utilised. 
The code provided in Section B1 explores bias in incidence estimation for modelled 
scenarios, and was used to produce Figure 2.2 in Section 2.2.1. 
Code to assess the accuracy of the delta method approximation for the coefficient of 
variation of the incidence estimator, arising from variability in realised sample counts, 
is provided in Section B2. This code produces analysis outputs that support the 
discussion in Section 2.2.2. 
In Section B3, a function for estimating the MDRI from longitudinal data is provided, 
and was used in the benchmarking exercise described in Section 4.1. In particular, code 
for Methods 1 and 2 (‘Interp_Linear_SE’ and ‘Interp_Linear_ME’) of Figure 4.1 is 
presented, together with example input data and outputs. 
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B1	 Bias	of	the	Incidence	Estimator	
The function fn_biascalc calculates the true (weighting of recent) incidence that one aims 
to measure, the expected value of the incidence estimator, and the error terms ߛଵ, ߛଶ and 
ߛଷ , in specified scenarios. The script figure2p2, which calls the function, produces 
Figure 2.2 (see Section 2.2.1 for more details of the analysis). 
Function	‘fn_biascalc.m’	
function [I_T_true, I_T_hat, gamma1, gamma2, gamma3] = ... 
    fn_biascalc (T,... 
    H0, r_vec,... 
    scenario_inc, I_vec, I_ref, ... 
    musurv_vec, covsurv, ... 
    T0, T1, frr_constant) 
% 
% Calculates (i) true incidence, (ii) expected value of the 
%   incidence estimator, (iii) gamma 1, gamma 2 and gamma 3 error terms, 
%   as a function of (a) population growth rate, (b) value to which  
%   incidence increases or from which it decreases, (c) mean survival time 
% 
% Inputs  
%   T: post- infection time cut-off in definition of incidence estimator 
%   H0: susceptible population size at time t = 0 (time of survey) 
%   r_vec: historical annual growth rate of population (a) 
%   scenario_inc: 1 for increasing incidence / 2 for decreasing incidence 
%   I_vec: incidence at t = 0 / incidence up until t = -T (b)  
%   I_ref: incidence up until t = -T / incidence at t = 0 
%   musurv_vec: mean survival time (c) (Weibull distribution) 
%   covsurv: coefficient of variation of survival time (extreme values create instabilities) 
%   T0: probability of being ‘recent’|alive remains at 1 until time T0 after infection... 
%   T1: ...then linearly decreases until time T1... 
%   frr_constant: ...to a constant value of frr_constant, for all times larger than T1 
% Inputs (a),(b),(c) are vectors (to capture multiple input values), 
%   other inputs are scalars, time is in years 
% 
% Outputs 
%   I_T_true: the true (weighted) incidence to be measured 
%   I_T_hat: the expected value of the incidence estimator 
%   gamma1, gamma2, gamma3: the first three (typically largest) error terms 
% Outputs are three dimensional, dimension 1 captures (the different values 
%   in) r_vec, 2 captures I_vec, and 3 captures musurv_vec 
% 
% Measure input dimensions 
n_r = length(r_vec); 
n_I = length(I_vec);  
n_musurv = length(musurv_vec); 
% Solve for shape and scale parameters of Weibull survival function 
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Solve_b = @(b) covsurv^2 - (gamma(1+2/b)-(gamma(1+1/b))^2)/(gamma(1+1/b))^2; 
[b_est,~,~] = fzero(Solve_b, 4); 
a_estvec = musurv_vec/gamma(1+1/b_est); 
% Initialise results variables 
gamma1 = NaN(n_r,n_I,n_musurv); % gamma 1 varies with all dimensions 
gamma2 = NaN(n_r,n_I,n_musurv); % gamma 2 varies with dimension 1 
gamma3 = NaN(n_r,n_I,n_musurv); % gamma 3 varies with dimension 3 
Omega_T = NaN(n_r,n_I,n_musurv); % MDRI varies with dimension 3 
beta_T = NaN(n_r,n_I,n_musurv);        % FRR varies with all dimensions  
% (in principle, although in this contrived example it is constant) 
I_T_true = NaN(n_r,n_I,n_musurv);        % true weighted incidence varies with all dimensions 
P_R = NaN(n_r,n_I,n_musurv);              % proportion of population 'recently' infected at t = 0  
% varies with all dimensions 
P_NR = NaN(n_r,n_I,n_musurv);            % proportion of population 'non-recently' infected at t = 0 
% varies with all dimensions 
% Perform calculations, looping over dimension 1, then 3, then 2 
PRonA_ = @(x) 1-((x>T0)&(x<T1)).*(x-T0)*(1-frr_constant)/(T1-T0)-(x>=T1)*(1-frr_constant); 
    % probability 'recent'|alive function 
for d1 = 1:n_r 
    r = r_vec(d1); 
    NS_ = @(x) H0*(1+r).^x; % susceptible population size function  
    delta_NS_ = @(x) NS_(x)/NS_(0)-1; % susceptible population size deviation function 
    gamma2(d1,:,:) = integral(@(x) delta_NS_(x),-T,0)/T; % gamma 2 value 
    for d3 = 1:n_musurv  
        a_est = a_estvec(d3); 
        PA_ = @(x) 1-wblcdf(x,a_est,b_est); % probability of being alive function 
        PRA_ = @(x) PRonA_(x).*PA_(x); % probability of being 'recently' infected and alive function 
        delta_PA_ = @(x) PA_(x)-1; % probability of being alive deviation function 
        if d1==1 
gamma3(:,:,d3) = integral(@(x) delta_PA_(-x),-T,0)/T ; % gamma 3 value 
Omega_T(:,:,d3) = integral(@(x) PRA_(-x),-T,0); % MDRI value 
        end 
        max_surv = ceil(wblinv(0.99999,a_est,b_est));  
        for d2 = 1:n_I 
            if scenario_inc == 1 
                I0 = I_ref; I1 = I_vec(d2); 
            elseif scenario_inc == 2 
                I0 = I_vec(d2); I1 = I_ref; 
            end 
            Inc_ = @(x) I0+((x<0)&(x>-T)).*(x+T)/T*(I1-I0)+(x>=0)*(I1-I0); % incidence function 
            I_T_true(d1,d2,d3) = ... 
                integral(@(x) Inc_(x).*NS_(x).*PRA_(-x),-T,0)/... 
                integral(@(x) NS_(x).*PRA_(-x),-T,0); % true incidence value 
            delta_I_ = @(x) Inc_(x)/I_T_true(d1, d2, d3)-1; % incidence deviation function 
            gamma1(d1,d2,d3)  = integral(@(x) delta_I_(x),-T,0)/T; % gamma 1 value 
            beta_T(d1,d2,d3) = ... 
                integral(@(x) Inc_(x).*NS_(x).*PRA_(-x),-max_surv,-T) /... 
                integral(@(x) Inc_(x).*NS_(x).*PA_(-x),-max_surv,-T); % FRR value 
            N_R  = integral(@(x) Inc_(x).*NS_(x).*PRA_(-x),-max_surv,0); % Number 'recent' at t = 0 
            N_NR = integral(@(x) Inc_(x).*NS_(x).*PA_(-x),-max_surv,0)-N_R;  % Number 'non-recent' at t = 0 
            N_S = NS_(0); % Number susceptible at t = 0 
            N = N_R+N_NR+N_S; 
            P_R(d1,d2,d3) = N_R/N; % Proportion 'recent' at t = 0 
            P_NR(d1,d2,d3) = N_NR/N; % Proportion 'non-recent' at t = 0  
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        end       
    end   
end 
I_T_hat = (P_R-beta_T.*(P_NR+P_R))./((Omega_T-T*beta_T).*(1-P_NR-P_R)); 
    % Expected value of incidence estimator 
end 
Script	‘figure2p2.m’	
%  
% Script to produce Figure 2.2, 
%   calls on function fn_biascalc 
% 
% Inputs common to scenarios 1A, 1B, 2A, 2B 
T = 1;                 
H0 = 1e6;
r_vec = -0.1:0.01:0.1;
I_vec = [0.01:0.0025:0.05];   
I_ref = 0.01;       
musurv_vec = 8;
covsurv = 0.5;    
T0 = 0.25;          
T1 = 0.75;          
% Create figure window and plot relative bias for each scenario in turn 
scrsz = get(0,'ScreenSize'); 
figure('OuterPosition',[1 1 scrsz(3)/2 scrsz(4)]) 
% Scenario 1A 
subplot(2,2,1) 
scenario_inc = 1;
frr_constant = 0.01;
[I_T_true,I_T_hat,~,~,~] = ... 
    fn_biascalc(T,H0,r_vec,scenario_inc,I_vec,I_ref,musurv_vec,covsurv,T0,T1,frr_constant); 
[C,h] = contour(100*(I_vec-I_ref)./I_ref,100*r_vec,100*(I_T_hat./I_T_true-1),100*(-0.1:0.005:0.1)); 
set(h,'LineWidth',3) 
title(['Scenario 1A: Increasing incidence, {\it\beta_T}=' num2str(100*frr_constant) '%']) 
ylabel('Annual growth of population size (%)') 
clabel(C,h,'LabelSpacing',72*3) 
set(gca,'FontName','Times','FontSize', 12) 
set(gca,'YTick',-10:5:10) 
% Scenario 1B 
subplot(2,2,2) 
scenario_inc = 1;
frr_constant = 0.05;
[I_T_true,I_T_hat,~,~,~] = ... 
    fn_biascalc(T,H0,r_vec,scenario_inc,I_vec,I_ref,musurv_vec,covsurv,T0,T1,frr_constant); 
[C,h] = contour(100*(I_vec-I_ref)./I_ref,100*r_vec,100*(I_T_hat./I_T_true-1),100*(-0.1:0.005:0.1)); 
set(h,'LineWidth',3) 
title(['Scenario 1B: Increasing incidence, {\it\beta_T} =' num2str(100*frr_constant) '%']) 
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clabel(C,h,'LabelSpacing',72*3) 
set(gca,'FontName','Times','FontSize', 12) 
set(gca,'YTick',-10:5:10) 
text(-50, -13, {['Percentage increase in incidence over the last {\itT} = ' num2str(T) ' year period,'];... 
     ['from an equilibrium of ' num2str(I_ref*100) '% per annum']}, 'HorizontalAlignment','center') 
 % Scenario 2A 
subplot(2,2,3) 
scenario_inc = 2; 
frr_constant = 0.01; 
[I_T_true,I_T_hat,~,~,~] = ... 
    fn_biascalc(T,H0,r_vec,scenario_inc,I_vec,I_ref,musurv_vec,covsurv,T0,T1,frr_constant);  
[C,h] = contour(-100*(I_ref-I_vec)./I_vec,100*r_vec,100*(I_T_hat./I_T_true-1),100*(-0.1:0.005:0.1)); 
set(h,'LineWidth',3) 
title(['Scenario 2A: Decreasing incidence, {\it\beta_T} =' num2str(100*frr_constant) '%']) 
ylabel('Annual growth of population size (%)') 
clabel(C,h,'LabelSpacing',72*3) 
set(gca,'FontName','Times','FontSize', 12) 
set(gca,'YTick',-10:5:10) 
% Scenario 2B 
subplot(2,2,4) 
scenario_inc = 2;
frr_constant = 0.05;
[I_T_true,I_T_hat,~,~,~] = ... 
    fn_biascalc(T,H0,r_vec,scenario_inc,I_vec,I_ref,musurv_vec,covsurv,T0,T1,frr_constant);  
[C,h] = contour(-100*(I_ref-I_vec)./I_vec,100*r_vec,100*(I_T_hat./I_T_true-1),100*(-0.1:0.005:0.1)); 
set(h,'LineWidth',3) 
title(['Scenario 2B: Decreasing incidence, {\it\beta_T} =' num2str(100*frr_constant) '%']) 
clabel(C,h,'LabelSpacing',72*3) 
set(gca,'FontName','Times','FontSize', 12) 
set(gca,'YTick',-10:5:10) 
text(-10, -13, {['Percentage decrease in incidence over the last {\itT} = ' num2str(T) ' year period,'];... 
     ['from an equilibrium to ' num2str(I_ref*100) '% per annum']},'HorizontalAlignment','center')   
c = findall(gcf,'Type','text'); 
set(c, 'FontName', 'Times', 'Fontsize', 12) 
B2	 Accuracy	of	the	Delta	Method	
Uncertainty	for	the	Incidence	
Estimator	
The function fn_cov calculates the coefficient of variation (CoV) of the incidence 
estimator, arising from variability in realised sample counts of HIV-negative, ‘recently’ 
infected and ‘non-recently’ infected subjects in an incidence survey. The CoV is 
calculated (i) using the delta method approximation (based on Gaussian uncertainty of 
counts), and (ii) by directly enumerating all possible counts (based on a trinomial 
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distribution). The script comparecov_section2p2p2 compares the two output CoVs for a 
selection of scenarios (see Section 2.2.2). 
Function	‘fn_cov.m’	
function [CoVDelta, CoVTrinomial] = ... 
    fn_cov (T, Inc_vec, PrevInc_vec, MDRI_vec, FRR_vec, N) 
%  
% Calculates the CoV of the incidence estimator, 
%   resulting from uncertainty in sample counts 
%   (i) using the delta method, 
%   (ii) by directly enumerating all possible trinomial counts 
%   as a function of (a) incidence, (b) prevalence to incidence ratio, 
%   (c) MDRI, (d) FRR  
% 
% Inputs 
%   T: post-infection time cut-off in definition of incidence estimator 
%   Inc_vec: Incidence value (a) 
%   PrevInc_vec: Prevalence to incidence ratio (b) 
%   MDRI_vec: mean duration of recent infection (c) 
%   FRR_vec: false-recent rate (d) 
%   N: cross-sectional incidence survey size 
% Inputs (a)-(d) are vectors (to capture multiple input values), 
%   other inputs are scalars, time is in years  
%  
% Outputs 
%   CoVDelta: CoV of incidence estimator, approximated using the delta method 
%   CoVTrinomial: CoV of incidence estimator, enumerating all possible 
%       trinomial draws 
% Outputs are four-dimensional, dimension 1 captures (the different values 
%   in) Inc_vec, 2 captures PrevInc_vec, 3 captures MDRI_vec, and  
%   4 captures FRR_vec 
% 
% Measure input dimensions 
n_Inc = length(Inc_vec); 
n_PrevInc = length(PrevInc_vec); 
n_MDRI = length(MDRI_vec); 
n_FRR = length(FRR_vec); 
n_total = n_Inc*n_PrevInc*n_MDRI*n_FRR; 
% Initialise results variables 
CoVDelta = NaN(n_Inc,n_PrevInc,n_MDRI,n_FRR); 
CoVTrinomial = NaN(n_Inc,n_PrevInc,n_MDRI,n_FRR); 
% Perform calculations, looping over dimensions 4 to 1 
count = 0; 
for d4 = 1:n_FRR 
    FRR = FRR_vec(d4); 
    for d3 = 1:n_MDRI 
        MDRI = MDRI_vec(d3); 
        for d2 = 1:n_PrevInc 
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            PrevInc = PrevInc_vec(d2); 
            for d1 = 1:n_Inc  
                Inc = Inc_vec(d1); 
                Prev = Inc*PrevInc; 
                P_S = 1-Prev; % proportion of population susceptible 
                P_R = Inc*(1-Prev)*(MDRI-FRR*T)+FRR*Prev; % proportion of population 'recently' infected 
                P_NR = Prev-P_R; % proportion of population 'non-recently' infected 
                [N_S, N_R] = meshgrid(1:N,0:N); % exclude 0 susceptible counts (improbable) 
                N_S = N_S(:); N_R = N_R(:); 
                inclIndex = N_S+N_R<=N; N_S = N_S(inclIndex); N_R = N_R(inclIndex); N_NR = N-N_S-N_R; 
                prob_sample = mnpdf([N_S N_R N_NR],[P_S P_R P_NR]); % probability of each draw of counts 
                inc_sample = (N_R-FRR*(N_R+N_NR))./N_S./(MDRI-FRR*T);  
% incidence estimate for each draw of counts 
                mean_inc_sample = sum(inc_sample.*prob_sample); % mean incidence estimate 
                mean_inc_sample2 = sum((inc_sample.^2).*prob_sample); % mean squared incidence estimate  
                CoVTrinomial(d1,d2,d3,d4) =  ... 
(mean_inc_sample2-mean_inc_sample^2)^0.5/mean_inc_sample; % true CoV   
                CoVDelta(d1,d2,d3,d4) =  ... 
(1/N*1/(P_R+P_NR)*(1/P_S+P_R*P_NR/(P_R-FRR*(P_R+P_NR))^2))^0.5; % delta method CoV 
                count = count+1; 
                if mod(count,500)==0, disp(['Loop ' num2str(count) ' of '  num2str(n_total) ' complete']), end 
            end 
        end 
    end 
end 
disp('Complete') 
end 
Script	‘deltacov_section2p2p2.m’	
% 
% Compares the delta method CoV of the incidence estimator 
%   to the true CoV, 
%   not accounting for uncertainty in test characteristics 
% 
% Inputs 
T = 1; 
Inc_vec = (0.1:0.1:3)/100; 
PrevInc_vec = 2:1:10; 
MDRI_vec = (100:50:300)/365.25; 
FRR_vec = 0:0.025:0.15; 
N = 100; 
% Perform calculations (function call) 
[CoVDelta, CoVTrinomial] = ... 
    fn_cov(T,Inc_vec,PrevInc_vec,MDRI_vec,FRR_vec,N); 
% Summarise outputs by limits of differences 
[min(CoVDelta(:)-CoVTrinomial(:)),... 
    max(CoVDelta(:)-CoVTrinomial(:))] 
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B3	 MDRI	Estimation	by	Linear	
Interpolation	
The function fn_mdri_linearint estimates the MDRI by linearly interpolating between 
data points (see Section 4.1.2 for more details). By setting the input ‘se’ to 1, single 
continuous sojourns in the ‘recent’ infection state are enforced (corresponding to 
Method 1, ‘Interp_Linear_SE’), and by setting ‘se’ to 0, multiple transitions between the 
‘recent’ and ‘non-recent’ infection states are allowed (corresponding to Method 2, 
‘Interp_Linear_ME’). The script eg_mdri_linearint presents an example application of 
the function. The outputs produced by the script are also summarised. 
Function	‘fn_mdri_linearint.m’	
function [mdrihat, lowerci, upperci, covmdrihat, stopmsg] = ... 
    fn_mdri_linearint (datatimes, datavals, dataints, ... 
    thresholds, T, ... 
    fig_ind, n_intervals,... 
    starting_value, se, ... 
    ci_ind, alphaci, n_bootstrap) 
% 
% Estimates MDRI for a biomarker for recent infection, 
%   by linear interpolating between data points 
%   as a function of (a) threshold (below which a measurement  
%   indicates ‘recent’ infection) 
% 
% Inputs 
%   datatimes: matrix of (increasing) visits times, one row per subject, 
%       time of first HIV-positive visit is reference time 0 per subject, 
%       NaNs for missing values / where data is absent 
%   datavals: matrix of corresponding biomarker readings 
%   dataints: vector capturing the interval from last HIV-negative visit 
%       to first HIV-positive visit per subject 
%   thresholds: readings below the threshold indicate 'recent' infections (a) 
%       (multiple values can be provided in vector) 
%   T: post-infection time cut-off contained in definition of MDRI 
%   alphaci: confidence interval (CI) should provide (1- alphaci)*100% coverage 
%       (multiple values can be provided in vector) 
%   ci_ind: 1 to produce CIs (by bootstrap resampling, percentile CIs) 
%   n_bootstrap: number of bootstrap samples for CI calculation 
%   fig_ind: 1 to show estimated P_R(t) as a function of t 
%   n_intervals: number of intervals into which [0,T] is divided when 
%       integrating estimated P_R(t) using the (composite) trapezoidal rule 
%   starting_value: assumed biomarker value at infection time (unless 
%       a value is already provided in the data) 
%   se: 1 for enforcing single (earliest) exits out of the 'recent' state 
% 
% Outputs 
%   mdrihat: estimated MDRI, entry (i) for thresholds(i) 
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%   lowerci: lower CI limit (NaN if ci_ind is not 1), 
%       entry (i,j) relates to thresholds(i) and alphaci(j) 
%   upperci: upper CI limit (NaN if ci_ind is not 1), 
%       entry (i,j) relates to thresholds(i) and alphaci(j) 
%   covmdrihat: coefficient of variation of bootstrap MDRI estimate replicates 
%       (NaN if ci_ind is not 1), entry (i) for thresholds(i) 
%   stopmsg: 1 if data is insufficient (mdrihat, lowerci, upperci, covmdrihat then 
%       contain NaN), 0 otherwise 
% 
% Data cleaning (remove empty panels and panels with missing HIV-negative to -positive visit gaps) 
dataints = dataints(:); 
inclindex = (sum(not(isnan(datavals)|isnan(datatimes)),2)>0)&not(isnan(dataints));  
datatimes = datatimes(inclindex,:); datavals = datavals(inclindex,:); dataints = dataints(inclindex); 
% Reshape and manipulate inputs, and measure their dimensions 
alphaci = alphaci(:)';                  
n_alpha = length(alphaci); 
n_times = n_intervals + 1; 
time_boundaries = linspace(0,T,n_times); % times at which to evaluate P_R(t) (*) 
thresholds = thresholds(:);              
n_thresholds = length(thresholds); 
thresholdmatrix = repmat(thresholds,1,n_times); 
n_subjects = size(datatimes,1);  
n_obs = size(datatimes,2); 
datatimes_mp = datatimes + repmat(dataints/2,1,n_obs); % midpoints used as infection times 
% For each threshold, time point in (*), and subject,  
%   store whether the biomarker reading produces a 'recent' result (1) 
%   or 'non-recent' result (0), or is unknown (NaN) 
threshold_time_subject_class = NaN(n_thresholds, n_times, n_subjects); 
for subjectcount = 1:n_subjects  
    datatimes_ind = datatimes_mp(subjectcount,:); datavals_ind = datavals(subjectcount,:); 
    inclindex = not(isnan(datatimes_ind)|isnan(datavals_ind)); 
    n_incl = sum(inclindex); 
    datatimes_ind = datatimes_ind(inclindex); datavals_ind = datavals_ind(inclindex); 
    if datatimes_ind(1) ~= 0 
        datatimes_ind = [0 datatimes_ind]; datavals_ind = [starting_value datavals_ind]; 
        n_incl = n_incl + 1; 
    end 
    if n_incl > 1 
        f = @(t) interp1q(datatimes_ind', datavals_ind', t')'; 
        threshold_time_subject_class(:,:,subjectcount) = ... 
            repmat(f(time_boundaries),n_thresholds,1) <= thresholdmatrix;  
        threshold_time_subject_class(:,isnan(f(time_boundaries)),subjectcount) = NaN; 
    end 
end  
% If single exits, all classifications after each subject's first 'non-recent' result become 'non-recent'  
if se == 1 
    afternr = cumsum(threshold_time_subject_class==0,2)>0; 
    threshold_time_subject_class(afternr) = 0; 
end 
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% Measure the proportion of 'recently' infected subjects, among subjects not yet lost to follow-up, 
%   at each time point in (*) and each threshold 
n_recent = sum(threshold_time_subject_class==1,3); 
n_total = sum(threshold_time_subject_class>=0,3);  
P_recent = n_recent./n_total; 
% Check that at least one subject provides data until T after (estimated) infection 
if n_total(1,end) == 0       % Exit function due to insufficient data 
    stopmsg = 1; 
    mdrihat = NaN(n_thresholds,1); 
    lowerci = NaN(n_thresholds,n_alpha); 
    upperci = NaN(n_thresholds,n_alpha);  
    covmdrihat = NaN(n_thresholds,1); 
else % Continue with estimation 
    stopmsg = 0; 
    % Estimate MDRI using the composite trapezoidal rule 
    mdrihat = (2*sum(P_recent,2)-P_recent(:,1)-P_recent(:,end))/2*(T/n_intervals); 
    % Plot estimated P_R(t) 
    if fig_ind == 1 
        figure 
        plot(time_boundaries', P_recent','LineWidth',2) 
        legend(num2str(thresholds), 'location', 'eastoutside') 
        xlabel('Time since infection','FontName','Times','FontSize',11) 
        ylabel('Probability of testing ''recent''','FontName','Times','FontSize',11) 
        grid on 
        set(gca,'FontName','Times','FontSize',11) 
        set(gca,'YLim',[0 1]) 
        set(gca,'XLim',[0 T*1.05]) 
        hold on, plot([T T],[0 1],'k--','LineWidth',2), hold off 
    end 
    % Obtain confidence interval limits from percentiles of bootstrap MDRI estimate replicates    
    if ci_ind == 1 
        bootstrapmdri = NaN(n_thresholds,n_bootstrap); 
        for bootstrapcount = 1:n_bootstrap 
            bootstrapindex = randsample(1:n_subjects,n_subjects,true); 
            bootstrap_class = threshold_time_subject_class(:,:,bootstrapindex); 
            n_recent = sum(bootstrap_class==1,3); 
            n_total = sum(bootstrap_class>=0,3);  
            P_recent = n_recent./n_total; 
            if n_total(1,end) ~= 0  
                bootstrapmdri(:,bootstrapcount) = … 
   (2*sum(P_recent,2)-P_recent(:,1)-P_recent(:,end))/2*(T/n_intervals); 
            end 
        end 
        if n_thresholds > 1 
            bootstrapmdri = bootstrapmdri(:,not(isnan(bootstrapmdri(1,:)))); 
        else 
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            bootstrapmdri = bootstrapmdri(not(isnan(bootstrapmdri))); 
        end 
        lowerci = prctile(bootstrapmdri,alphaci/2*100,2); 
        upperci = prctile(bootstrapmdri,100-alphaci/2*100,2); 
        covmdrihat = std(bootstrapmdri,[],2)./mean(bootstrapmdri,2); 
    else 
        lowerci = NaN(n_thresholds,n_alpha); 
        upperci = NaN(n_thresholds,n_alpha);  
        covmdrihat = NaN(n_thresholds,1); 
    end 
end 
end 
Script	‘eg_mdri_linearint.m’	
% 
% Demonstrates application of fn_mdri_linearint 
% 
 % Dataset 
datatimes = [  
0.2675 0.4277 0.6396 0.9542 NaN NaN NaN NaN NaN 
0.4241 0.615 0.8653 1.0678 1.4144 1.6966 1.976 NaN NaN 
0.2171 0.447 0.7267 NaN NaN NaN NaN NaN NaN 
0.3031 0.529 0.756 1.0553 1.31 1.5768 1.806 NaN NaN 
0.1826 0.4799 0.6827 0.9863 1.2467 1.4974 1.7532 2.0181 NaN 
0.3068 0.5752 0.8277 0.9795 1.25 1.5843 NaN NaN NaN 
0.2287 0.4841 0.7531 0.9521 1.2125 NaN NaN NaN NaN 
0.1636 0.4299 NaN NaN NaN NaN NaN NaN NaN 
0.2174 0.457 0.7753 1.0156 1.2352 1.4146 1.6271 1.8641 2.1053 
0.2427 0.4439 0.7162 1.007 1.2991 NaN NaN NaN NaN 
0.2185 0.4832 0.7504 0.967 1.2367 1.4919 1.8043 NaN NaN 
0.3116 0.5438 0.7895 1.07 1.4269 1.6547 1.8606 NaN NaN 
0.313 0.5456 0.8284 1.054 1.3397 1.5123 1.7787 NaN NaN 
0.2878 0.5382 0.7905 1.1004 1.3466 NaN NaN NaN NaN 
0.2257 0.4099 0.6935 0.9032 1.1561 1.9865 2.1556 NaN NaN 
   ]; 
datavals = [ 
10.6283 0.0125 20.0914 63.7114 NaN NaN NaN NaN NaN 
0.9405 12.4182 45.4135 62.6159 77.891 68.1201 79.9291 NaN NaN 
1.8642 42.5928 55.0881 NaN NaN NaN NaN NaN NaN 
3.0956 13.0108 37.8741 48.0773 63.1614 70.7904 77.8083 NaN NaN 
0.9861 NaN 39.5436 63.925 68.7903 62.3159 70.5174 78.6165 NaN 
4.8589 21.5184 44.7078 32.5498 50.5489 70.3637 NaN NaN NaN 
2.1248 13.7792 50.1477 73.6649 69.6588 NaN NaN NaN NaN 
0.8965 0.5121 NaN NaN NaN NaN NaN NaN NaN 
1.5689 3.2719 20.1856 44.3737 35.2546 61.3277 63.072 81.7462 77.4984 
0.2678 0.7413 25.6545 41.1602 75.0971 NaN NaN NaN NaN 
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4.818 18.2466 36.031 53.9034 57.0645 63.6801 69.9678 NaN NaN 
9.7489 32.7693 52.5553 68.2775 72.4863 73.3452 70.2274 NaN NaN 
2.5468 25.4565 10.6181 48.1057 69.4896 34.548 70.9096 NaN NaN 
5.9428 20.1445 51.351 70.5699 89.5246 NaN NaN NaN NaN 
2.0306 26.8103 65.1453 80.0954 72.5498 NaN NaN NaN NaN 
   ]; 
dataints = [ 
0.1756 
0.2004 
0.2458 
0.1986 
0.1255 
0.2259 
0.2175 
0.2158 
0.163 
0.1872 
0.1438 
0.2203 
0.2211 
NaN 
0.2221 
   ]; 
% Inputs for fn_mdri_linearint 
thresholds = 30:10:50; 
T = 1.5; 
figind = 1; 
n_intervals = 20000; 
starting_value = 0; 
ci_ind = 1; 
alphaci = [0.05 0.2]; 
n_bootstrap = 10000; 
% Single-exit estimation 
se = 1; 
[mdrihat,lowerci,upperci,covmdrihat,stopmsg] = ... 
    fn_mdri_linearint(datatimes,datavals,dataints, ... 
    thresholds,T, ... 
    figind,n_intervals,... 
    starting_value,se,... 
    ci_ind,alphaci,n_bootstrap);  
[ [mdrihat lowerci(:,1) upperci(:,1) lowerci(:,2) upperci(:,2)]*365.25 covmdrihat*100] % Results 
% Multiple-transition estimation 
se = 0; 
[mdrihat,lowerci,upperci,covmdrihat,stopmsg] = ... 
    fn_mdri_linearint (datatimes,datavals,dataints, ... 
    thresholds,T, ... 
    figind,n_intervals,... 
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    starting_value,se,... 
    ci_ind,alphaci,n_bootstrap); 
[ [mdrihat lowerci(:,1) upperci(:,1) lowerci(:,2) upperci(:,2)]*365.25 covmdrihat*100] % Results 
Outputs	from	‘eg_mdri_linearint.m’	
Outputs produced by the script file eg_mdri_linearint.m are summarised below. The 
results obtained when enforcing a single continuous sojourn in the ‘recent’ state are 
provided in Figure B1 and Table B1, and those obtained when allowing multiple 
transitions between states are provided in Figure B2 and Table B2. 
Figure B1: Example of a fitted probability of being ‘recently’ infected over time 
since infection, by threshold, using linear interpolation and enforcing single exits 
from the ‘recent’ state  
The fitted probability of testing ‘recently’ infected is shown as a function of time since 
infection, and was obtained by applying the function fn_mdri_linearint to an example 
dataset, as outlined in the script eg_mdri_linearint. The probability is shown for a 
threshold of 30, 40 and 50 in turn (a biomarker reading below the threshold indicates 
‘recent’ infection). Biomarker readings are linearly interpolated, and single exits from the 
‘recent’ state are enforced. 
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Threshold Estimated MDRI (days) 
95% CI for 
MDRI (days) 
80% CI for 
MDRI (days) 
CoV of MDRI 
estimator (%) 
30 277 246-308 257-298 5.7
40 314 281-346 293-336 5.3
50 374 331-419 346-403 6.0
Table B1: Example of MDRI estimation outputs, by threshold, using linear 
interpolation and enforcing single exits from the ‘recent’ state  
Estimates of the MDRI (days) are shown, and were obtained by applying the function 
fn_mdri_linearint to an example dataset, as captured in the script eg_mdri_linearint. 
Confidence intervals (CIs) for the MDRI (days) and estimated coefficients of variation 
(CoVs) of the MDRI estimator (%) are also provided. The MDRI was estimated for a 
threshold of 30, 40 and 50 in turn (a biomarker reading below the threshold indicates 
‘recent’ infection), and ܶ ൌ 1.5 years. Biomarker readings were linearly interpolated, and 
single exits from the ‘recent’ state were enforced. 
Figure B2: Example of a fitted probability of being ‘recently’ infected over time 
since infection, by threshold, using linear interpolation and allowing multiple 
transitions between ‘recent’ and ‘non-recent’ states  
The fitted probability of testing ‘recently’ infected is shown as a function of time since 
infection, and was obtained by applying the function fn_mdri_linearint to an example 
dataset, as outlined in the script file eg_mdri_linearint. The probability is shown for a 
threshold of 30, 40 and 50 in turn (a biomarker reading below the threshold indicates 
‘recent’ infection). Biomarker readings are linearly interpolated, and multiple transitions 
between the ‘recent’ and ‘non-recent’ states are allowed. 
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Threshold Estimated MDRI (days) 
95% CI for 
MDRI (days) 
80% CI for 
MDRI (days) 
CoV of MDRI 
estimator (%) 
30 278 247-308 258-298 5.6
40 328 290-365 303-353 5.9
50 385 338-429 353-414 6.1
Table B2: Example of MDRI estimation outputs, by threshold, using linear 
interpolation and allowing multiple transitions between states 
Estimates of the MDRI (days) are shown, and were obtained by applying the function 
fn_mdri_linearint to an example dataset, as captured in the script eg_mdri_linearint. 
Confidence intervals (CIs) for the MDRI (days) and estimated coefficients of variation 
(CoVs) of the MDRI estimator (%) are also provided. The MDRI was estimated for a 
threshold of 30, 40 and 50 in turn (a biomarker reading below the threshold indicates 
‘recent’ infection), and ܶ ൌ 1.5 years. Biomarker readings were linearly interpolated, and 
multiple transitions between the ‘recent’ and ‘non-recent’ states were allowed. 
References  232 
 
References	
1. Gallo RC. Historical essay: The early years of HIV/AIDS. Science 2002,
298(5599):1728-1730.
2. Montagnier L. Historical essay: A history of HIV discovery. Science 2002,
298(5599):1727-1728.
3. Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J
Med 2003, 349(24):2283-2285.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report:
UNAIDS Report on the Global AIDS Epidemic 2013. 2013.
5. The South African Department of Health. The 2011 National Antenatal Sentinel
HIV and Syphilis Prevalence Survey. 2012.
6. Rehle T, Lazzari S, Dallabetta G, Asamoah-Odei E. Second-generation HIV
surveillance: Better data for decision-making. Bull World Health Organ 2004,
82(2):121-127.
7. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus
incidence rates from a cross-sectional survey using early diagnostic tests. Am J
Epidemiol 1995, 141(2):166-172.
8. Le Vu S, Pillonel J, Semaille C, Bernillon P, Le Strat Y, Meyer L, Desenclos JC.
Principles and uses of HIV incidence estimation from recent infection testing – a
review. Euro Surveill 2008, 13(36):11-16.
9. Murphy G, Parry JV. Assays for the detection of recent infections with human
immunodeficiency virus type 1. Euro Surveill 2008, 13(36):4-10.
10. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, Rodriguez W,
Rousseau C, Rehle TM, Welte A, Averill MD, Garcia Calleja JM. Beyond
detuning: 10 years of progress and new challenges in the development and
application of assays for HIV incidence estimation. AIDS 2010, 24(18):2763-
2771. 
11. Welte A, McWalter TA, Laeyendecker O, Hallett TB. Using tests for recent
infection to estimate incidence: Problems and prospects for HIV. Euro Surveill
2010, 15(24):pii=19589.
12. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, Laeyendecker O, Oluoch T,
Garcia-Calleja JM. Estimating HIV incidence in populations using tests for recent
infection: Issues, challenges and the way forward. J HIV AIDS Surveill Epidemiol
2010, 2(1):1-14.
13. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance.
When and How to Use Assays for Recent Infection to Estimate HIV Incidence at
a Population Level.
http://www.who.int/diagnostics_laboratory/hiv_incidence_may13_final.pdf.
2011. 
 
References  233 
14. Incidence Assay Critical Path Working Group. More and better information to 
tackle HIV epidemics: Towards improved HIV incidence assays. PLOS Med 
2011, 8(6):e1001045. 
15. Kaplan EH, Brookmeyer R. Snapshot estimators of recent HIV incidence rates. 
Operations Research 1999, 47:29-37. 
16. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, Ackers M, 
Gurwith M. Comparison of HIV type 1 incidence observed during longitudinal 
follow-up with incidence estimated by cross-sectional analysis using the BED 
capture enzyme immunoassay. AIDS Res Hum Retroviruses 2006, 22(10):945-
952. 
17. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, McDougal JS, Ntozini R, 
Chidawanyika H, Moulton LH, Ward B, Nathoo K, Iliff PJ, Kopp E. Improved 
HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 
2008, 22(4):511-518. 
18. Brookmeyer R. Should biomarker estimates of HIV incidence be adjusted? AIDS 
2009, 23(4):485-491. 
19. Hargrove JW. BED estimates of HIV incidence must be adjusted. AIDS 2009, 
23(15):2061-2062; author reply 2066-2068. 
20. McDougal JS. BED estimates of HIV incidence must be adjusted. AIDS 2009, 
23(15):2064-2065; author reply 2066-2068. 
21. Welte A, McWalter TA, Bärnighausen T. Reply to ‘Should biomarker estimates 
of HIV incidence be adjusted?’. AIDS 2009, 23(15):2062-2063; author reply 
2066-2068. 
22. Brookmeyer R. Response to correspondence on ‘Should biomarker estimates of 
HIV incidence be adjusted?’. AIDS  2009, 23(15):2066-2068. 
23. McWalter TA, Welte A. A comparison of biomarker based incidence estimators. 
PLOS One 2009, 4(10):e7368. 
24. Wang R, Lagakos SW. On the use of adjusted cross-sectional estimators of HIV 
incidence. JAIDS 2009, 52(5):538-547. 
25. McWalter TA, Welte A. Relating recent infection prevalence to incidence with a 
sub-population of assay non-progressors. J Math Biol 2010, 60(5):687-710. 
26. Bärnighausen T, McWalter TA, Rosner Z, Newell ML, Welte A. HIV incidence 
estimation using the BED capture enzyme immunoassay: Systematic review and 
sensitivity analysis. Epidemiology 2010, 21(5):685-697. 
27. Brookmeyer R. On the statistical accuracy of biomarker assays for HIV 
incidence. JAIDS 2010, 54(4):406-414. 
28. UNAIDS Reference Group on Estimates, Modelling and Projections. Statement 
on the use of the BED assay for the estimation of HIV-1 incidence for 
surveillance or epidemic monitoring. Wkly Epidemiol Rec 2006, 81(4):40. 
29. Kassanjee R, McWalter TA, Bärnighausen T, Welte A. A new general 
biomarker-based incidence estimator. Epidemiology 2012, 23(5):721-728. 
30. Kassanjee R, McWalter TA, Welte A. Defining optimality of a test for recent 
infection for HIV incidence surveillance. AIDS Res Hum Retroviruses 2014, 
30(1):45-49. 
31. Kassanjee R, Welte A, McWalter TA, Keating SM, Vermeulen M, Stramer SL, 
Busch MP. Seroconverting blood donors as a resource for characterising and 
optimising recent infection testing algorithms for incidence estimation. PLOS 
One 2011, 6(6):e20027. 
References  234 
32. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA,
Martin JN, Little S, Hecht FM, Kallas EG, Welte A, Busch MP, Murphy G:
Independent assessment of candidate HIV incidence assays on specimens in the
CEPHIA repository. AIDS 2014, 28(16):2439-2449.
33. Kassanjee R, Welte A, McWalter TA, Viljoen J, Bärnighausen T, Newell ML,
Fatti LP. Calibration of BED assay for use in incidence estimation. E-poster
CDB018 at the 5th IAS Conference on HIV Pathogenesis, Treatment and
Prevention, 19-22 July 2009, South Africa.
34. Kassanjee R, Hargrove J, Marinda E, Humphrey J, McWalter TA, Welte A. New
criteria for defining biomarker-derived ‘recent HIV infection’ for the purposes of
incidence estimation. E-poster CDC0474 at the XVIII International AIDS
Conference,18-23 July 2010, Austria.
35. Kassanjee R, Welte A, Jehuda-Cohen T. SMARTubeTM as a test for recent
infection. Poster 41 and presentation at the 2010 HIV Diagnostics Conference,
24 -26 March 2010, Florida.
36. Welte A, Kassanjee R. Defining and measuring ‘recent infection’ and
‘incidence’. Presentation at the 52nd Annual Conference of the South African
Statistical Association, 8-12 November 2010, South Africa.
37. Pilcher CD, Busch MP, Facente S, Kassanjee R, Keating S, Hecht FM, Deeks S,
McKinney E, Murphy G, Kamali A, Amornkul P, Welte A, Martin J, Little S.
CEPHIA: A specimen and data repository for independent evaluation of HIV
incidence assays. Poster at the 2012 HIV Diagnostics Conference, 12-14
December 2012, Atlanta, GA.
38. Pilcher CD, Busch MP, Welte A, Facente S, Kassanjee R, Keating SM,
McKinney E, Amornkul P, Kamali A, Hecht FM, Martin J, Deeks S, Little S,
Murphy G, on behalf of the Consortium for the Evaluation and Performance of
HIV Incidence Assays (CEPHIA). A novel specimen and data repository for
evaluation of HIV incidence assays. Poster and abstract TUPE192 at the XIX
International AIDS Conference, July 22-27 2012, Washington, DC.
39. Pilcher CD, Kassanjee R, Motta L, Facente S, Keating SM, McKinney E,
Gunasekera D, Hecht FM, Sperhacke RD, Santos B, Busch MP, Murphy G,
Esfandiari J, Welte A. A novel quantitative, multi-analyte rapid test for recent
HIV infection and HIV incidence estimation. Poster and abstract TUPE194 at the
XIX International AIDS Conference, July 22-27 2012, Washington, DC.
40. Pilcher CD, Kassanjee R, Motta L, Facente S, Keating S, McKinney E, Hecht
FM, Sperhacke RD, Busch MP, Murphy G, Esfandiari J, Welte A. DPP
supplemental rapid test data can discriminate recent from longstanding HIV
infection. Presentation at the 2012 HIV Diagnostics Conference, 12-14 December
2012, Atlanta, GA.
41. Kassanjee R, Murphy G, Busch MP, Pilcher CD, McKinney E, Keating S,
Facente S, MacArthur J, Welte A. The performance of candidate assays to detect
recent HIV infection for cross-sectional incidence estimation: An independent,
comparative evaluation. Poster 1056 / abstract X-168 at the 20th Conference on
Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, GA.
42. Kassanjee R, Murphy G, Busch MP, Pilcher CD, McKinney E, Keating S,
Facente S, Welte A, on behalf of the Consortium for the Evaluation and
Performance of HIV Incidence Assays (CEPHIA). Evaluation panel analysis
 
References  235 
results. Presentation (satellite session) at the 20th Conference for Retroviruses 
and Opportunistic Infections, 3-6 March 2013, Atlanta, GA. 
43. Kassanjee R, Pilcher CD, Keating SM, Facente SN, Price MA, Martin JN, 
Little S, Welte A, Busch MP, Murphy G, on behalf of the Consortium for the 
Evaluation and Performance of HIV Incidence Assays (CEPHIA). Independent 
evaluation of predicate incidence assays for HIV surveillance. Poster 1005 and 
themed discussion presentation at the Conference for Retroviruses and 
Opportunistic Infections 2014, 3-6 March 2014, Boston, MA. 
44. Keating SM, Murphy G, Welte A, Kassanjee R, Matten D, Facente SN, 
Lebedeva L, Busch MP, Pilcher CD, on behalf of the Consortium for the 
Evaluation and Performance of HIV Incidence Assays (CEPHIA). Application of 
the Geenius™ HIV1/2 Supplemental Assay for detection of recent HIV 
infections. Poster 615 at the Conference for Retroviruses and Opportunistic 
Infections 2014, 3-6 March 2014, Boston, MA. 
45. Kassanjee R. Testing for recent infection to estimate HIV incidence from single 
cross-sectional surveys. SACEMA Quarterly Nov 2011. 
46. Kassanjee R. 20th Conference for Retroviruses and Opportunistic Infections: 
Highlights, and developments in HIV incidence estimation. SACEMA Quarterly 
June 2013. 
47. The Consortium for the Evaluation and Performance of HIV Incidence Assays 
(CEPHIA). http://www.incidence-estimation.com/page/cephia. Accessed 1 July 
2014. 
48. Incidence-Estimation, SACEMA's online resource for incidence estimation. 
http://www.incidence-estimation.com. Accessed 1 July 2014. 
49. World Health Organization. Meeting report: Annual meeting of the WHO 
technical working group on HIV incidence assays, 26-27 September 2012, 
Geneva, Switzerland.  
 http://apps.who.int/iris/bitstream/10665/86397/1/9789241506069_eng.pdf.  2013. 
50. SACEMA Holds Training Course on Estimating HIV Cases.  
https://blogs.sun.ac.za/news/2012/05/23/sacema-holds-training-course-on-
estimating-hiv-cases. Accessed 1 July 2014.    
51. Centers for Disease Control and Prevention. http://www.cdc.gov. Accessed 1 July 
2014.    
52. WHO Technical Working Group on HIV Incidence Assays.  
http://www.who.int/diagnostics_laboratory/links/hiv_incidence_assay/en. 
Accessed 1 July 2014.  
53. HIV Modelling Consortium Work Package on Characterisation of Tests for 
Recent Infection. http://www.hivmodelling.org/projects/incidence-estimation.  
Accessed 1 July 2014. 
54. Brookmeyer R. Accounting for follow-up bias in estimation of human 
immunodeficiency virus incidence rates. J R Stat Soc Ser A 1997, 160(1):127-
140. 
55. Brookmeyer R. Measuring the HIV/AIDS epidemic: Approaches and challenges. 
Epidemiol Rev 2010, 32(1):26-37. 
56. Podgor MJ, Leske MC. Estimating incidence from age-specific prevalence for 
irreversible diseases with differential mortality. Stat Med 1986, 5(6):573-578. 
References  236 
57. Brunet RC, Struchiner CJ. A non-parametric method for the reconstruction of
age- and time-dependent incidence from the prevalence data of irreversible
diseases with differential mortality. Theor Popul Biol 1999, 56(1):76-90.
58. Williams B, Gouws E, Wilkinson D, Karim SA. Estimating HIV incidence rates
from age prevalence data in epidemic situations. Stat Med 2001, 20(13):2003-
2016. 
59. Hallett TB, Zaba B, Todd J, Lopman B, Mwita W, Biraro S, Gregson S, Boerma
JT. Estimating incidence from prevalence in generalised HIV epidemics:
Methods and validation. PLOS Med 2008, 5(4):e80.
60. Mahiane GS, Ouifki R, Brand H, Delva W, Welte A. A general HIV incidence
inference scheme based on likelihood of individual level data and a population
renewal equation. PLOS One 2012, 7(9):e44377.
61. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Zungu NP, Labadarios D,
Onoya D, Davids A, Ramlagan S, Mbelle N, van Zyl J, Onoya D, Wabiri N.
South African National HIV Prevalence, Incidence and Behaviour Survey, 2012.
HSRC Press, 2014.
62. Bao L, Salomon JA, Brown T, Raftery AE, Hogan DR. Modelling national
HIV/AIDS epidemics: Revised approach in the UNAIDS Estimation and
Projection Package 2011. Sex Transm Infect 2012, 88 Suppl 2:i3-10.
63. Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and
Projection Package (EPP) model to estimate HIV trends for adults and children.
Sex Transm Infect 2012, 88 Suppl 2:i11-16.
64. United Nations AIDS (UNAIDS) Spectrum/EPP 2014.
http://www.unaids.org/en/dataanalysis/datatools/spectrumepp2013. Accessed 1
July 2014.
65. Aalen OO, Farewell VT, De Angelis D, Day NE, Gill ON. A Markov model for
HIV disease progression including the effect of HIV diagnosis and treatment:
Application to AIDS prediction in England and Wales. Stat Med 1997,
16(19):2191-2210.
66. Bellocco R, Marschner IC. Joint analysis of HIV and AIDS surveillance data in
back-calculation. Stat Med 2000, 19(3):297-311.
67. Cui J, Becker NG. Estimating HIV incidence using dates of both HIV and AIDS
diagnoses. Stat Med 2000, 19(9):1165-1177.
68. Posner SJ, Myers L, Hassig SE, Rice JC, Kissinger P, Farley TA. Estimating HIV
incidence and detection rates from surveillance data. Epidemiology 2004,
15(2):164-172.
69. Case KK, Ghys PD, Gouws E, Eaton JW, Borquez A, Stover J, Cuchi P, Abu-
Raddad LJ, Garnett GP, Hallett TB. Understanding the modes of transmission
model of new HIV infection and its use in prevention planning. Bull World
Health Organ 2012, 90(11):831-838A.
70. United Nations AIDS (UNAIDS) Incidence by Modes of Transmission.
http://www.unaids.org/en/dataanalysis/datatools/incidencebymodesoftransmission.
Accessed 1 July 2014.
71. Freeman J, Hutchison GB. Prevalence, incidence and duration. Am J Epidemiol
1980, 112(5):707-723.
72. Killian MS, Norris PJ, Rawal BD, Lebedeva M, Hecht FM, Levy JA, Busch MP.
The effects of early antiretroviral therapy and its discontinuation on the HIV-
specific antibody response. AIDS Res Hum Retroviruses 2006, 22(7):640-647.
References  237 
73. Hayashida T, Gatanaga H, Tanuma J, Oka S. Effects of low HIV type 1 load and
antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res
Hum Retroviruses 2008, 24(3):495-498.
74. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, Kraus
CK, Shahan J, Kelen GD, Quinn TC. The effect of viral suppression on cross-
sectional incidence testing in the Johns Hopkins Hospital emergency department.
JAIDS 2008, 48(2):211-215.
75. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, Levin J, Moulton
LH, Welte A, Humphrey J. Significantly diminished long-term specificity of the
BED capture enzyme immunoassay among patients with HIV-1 with very low
CD4 counts and those on antiretroviral therapy. JAIDS 2010, 53(4):496-499.
76. Hladik W, Olara D, Mermin J, Moore D, Were W, Alexander L, Downing R.
Effect of CD4(+) T cell count and antiretroviral treatment on two serological HIV
incidence assays. AIDS Res Hum Retroviruses 2012, 28(1):95-99.
77. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, Mueller AC,
Jacobson LP, Margolick JB, Brown J, Rinaldo CR, Quinn TC, Eshleman SH, for
The Multicenter AIDS Cohort Study (MACS). Factors associated with incorrect
identification of recent HIV infection using the BED capture immunoassay. AIDS
Res Hum Retroviruses 2012, 28(8):816-822.
78. Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC,
Brookmeyer R, Quinn TC, Laeyendecker O. Effect of natural and ARV-induced
viral suppression and viral breakthrough on anti-HIV antibody proportion and
avidity in patients with HIV-1 subtype B infection. PLOS One 2013,
8(2):e55525.
79. Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman
SH, Laeyendecker O. Incorrect identification of recent HIV infection in adults in
the United States using a limiting-antigen avidity assay. AIDS 2014, 28(8):1227-
1232. 
80. Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V,
Quinn TC, Eshleman SH, Laeyendecker O. Immune responses in Ugandan
women infected with Subtypes A and D HIV using the BED Capture
Immunoassay and an antibody avidity assay. JAIDS 2014, 65(4):390-396.
81. Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn
TC, Eshleman SH, Laeyendecker O. Impact of HIV subtype on performance of
the Limiting Antigen-Avidity Enzyme Immunoassay, the Bio-Rad Avidity Assay,
and the BED Capture Immunoassay in Rakai, Uganda. AIDS Res Hum
Retroviruses 2014, 30(4):339-344.
82. Welte A, McWalter TA, Bärnighausen T. A simplified formula for inferring HIV
incidence from cross-sectional surveys using a test for recent infection. AIDS Res
Hum Retroviruses 2009, 25(1):125-126.
83. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, Chaix
ML, Marchadier E, Vilde JL, Delfraissy JF, Meyer L, Rouzioux. Natural history
of serum HIV-1 RNA levels in 330 patients with a known date of infection – The
SEROCO Study Group. AIDS 2000, 14(2):123-131.
84. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS.
Determinants of survival following HIV-1 seroconversion after the introduction
of HAART. Lancet 2003, 362(9392):1267-1274.
 
References  238 
85. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg 
RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, 
Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, 
Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, 
Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, 
Freeman AM, Moore RD. Effect of early versus deferred antiretroviral therapy 
for HIV on survival. N Engl J Med 2009, 360(18):1815-1826. 
86. Curtis K, Kennedy S, Charurat ME, Nasidi A, Delaney K, Spira T, Owen M. 
Development and characterization of a bead-based, multiplex assay for 
estimation of recent HIV-1 infection. AIDS Res Hum Retroviruses 2012, 
28(2):188-197. 
87. McKeown K, Jewell NP. Current status observation of a three-state counting 
process with application to simultaneous accurate and diluted HIV test data. Can 
J Stat 2011, 39(3):475–487. 
88. Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell 
D, Celum C, Buchbinder SP, Seage GR, Kirk GD, Mehta SH, Astemborski J, 
Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH. HIV incidence 
determination in the United States: A multiassay approach. J Infect Dis 2013, 
207(2):232-239.  
89. Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk 
D, Mullis CE, Chin C, Swanson P, Hackett Jr. J, Clarke W, Marzinke M, 
Szekeres G, Gray G, Richter L, Alexandre MW, Chariyalertsak S, Chingono A, 
Celentano DD, Morin SF, Sweat M, Coates T, Eshleman SH. Estimation of HIV 
incidence in a large, community-based, randomized clinical trial: NIMH Project 
Accept (HIV Prevention Trials Network 043). PLOS One 2013, 8(7):e68349. 
90. Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH. Cross-sectional HIV 
incidence estimation in HIV prevention research. JAIDS 2013, 63 Suppl 2:S233-
239. 
91. Janssen RS, Satten GA, Stramer SL, Rawal BD, O’Brien TR, Weiblen BJ, Hecht 
FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP. New testing 
strategy to detect early HIV-1 infection for use in incidence estimates and for 
clinical and prevention purposes. JAMA 1998, 280(1):42-48. 
92. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, Hu DJ, 
Vanichseni S, Young NL, Choopanya K, Mastro TD, McDougal JS. Quantitative 
detection of increasing HIV type 1 antibodies after seroconversion: A simple 
assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum 
Retroviruses 2002, 18(4):295-307. 
93. Wang R, Lagakos SW. Augmented cross-sectional prevalence testing for 
estimating HIV incidence. Biometrics 2009, 66(3):864-874. 
94. Sweeting MJ, De Angelis D, Parry J, Suligoi B. Estimating the distribution of the 
window period for recent HIV infections: A comparison of statistical methods. 
Stat Med 2010, 29(30):3194-3202. 
95. Braunstein SL, Nash D, Kim AA, Ford K, Mwambarangwe L, Ingabire CM, 
Vyankandondera J, van de Wijgert JH. Dual testing algorithm of BED-CEIA and 
AxSYM Avidity Index assays performs best in identifying recent HIV infection 
in a sample of Rwandan sex workers. PLOS One 2011, 6(4):e18402. 
96. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, Dobbs T, Constantine 
N, Overbaugh J, McDougal JS. Determination of mean recency period for 
References  239 
estimation of HIV type 1 Incidence with the BED-capture EIA in persons 
infected with diverse subtypes. AIDS Res Hum Retroviruses 2011, 27(3):265-273. 
97. Sommen C, Commenges D, Le Vu S, Meyer L, Alioum A. Estimation of the
distribution of infection times using longitudinal serological markers of HIV:
Implications for the estimation of HIV incidence. Biometrics 2011, 67(2):467-75.
98. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, Nkengasong JN,
Parekh BS. Detection of recent HIV-1 infection using a new limiting-antigen
avidity assay: Potential for HIV-1 incidence estimates and avidity maturation
studies. PLOS One 2012, 7(3):e33328.
99. Hargrove J, Eastwood H, Mahiane G, van Schalkwyk C. How should we best
estimate the mean recency duration for the BED method? PLOS One 2012,
7(11):e49661.
100. Keating SM, Hanson D, Lebedeva M, Laeyendecker O, Ali-Napo NL, Owen SM, 
Stramer SL, Moore RD, Norris PJ, Busch MP. Lower-sensitivity and avidity 
modifications of the Vitros anti-HIV 1+2 assay for detection of recent HIV 
infections and incidence estimation. J Clin Microbiol 2012, 50(12):3968-3976. 
101. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. Estimation of HIV 
incidence using multiple biomarkers. Am J Epidemiol 2013, 177(3):264-272. 
102. Curtis KA, Hanson DL, Kennedy MS, Owen SM. Evaluation of a multiplex assay 
for estimation of HIV-1 incidence. PLOS One 2013, 8(5):e64201. 
103. Mahiane SG, Fiamma A, Auvert B. Mixture models for calibrating the BED for 
HIV incidence testing. Stat Med 2014, 33(10):1767-1783. 
104. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, Busch 
MP. Development of a new less-sensitive enzyme immunoassay for detection of 
early HIV-1 infection. JAIDS 2003, 33(3):349-355. 
105. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, Mei JV. 
Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay 
for use in estimating HIV seroincidence. JAIDS 2003, 33(5):625-634. 
106. Li H, Ketema F, Sill AM, Kreisel KM, Cleghorn FR, Constantine NT. A simple 
and inexpensive particle agglutination test to distinguish recent from established 
HIV-1 infection. Int J Infect Dis 2007, 11(5):459-465. 
107. Parekh BS, McDougal JS. New approaches for detecting recent HIV-1 infection. 
AIDS Review 2001, 3:183-193. 
108. Parekh BS, McDougal JS. Application of laboratory methods for estimation of 
HIV-1 incidence. Indian J Med Res 2005, 121(4):510-518. 
109. Sakarovitch C, Rouet F, Murphy G, Minga AK, Alioum A, Dabis F, Costagliola 
D, Salamon R, Parry JV, Barin F. Do tests devised to detect recent HIV-1 
infection provide reliable estimates of incidence in Africa? JAIDS 2007, 
45(1):115-122. 
110. Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, 
Brookmeyer R, Nalugoda F, Kigozi G, Kagaayi J, Tobian AA, Wawer M, Gray 
RH, Quinn TC, Laeyendecker O. Differential specificity of HIV incidence assays 
in HIV subtypes A and D-infected individuals from Rakai, Uganda. AIDS Res 
Hum Retroviruses 2013, 29(8):1146-1150. 
111. Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, Kamali A, Sanders EJ, 
Anzala O, Katende M, Ketter N. Investigating the utility of the HIV-1 BED 
capture enzyme immunoassay using cross-sectional and longitudinal 
seroconverter specimens from Africa. AIDS 2007, 21(4):403-408. 
References  240 
112. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, Rehle T, Hargrove J, 
Remis RS, Kaldor JM. Accuracy of serological assays for detection of recent 
infection with HIV and estimation of population incidence: A systematic review. 
Lancet Infect Dis 2009, 9(12):747-759. 
113. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, Parekh BS. 
Development of two avidity-based assays to detect recent HIV type 1 
seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum 
Retroviruses 2010, 26(1):61-71. 
114. Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder 
SP, Seage GR, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer 
KH, Koblin BA, Justman JE, Hodder SL, Quinn TC, Eshleman SH, 
Laeyendecker O. Performance of a limiting-antigen avidity enzyme immunoassay 
for cross-sectional estimation of HIV incidence in the United States. PLOS One 
2013, 8(12):e82772. 
115. Suligoi B, Galli C, Massi M, Di Sora F, Sciandra M, Pezzotti P, Recchia O, 
Montella F, Sinicco A, Rezza G. Precision and accuracy of a procedure for 
detecting recent human immunodeficiency virus infections by calculating the 
antibody avidity index by an automated immunoassay-based method. J Clin 
Microbiol 2002, 40(11):4015-4020. 
116. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, Recchia O, 
Montella F, Sinicco A, Rezza G. Identifying recent HIV infections using the 
avidity index and an automated enzyme immunoassay. JAIDS 2003, 32(4):424-
428. 
117. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham 
PH, Kemp BE, Branson BM, Dax EM. Incidence immunoassay for distinguishing 
recent from established HIV-1 infection in therapy-naive populations. AIDS 
2004, 18(17):2253-2259. 
118. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A, Desenclos JC, 
Costagliola D. Development and validation of an immunoassay for identification 
of recent human immunodeficiency virus type 1 infections and its use on dried 
serum spots. J Clin Microbiol 2005, 43(9):4441-4447. 
119. Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, Parry JV, Phillips A, 
Geretti AM. Human immunodeficiency virus (HIV) antibody avidity testing to 
identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive 
persons infected with diverse HIV-1 subtypes. J Clin Microbiol 2007, 45(2):415-
420. 
120. Schupbach J, Gebhardt MD, Tomasik Z, Niederhauser C, Yerly S, Burgisser P, 
Matter L, Gorgievski M, Dubs R, Schultze D, Steffen I, Andreutti C, Martinetti 
G, Guntert B, Staub R, Daneel S, Vernazza P. Assessment of recent HIV-1 
infection by a line immunoassay for HIV-1/2 confirmation. PLOS Med 2007, 
4(12):e343. 
121. Suligoi B, Rodella A, Raimondo M, Regine V, Terlenghi L, Manca N, Casari S, 
Camoni L, Salfa MC, Galli C. Avidity Index for anti-HIV antibodies: comparison 
between third- and fourth-generation automated immunoassays. J Clin Microbiol 
2011, 49(7):2610-2613. 
122. Andersson E, Shao W, Bontell I, Cham F, Cuong do D, Wondwossen A, Morris 
L, Hunt G, Sonnerborg A, Bertagnolio S, Maldarelli F, Jordan MR. Evaluation of 
sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 
References  241 
infection in transmitted drug resistance surveys. Infect Genet Evol 2013, 18:125-
131. 
123. Cousins MM, Laeyendecker O, Beauchamp G, Brookmeyer R, Towler WI, 
Hudelson SE, Khaki L, Koblin B, Chesney M, Moore RD, Kelen GD, Coates T, 
Celum C, Buchbinder SP, Seage GR, Quinn TC, Donnell D, Eshleman SH. Use 
of a high resolution melting (HRM) assay to compare gag, pol, and env diversity 
in adults with different stages of HIV infection. PLOS One 2011, 6(11):e27211. 
124. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, Merks H, Vallee D, Caminiti K, 
Rekart M, Krajden M, Cook D, Kim J, Malloch L, Sandstrom P, Brooks J. 
Genetic diversity as a marker for timing infection in HIV-infected patients: 
evaluation of a 6-month window and comparison with BED. J Infect Dis 2012, 
206(5):756-764. 
125. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, Lee HY. Designing a 
genome-based HIV incidence assay with high sensitivity and specificity. AIDS 
2011, 25(16):F13-19. 
126. Puren A, Takuva S. HIV incidence estimates for South Africa: Update on 
laboratory methods and post-test algorithms. Communicable Diseases 
Surveillance Bulletin 2013, 11(4):115-121. 
127. Soroka SD, Granade TC, Candal D, Parekh BS. Modification of rapid human 
immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV 
seroconversion. Clin Diagn Lab Immunol 2005, 12(8):918-921. 
128. Kshatriya R, Cachafeiro AA, Kerr RJ, Nelson JA, Fiscus SA. Comparison of two 
rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and 
OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. 
J Clin Microbiol 2008, 46(10):3482-3483. 
129. Granade TC, Nguyen S, Kuehl DS, Parekh BS. Development of a novel rapid 
HIV test for simultaneous detection of recent or long-term HIV type 1 infection 
using a single testing device. AIDS Res Hum Retroviruses 2013, 29(1):61-67. 
130. World Health Organization. Meeting report: Annual meeting of the WHO 
technical working group on HIV incidence assays, 18-24 August 2011, Atlanta, 
Georgia. 
http://www.who.int/diagnostics_laboratory/links/who_incidence_meeting_draftre
port_december2011.pdf. 2011. 
131. Bärnighausen T, Wallrauch C, Welte A, McWalter TA, Mbizana N, Viljoen J, 
Graham N, Tanser F, Puren A, Newell ML. HIV incidence in rural South Africa: 
Comparison of estimates from longitudinal surveillance and cross-sectional 
cBED assay testing. PLOS One 2008, 3(11):e3640. 
132. Kim AA, Hallett T, Stover J, Gouws E, Musinguzi J, Mureithi PK, Bunnell R, 
Hargrove J, Mermin J, Kaiser RK, Barsigo A, Ghys PD. Estimating HIV 
incidence among adults in Kenya and Uganda: A systematic comparison of 
multiple methods. PLOS One 2011, 6(3):e17535. 
133. McNicholl JM, McDougal JS, Wasinrapee P, Branson BM, Martin M, Tappero 
JW, Mock PA, Green TA, Hu DJ, Parekh B. Assessment of BED HIV-1 
incidence assay in seroconverter cohorts: Effect of individuals with long-term 
infection and importance of stable incidence. PLOS One 2011, 6(3):e14748. 
134. Lee LM, McKenna MT. Monitoring the incidence of HIV infection in the United 
States. Public Health Rep 2007, 122 Suppl 1:72-79. 
 
References  242 
135. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, 
Kaplan EH, McKenna MT, Janssen RS. Estimation of HIV incidence in the 
United States. JAMA 2008, 300(5):520-529. 
136. Karon JM, Song R, Brookmeyer R, Kaplan EH, Hall HI. Estimating HIV 
incidence in the United States from HIV/AIDS surveillance data and biomarker 
HIV test results. Stat Med 2008, 27(23):4617-4633. 
137. Le Vu S, Le Strat Y, Barin F, Pillonel J, Cazein F, Bousquet V, Brunet S, Thierry 
D, Semaille C, Meyer L, Desenclos JC. Population-based HIV-1 incidence in 
France, 2003-08: A modelling analysis. Lancet Infect Dis 2010, 10(10):682-687. 
138. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, Lin LS, An Q, 
Mermin J, Lansky A, Hall HI. Estimated HIV incidence in the United States, 
2006-2009. PLOS One 2011, 6(8):e17502. 
139. Garrett N, Lattimore S, Gilbart V, Aghaizu A, Mensah G, Tosswill J, Murphy G, 
Delpech V. The Recent Infection Testing Algorithm (RITA) in clinical practice: 
A survey of HIV clinicians in England and Northern Ireland. HIV Med 2012, 
13(7):444-447. 
140. European Centre for Disease Prevention and Control. Technical Report: 
Monitoring Recently Acquired HIV Infections in the European Context. 
http://www.ecdc.europa.eu/en/publications/Publications/monitoring-recently-
acquired-HIV-infections-european-context.pdf. 2013. 
141. Aghaizu A, Murphy G, Tosswill J, DeAngelis D, Charlett A, Gill ON, Ward H, 
Lattimore S, Simmons R, Delpech V. Recent infection testing algorithm (RITA) 
applied to new HIV diagnoses in England, Wales and Northern Ireland, 2009 to 
2011. Euro Surveill 2014, 19(2):pii: 20673. 
142. Schwarcz S, McFarland W, Delgado V, Dilley J, Rinaldi J, Adler B, Withum D. 
Partner notification for persons recently infected with HIV: Experience in San 
Francisco. JAIDS  2001, 28(4):403-404. 
143. Welte A. Relating incidence to ‘recent infection’ prevalence: Application to HIV. 
S Afr J Sci 2008, 104:199-202. 
144. HIV Modelling Consortium. http://www.hivmodelling.org. Accessed 1 July 
2014.  
145. Balasubramanian R, Lagakos SW. Estimating HIV incidence based on combined 
prevalence testing. Biometrics 2010, 66(1):1-10. 
146. McWalter TA, Kassanjee R, Welte A. Incidence from cross-sectional surveys: 
Improved characterization of tests for recent infection. E-poster CDC0473 at the 
XVIII International AIDS Conference, 18-23 July 2010, Austria. 
147. Hallett TB. Estimating the HIV incidence rate: Recent and future developments. 
Curr Opin HIV AIDS 2011, 6(2):102-107. 
148. Agresti A. Categorical data analysis. Second Edition. New York: Wiley, 2002. 
149. Claggett B, Lagakos SW, Wang R. Augmented cross-sectional studies with 
abbreviated follow-up for estimating HIV incidence. Biometrics 2012, 68(1):62-
74. 
150. Rice JA. Mathematical statistics and data analysis. Third Edition. Belmont, CA: 
Duxbury Press, 2007. 
151. David M, Masson S, Zeh C, Mukui I, Kiubi B, Szumilin E, Welte A, Riche B, 
Etard JF. High incidence despite increasing ART and circumcision coverage in 
Western Kenya: The Ndhiwa HIV impact in population study. Abstract PB176 at 
 
References  243 
the 17th International Conference on AIDS and Sexually Transmitted Infections 
in Africa (ICASA), 7- 11 December 2013, South Africa. 
152. The R Project for Statistical Computing. http://www.r-project.org. Accessed 
1 July 2014.  
153. Keating SM, Hanson D, Lebedeva L, Laeyendecker O, Ali-Napo L, Contestable 
P, Edwards S, Ethridge S, Branson B, Norris PJ, Busch MP. Optimization and 
calibration of less sensitive and avidity modified protocols for the Vitros 
immunodiagnostic products anti-HIV1+2 assay for detection of early HIV 
infections and incidence estimation. Presentation at the 2010 HIV Diagnostics 
Conference, 24-26 March 2010, Orlando, FL. 
154. Avioq, Inc. Avioq HIV-1 Microelisa System: Package Insert. 2009. 
155. Remis RS, Palmer RW. Testing bias in calculating HIV incidence from the 
Serologic Testing Algorithm for Recent HIV Seroconversion. AIDS 2009, 
23(4):493-503. 
156. Schreiber GB, Glynn SA, Satten GA, Kong F, Wright D, Busch MP, Tu Y, 
Kleinman SH. HIV seroconverting donors delay their return: Screening test 
implications. Transfusion 2002, 42(4):414-421. 
157. Cox DR. Principles of Statistical Inference. New York: Cambridge University 
Press, 2006. 
158. Hart JD. Nonparametric Smoothing and Lack-of-Fit Tests. New York: Springer-
Verlag, 1997. 
159. Schwarcz S, Weinstock H, Louie B, Kellogg T, Douglas J, Lalota M, Dickinson 
G, Torian L, Wendell D, Paul S, Goza G, Ruiz J, Boyett B, McCormick L, 
Bennett D. Characteristics of persons with recently acquired HIV infection: 
Application of the serologic testing algorithm for recent HIV seroconversion in 
10 US cities. JAIDS 2007, 44(1):112-115. 
160. Busch MP, Stramer SL, Vermeulen M, Goncales T, Keating SM, Remis RS. 
Derivation of HIV incidence assay ‘window periods’ from seroconverting blood 
donors in countries with diverse HIV clades. Poster 995a at the 16th Conference 
on Retroviruses and Opportunistic Infections,  8-11 February 2009, Canada. 
161. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, Nelson R, Mock PA, 
Choopanya K, Janssen R, Mastro TD, Mei JV. Evaluation of a sensitive/less 
sensitive testing algorithm using the bioMerieux Vironostika-LS assay for 
detecting recent HIV-1 subtype B’ or E infection in Thailand. AIDS Res Hum 
Retroviruses 2003, 19(6):481-486. 
162. Fang CT, Field SP, Busch MP, Heyns Adu P. Human immunodeficiency virus-1 
and hepatitis C virus RNA among South African blood donors: Estimation of 
residual transfusion risk and yield of nucleic acid testing. Vox Sang 2003, 
85(1):9-19. 
163. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global 
distribution and regional spread of HIV-1 genetic subtypes in the year 2000. 
JAIDS 2002, 29(2):184-190. 
164. Brennan CA, Stramer SL, Holzmayer V, Yamaguchi J, Foster GA, Notari Iv EP, 
Schochetman G, Devare SG. Identification of human immunodeficiency virus 
type 1 non-B subtypes and antiretroviral drug-resistant strains in United States 
blood donors. Transfusion 2009, 49(1):125-133. 
References  244 
165. Delwart EL, Orton S, Parekh B, Dobbs T, Clark K, Busch MP. Two percent of 
HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS 
Res Hum Retroviruses 2003, 19(12):1065-1070. 
166. Calypte Biomedical Corporation. AwareTM BEDTM EIA HIV-1 Incidence Test 
(IgG-Capture HIV EIA): Enzyme Immunoassay for Population Estimates of 
HIV-1 Incidence, Cat.  No. 98003. 2008. 
167. The South African Department of Health. 2008 National Antenatal Sentinel HIV 
& Syphilis Prevalence Survey. www.gov.za/documents/download.php?f=109007. 
2009. 
168. Statistics South Africa. Mid-year Population Estimates 2009, Statistical Release 
P0302. http://www.statssa.gov.za/publications/P0302/P03022009.pdf. 2009. 
169. Smart Biotech Ltd. http://www.smartube-bio.com. Accessed 1 July 2014. 
170. Novikov I, Jehuda-Cohen T. HIV type 1 infection among Ethiopian immigrants 
to Israel: Enhanced in vitro antibody stimulation for estimating the length of the 
window period. AIDS Res Hum Retroviruses 2009, 25(2):165-174. 
171. Mumo J, Vansover A, Jehuda-Cohen T. Detecting seronegative-early HIV 
infections among adult versus student Kenyan blood donors, by using 
Stimmunology. Exp Biol Med 2009, 234(8):931-939. 
172. Africa Centre for Health and Population Studies. http://www.africacentre.ac.za. 
Accessed 1 July 2014. 
173. Bärnighausen T, Tanser F, Newell ML. Lack of a decline in HIV incidence in a 
rural community with high HIV prevalence in South Africa, 2003-2007. AIDS 
Res Hum Retroviruses 2009, 25(4):405-409. 
174. Efron B, Tibshirani RJ. An Introduction to the Bootstrap (Monographs on 
Statistics and Applied Probability 57). New York: Chapman & Hall / CRC, 1993. 
175. Burchell AN, Calzavara L, Ramuscak N, Myers T, Major C, Rachlis A, Gough 
K, Raboud J, Remis RS. Symptomatic primary HIV infection or risk 
experiences? Circumstances surrounding HIV testing and diagnosis among recent 
seroconverters. Int J STD AIDS 2003, 14(9):601-608. 
176. Centers for Disease Control and Prevention. HIV Testing Survey, 2002. 
http://www.cdc.gov/hiv/pdf/statistics_2004_HIV_Surveillance_special_no5.pdf. 
2004. 
177. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. 
J Am Stat Assoc 1958, 53(282):457-481. 
178. Klein J, Moeschnerger M. Survival Analysis Techniques for Censored and 
Truncated Data. Second Edition. New York: Springer-Verlag, 2003. 
179. Turnbull BW. The empirical distribution function with arbitrarily grouped, 
censored and truncated data. J R Stat Soc Ser B Method 1976, 38(3):290-295. 
180. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, 
Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV 
viremia and antibody seroconversion in plasma donors: Implications for 
diagnosis and staging of primary HIV infection. AIDS 2003, 17(13):1871-1879. 
181. Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, 
Pham KT, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Hahn BH, 
Shaw GM, Korber BT, Bhattacharya T, Perelson AS. Modeling sequence 
evolution in acute HIV-1 infection. J Theor Biol 2009, 261(2):341-360. 
182. Iweala OI. HIV diagnostic tests: an overview. Contraception 2004, 
70(2):141-147. 
References  245 
183. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined 
p24 antigen and antibody assays replace p24 antigen specific assays? J Virol 
Methods 2007, 143(1):86-94. 
184. Owen SM, Yang C, Spira T, Ou CY, Pau CP, Parekh BS, Candal D, Kuehl D, 
Kennedy MS, Rudolph D, Luo W, Delatorre N, Masciotra S, Kalish ML, Cowart 
F, Barnett T, Lal R, McDougal JS. Alternative algorithms for human 
immunodeficiency virus infection diagnosis using tests that are licensed in the 
United States. J Clin Microbiol 2008, 46(5):1588-1595. 
185. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. 
Evaluation of an alternative HIV diagnostic algorithm using specimens from 
seroconversion panels and persons with established HIV infections. J Clin Virol 
2011, 52 Suppl 1:S17-22. 
186. Hargrove J, van Schalkwyk C, Eastwood H. BED estimates of HIV incidence: 
resolving the differences, making things simpler. PLOS One 2012, 7(1):e29736. 
187. Masciotra S, Dobbs T, Candal D, Hanson D, Delaney K, Rudolph D, Charurat M, 
Harrigan R, McDougal S, Owen M. Antibody avidity-based assay for identifying 
recent HIV-1 infections based on Genetic SystemsTM 1/2 Plus O EIA. Abstract 
937 at the 17th Conference on Retroviruses and Opportunistic Infections, 16-19 
February 2010, San Francisco, CA. 
188. Bill & Melinda Gates Foundation Letters of Inquiry (LOI): New Biomarkers for 
HIV Incidence Measurement. https://docs.gatesfoundation.org/Documents/hiv-
incidence-rules-and-guidelines.pdf. Accessed 1 July 2014. 
189. Hallett TB, Ghys P, Bärnighausen T, Yan P, Garnett GP. Errors in ‘BED’-derived 
estimates of HIV incidence will vary by place, time and age. PLOS One 2009, 
4(5):e5720. 
190. American Red Cross. http://www.redcrossblood.org. Accessed 1 July 2014.  
191. Blood Centers of the Pacific. http://www.bloodcenters.org. Accessed 1 July 2014. 
192. South African National Blood Service. http://www.sanbs.org.za. Accessed 1 July 
2014.   
193. Fundacao Pro-Sangue Hemocentro de Sao Paulo 
http://www.prosangue.sp.gov.br/hemocentros/Default.aspx. Accessed 1 July 
2014. 
194. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, 
Pilcher CD, Grant RM, Deeks SG, Hecht FM. Transmitted drug resistance in 
persons with acute/early HIV-1 in San Francisco, 2002-2009. PLOS One 2010, 
5(12):e15510. 
195. Winkelstein Jr. W, Wiley JA, Padian NS, Samuel M, Shiboski S, Ascher MS, 
Levy JA. The San Francisco Men’s Health Study: Continued decline in HIV 
seroconversion rates among homosexual/bisexual men. Am J Public Health 1988, 
78(11):1472-1474. 
196. Morris SR, Little SJ, Cunningham T, Garfein RS, Richman DD, Smith DM. 
Evaluation of an HIV nucleic acid testing program with automated internet and 
voicemail systems to deliver results. Ann Intern Med 2010, 152(12):778-785. 
197. Costa PR, Hartogensis W, Diaz RS, Bacchetti P, Hecht R, Santos BR, AMPLIAR 
study team, Kallas EG, Pilcher C. Subjects infected with Clade C-Containing 
HIV exhibit higher CD4+ T cell activation. Poster 289 at the 2014 Conference on 
Retroviruses and Opportunistic Infections, March 3-6 2014, Boston, MA. 
References  246 
198. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, 
Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira 
E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SL, Schaefer M, 
Papathanasopoulos MA, Stevens W, Gilmour J. Transmitted HIV type 1 drug 
resistance among individuals with recent HIV infection in East and Southern 
Africa. AIDS Res Hum Retroviruses 2011, 27(1):5-12. 
199. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue 
P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship 
between T cell activation and CD4+ T cell count in HIV-seropositive individuals 
with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 
2008, 197(1):126-133. 
200. Sedia Biosciences Corporation. Sedia™ HIV-1 LAg-Avidity EIA: Single Well 
Avidity Enzyme Immunoassay for Detection of Recent HIV-1 Infection Using 
Liquid Serum or Plasma, Cat. No. 1002. 2013. 
201. Sedia Biosciences Corporation. Sedia™ HIV-1 LAg-Avidity EIA: Single Well 
Avidity Enzyme Immunoassay for Detection of Recent Infection, Cat. No. 1002. 
2012. 
202. Bollinger RC, Brookmeyer RS, Mehendale SM, Paranjape RS, Shepherd ME, 
Gadkari DA, Quinn TC. Risk factors and clinical presentation of acute primary 
HIV infection in India. JAMA 1997, 278(23):2085-2089. 
203. Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, Kerndt P, Glorgi JV, 
Bai J, Gaut P, Richman DD, Mandel S, Nichols S. Diagnosis of primary HIV-1 
infection – Los Angeles County Primary HIV Infection Recruitment Network. 
Ann Intern Med 2001, 134(1):25-29. 
204. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, 
Chesney M, Anderson J, Levy J, Kahn JO. Use of laboratory tests and clinical 
symptoms for identification of primary HIV infection. AIDS  2002, 16(8): 
1119-1129. 
205. Powers KA, Miller WC, Pilcher CD, Mapanje C, Martinson FE, Fiscus SA, 
Chilongozi DA, Namakhwa D, Price MA, Galvin SR, Hoffman IF, Cohen MS. 
Improved detection of acute HIV-1 infection in sub-Saharan Africa: 
Development of a risk score algorithm. AIDS 2007, 21(16):2237-2242. 
206. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic 
features of primary HIV infection. Ann Intern Med 1996, 125(4):257-264. 
207. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, 
Gairin JE, Hahn BH, Oldstone MB, Shaw GM. Antiviral pressure exerted by 
HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection 
demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3(2): 
205-211. 
208. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult 
A, Sonnerborg A, Biberfeld G, Gaines H. Diagnosis of primary HIV-1 infection 
and duration of follow-up after HIV exposure – Karolinska Institute Primary HIV 
Infection Study Group. AIDS 2000, 14(15):2333-2339. 
209. Pilcher CD, Eron JJ, Jr., Vemazza PL, Battegay M, Harr T, Yerly S, Vom S, 
Perrin L. Sexual transmission during the incubation period of primary HIV 
infection. JAMA 2001, 286(14):1713-1714. 
210. Agresti A, Coull BA. Approximate is better than “exact” for interval estimation 
of binomial proportions. Am Stat 1998, 52(2):119-126. 
References  247 
211. Mehrotra DV, Chan IS, Berger RL. A cautionary note on exact unconditional 
inference for a difference between two independent binomial proportions. 
Biometrics 2003, 59(2):441-450. 
212. Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2 ൈ 
2 tables. Stat Med 2009, 28(7):1159-1175. 
213. Chaillon A, Le Vu S, Brunet S, Gras G, Bastides F, Bernard L, Meyer L, Barin F. 
Decreased specificity of an assay for recent infection in HIV-1-infected patients 
on highly active antiretroviral treatment: Implications for incidence estimates. 
Clin Vaccine Immunol 2012, 19(8):1248-1253. 
214. Department of Health and Human Services. Guidelines for the use of 
antiretroviral agents in HIV-1-infected adults and adolescents. 
http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.  
Accessed 5 March 2014. 
215. South African Department of Health. The South African Antiretroviral Treatment 
Guidelines,Version 14, March 2013. 
http://www.sahivsoc.org/upload/documents/2013%20ART%20Guidelines-
Short%20Combined%20FINAL%20draft%20guidelines%2014%20March%2020
13.pdf. Accessed 5 March 2014.
216. Le Vu S, Velter A, Meyer L, Peytavin G, Guinard J, Pillonel J, Barin F, 
Semaille C. Biomarker-based HIV incidence in a community sample of men who 
have sex with men in Paris, France. PLOS One 2012, 7(6):e39872. 
217. Sharma UK, Schito M, Welte A, Rousseau C, Fitzgibbon J, Keele B, Shapiro S, 
McMichael A, Burns DN. Workshop summary: Novel biomarkers for HIV 
incidence assay development. AIDS Res Hum Retroviruses 2012, 28(6):532-539. 
218. National Institutes of Health: Funding opportunity announcement for ‘HIV 
Incidence Assays with Improved Specificity’. 
http://grants.nih.gov/grants/guide/pa-files/PA-12-012.html. Accessed 1 July 
2014. 
219. Braunstein SL, Nash D, Ingabire C, Mwamarangwe L, van de Wijgert JH. 
Performance of BED-CEIA and Avidity Index assays in a sample of ART-naïve, 
female sex workers in Kigali, Rwanda. Abstract 939 at the 17th Conference on 
Retroviruses and Opportunistic Infection, 16-19 February 2010, San Francisco, 
CA. 
220. Cousins MM, Donnell D, Eshleman SH. Impact of mutation type and amplicon 
characteristics on genetic diversity measures generated using a high-resolution 
melting diversity assay. J Mol Diagn 2013, 15(1):130-137. 
221. Grant opportunity: Population-based HIV Impact Assessments in Resource-
Constrained Settings under the President’s Emergency Plan for AIDS Relief 
(PEPFAR).  
http://www.grants.gov/web/grants/view-opportunity.html?oppId=252788.  
Accessed 1 July 2014. 
222. Greene WH. Econometric Analysis. Seventh Edition. Upper Saddle River, New 
Jersey: Prentice Hall, 2011. 
